

(51) International Patent Classification:

C07D 277/64 (2006.01) C07D 417/14 (2006.01)
 C07D 417/04 (2006.01) A61K 31/428 (2006.01)
 C07D 417/10 (2006.01) A61P 9/10 (2006.01)
 C07D 417/12 (2006.01)

(21) International Application Number:

PCT/US2013/050972

(22) International Filing Date:

18 July 2013 (18.07.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/673,488 19 July 2012 (19.07.2012) US
 61/770,523 28 February 2013 (28.02.2013) US

(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY
 [US/US]; P.O. Box 4000, Route 206 and ProvinceLine
 Road, Princeton, New Jersey 08543-4000 (US).

(72) Inventors: FINLAY, Heather; c/o Bristol-Myers Squibb
 Company, 311 Pennington-Rocky Hill Road, Pennington,
 New Jersey 08534 (US). JIANG, Ji; c/o Bristol-Myers
 Squibb Company, 311 Pennington-Rocky Hill Road, Pen-
 nington, New Jersey 08534 (US). KIM, Soong-Hoon; c/o
 Bristol-Myers Squibb Company, 311 Pennington-Rocky
 Hill Road, Pennington, New Jersey 08534 (US).
 PARKHURST, Brandon; 443 Beech Street, Holland,
 Michigan 49424 (US). QIAO, Jennifer X.; c/o Bris-
 tol-Myers Squibb Company, 311 Pennington-Rocky Hill
 Road, Pennington, New Jersey 08534 (US). WANG,
 Tammy C.; c/o Bristol-Myers Squibb Company, 311 Pen-
 nington-Rocky Hill Road, Pennington, New Jersey 08534
 (US). PI, Zulan; c/o Bristol-Myers Squibb Company, 311
 Pennington-Rocky Hill Road, Pennington, New Jersey
 08534 (US). TORA, George O.; c/o Bristol-Myers Squibb
 Company, 311 Pennington-Rocky Hill Road, Pennington,
 New Jersey 08534 (US). LLOYD, John; c/o Bristol-Myers

Squibb Company, 311 Pennington-Rocky Hill Road, Pen-
 nington, New Jersey 08534 (US). JOHNSON, James A.;
 c/o Bristol-Myers Squibb Company, 311 Penning-
 ton-Rocky Hill Road, Pennington, New Jersey 08534 (US).

(74) Agents: SUN, Jing G. et al.; Bristol-Myers Squibb Com-
 pany, P.O. Box 4000, Princeton, New Jersey 08543-4000
 (US).

(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,
 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC,
 SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
 KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHAZOLE INHIBITORS OF ENDOTHELIAL LIPASE



(57) Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions compris-
 ing any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.

AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHAZOLE INHIBITORS
OF ENDOTHELIAL LIPASE

FIELD OF THE INVENTION

5 **[0001]** The present invention provides novel amide, urea or sulfone amide linked benzothiazole compounds and analogues, which are endothelial lipase (EL) inhibitors, compositions containing them, and methods of using them, for example, for the treatment and/or prophylaxis of dyslipidemias and the sequelae thereof.

10 **BACKGROUND OF THE INVENTION**

[0002] Cardiovascular disease is a major health risk throughout the industrialized world. Atherosclerosis, the most prevalent of cardiovascular diseases, is the principal cause of heart attack, and stroke, and thereby the principal cause of death in the United States.

15 **[0003]** Atherosclerosis is a complex disease involving many cell types and molecular factors (for a detailed review, *see* Ross, R., *Nature*, 362(6423):801-809 (1993)). Results from epidemiologic studies have clearly established an inverse relationship between levels of high density lipoprotein (HDL), which transports endogenous cholesterol from tissues to the liver as well as mediating selective cholesteryl ester delivery to
20 steroidogenic tissues, and the risk for atherosclerosis (Gordon, D.J. et al., *N. Engl. J. Med.*, 321(19):1311-1316 (1989)).

[0004] The metabolism of HDL is influenced by several members of the phospholipase and triacylglycerol (TG) lipase family of proteins, which hydrolyze triglycerides, phospholipids (PL), and cholesteryl esters (CE), generating fatty acids to
25 facilitate intestinal absorption, energy production, or storage. Of the TG lipases, lipoprotein lipase (LPL) influences the metabolism of HDL cholesterol by hydrolyzing triglycerides in triglyceride-rich lipoproteins, resulting in the transfer of lipids and apolipoproteins to HDL and is responsible for hydrolyzing chylomicron and very low density lipoprotein (VLDL) in muscle and adipose tissues. Hepatic lipase (HL)
30 hydrolyzes HDL triglyceride and phospholipids, generating smaller, lipid-depleted HDL particles, and plays a role in the uptake of HDL cholesterol (Jin, W. et al., *Trends Endocrinol. Metab.*, 13(4):174-178 (2002); Wong, H. et al., *J. Lipid Res.*, 43:993-999

(2002)). Endothelial lipase (also known as EDL, EL, LIPG, endothelial-derived lipase, and endothelial cell-derived lipase) is synthesized in endothelial cells, a characteristic that distinguishes it from the other members of the family.

[0005] Recombinant endothelial lipase protein has substantial phospholipase activity but has been reported to have less hydrolytic activity toward triglyceride lipids (Hirata, K. et al., *J. Biol. Chem.*, 274(20):14170-14175 (1999); Jaye, M. et al., *Nat. Genet.*, 21:424-428 (1999)). However, endothelial lipase does exhibit triglyceride lipase activity ex vivo in addition to its HDL phospholipase activity, and endothelial lipase was found to hydrolyze HDL more efficiently than other lipoproteins (McCoy, M.G. et al., *J. Lipid Res.*, 43:921-929 (2002)). Overexpression of the human endothelial lipase gene in the livers of mice markedly reduces plasma concentrations of HDL cholesterol and its major protein, apolipoprotein A-I (apoA-I) (Jaye, M. et al., *Nat. Genet.*, 21:424-428 (1999)).

[0006] Various types of compounds have been reported to modulate the expression of endothelial lipase, for example, 3-oxo-1,3-dihydro-indazole-2-carboxamides (WO 2004/093872, US 2006/0211755A1), 3-oxo-3-H-benzo[d]isoxazole-2-carboxamides (WO 2004/094393, U.S. Patent No. 7,217,727), and benzisothiazol-3-one-2-carboxamides (WO 2004/094394, U.S. Patent No. 7,595,403) by Eli Lilly & Co.; diacylindazole derivatives (WO 2007/042178, US 2008/0287448A1) and imidazopyridin-2-one derivatives (WO 2007/110215, US 2009/0076068A1), and azolopyridin-3-one derivatives (WO 2007/110216, US 2009/0054478A1) by Sanofi-Aventis; heterocyclic derivatives (WO 2009/123164), keto-amide derivatives (WO 2009/133834), acetic acid amide derivatives (WO2010/44441, US 2011/0251386A1), oxadiazole derivatives (WO 2011074560, US2012253040 A1), benzothiazole and azabenzothiazole derivatives (WO 2012081563) and amino derivatives (WO2012173099) by Shionogi & Co., Ltd.

However, because endothelial lipase is a relatively new member in the lipase gene family, a full understanding of the potential of endothelial lipase inhibitors to human health, as well as the inhibitors of other lipases in general, requires more studies.

[0007] Thus, there is a clear need for new types of compounds capable of inhibiting the activity of lipases, particularly endothelial lipase, that would constitute effective treatments to the diseases or disorders associated with the activity of such lipases.

SUMMARY OF THE INVENTION

[0008] The present disclosure provides amide, urea or sulfone amide linked benzothiazole compounds and their analogues, including stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, which are useful as EL inhibitors.

5 [0009] The present invention also provides processes and intermediates for making the compounds of the present invention.

[0010] The present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof.

[0011] The compounds of the invention may be used in the treatment and/or prophylaxis of dyslipidemias and the sequelae thereof.

[0012] The compounds of the invention may be used in therapy.

15 [0013] The compounds of the invention may be used for the manufacture of a medicament for the treatment and/or prophylaxis of dyslipidemias and the sequelae thereof.


[0014] The compounds of the invention can be used alone, in combination with other compounds of the present invention, or in combination with one or more, preferably one to two other agent(s).

20 [0015] Other features and advantages of the invention will be apparent from the following detailed description and claims.

DETAILED DESCRIPTION OF THE INVENTION


25 I. COMPOUNDS OF THE INVENTION

[0016] In a first aspect, the present invention provides, *inter alia*, a compound of Formula (I):



or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof,
30 wherein:



R^1 is independently selected from: halogen, CN, $\text{CO}_2(\text{C}_{1-4} \text{ alkyl})$, $-\text{CO}-\text{R}^j$,



(a 5- to 6-membered heteroaryl comprising: carbon atoms and 1-4 heteroatoms selected from N, NR^c , O, and $\text{S}(\text{O})_p$; wherein said heteroaryl is substituted with 0-3 R^a);


R^2 is, independently at each occurrence, selected from: halogen, OH, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, CN, NH_2 , NO_2 , $\text{NH}(\text{C}_{1-4} \text{ alkyl})$, $\text{N}(\text{C}_{1-4} \text{ alkyl})_2$, CO_2H , $\text{CO}_2(\text{C}_{1-4} \text{ alkyl})$, and CONH_2 ;

R^3 is independently selected from: $-\text{SO}_2\text{R}^5$ and $-\text{NHCOR}^6$;

R^4 independently selected from:  and ;


R^5 is independently selected from: C_{1-6} alkyl substituted with 0-1 R^9 , C_{2-6} alkenyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, $-(\text{CH}_2)_m-(\text{O})_n-(\text{C}_{3-6} \text{ carbocycle substituted with 0-3 } R^b)$, and $-(\text{CH}_2)_m-(\text{O})_n-(5\text{- to } 6\text{-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, } \text{NR}^c, \text{O, and } \text{S}(\text{O})_p; \text{ wherein said heterocycle is substituted with 0-2 } R^b)$;




R^6 is independently selected from: C_{1-6} alkyl, C_{2-6} alkenyl, C_{1-6} alkoxy, C_{1-4} haloalkyl, $-(\text{CH}_2)_m-(\text{C}_{3-6} \text{ carbocycle substituted with 0-3 } R^b)$, $-(\text{CH}_2)_m-(\text{pyridyl substituted with 0-2 } R^b)$, $-\text{NH}(\text{C}_{1-4} \text{ alkyl})$, $-\text{NHCH}_2\text{CO}_2(\text{C}_{1-4} \text{ alkyl})$,







R^7 is independently selected from: CONH_2 , $\text{CONH}(\text{C}_{1-4} \text{ alkyl})$, $\text{CON}(\text{C}_{1-4} \text{ alkyl})_2$, $\text{SO}_2\text{NHSO}_2(\text{C}_{1-4} \text{ alkyl})$, $\text{SO}_2\text{NH}(\text{CH}_2)_2\text{CO}_2(\text{C}_{1-4} \text{ alkyl})$,

NHSO₂NH₂, NHSO₂(C₁₋₄ alkyl), N(C₁₋₄ alkyl)SO₂NH₂,

N(CO₂C₁₋₄ alkyl)SO₂(C₁₋₄ alkyl), SO₂R¹⁰, and  ;


R⁸ is independently selected from ₁₋₃, ₁₋₂, ,



phenyl and a 5- to 6-membered heteroaryl comprising: carbon atoms and 1-4 heteroatoms selected from N, NR^c, O, and S(O)_p; wherein said phenyl and heteroaryl are substituted with 0-2 R¹¹;

R⁹ is independently selected from: halogen, C₁₋₄ alkoxy, C₁₋₄ haloalkyl,

10 C₁₋₄ haloalkoxy, NH₂, CO₂H, CO₂(C₁₋₄ alkyl), SO₃H, CONHR^d, NHCONHR^d,




and 5- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR^g, O, and S(O)_p;

R¹⁰ is independently selected from: OH, C₁₋₆ alkyl, C₂₋₆ alkenyl, NH₂,

NH(C₁₋₆ alkyl substituted with 0-1 CO₂(C₁₋₄ alkyl)), NH(C₂₋₆ alkyl),

NH(C₁₋₄ haloalkyl), NPh, phenyl substituted with 0-2 halogens, and




R¹¹ is, independently at each occurrence, selected from: halogen, C₁₋₄ alkyl,

C₁₋₄ haloalkyl, NH₂, and phenyl;

- 5 R^a is, independently at each occurrence, selected from: halogen, C₁₋₆ alkyl substituted with 0-1 R^f, C₁₋₄ alkoxy substituted with 0-1 R^f, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, OH, CN, NO₂, CO₂H, CO₂(C₁₋₄ alkyl), NR^gR^h, CONR^gR^h, CONR^gR^j, NHCORⁱ, NHCO₂Rⁱ, SO₂NR^gR^h, -(O)_n-(CH₂)_t-R^j, and -CO-R^j;

- 10 R^b is, independently at each occurrence, selected from: halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy, OH, CN, NH₂, NO₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂, CO₂H, CO₂(C₁₋₄ alkyl), SO₂(C₁₋₄ alkyl), CONH₂, and CONH(C₁₋₄ alkyl);

- 15 R^c is, independently at each occurrence, selected from: H, C₁₋₆ alkyl substituted with 0-1 R^e, CO(C₁₋₄ alkyl), CO₂(C₁₋₄ alkyl), COBn, CO₂Bn, -(CH₂)_t-piperidinyl, -(CH₂)_t-morpholinyl, -(CH₂)_t-piperazinyl, pyrimidinyl,



R^d is, independently at each occurrence, selected from: C₁₋₆ alkyl and -(CH₂)_t-(phenyl substituted with 0-2 R^e);

- 20 R^e is, independently at each occurrence, selected from: halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, and C₁₋₄ haloalkoxy;

R^f is, independently at each occurrence, selected from: OH, halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, and C₁₋₄ haloalkoxy;

R^g is, independently at each occurrence, selected from: H and C₁₋₄ alkyl;

- 25 R^h is, independently at each occurrence, selected from: H, C₁₋₆ haloalkyl and C₁₋₆ alkyl substituted with 0-1 R^f;

R^i is, independently at each occurrence, selected from: C_{1-4} haloalkyl and C_{1-4} alkyl substituted with 0-1 R^f ;

R^j is, independently at each occurrence: C_{3-6} carbocycle or a 4- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR^g , O, and $S(O)_p$; wherein said carbocycle and heterocycle are substituted with 0-2 R^f ;



m and t are, independently at each occurrence, selected from 0, 1, 2, and 3;

n is, independently at each occurrence, selected from 0 and 1;

p is, independently at each occurrence, selected from 0, 1, and 2; and

s is, independently at each occurrence, selected from 1, 2, and 3.

[0017] In a second aspect, the present invention includes a compound of Formula (Ia) or (Ib):





or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, within the scope of the first aspect, wherein:

m and t are, independently at each occurrence, selected from 0, 1, and 2; and

s is, independently at each occurrence, selected from 1 and 2.

[0018] In a third aspect, the present invention includes a compound of Formula (IIa) or (IIb):




or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, within the scope of any of the first and second aspects; wherein:

- 5 R^2 is independently selected from: halogen and C_{1-4} alkyl.

[0019] In a fourth aspect, the present invention includes a compound of Formula (Ia) (IIa) or (IIb), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, within the scope of the first, second and third aspects, wherein:

- 10 R^1 is independently selected from: 4-halo-Ph, 6-halo-pyrid-3-yl, and





R^4 is SO_2NH_2 ; and

R^6 is independently selected from: C_{1-4} alkyl, $-CHF_2$, $NHBn$, 4- CF_3 -Ph, and pyrid-3-yl.

15

[0020] In a fifth aspect, the present invention includes a compound of Formula (IIIa) or (IIIb):







or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, within the scope of any of the first and second aspects; wherein:

R^2 is independently selected from: halogen, C_{1-4} alkyl and C_{1-4} haloalkyl.



5

[0021] In a sixth aspect, the present invention includes a compound of Formula (I), (Ib), (IIIa) or (IIIb), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, within the scope of any of the first, second and fifth aspects, wherein:

R^1 is independently selected from:




10




, (phenyl substituted with 0-2 R^a), and (a heteroaryl substituted with 0-2

R^a and selected from: isoxazolyl, pyrazolyl, 1- R^c -pyrazolyl, pyridyl, and pyrimidinyl);


R^4 is independently selected from:



15




R^5 is independently selected from: C_{1-4} alkyl substituted with 0-1 R^9 , C_{2-4} alkenyl, $-(CH_2)_{0-1}-C_{3-6}$ cycloalkyl, $-(CH_2)_{0-1}$ -(phenyl substituted with 0-1 R^b) and



R^9 is independently selected from: C_{1-4} alkoxy, C_{1-4} haloalkyl, NH_2 , and $NHCO_2Bn$;

R^a is, independently at each occurrence, selected from: OH, halogen, CN, C_{1-4} alkyl substituted with 0-1 OH, C_{1-4} alkoxy, $-O(CH_2)_{1-2}O(C_{1-4}$ alkyl), C_{1-4} haloalkyl, C_{1-4} haloalkoxy, NH_2 , CO_2H , $CO_2(C_{1-4}$ alkyl), $CONH_2$, $CONH(C_{1-4}$ alkyl), $CONH(CH_2)_{2-3}OH$, $CONH(CH_2)_{1-3}O(C_{1-4}$ alkyl), $CON(C_{1-4}$ alkyl) $(CH_2)_{1-3}O(C_{1-4}$ alkyl), $CONH(C_{1-4}$ haloalkyl), $NHCO(C_{1-4}$ alkyl), $NHCO(C_{1-4}$ haloalkyl), $NHCO_2(C_{1-4}$ alkyl), $SO_2N(C_{1-4}$ alkyl) $_2$, $SO_2NH(CH_2)_{2-3}OH$,

pyrazolyl, $-(CH_2)_{0-2}$ -morpholinyl, $-CO$ -morpholinyl, piperazinyl,



R^b is independently selected from: halogen and C_{1-4} haloalkyl;


R^c is, independently at each occurrence, selected from: H, C_{1-4} alkyl, $-(CH_2)_2(C_{1-4}$ alkoxy), $-(CH_2)_{0-2}$ -(phenyl substituted with 0-1 halo),




$-(CH_2)_{0-2}$ -piperidinyl, $-(CH_2)_{0-2}$ -morpholinyl, and



R^f is, independently at each occurrence, selected from: OH, halogen, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, and C_{1-4} haloalkoxy.


[0022] In a seventh aspect, the present invention includes a compound of Formula (I), (Ib), (IIIa) or (IIIb), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, within the scope of any of the first, second, fifth and sixth aspects, wherein:

R^1 is independently selected from: Ph, 3-halo-Ph, 4-halo-Ph, 3- C_{1-4} alkoxy-Ph, 4- CH_2OH -Ph, 3-CN-Ph, 4-CN-Ph, 4- CO_2H -Ph, 4- $CO_2(C_{1-4}$ alkyl)-Ph, 3-NHCO(C_{1-4} alkyl)-Ph, 4-NHCO(C_{1-4} alkyl)-Ph, 4-(pyrazol-1-yl)-Ph,

2- C_{1-4} alkoxy-pyridyl, pyrimidinyl and  ;

R^4 is independently selected from: , , ,

, , and

.


R^5 is independently selected from: C_{1-4} alkyl substituted with 0-1 R^9 , and C_{2-4} alkenyl, Bn, and 4-halo-Bn; and

R^9 is independently selected from: C_{1-4} alkoxy, C_{1-4} haloalkyl, NH_2 , and $NHCO_2Bn$.

[0023] In an eighth aspect, the present invention includes a compound of Formula (I), (Ib), (IIIa) or (IIIb), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, within the scope of any of the first, second, fifth, sixth and seventh aspects, wherein:

R^1 is independently selected from: Ph, 3-halo-Ph, 4-halo-Ph, 3- C_{1-4} alkoxy-Ph, 4- CH_2OH -Ph, 3-CN-Ph, 4-CN-Ph, 4- CO_2H -Ph, 4- $CO_2(C_{1-4}$ alkyl)-Ph,

3-NHCO(C₁₋₄ alkyl)-Ph, 4-NHCO(C₁₋₄ alkyl)-Ph, 4-(pyrazol-1-yl)-Ph, pyrimidinyl and



R⁴ is ;

R⁵ is independently selected from: C₁₋₄ alkyl substituted with 0-1 R⁹, and

5 C₂₋₄ alkenyl, Bn, and 4-halo-Bn; and

R⁹ is independently selected from: C₁₋₄ alkoxy, C₁₋₄ haloalkyl, NH₂, and NHCO₂Bn.

[0024] In a ninth aspect, the present invention includes a compound of Formula (I),
 10 (Ib), (IIIa) or (IIIb), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, within the scope of any of the first, second, fifth, sixth, seventh and eighth aspects, wherein:

R¹ is independently selected from: Ph, 3-F-Ph, 4-F-Ph, 3-OMe-Ph, 4-CH₂OH-Ph, 3-CN-Ph, 4-CN-Ph, 4-CO₂H-Ph, 4-CO₂Me-Ph, 3-NHCOMe-Ph, 4-NHCOMe-Ph,


15 4-(pyrazol-1-yl)-Ph, pyrimidin-5-yl, and ; and

R⁵ is independently selected from: Me, Et, Pr, *i*-Bu, , Bn, 4-F-Bn, -(CH₂)₂OMe, -(CH₂)₂CF₃, -(CH₂)₂NH₂, and -(CH₂)₂NHCO₂Bn.

[0025] In a tenth aspect, the present invention includes a compound of Formula (I),
 20 (Ib), (IIIa) or (IIIb), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, within the scope of any of the first, second, fifth, sixth and seventh aspects, wherein:


R¹ is Ph;

R⁴ is independently selected from: SO₂NH(C₂₋₆ alkenyl),



R⁵ is independently selected from: C₁₋₄ alkyl, C₂₋₄ alkenyl, -(CH₂)₂O(C₁₋₄ alkyl),
5 and -(CH₂)₂NHCO₂Bn.


[0026] In an eleventh aspect, the present invention includes a compound of Formula (Ib), (IIIa) or (IIIb), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, within the scope of any of the first, second, fifth, sixth, seventh and tenth
10 aspects, wherein:



R⁵ is independently selected from: Me, , -(CH₂)₂OMe, and -(CH₂)₂NHCO₂Bn.


15 [0027] In a twelfth aspect, the present invention includes a compound of Formula (I), (Ib), (IIIa) or (IIIb), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, within the scope of any of the first, second, fifth and sixth aspects, wherein:

R¹ is independently selected from:




(phenyl substituted with 0-2 R^a), and (a heteroaryl substituted with 0-2 R^a and selected from: isoxazolyl, pyrazolyl, 1-R^c-pyrazolyl, pyridyl, and pyrimidinyl);

R⁴ is independently selected from:



R⁵ is independently selected from: C₁₋₄ alkyl substituted with 0-1 R⁹,

-(CH₂)₀₋₁-C₃₋₆ cycloalkyl, benzyl substituted with 0-1 R^b, and



R⁹ is independently selected from: C₁₋₄ alkoxy, C₁₋₄ haloalkyl, NH₂, and NHCO₂Bn;


R^a is, independently at each occurrence, selected from: OH, halogen, C₁₋₄ alkyl

substituted with 0-1 OH, C₁₋₄ alkoxy, -O(CH₂)₂O(C₁₋₄ alkyl), C₁₋₄ haloalkyl,

C₁₋₄ haloalkoxy, NH₂, CONH₂, CONH(C₁₋₄ alkyl), CONH(CH₂)₂₋₃OH,


CONH(CH₂)₁₋₃O(C₁₋₄ alkyl), CON(C₁₋₄ alkyl)(CH₂)₁₋₃O(C₁₋₄ alkyl),

CONH(C₁₋₄ haloalkyl), NHCO₂(C₁₋₄ alkyl), SO₂N(C₁₋₄ alkyl)₂, SO₂NH(CH₂)₂₋₃OH,



R^b is independently selected from: CN, halogen and C_{1-4} haloalkyl;


R^c is, independently at each occurrence, selected from: H, C_{1-4} alkyl substituted
 5 with 0-1 C_{1-4} alkoxy, $-(CH_2)_{0-2}$ -(phenyl substituted with 0-1 halo), $-(CH_2)_{0-2}$ -piperidinyl,



R^f is, independently at each occurrence, selected from: OH, CN, halogen,
 C_{1-4} alkyl, and C_{1-4} alkoxy.

10 **[0028]** In a thirteenth aspect, the present invention includes a compound of Formula
 (I), (Ib), (IIIa) or (IIIb), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt,
 or a solvate thereof, within the scope of any of the first, second, fifth, sixth and twelfth
 aspects, wherein:


R^1 is independently selected from: 3- $(CH_2)_2$ OH-Ph, 4- $(CH_2)_2$ OH-Ph,
 15 4-O $(CH_2)_2$ O(C_{1-4} alkyl)-Ph, 4- C_{1-4} haloalkoxy-Ph, 4-NH₂-Ph, 4-CONH₂-Ph,
 4-CONH(C_{1-4} alkyl)-Ph, 4-CONH $(CH_2)_2$ OH-Ph, 3-CONH $(CH_2)_2$ O(C_{1-4} alkyl)-Ph,
 4-CONH $(CH_2)_2$ O(C_{1-4} alkyl)-Ph, 4-CONH(C_{1-4} haloalkyl)-Ph,
 3-CON(C_{1-4} alkyl) $(CH_2)_2$ O(C_{1-4} alkyl)-Ph, 4-NHCO₂(C_{1-4} alkyl)-Ph,
 4-SO₂N(C_{1-4} alkyl)₂-Ph, 4-SO₂NH $(CH_2)_2$ OH-Ph, 1*H*-3- C_{1-4} haloalkyl-pyrazol-4-yl,
 20 1- C_{1-4} alkyl-pyrazol-4-yl, 1-Bn-pyrazol-4-yl, 3- C_{1-4} alkyl-pyrid-4-yl, 6-OH-pyrid-2-yl,
 6-OH-pyrid-3-yl, 2-OH-pyrid-4-yl, 6- C_{1-4} alkoxy-pyrid-2-yl, 2- C_{1-4} alkoxy-pyrid-3-yl,
 6- C_{1-4} alkoxy-pyrid-3-yl, 2- C_{1-4} alkoxy-pyrid-4-yl, 6-halo-pyrid-3-yl, 2-halo-pyrid-4-yl,
 6- C_{1-4} haloalkyl-pyrid-3-yl, 5- C_{1-4} alkyl-6-halo-pyrid-3-yl,
 3-halo-6- C_{1-4} alkoxy-pyrid-4-yl, pyrimidin-5-yl,






[0029] In a fourteenth aspect, the present invention includes a compound of Formula (I), (Ib), (IIIa) or (IIIb), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, within the scope of any of the first, second, fifth, sixth, twelfth and

5 thirteenth aspects, wherein:

- R^1 is independently selected from: 3-(CH₂)₂OH-Ph, 4-(CH₂)₂OH-Ph, 4-O(CH₂)₂OMe-Ph, 4-OCF₃-Ph, 4-NH₂-Ph, 4-CONH₂-Ph, 4-CONH(*t*-Bu)-Ph, 4-CONH(CH₂)₂OH-Ph, 3-CONH(CH₂)₂OMe-Ph, 4-CONH(CH₂)₂OMe-Ph, 4-CON(Me)(CH₂)₂OMe-Ph, 4-CONHCH₂CF₃-Ph, 4-NHCO₂Me-Ph, 10 4-NHCO₂(*t*-Bu)-Ph, 4-SO₂N(Me)₂-Ph, 4-SO₂NH(CH₂)₂OH-Ph, 1*H*-3-CF₃-pyrazol-4-yl, 1-Me-pyrazol-4-yl, 1-(*i*-Bu)-pyrazol-4-yl, 1-Bn-pyrazol-4-yl, 3-Me-pyrid-4-yl, 6-OH-pyrid-2-yl, 6-OH-pyrid-3-yl, 2-OH-pyrid-4-yl, 6-OMe-pyrid-2-yl, 2-OMe-pyrid-3-yl, 6-OMe-pyrid-3-yl, 2-OMe-pyrid-4-yl, 6-F-pyrid-3-yl, 2-F-pyrid-4-yl, 2-Cl-pyrid-4-yl, 6-CF₃-pyrid-3-yl, 5-Me-6-F-pyrid-3-yl, 3-F-6-OMe-pyrid-4-yl,







[0030] In another aspect, the present invention provides a compound of Formula (I),
 or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof,
 15 within the scope of the first aspect, wherein:





R^1 is independently selected from: phenyl and a 5- to 6-membered heteroaryl
 comprising: carbon atoms and 1-4 heteroatoms selected from N, NR^c , O, and $S(O)_p$;
 wherein each phenyl and heteroaryl are substituted with 0-3 R^a ;

R² is, independently at each occurrence, selected from: halogen, OH, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy, CN, NH₂, NO₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂, CO₂H, CO₂(C₁₋₄ alkyl), and CONH₂;


R³ is independently selected from: -SO₂R⁵ and -NHCOR⁶;

5 R⁴ independently selected from:  and  ;


R⁵ is independently selected from: C₁₋₆ alkyl, C₂₋₆ alkenyl, -(CH₂)_mCHF₂, -(CH₂)_mCF₃, -(CH₂)_m-(O)_n-(C₃₋₆ carbocycle substituted with 0-3 R^b), -(CH₂)_m-(O)_n-(pyridyl substituted with 0-2 R^b), -(CH₂)_sNHCONHR^d,




- (CH₂)_sNHCO₂R^d, , , , and  ;







10 R⁶ is independently selected from: C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ alkoxy, -(CH₂)_mCHF₂, -(CH₂)_mCF₃, -(CH₂)_m-(C₃₋₆ carbocycle substituted with 0-3 R^b), -(CH₂)_m-(pyridyl substituted with 0-2 R^b), -NH(C₁₋₄ alkyl), -NHCH₂CO₂(C₁₋₄ alkyl),


-NH(4-halo-Ph), -NHBn, and  ;

15 R⁷ is independently selected from: CONH₂, CONH(C₁₋₄ alkyl), CON(C₁₋₄ alkyl)₂, SO₂OH, SO₂(4-halo-Ph), SO₂NH₂, SO₂NHCH₂CF₃, SO₂NHPh, NHSO₂NH₂, NHSO₂(C₁₋₄ alkyl), N(C₁₋₄ alkyl)SO₂NH₂,


N(CO₂C₁₋₄ alkyl)SO₂(C₁₋₄ alkyl), and  ;

R⁸ is independently selected from: , , ,

, , , , ,  ,




- R^a is, independently at each occurrence, selected from: halogen, C_{1-6} alkyl substituted with 0-1 OH, C_{1-4} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, OH, CN, NO_2 , NH_2 , $NH(C_{1-4} \text{ alkyl})$, $N(C_{1-4} \text{ alkyl})_2$, CO_2H , $CO_2(C_{1-4} \text{ alkyl})$, $CONH_2$, $CONH(C_{1-4} \text{ alkyl})$, SO_2NH_2 , $SO_2N(C_{1-4} \text{ alkyl})_2$, $CONH(CH_2)_{1-3}CF_3$, pyrazolyl,



- R^b is, independently at each occurrence, selected from: halogen, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, OH, CN, NH_2 , NO_2 , $NH(C_{1-4} \text{ alkyl})$, $N(C_{1-4} \text{ alkyl})_2$, CO_2H , $CO_2(C_{1-4} \text{ alkyl})$, $SO_2(C_{1-4} \text{ alkyl})$, $CONH_2$, and $CONH(C_{1-4} \text{ alkyl})$;

R^c is, independently at each occurrence, selected from: H, C_{1-6} alkyl,

$CO(C_{1-4} \text{ alkyl})$, $CO_2(C_{1-4} \text{ alkyl})$, $COBn$, CO_2Bn , , pyrimidinyl and $-(CH_2)_t-(C_{3-6} \text{ carbocycle substituted with 0-2 } R^e)$;

- R^d is, independently at each occurrence, selected from: C_{1-6} alkyl and $-(CH_2)_t$ -(phenyl substituted with 0-2 R^e);

R^e is, independently at each occurrence, selected from: halogen, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, and C_{1-4} haloalkoxy;

m and t are, independently at each occurrence, selected from 0, 1, 2, and 3;



- n is, independently at each occurrence, selected from 0 and 1;





p is, independently at each occurrence, selected from 0, 1, and 2; and


s is, independently at each occurrence, selected from 1, 2, and 3.

[0031] In another aspect, the present invention includes a compound of Formula (I),

(Ia) or (Ib), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, within the scope of the first or second aspect, wherein:

R⁴ is independently selected from: , ,

, , , , and





.



10





[0032] In another aspect, the present invention includes a compound of Formula (I), (Ib) or (IIIa), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, wherein:

R¹ is independently selected from: Ph, 4-CO₂(C₁₋₄ alkyl)-Ph, 4-NH₂-Ph,


4-CONH₂-Ph, 4-SO₂N(C₁₋₄ alkyl)₂-Ph, 4-NHCO₂(C₁₋₄ alkyl)-Ph, 4-(pyrazol-1-yl)-Ph, 3-C₁₋₄ alkyl-pyrid-4-yl, 6-C₁₋₄ alkoxy-pyrid-3-yl, 6-halo-pyrid-3-yl, 3-halo-pyrid-4-yl,

6-CF₃-pyrid-3-yl, , , and ; 

R⁴ is independently selected from: , ,

, , , , and

20

; and

R⁵ is independently selected from: C₁₋₄ alkyl, C₂₋₄ alkenyl, Bn, 4-CF₃-Bn, and -(CH₂)₁₋₃CF₃.

[0033] In another aspect, the present invention includes a compound of Formula (I), (Ib) or (IIIa), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, wherein:

R^1 is independently selected from: Ph, 4-CO₂(C₁₋₄ alkyl)-Ph and


5 4-(pyrazol-1-yl)-Ph;

R^4 is SO₂NH₂; and

R^5 is independently selected from: C₁₋₄ alkyl and C₂₋₄ alkenyl.

[0034] In another aspect, the present invention includes a compound of Formula (I), (Ib) or (IIIa), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, wherein:

R^1 is independently selected from: Ph, 4-CO₂Me-Ph and 4-(pyrazol-1-yl)-Ph; and


R^5 is independently selected from: Me and .



[0035] In another aspect, the present invention includes a compound of Formula (I), (Ib) or (IIIa), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, within the scope of any of the first, second, third, sixth and seventh aspects, wherein:


R^1 is independently selected from: 4-NH₂-Ph, 4-CONH₂-Ph,


20 4-SO₂N(C₁₋₄ alkyl)₂-Ph, 4-NHCO₂(C₁₋₄ alkyl)-Ph, 3-C₁₋₄ alkyl-pyrid-4-yl,

6-C₁₋₄ alkoxy-pyrid-3-yl, 6-halo-pyrid-3-yl, 3-halo-pyrid-4-yl, 6-CF₃-pyrid-3-yl,



R^4 is independently selected from: , ,













25 ; and

R^5 is independently selected from: C₁₋₄ alkyl, Bn, 4-CF₃-Bn, and -(CH₂)₁₋₃CF₃.

[0036] In another aspect, the present invention includes a compound of Formula (I), (Ib) or (IIIa), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, within the scope of any of the first, second, third, sixth and tenth aspects, wherein:

R^1 is independently selected from: 4-NH₂-Ph, 4-CONH₂-Ph, 4-SO₂N(Me)₂-Ph, 4-NHCO₂Me-Ph, 3-Me-pyrid-4-yl, 6-OMe-pyrid-3-yl, 6-F-pyrid-3-yl, 3-F-pyrid-4-yl,




3-Cl-pyrid-4-yl, 6-CF₃-pyrid-3-yl, , , and  ;


R^4 is independently selected from: , , , , , , and  ; and

R^5 is independently selected from: Me, Pr, *i*-Pr, Bn, 4-CF₃-Bn, and -(CH₂)₂CF₃.

[0037] In another aspect, the present invention includes a compound of Formula (I), (Ib), (IIIa) or (IIIb), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, wherein:

R^1 is independently selected from: 4-CO₂H-Ph, 4-NHCO(C₁₋₄ alkyl)-Ph, 4-CONH₂-Ph, 4-CONH(CH₂)₂₋₃OH-Ph, 4-CONH(CH₂)₂O(C₁₋₄ alkyl)-Ph, 4-CONH(CH₂)C(C₁₋₄ alkyl)₂OH-Ph, 4-CONH(C₃₋₆ cycloalkyl)-Ph, 3-halo-4-CON(C₁₋₄ alkyl)₂-Ph, 6-halo-pyrid-3-yl, 6-OH-pyrid-2-yl, 6-OH-pyrid-3-yl, 2-OH-pyrid-4-yl, 2-OH-3-halo-pyrid-4-yl, 2-OH-5-halo-pyrid-4-yl,

pyrimidin-5-yl, , , ,



R^4 is independently selected from: and ;

R^5 is independently selected from: C_{1-4} alkyl substituted with 0-1 R^9 ,
 $-CH_2-C_{3-6}$ cycloalkyl, and benzyl substituted with 0-1 R^b ;


R^9 is independently selected from: C_{1-4} alkoxy, and C_{1-4} haloalkyl; and


R^b is independently selected from: CN, halogen C_{1-4} haloalkyl and
 C_{1-4} haloalkoxy.



10

[0038] In another aspect, the present invention includes a compound of Formula (I),
 (Ib), (IIIa) or (IIIb), or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a
 solvate thereof, wherein:

R^1 is independently selected from: 4-CO₂H-Ph, 4-NHCOMe-Ph, 4-CONH₂-Ph,
 4-CONH(CH₂)₂₋₃OH-Ph, 4-CONH(CH₂)₂OMe-Ph, 4-CONH(CH₂)C(Me)₂OH-Ph,
 4-CONH(cyclopropyl)-Ph, 3-F-4-CON(Me)₂-Ph, 6-F-pyrid-3-yl, 6-OH-pyrid-2-yl,
 6-OH-pyrid-3-yl, 2-OH-pyrid-4-yl, 2-OH-3-F-pyrid-4-yl, 2-OH-5-F-pyrid-4-yl,





R^4 is independently selected from:  SO_2NH_2 and  ; and

R^5 is independently selected from: Me, *i*-Pr, $-(\text{CH}_2)_2\text{OMe}$, $-(\text{CH}_2)_2\text{CF}_3$,
 5 cyclopropylmethyl, Bn, 3-CN-Bn, 3-F-Bn, 4-F-Bn, 4- CF_3 -Bn, and 4- OCF_3 -Bn.

[0039] In a fifteenth aspect, the present invention provides a compound selected from the exemplified examples or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof.

10 [0040] In another aspect, the present invention provides a compound selected from any subset list of compounds within the scope of the twelfth aspect.

[0041] In another embodiment, the compounds of the present invention have EL IC_{50} values ≤ 500 nM.

15 [0042] In another embodiment, the compounds of the present invention have EL IC_{50} values ≤ 100 nM.

[0043] In another embodiment, the compounds of the present invention have EL IC_{50} values ≤ 50 nM.

[0044] In another embodiment, the compounds of the present invention have EL IC_{50}
 20 values ≤ 25 nM.

[0045] In another embodiment, the compounds of the present invention have EL IC_{50} values ≤ 10 nM.

II. OTHER EMBODIMENTS OF THE INVENTION

[0046] In another embodiment, the present invention provides a composition comprising at least one of the compounds of the present invention or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof.

5 [0047] In another embodiment, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one of the compounds of the present invention or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof.

10 [0048] In another embodiment, the present invention provides a pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof.

[0049] In another embodiment, the present invention provides a process for making a compound of the present invention.

15 [0050] In another embodiment, the present invention provides an intermediate for making a compound of the present invention.

[0051] In another embodiment, the present invention provides a pharmaceutical composition as defined above further comprising additional therapeutic agent(s).

20 [0052] In another embodiment, the present invention provides a method for the treatment and/or prophylaxis of dyslipidemias and the sequelae thereof comprising administering to a patient in need of such treatment and/or prophylaxis a therapeutically effective amount of at least one of the compounds of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.

25 [0053] Examples of diseases or disorders associated with the activity of endothelial lipase that can be prevented, modulated, or treated according to the present invention include, but are not limited to, atherosclerosis, coronary heart disease, coronary artery disease, coronary vascular disease, cerebrovascular disorders, Alzheimer's disease, venous thrombosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-
30 hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia.

[0054] In one embodiment, the present invention provides a method for the treatment and/or prophylaxis of atherosclerosis, coronary heart disease, cerebrovascular disorders and dyslipidemia, comprising administering to a patient in need of such treatment and/or prophylaxis a therapeutically effective amount of at least one of the compounds of the present invention, alone, or, optionally, in combination with another compound of the present invention and/or at least one other type of therapeutic agent.

[0055] In another embodiment, the present invention provides a compound of the present invention for use in therapy.

[0056] In another embodiment, the present invention provides a compound of the present invention for use in therapy for the treatment and/or prophylaxis of dyslipidemias and the sequelae thereof.

[0057] In another embodiment, the present invention also provides the use of a compound of the present invention for the manufacture of a medicament for the treatment and/or prophylaxis of dyslipidemias and the sequelae thereof.

[0058] In another embodiment, the present invention provides a method for the treatment and/or prophylaxis of dyslipidemias and the sequelae thereof, comprising: administering to a patient in need thereof a therapeutically effective amount of a first and second therapeutic agent, wherein the first therapeutic agent is a compound of the present invention.

[0059] In another embodiment, the present invention provides a combined preparation of a compound of the present invention and additional therapeutic agent(s) for simultaneous, separate or sequential use in therapy.

[0060] In another embodiment, the present invention provides a combined preparation of a compound of the present invention and additional therapeutic agent(s) for simultaneous, separate or sequential use in the treatment and/or prophylaxis of dyslipidemias and the sequelae thereof.

[0061] The compounds of the present invention may be employed in combination with additional therapeutic agent(s) selected from one or more, preferably one to three, of the following therapeutic agents: anti-atherosclerotic agents, anti-dyslipidemic agents, anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-thrombotic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity

agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, anti-pancreatic agents, lipid lowering agents, anorectic agents, memory enhancing agents, anti-dementia agents, cognition promoting agents, appetite suppressants, treatments for heart failure, treatments for peripheral arterial disease, treatment for malignant tumors, and anti-inflammatory agents.

[0062] In another embodiment, additional therapeutic agent(s) used in combined pharmaceutical compositions or combined methods or combined uses, are selected from one or more, preferably one to three, of the following therapeutic agents in treating atherosclerosis: anti-hyperlipidemic agents, plasma HDL-raising agents, anti-hypercholesterolemic agents, cholesterol biosynthesis inhibitors (such as HMG CoA reductase inhibitors), acyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitors, LXR agonist, probucol, raloxifene, nicotinic acid, niacinamide, cholesterol absorption inhibitors, bile acid sequestrants (such as anion exchange resins, or quaternary amines (*e.g.*, cholestyramine or colestipol)), low density lipoprotein receptor inducers, clofibrate, fenofibrate, benzofibrate, ciprofibrate, gemfibrozil, vitamin B₆, vitamin B₁₂, anti-oxidant vitamins, β -blockers, anti-diabetes agents, angiotensin II antagonists, angiotensin converting enzyme inhibitors, platelet aggregation inhibitors, fibrinogen receptor antagonists, aspirin or fibrin acid derivatives.

[0063] In another embodiment, additional therapeutic agent(s) used in combined pharmaceutical compositions or combined methods or combined uses, are selected from one or more, preferably one to three, of the following therapeutic agents in treating cholesterol biosynthesis inhibitor, particularly an HMG-CoA reductase inhibitor. Examples of suitable HMG-CoA reductase inhibitors include, but are not limited to, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, and rivastatin.

[0064] The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof. This invention encompasses all combinations of preferred aspects of the invention noted herein. It is understood that any and all embodiments of the present invention may be taken in conjunction with any other embodiment or embodiments to describe additional embodiments. It is also understood that each individual element of the embodiments is its own independent embodiment.

Furthermore, any element of an embodiment is meant to be combined with any and all other elements from any embodiment to describe an additional embodiment.

III. CHEMISTRY

- 5 [0065] Throughout the specification and the appended claims, a given chemical formula or name shall encompass all stereo and optical isomers and racemates thereof where such isomers exist. Unless otherwise indicated, all chiral (enantiomeric and diastereomeric) and racemic forms are within the scope of the invention. Many geometric isomers of C=C double bonds, C=N double bonds, ring systems, and the like
10 can also be present in the compounds, and all such stable isomers are contemplated in the present invention. *Cis*- and *trans*- (or *E*- and *Z*-) geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. The present compounds can be isolated in optically active or racemic forms. Optically active forms may be prepared by resolution of racemic forms or
15 by synthesis from optically active starting materials. All processes used to prepare compounds of the present invention and intermediates made therein are considered to be part of the present invention. When enantiomeric or diastereomeric products are prepared, they may be separated by conventional methods, for example, by chromatography or fractional crystallization. Depending on the process conditions the
20 end products of the present invention are obtained either in free (neutral) or salt form. Both the free form and the salts of these end products are within the scope of the invention. If so desired, one form of a compound may be converted into another form. A free base or acid may be converted into a salt; a salt may be converted into the free compound or another salt; a mixture of isomeric compounds of the present invention may
25 be separated into the individual isomers. Compounds of the present invention, free form and salts thereof, may exist in multiple tautomeric forms, in which hydrogen atoms are transposed to other parts of the molecules and the chemical bonds between the atoms of the molecules are consequently rearranged. It should be understood that all tautomeric forms, insofar as they may exist, are included within the invention.
- 30 [0066] As used herein, the term "alkyl" or "alkylene" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. For example, "C₁ to C₁₀ alkyl" or "C₁₋₁₀ alkyl" (or alkylene), is

intended to include C₁, C₂, C₃, C₄, C₅, C₆, C₇, C₈, C₉, and C₁₀ alkyl groups.

Additionally, for example, "C₁ to C₆ alkyl" or "C₁₋₆ alkyl" denotes alkyl having 1 to 6 carbon atoms. Alkyl group can be unsubstituted or substituted with at least one hydrogen being replaced by another chemical group. Example alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (*e.g.*, n-propyl and isopropyl), butyl (*e.g.*, n-butyl, isobutyl, *t*-butyl), and pentyl (*e.g.*, n-pentyl, isopentyl, neopentyl). When "C₀ alkyl" or "C₀ alkylene" is used, it is intended to denote a direct bond.

[0067] "Alkenyl" or "alkenylene" is intended to include hydrocarbon chains of either straight or branched configuration having the specified number of carbon atoms and one or more, preferably one to two, carbon-carbon double bonds that may occur in any stable point along the chain. For example, "C₂ to C₆ alkenyl" or "C₂₋₆ alkenyl" (or alkenylene), is intended to include C₂, C₃, C₄, C₅, and C₆ alkenyl groups. Examples of alkenyl include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl, and 4-methyl-3-pentenyl.

[0068] "Alkynyl" or "alkynylene" is intended to include hydrocarbon chains of either straight or branched configuration having one or more, preferably one to three, carbon-carbon triple bonds that may occur in any stable point along the chain. For example, "C₂ to C₆ alkynyl" or "C₂₋₆ alkynyl" (or alkynylene), is intended to include C₂, C₃, C₄, C₅, and C₆ alkynyl groups; such as ethynyl, propynyl, butynyl, pentynyl, and hexynyl.

[0069] The term "alkoxy" or "alkyloxy" refers to an -O-alkyl group. "C₁ to C₆ alkoxy" or "C₁₋₆ alkoxy" (or alkyloxy), is intended to include C₁, C₂, C₃, C₄, C₅, and C₆ alkoxy groups. Example alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (*e.g.*, n-propoxy and isopropoxy), and *t*-butoxy. Similarly, "alkylthio" or "thioalkoxy" represents an alkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge; for example methyl-S- and ethyl-S-.

[0070] "Halo" or "halogen" includes fluoro, chloro, bromo, and iodo. "Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogens. Examples of haloalkyl include, but are not limited to, fluoromethyl,

difluoromethyl, trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2,2,2-trifluoroethyl, heptafluoropropyl, and heptachloropropyl. Examples of haloalkyl also include "fluoroalkyl" that is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more fluorine atoms.

[0071] "Haloalkoxy" or "haloalkyloxy" represents a haloalkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge. For example, "C₁ to C₆ haloalkoxy" or "C₁₋₆ haloalkoxy", is intended to include C₁, C₂, C₃, C₄, C₅, and C₆ haloalkoxy groups. Examples of haloalkoxy include, but are not limited to, trifluoromethoxy, 2,2,2-trifluoroethoxy, and pentafluoroethoxy. Similarly, "haloalkylthio" or "thiohaloalkoxy" represents a haloalkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge; for example trifluoromethyl-S-, and pentafluoroethyl-S-.

[0072] The term "cycloalkyl" refers to cyclized alkyl groups, including mono-, bi- or poly-cyclic ring systems. "C₃ to C₇ cycloalkyl" or "C₃₋₇ cycloalkyl" is intended to include C₃, C₄, C₅, C₆, and C₇ cycloalkyl groups. Example cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and norbornyl. Branched cycloalkyl groups such as 1-methylcyclopropyl and 2-methylcyclopropyl are included in the definition of "cycloalkyl".

[0073] As used herein, "carbocycle," "carbocyclyl," or "carbocyclic residue" is intended to mean any stable 3-, 4-, 5-, 6-, 7-, or 8-membered monocyclic or bicyclic or 7-, 8-, 9-, 10-, 11-, 12-, or 13-membered bicyclic or tricyclic ring, any of which may be saturated, partially unsaturated, unsaturated or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptenyl, cycloheptyl, cycloheptenyl, adamantyl, cyclooctyl, cyclooctenyl, cyclooctadienyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, anthracenyl, and tetrahydronaphthyl (tetralin). As shown above, bridged rings are also included in the definition of carbocycle (*e.g.*, [2.2.2]bicyclooctane). Preferred carbocycles, unless otherwise specified, are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, indanyl, and tetrahydronaphthyl. When the term "carbocycle" is used, it is intended to include "aryl." A bridged ring occurs when one or more, preferably

one to three, carbon atoms link two non-adjacent carbon atoms. Preferred bridges are one or two carbon atoms. It is noted that a bridge always converts a monocyclic ring into a tricyclic ring. When a ring is bridged, the substituents recited for the ring may also be present on the bridge.

5 [0074] As used herein, the term "bicyclic carbocycle" or "bicyclic carbocyclic group" is intended to mean a stable 9- or 10-membered carbocyclic ring system that contains two fused rings and consists of carbon atoms. Of the two fused rings, one ring is a benzo ring fused to a second ring; and the second ring is a 5- or 6-membered carbon ring which is saturated, partially unsaturated, or unsaturated. The bicyclic carbocyclic group may be
10 attached to its pendant group at any carbon atom which results in a stable structure. The bicyclic carbocyclic group described herein may be substituted on any carbon if the resulting compound is stable. Examples of a bicyclic carbocyclic group are, but not limited to, naphthyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, and indanyl.

[0075]

15 [0076] "Aryl" groups refer to monocyclic or polycyclic aromatic hydrocarbons, including, for example, phenyl, naphthyl, and phenanthryl. Aryl moieties are well known and described, for example, in Lewis, R.J., ed., *Hawley's Condensed Chemical Dictionary*, 13th Edition, John Wiley & Sons, Inc., New York (1997). "C₆ or C₁₀ aryl" or "C₆₋₁₀ aryl" refers to phenyl and naphthyl. Unless otherwise specified, "aryl", "C₆ or
20 C₁₀ aryl," "C₆₋₁₀ aryl," or "aromatic residue" may be unsubstituted or substituted with 1 to 5 groups, preferably 1 to 3 groups, selected from -OH, -OCH₃, -Cl, -F, -Br, -I, -CN, -NO₂, -NH₂, -N(CH₃)H, -N(CH₃)₂, -CF₃, -OCF₃, -C(O)CH₃, -SCH₃, -S(O)CH₃, -S(O)₂CH₃, -CH₃, -CH₂CH₃, -CO₂H, and -CO₂CH₃.

[0077] The term "benzyl," as used herein, refers to a methyl group on which one of
25 the hydrogen atoms is replaced by a phenyl group, wherein said phenyl group may optionally be substituted with 1 to 5 groups, preferably 1 to 3 groups, OH, OCH₃, Cl, F, Br, I, CN, NO₂, NH₂, N(CH₃)H, N(CH₃)₂, CF₃, OCF₃, C(=O)CH₃, SCH₃, S(=O)CH₃, S(=O)₂CH₃, CH₃, CH₂CH₃, CO₂H, and CO₂CH₃.

[0078] As used herein, the term "heterocycle," "heterocyclyl," or "heterocyclic group"
30 is intended to mean a stable 3-, 4-, 5-, 6-, or 7-membered monocyclic or bicyclic or 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered polycyclic heterocyclic ring that is saturated,

partially unsaturated, or fully unsaturated, and that contains carbon atoms and 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O and S; and including any polycyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized (i.e., N→O and S(O)_p, wherein p is 0, 1 or 2). The nitrogen atom may be substituted or unsubstituted (i.e., N or NR wherein R is H or another substituent, if defined). The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. A nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1. When the term "heterocycle" is used, it is intended to include heteroaryl.

- 15 **[0079]** Examples of heterocycles include, but are not limited to, acridinyl, azetidiny, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazoliny, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazoliny, carbazolyl, 4aH-carbazolyl, carboliny, chromanyl, chromenyl, cinnoliny, decahydroquinoliny,
- 20 2H,6H-1,5,2-dithiaziny, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidiny, imidazoliny, imidazolyl, 1H-indazolyl, imidazolopyridiny, indolenyl, indoliny, indoliziny, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindoliny, isoindolyl, isoquinoliny, isothiazolyl, isothiazolopyridiny, isoxazolyl, isoxazolopyridiny, methylenedioxyphenyl, morpholiny, naphthyridiny,
- 25 octahydroisoquinoliny, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidiny, oxazolyl, oxazolopyridiny, oxazolidinyperimidiny, oxindolyl, pyrimidiny, phenanthridiny, phenanthroliny, phenaziny, phenothiaziny, phenoxathiiny, phenoxaziny, phthalaziny, piperaziny, piperidiny, piperidony, 4-piperidony, piperonyl, pteridiny, puriny, pyranly, pyraziny,
- 30 pyrazolidiny, pyrazoliny, pyrazolopyridiny, pyrazolyl, pyridaziny, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridiny, pyrimidiny, pyrrolidiny, pyrroliny, 2-pyrrolidony, 2H-pyrroly, pyrroly, quinazoliny, quinoliny, 4H-quinoliziny,

quinoxaliny, quinuclidiny, tetrazoly, tetrahydrofurany, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6*H*-1,2,5-thiadiaziny, 1,2,3-thiadiazoly, 1,2,4-thiadiazoly, 1,2,5-thiadiazoly, 1,3,4-thiadiazoly, thianthrenyl, thiazoly, thienyl, thiazolopyridiny, thienothiazoly, thienooxazoly, thienoimidazoly, thiophenyl, triaziny, 1,2,3-triazoly, 1,2,4-triazoly, 1,2,5-triazoly, 1,3,4-triazoly, and xanthenyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.

[0080] Examples of 5- to 10-membered heterocycles include, but are not limited to, pyridiny, furany, thienyl, pyrroly, pyrazoly, pyraziny, piperaziny, piperidiny, imidazoly, imidazolidiny, indoly, tetrazoly, isoxazoly, morpholiny, oxazoly, oxadiazoly, oxazolidiny, tetrahydrofurany, thiadiaziny, thiadiazoly, thiazoly, triaziny, triazoly, benzimidazoly, 1*H*-indazoly, benzofurany, benzothiofurany, benztetrazoly, benzotriazoly, benzisoxazoly, benzoxazoly, oxindoly, benzoxazolinyl, benzthiazoly, benzisothiazoly, isatinoyl, isoquinolinyl, octahydroisoquinolinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, isoxazolopyridiny, quinazolinyl, quinolinyl, isothiazolopyridiny, thiazolopyridiny, oxazolopyridiny, imidazolopyridiny, and pyrazolopyridiny.

[0081] Examples of 5- to 6-membered heterocycles include, but are not limited to, pyridiny, furany, thienyl, pyrroly, pyrazoly, pyraziny, piperaziny, piperidiny, imidazoly, imidazolidiny, indoly, tetrazoly, isoxazoly, morpholiny, oxazoly, oxadiazoly, oxazolidiny, tetrahydrofurany, thiadiaziny, thiadiazoly, thiazoly, triaziny, and triazoly. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.

[0082] As used herein, the term "bicyclic heterocycle" or "bicyclic heterocyclic group" is intended to mean a stable 9- or 10-membered heterocyclic ring system which contains two fused rings and consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O and S. Of the two fused rings, one ring is a 5- or 6-membered monocyclic aromatic ring comprising a 5-membered heteroaryl ring, a 6-membered heteroaryl ring or a benzo ring, each fused to a second ring. The second ring is a 5- or 6-membered monocyclic ring which is saturated, partially unsaturated, or unsaturated, and comprises a 5-membered heterocycle, a 6-membered heterocycle or a carbocycle (provided the first ring is not benzo when the second ring is a carbocycle).

[0083] The bicyclic heterocyclic group may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The bicyclic heterocyclic group described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1.

[0084] Examples of a bicyclic heterocyclic group are, but not limited to, quinolinyl, isoquinolinyl, phthalazinyl, quinazolinyl, indolyl, isoindolyl, indolinyl, 1H-indazolyl, benzimidazolyl, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, 5,6,7,8-tetrahydro-quinolinyl, 2,3-dihydro-benzofuranyl, chromanyl, 1,2,3,4-tetrahydro-quinoxalyl, and 1,2,3,4-tetrahydro-quinazolinyl.

[0085] As used herein, the term "aromatic heterocyclic group" or "heteroaryl" is intended to mean stable monocyclic and polycyclic aromatic hydrocarbons that include at least one heteroatom ring member such as sulfur, oxygen, or nitrogen. Heteroaryl groups include, without limitation, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, benzodioxolanyl, and benzodioxane. Heteroaryl groups are substituted or unsubstituted.

The nitrogen atom is substituted or unsubstituted (*i.e.*, N or NR wherein R is H or another substituent, if defined). The nitrogen and sulfur heteroatoms may optionally be oxidized (*i.e.*, N→O and S(O)_p, wherein p is 0, 1 or 2).

[0086] Bridged rings are also included in the definition of heterocycle. A bridged ring occurs when one or more, preferably one to three, atoms (*i.e.*, C, O, N, or S) link two non-adjacent carbon or nitrogen atoms. Examples of bridged rings include, but are not limited to, one carbon atom, two carbon atoms, one nitrogen atom, two nitrogen atoms, and a carbon-nitrogen group. It is noted that a bridge always converts a monocyclic ring into a tricyclic ring. When a ring is bridged, the substituents recited for the ring may also be present on the bridge.

[0087] The term "counter ion" is used to represent a negatively charged species such as chloride, bromide, hydroxide, acetate, and sulfate.

[0088] When a dotted ring is used within a ring structure, this indicates that the ring structure may be saturated, partially saturated or unsaturated.

[0089] As referred to herein, the term "substituted" means that at least one hydrogen atom is replaced with a non-hydrogen group, provided that normal valencies are

5 maintained and that the substitution results in a stable compound. When a substituent is keto (*i.e.*, =O), then 2 hydrogens on the atom are replaced. Keto substituents are not present on aromatic moieties. When a ring system (*e.g.*, carbocyclic or heterocyclic) is said to be substituted with a carbonyl group or a double bond, it is intended that the carbonyl group or double bond be part (*i.e.*, within) of the ring. Ring double bonds, as
10 used herein, are double bonds that are formed between two adjacent ring atoms (*e.g.*, C=C, C=N, or N=N).

[0090] In cases wherein there are nitrogen atoms (*e.g.*, amines) on compounds of the present invention, these may be converted to N-oxides by treatment with an oxidizing agent (*e.g.*, mCPBA and/or hydrogen peroxides) to afford other compounds of this

15 invention. Thus, shown and claimed nitrogen atoms are considered to cover both the shown nitrogen and its N-oxide (N→O) derivative.


[0091] When any variable occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-3 R
20 groups, then said group may optionally be substituted with up to three R groups, and at each occurrence R is selected independently from the definition of R.

[0092] Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

[0093] When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a
25 substituent is listed without indicating the atom in which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

30 [0094] As a person of ordinary skill in the art would be able to understand that imine and carbonyl groups in a molecule may tautomerize to their enamine and enol forms, and

the double bond can exist as geometrical (E and Z) isomers as shown in the following equation, wherein R¹, R², R³ and R⁴ are as defined above:



[0095] Thus, this disclosure is intended to cover all possible tautomers even when a
5 structure depicts only one of them.

[0096] The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, and/or other problem or complication, commensurate with a reasonable benefit/risk ratio.

[0097] As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic groups such as amines; and alkali or organic salts of acidic groups such as carboxylic acids. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pantoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, and isethionic.

[0098] The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the

free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in *Remington: The Science and Practice of*
5 *Pharmacy*, 22nd Edition, Allen, L. V. Jr., Ed.; Pharmaceutical Press, London, UK (2012), the disclosure of which is hereby incorporated by reference.

[0099] In addition, compounds of Formula (I), Formula (II), or Formula (III) may have prodrug forms. Any compound that will be converted *in vivo* to provide the bioactive agent (*i.e.*, a compound of Formula (I), Formula (II) or Formula (III)) is a
10 prodrug within the scope and spirit of the invention. Various forms of prodrugs are well known in the art. For examples of such prodrug derivatives, see:

a) Bundgaard, H., ed., *Design of Prodrugs*, Elsevier (1985), and Widder, K. et al., eds., *Methods in Enzymology*, 112:309-396, Academic Press (1985);

b) Bundgaard, H., Chapter 5, "Design and Application of Prodrugs,"
15 Krosgaard-Larsen, P. et al., eds., *A Textbook of Drug Design and Development*, pp. 113-191, Harwood Academic Publishers (1991);

c) Bundgaard, H., *Adv. Drug Deliv. Rev.*, 8:1-38 (1992);

d) Bundgaard, H. et al., *J. Pharm. Sci.*, 77:285 (1988);

e) Kakeya, N. et al., *Chem. Pharm. Bull.*, 32:692 (1984); and

20 f) Rautio, J (Editor). *Prodrugs and Targeted Delivery (Methods and Principles in Medicinal Chemistry)*, Vol 47, Wiley-VCH, 2011.

[00100] Compounds containing a carboxy group can form physiologically hydrolyzable esters that serve as prodrugs by being hydrolyzed in the body to yield
25 Formula (I), (IIa), (IIb), (IIIa) or (IIIb) compounds *per se*. Such prodrugs are preferably administered orally since hydrolysis in many instances occurs principally under the influence of the digestive enzymes. Parenteral administration may be used where the ester *per se* is active, or in those instances where hydrolysis occurs in the blood. Examples of physiologically hydrolyzable esters of compounds of the present invention
30 include C₁ to C₆ alkyl, C₁ to C₆ alkylbenzyl, 4-methoxybenzyl, indanyl, phthalyl, methoxymethyl, C₁₋₆ alkanoyloxy-C₁₋₆ alkyl (*e.g.*, acetoxymethyl, pivaloyloxymethyl or propionyloxymethyl), C₁ to C₆ alkoxycarbonyloxy-C₁ to C₆ alkyl (*e.g.*,

methoxycarbonyl-oxymethyl or ethoxycarbonyloxymethyl, glycyloxymethyl, phenylglycyloxymethyl, (5-methyl-2-oxo-1,3-dioxolen-4-yl)-methyl), and other well known physiologically hydrolyzable esters used, for example, in the penicillin and cephalosporin arts. Such esters may be prepared by conventional techniques known in the art.

[00101] Preparation of prodrugs is well known in the art and described in, for example, King, F.D., ed., *Medicinal Chemistry: Principles and Practice*, The Royal Society of Chemistry, Cambridge, UK (2nd edition, reproduced, 2006); Testa, B. et al., *Hydrolysis in Drug and Prodrug Metabolism. Chemistry, Biochemistry and Enzymology*, VCHA and Wiley-VCH, Zurich, Switzerland (2003); Wermuth, C.G., ed., *The Practice of Medicinal Chemistry*, 3rd edition, Academic Press, San Diego, CA (2008).

[00102] The present invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include ¹³C and ¹⁴C.

Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed. Such compounds have a variety of potential uses, e.g., as standards and reagents in determining the ability of a potential pharmaceutical compound to bind to target proteins or receptors, or for imaging compounds of this invention bound to biological receptors *in vivo* or *in vitro*.

[00103] "Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. It is preferred that compounds of the present invention do not contain a N-halo, S(O)₂H, or S(O)H group.

[00104] The term "solvate" means a physical association of a compound of this invention with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more, preferably one to three, solvent molecules are incorporated in the crystal lattice of the crystalline solid. The solvent molecules in the solvate may be present in a regular arrangement and/or a non-ordered

arrangement. The solvate may comprise either a stoichiometric or nonstoichiometric amount of the solvent molecules. "Solvate" encompasses both solution-phase and isolable solvates. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Methods of solvation are generally known in the art.

[00105] Abbreviations as used herein, are defined as follows: "1 x" for once, "2 x" for twice, "3 x" for thrice, "°C" for degrees Celsius, "eq" for equivalent or equivalents, "g" for gram or grams, "mg" for milligram or milligrams, "L" for liter or liters, "mL" for milliliter or milliliters, "μL" for microliter or microliters, "N" for normal, "M" for molar, "nM" for nanomolar, "mol" for mole or moles, "mmol" for millimole or millimoles, "min" for minute or minutes, "h" for hour or hours, "rt" for room temperature, "RT" for retention time, "atm" for atmosphere, "psi" for pounds per square inch, "conc." for concentrate, "sat" or "sat'd" for saturated, "MW" for molecular weight, "mp" for melting point, "MS" or "Mass Spec" for mass spectrometry, "ESI" for electrospray ionization mass spectroscopy, "HR" for high resolution, "HRMS" for high resolution mass spectrometry, "LCMS" for liquid chromatography mass spectrometry, "HPLC" for high pressure liquid chromatography, "RP HPLC" for reverse phase HPLC, "TLC" or "tlc" for thin layer chromatography, "NMR" for nuclear magnetic resonance spectroscopy, "nOe" for nuclear Overhauser effect spectroscopy, "¹H" for proton, "δ" for delta, "s" for singlet, "d" for doublet, "t" for triplet, "q" for quartet, "m" for multiplet, "br" for broad, "Hz" for hertz, and "α", "β", "R", "S", "E", and "Z" are stereochemical designations familiar to one skilled in the art.

AcOH or HOAc	acetic acid
AlCl ₃	aluminum chloride
Alk	alkyl
BBr ₃	boron tribromide
BCl ₃	boron trichloride
Bn	benzyl
Boc	<i>tert</i> -butoxycarbonyl

BOP reagent	benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate
Bu	butyl
<i>i</i> -Bu	isobutyl
<i>t</i> -Bu	<i>tert</i> -butyl
<i>t</i> -BuOH	<i>tert</i> -butanol
Cbz	carbobenzyloxy
CDCl ₃	deutero-chloroform
CD ₃ OD	deutero-methanol
CH ₂ Cl ₂	dichloromethane
CH ₃ CN or ACN	acetonitrile
CHCl ₃	chloroform
CO ₂	carbon dioxide
mCPBA or m-CPBA	<i>meta</i> -chloroperbenzoic acid
Cs ₂ CO ₃	cesium carbonate
Cu(OAc) ₂	copper (II) acetate
DBU	1,8-diazabicyclo[5.4.0]undec-7-ene
DCE	1,2-dichloroethane
DCM	dichloromethane
DEA	diethylamine
DIC or DIPCDI	diisopropylcarbodiimide
DIEA, DIPEA or	diisopropylethylamine
Hunig's base	
DMAP	4-dimethylaminopyridine
DME	1,2-dimethoxyethane
DMF	dimethyl formamide
DMSO	dimethyl sulfoxide
cDNA	complimentary DNA
Dppp	(<i>R</i>)-(+)-1,2-bis(diphenylphosphino)propane
EDC	<i>N</i> -(3-dimthylaminopropyl)- <i>N'</i> -ethylcarbodiimide

EDTA	ethylenediaminetetraacetic acid
Et	ethyl
Et ₃ N or TEA	triethylamine
Et ₂ O	diethyl ether
EtOAc	ethyl acetate
EtOH	ethanol
HATU	(2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate)
HCl	hydrochloric acid
HOBt or HOBT	1-hydroxybenzotriazole
HPLC	high-performance liquid chromatography
H ₃ PO ₄	phosphoric acid
H ₂ SO ₄	sulfuric acid
K ₂ CO ₃	potassium carbonate
KOAc	potassium acetate
K ₃ PO ₄	potassium phosphate
LAH	lithium aluminum hydride
LDA	lithium diisopropylamide
LG	leaving group
LiOH	lithium hydroxide
Me	methyl
MeOH	methanol
MgSO ₄	magnesium sulfate
MsOH or MSA	methanesulfonic acid
NaCl	sodium chloride
Na ₂ CO ₃	sodium carbonate
NaH	sodium hydride
NaHB(OAc) ₃	sodium triacetoxyborohydride
NaHCO ₃	sodium bicarbonate
NaHMDS	sodium hexamethyldisilazane

NaOH	sodium hydroxide
NaOMe	sodium methoxide
Na ₂ SO ₃	sodium sulfite
Na ₂ SO ₄	sodium sulfate
NBS	N-bromosuccinimide
NH ₃	ammonia
NH ₄ Cl	ammonium chloride
NH ₄ OAc	ammonium acetate
NH ₄ OH	ammonium hydroxide
OTf	triflate or trifluoromethanesulfonate
Pd ₂ (dba) ₃	tris(dibenzylideneacetone)dipalladium(0)
Pd(OAc) ₂	palladium(II) acetate
Pd/C	palladium on carbon
Pd(dppf)Cl ₂	[1,1'-bis(diphenylphosphino)-ferrocene]dichloropalladium(II)
Ph ₃ PCl ₂	triphenylphosphine dichloride
PG	protecting group
Ph	phenyl
PMB	p-methoxybenzyl
POCl ₃	phosphorus oxychloride
Pr	propyl
<i>i</i> -Pr	isopropyl
<i>i</i> -PrOH or IPA	isopropanol
PS	polystyrene
PS-Pd(Ph ₃) ₄	tetrakis(triphenylphosphine)palladium (0) on polystyrene support
PyBOP	(benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate
SiO ₂	silica oxide
SnCl ₂	tin(II) chloride
TBAF	tetra- <i>n</i> -butylammonium fluoride

TBAI	tetra- <i>n</i> -butylammonium iodide
TEA	triethylamine
TFA	trifluoroacetic acid
THF	tetrahydrofuran
TMSCHN ₂	trimethylsilyldiazomethane
T3P	1-propanephosphonic acid cyclic anhydride
Xantphos or X-Phos	4,5-bis(diphenylphosphino)-9,9-dimethylxanthene

SYNTHESIS


- [00106] The compounds of the present invention can be prepared in a number of ways known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. The reactions are performed in a solvent or solvent mixture appropriate to the reagents and materials employed and suitable for the transformations being affected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention.
- 15 [00107] A particularly useful compendium of synthetic methods which may be applicable to the preparation of compounds of the present invention may be found in Larock, R.C., *Comprehensive Organic Transformations*, VCH Publishers, Inc., New York (1999). Preferred methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety herein by reference.
- 20 [00108] The novel compounds of this invention may be prepared using the reactions and techniques described in this section. Also, in the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction, which
- 25 should be readily recognized by one skilled in the art. Restrictions to the substituents that

are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods must then be used.

[00109] It will also be recognized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention. An authoritative account describing the many alternatives to the trained practitioner is Wuts, P. G. M. and Greene, T. W (*Protective Groups in Organic Synthesis*, 4th Edition, Wiley (2007)).

10 GENERIC SCHEMES

Scheme 1




15 Step 1

[00110] Step 1 describes the preparation of compounds of Formula (G1b) by reacting amides of Formula (G1a) with a sodium nitrite. A preferred solvent is water, and a preferred acid is acetic acid.

20 Step 2

[00111] Step 2 describes the preparation of amides and ureas of Formula (I) by reacting compounds of the Formula (G1b) with an anhydride or isocyanate and Pd/C in a hydrogen atmosphere. Preferred solvents are polar protic solvents, such as MeOH and EtOH.


Scheme 2



5 Step 1

[00112] Step 1 describes the preparation of compounds of Formula (I) by reacting a compound of Formula (G2a) with a sulfonylating reagent $\text{R}^5\text{-SO}_2\text{Cl}$. Preferred solvents are polar aprotic solvents (such as N,N-dimethylformamide) and ethers (such as tetrahydrofuran, dioxane and the like). Preferred bases include metal hydrides (such as sodium hydride and the like), metal amides (such as sodium bis(trimethylsilyl)amide and lithium diisopropylamide and the like) and organic amines (such as DBU, triethylamine and the like).

Scheme 3



15

Step 1

[00113] Step 1 describes the preparation of a compound of Formula (G3b) from a compound of Formula (G3a) and is analogous to Step 1 in Scheme 1.

20

Step 2

[00114] Step 2 describes the preparation of a compound of Formula (I) from a compound of Formula (G3b) by direct exchange of an ester group with an amine of formula H_2NR^4 . Preferred reaction solvents are polar aprotic solvents such as ethers (such as tetrahydrofuran, dioxane and the like), DMF and NMP. Bases such as an organic amine (such as triethylamine, diisopropylamine, DBU, 2,6-lutidine and the like) can be used.

GENERAL METHODS

10 [00115] The following methods were used in the exemplified Examples, except where noted otherwise.

[00116] Products were analyzed by reverse phase analytical HPLC carried out on a Shimadzu Analytical HPLC system running Discovery VP software using Method A: PHENOMENEX[®] Luna C18 column (4.6 x 50 mm or 4.6 x 75 mm) eluted at 4 mL/min with a 2, 4 or 8 min gradient from 100% A to 100% B (A: 10% methanol, 89.9% water, 0.1% TFA; B: 10% water, 89.9% methanol, 0.1% TFA, UV 220 nm), or Method B: PHENOMENEX[®] Luna C18 column (4.6 x 50 mm) eluted at 4 mL/min with a 4 min gradient from 100% A to 100% B (A: 10% acetonitrile, 89.9% water, 0.1% TFA; B: 10% water, 89.9% acetonitrile, 0.1% TFA, UV 220 nm) or Method C: PHENOMENEX[®] Luna C18 column (4.6 x 50 mm or 4.6 x 75 mm) eluted at 4 mL/min with a 2, 4 or 8 min gradient from 100% A to 100% B (A: 10% methanol, 89.9% water, 0.1% H_3PO_4 ; B: 10% water, 89.9% methanol, 0.1% H_3PO_4 , UV 220 nm) or Method D: PHENOMENEX[®] Luna C18 column (4.6 x 50 mm or 4.6 x 75 mm) eluted at 4 mL/min with a 2, 4 or 8 min gradient from 100% A to 100% B (A: 10% methanol, 89.9% water, 0.1% NH_4OAc ; B: 10% water, 89.9% methanol, 0.1% NH_4OAc , UV 220 nm).

[00117] Purification of intermediates and final products was carried out via either normal or reverse phase chromatography. Normal phase chromatography was carried out using prepacked SiO_2 cartridges eluted with gradients of hexanes and ethyl acetate or methylene chloride and methanol. Reverse phase preparative HPLC was carried out using a Shimadzu Preparative HPLC system running Discovery VP software using Method A: YMC Sunfire 5 μm C18 30 x 100 mm column with a 10 min gradient at 40

mL/min from 100% A to 100% B (A: 10% methanol, 89.9% water, 0.1% TFA; B: 10% water, 89.9% methanol, 0.1% TFA, UV 220 nm), Method B: PHENOMENEX[®] Axia Luna 5 µm C18 30 x 100 mm column with a 10 min gradient at 40 mL/min from 100% A to 100% B (A: 10% acetonitrile, 89.9% water, 0.1% TFA; B: 10% water, 89.9%

- 5 acetonitrile, 0.1% TFA, UV 220 nm), Method C: PHENOMENEX[®] Luna 5 µm C18 30 x 100 mm column with a 10 min gradient at 40 mL/min from 100% A to 100% B (A: 10% acetonitrile, 89.9% water, 0.1% TFA; B: 10% water, 89.9% acetonitrile, 0.1% TFA, UV 220 nm), or Method D: PHENOMENEX[®] Luna 5 µm C18 30 x 100 mm column with a 10 min gradient at 40 mL/min from 100% A to 100% B (A: 10% methanol, 89.9% water, 0.1% TFA; B: 10% water, 89.9% methanol, 0.1% TFA, UV 220 nm).

- [00118] Alternatively, reverse phase preparative HPLC was carried out using a Varian ProStar Preparative HPLC System running Star 6.2 Chromatography Workstation software using Method E: Dynamax 10 µm C18 41.4 x 250 mm column with a 30 min gradient at 30 mL/min from 10%B to 100% B (A 98% water, 2% acetonitrile, 0.05% TFA; B: 98% acetonitrile, 2% water, 0.05% TFA, UV 254 nm).

- [00119] LCMS chromatograms were obtained on a Shimadzu HPLC system running Discovery VP software, coupled with a Waters ZQ mass spectrometer running MassLynx version 3.5 software and using the following respective methods. Unless specified otherwise, for each method, the LC column was maintained at room temperature and UV detection was set to 220 nm.

[00120] Method A: A linear gradient using solvent A (10% methanol, 90% water, 0.1% of TFA) and solvent B (90% methanol, 10% water, 0.1% of TFA); 0-100% of solvent B over 4 min and then 100% of solvent B over 1 min. Column:

PHENOMENEX[®] Luna 5 µm C18 (4.5 x 50 mm). Flow rate was 4 mL/min.

- 25 [00121] Method B: A linear gradient using solvent A (10% methanol, 90% water, 0.1% of TFA) and solvent B (90% methanol, 10% water, 0.1% of TFA); 0-100% of solvent B over 2 min and then 100% of solvent B over 1 min. Column:

PHENOMENEX[®] Luna 5 µm C18 (2.0 x 30 mm). Flow rate was 1 mL/min.

- [00122] Method C: A linear gradient using solvent A (10% acetonitrile, 90% water, 10 mM NH₄OAc) and solvent B (90% acetonitrile, 10% water, 10 mM NH₄OAc); 0-

30

100% of solvent B over 4 min and then 100% of solvent B over 1 min. Column:

PHENOMENEX[®] Luna 5 µm C18 (4.5 x 50 mm). Flow rate was 4 mL/min.

- [00123] Method D: A linear gradient using solvent A (10% acetonitrile, 90% water, 0.05% of TFA) and solvent B (90% acetonitrile, 10% water, 0.05% of TFA); 0-100% of solvent B over 2 min and then 100% of solvent B over 1 min. Column:

PHENOMENEX[®] Luna 5 µm C18 (4.5 x 30 mm). Flow rate was 1 mL/min.

- [00124] Method E: A linear gradient using solvent A (10% MeOH, 90% water, 10 mM NH₄OAc) and solvent B (90% MeOH, 10% water, 10 mM NH₄OAc); 0-100% of solvent B over 4 min and then 100% of solvent B over 1 min. Column:

- 10 PHENOMENEX[®] Luna 5 µm C18 (4.5 x 50 mm). Flow rate was 4 mL/min.

[00125] Method F: A linear gradient using solvent A (10 mM NH₄OAc, 95% water, 5% ACN) and solvent B (10 mM NH₄OAc, 95% ACN, 5% water); 0-100% of solvent B over 4 min and then 100% of solvent B over 1 min. Column: Mac-Mod Halo (C18, 4.6 x 50 mm). Flow rate was 4 mL/min.

- 15 [00126] Method G: A linear gradient using solvent A (10% acetonitrile, 90% water, 0.1% TFA) and solvent B (90% acetonitrile, 10% water, 0.1% TFA); 0-100% of solvent B over 4 min and then 100% of solvent B over 1 min. Column: PHENOMENEX[®] Luna 3µm C18 (2.0 x 50 mm). Flow rate was 4 mL/min.

- [00127] Method H: A linear gradient using solvent A (10% methanol, 90% water, 0.1% of formic acid) and solvent B (90% methanol, 10% water, 0.1% of formic acid); 0-100% of solvent B over 2 min and then 100% of solvent B over 1 min. Column:

PHENOMENEX[®] Luna 3µm C18 (2.0 x 30 mm). Flow rate was 1 mL/min.

- [00128] Method I: A linear gradient using solvent A (10% MeOH, 90% water, 10 mM NH₄OAc) and solvent B (90% MeOH, 10% water, 10 mM NH₄OAc); 0-100% of solvent B over 2 min and then 100% of solvent B over 1 min. Column: PHENOMENEX[®] Luna 3µm C18 (2.0 x 30 mm). Flow rate was 1 mL/min.

- [00129] Method J: A linear gradient using solvent A (10% methanol, 90% water, 0.1% of formic acid) and solvent B (90% methanol, 10% water, 0.1% of TFA); 0-100% of solvent B over 4 min and then 100% of solvent B over 1 min. Column:

- 30 PHENOMENEX[®] Luna 5µm C18 (4.5 x 50 mm). Flow rate was 4 mL/min.

- [00130] Method K: A linear gradient using solvent A (10 mM NH₄OAc, 95% water, 5% ACN) and solvent B (10 mM NH₄OAc, 95% ACN, 5% water); 0-100% of solvent B over 5.5 min and then 100% of solvent B over 1.5 min. Column: SUPELCO[®] Ascentis 4.6x50mm 2.7µm C18. Flow rate was 4 mL/min.
- 5 [00131] Method L: A linear gradient using solvent A (5% methanol, 95% water, 0.05% of TFA) and solvent B (95% methanol, 5% water, 0.05% of TFA); 0-100% of solvent B over 4 min and then 100% of solvent B over 1 min. Column: WATERS[®] XBridge C18 (4.6 x 50 mm, 5µm). Flow rate was 4 mL/min. The LC column was maintained at 35 °C.
- 10 [00132] Method M: A linear gradient using of Solvent A (0.05% TFA, 100% water) and Solvent B (0.05% TFA, 100% ACN); 2 to 98% B over 1 min, with 0.5 min hold time at 98% B. Column: WATERS[®] BEH C18 (2.1 x 50 mm). Flow rate: 0.8 mL/min.
- [00133] Method N: A linear gradient using solvent A (5% ACN, 95% water, 10 mM NH₄OAc) and solvent B (95% ACN, 5% water, 10 mM NH₄OAc); 0-100% of solvent B
- 15 over 3 min and then 100% of solvent B over 1 min. Column: WATERS[®] BEH C18 (2.1 x 50 mm). Flow rate: 1.1 mL/min.
- [00134] Method O: A linear gradient using solvent A (5% ACN, 95% water, 0.05% of TFA) and solvent B (95% ACN, 5% water, 0.05% of TFA); 0-100% of solvent B over 3 min and then 100% of solvent B over 1 min. Column: WATERS[®] BEH C18 (2.1 x 50
- 20 mm). Flow rate: 1.1 mL/min.
- [00135] Method P: A linear gradient using solvent A (5% ACN, 95% water, 10 mM NH₄OAc) and solvent B (95% ACN, 5% water, 10 mM NH₄OAc); 0-100% of solvent B over 4 min and then 100% of solvent B over 1 min. Column: WATERS[®] XBridge C18 (4.6 x 50 mm, 5µm). Flow rate was 4 mL/min.
- 25 [00136] Method Q: A linear gradient using solvent A (10% MeOH, 90% water, 0.1% TFA) and solvent B (90% MeOH, 10% water, 0.1% TFA); 0-100% of solvent B over 2 min and then 100% of solvent B over 1 min. Column: PHENOMENEX[®] Luna 3µm C18 (2.0 x 50 mm). Flow rate was 1 mL/min.
- [00137] Method R: Column: Waters BEH C18, 2.0 x 50 mm, 1.7-µm particles; Mobile
- 30 Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 40 °C; Gradient: 0.5

min hold at 0%B, 0-100% B over 4 minutes, then a 0.5-minute hold at 100% B; Flow: 1 mL/min.

[00138] Preparative HPLC methods employed in the purification of products:

- 5 [00139] Method A: Linear gradient of 0 to 100% B over 10 min, with 5 min hold time at 100% B; Shimadzu LC-8A binary pumps

Waters ZQ mass spectrometer using Waters Masslynx 4.0 SP4 MS software
UV visualization at 220 nm

Column: WATERS® XBridge 19 x 150 mm 5µm C18

- 10 Flow rate: 20 mL/min

Peak collection triggered by mass spectrometry

Solvent A: 0.1% TFA, 10% ACN, 90% water

Solvent B: 0.1% TFA, 90% ACN, 10% water

- 15 NMR Employed in Characterization of Examples

[00140] ¹H NMR spectra were obtained with Bruker or JEOL Fourier transform spectrometers operating at frequencies as follows: ¹H NMR: 400 MHz (Bruker or JEOL) or 500MHz (JEOL). ¹³C NMR: 100 MHz (Bruker or JEOL). Spectra data are reported in the format: chemical shift (multiplicity, coupling constants, number of hydrogens).

- 20 Chemical shifts are specified in ppm downfield of a tetramethylsilane internal standard (δ units, tetramethylsilane = 0 ppm) and/or referenced to solvent peaks, which in ¹H NMR spectra appear at 2.49 ppm for CD₂HSOCD₃, 3.30 ppm for CD₂HOD, and 7.24 ppm for CHCl₃, and which in ¹³C NMR spectra appear at 39.7 ppm for CD₃SOCD₃, 49.0 ppm for CD₃OD, and 77.0 ppm for CDCl₃. All ¹³C NMR spectra were proton decoupled.

25

IV. BIOLOGY

- [00141] The endothelium occupies a pivotal position at the interface between the circulating humoral and cellular elements of the blood, and the solid tissues which constitute the various organs. In this unique position, endothelial cells regulate a large
- 30 number of critical processes, including leukocyte adherence and transit through the blood vessel wall, local control of blood vessel tone, modulation of the immune response, the balance between thrombosis and thrombolysis, and new blood vessel development. Thus,

endothelial cell dysfunction has been postulated as a central feature of vascular diseases such as hypertension and atherosclerosis. (WO 1999/032611 and references cited therein, e.g., Folkman, J. et al., *Science*, 235:442-447 (1987); Yanagisawa, M. et al., *Nature*, 332(6163):411-415 (1988); Folkman, J. et al., *J. Biol. Chem.*, 267(16):10931-10934 (1992); Janssens, S.P. et al., *J. Biol. Chem.*, 267(21):14519-14522 (1992); Lamas, S. et al., *Proc. Natl. Acad. Sci. U.S.A.*, 89(14):6348-6352 (1992); Luscher, T.F. et al., *Hypertension*, 19(2):117-130 (1992); Williams et al., *Am. Rev. Respir. Dis.*, 146:S45-S50 (1992); and Bevilacqua, M.P. et al., *J. Clin. Invest.*, 91(2):379-387 (1993)).

[00142] Atherosclerosis and its associated coronary artery disease (CAD) is the leading cause of mortality in the industrialized world. Despite attempts to modify secondary risk factors (smoking, obesity, lack of exercise) and treatment of dyslipidemia with dietary modification and drug therapy, coronary heart disease (CHD) remains the most common cause of death in the U.S. In 2008, cardiovascular disease accounted for 33% of all deaths in the U.S., and ~1 of every 6 deaths were specifically caused by atherosclerotic coronary heart disease (*Circulation* 125:e2-e220 (2012)).

[00143] Risk for development of atherosclerosis has been shown to be strongly correlated with certain plasma lipid levels. While elevated low density lipoprotein-cholesterol (LDL-C) may be the most recognized form of dyslipidemia, it is by no means the only significant lipid associated contributor to CHD. A low level of high density lipoprotein-cholesterol (HDL-C) is also a known risk factor for CHD (Gordon, D.J. et al., *Circulation*, 79(1):8-15 (1989)).

[00144] High LDL-C and triglyceride levels are positively correlated, while high levels of HDL-C are negatively correlated with the risk for developing cardiovascular diseases. Thus, dyslipidemia is not a unitary risk profile for CHD but may be comprised of one or more, preferably one to three, lipid aberrations.

[00145] At least 50% of the variation in HDL cholesterol levels is genetically determined. The phenotype of elevated HDL cholesterol is often dominantly inherited, but homozygous deficiency of HL or of the cholesteryl ester transfer protein (CETP), which result in elevated HDL cholesterol, are recessive conditions. Recently, several genetic variations in the human endothelial lipase gene have been identified, six of which potentially produce functional variants of the protein, and the frequencies of these variants were found to be associated with elevated levels of HDL cholesterol in human

subjects (deLemos, A.S. et al., *Circulation*, 106(11):1321-1326 (2002)). Notably, the endothelial lipase-mediated binding and uptake of HDL particles and the selective uptake of HDL-derived cholesterol esters have been reported to be independent of its enzymatic lipolytic activity (Strauss, J.G. et al., *Biochem. J.*, 368:69-79 (2002)).

5 [00146] Because of the beneficial effects widely associated with elevated HDL levels, an agent which inhibits EL activity in humans, by virtue of its HDL increasing ability, are expected to be useful for the treatment, prevention, the arrestment and/or regression of atherosclerosis, coronary heart disease, cerebrovascular disorders etc., especially those (but not restricted thereto) which are characterized by one or more of the following
10 factors: (a) high plasma triglyceride concentrations, high postprandial plasma triglyceride concentrations; (b) low HDL cholesterol concentration; (c) low apoA1 lipoprotein concentrations; (d) high LDL cholesterol concentrations; (e) high levels of small dense LDL cholesterol particles; and (f) high apoB lipoprotein concentrations.

[00147] The term "modulator" refers to a chemical compound with capacity to either
15 enhance (*e.g.*, "agonist" activity) or partially enhance (*e.g.*, "partial agonist" activity) or inhibit (*e.g.*, "antagonist" activity or "inverse agonist" activity) a functional property of biological activity or process (*e.g.*, enzyme activity or receptor binding); such enhancement or inhibition may be contingent on the occurrence of a specific event, such as activation of a signal transduction pathway, receptor internalization, and/or may be
20 manifest only in particular cell types.

[00148] It is also desirable and preferable to find compounds with advantageous and improved characteristics compared with known anti-atherosclerosis agents, in one or more of the following categories that are given as examples, and are not intended to be limiting: (a) pharmacokinetic properties, including oral bioavailability, half life, and
25 clearance; (b) pharmaceutical properties; (c) dosage requirements; (d) factors that decrease blood drug concentration peak-to-trough characteristics; (e) factors that increase the concentration of active drug at the receptor; (f) factors that decrease the liability for clinical drug-drug interactions; (g) factors that decrease the potential for adverse side-effects, including selectivity versus other biological targets; and (h) improved therapeutic
30 index.

[00149] As used herein, the term "patient" encompasses all mammalian species.

[00150] As used herein, the term "subject" refers to any human or non-human organism that could potentially benefit from treatment with an anti-atherosclerosis agent, *e.g.*, an endothelial lipase inhibitor. Exemplary subjects include human beings of any age with risk factors for atherosclerosis and its associated coronary artery disease. Common risk factors include, but are not limited to, age, sex, weight, and family history.

[00151] As used herein, "treating" or "treatment" cover the treatment of a disease-state in a mammal, particularly in a human, and include: (a) inhibiting the disease-state, *i.e.*, arresting its development; and/or (b) relieving the disease-state, *i.e.*, causing regression of the disease state.

[00152] As used herein, "prophylaxis" or "prevention" covers the preventive treatment of a subclinical disease-state in a mammal, particularly in a human, aimed at reducing the probability of the occurrence of a clinical disease-state. Patients are selected for preventative therapy based on factors that are known to increase risk of suffering a clinical disease state compared to the general population. "Prophylaxis" therapies can be divided into (a) primary prevention and (b) secondary prevention. Primary prevention is defined as treatment in a subject that has not yet presented with a clinical disease state, whereas secondary prevention is defined as preventing a second occurrence of the same or similar clinical disease state.

[00153] As used herein, "risk reduction" covers therapies that lower the incidence of development of a clinical disease state. As such, primary and secondary prevention therapies are examples of risk reduction.

[00154] "Therapeutically effective amount" is intended to include an amount of a compound of the present invention that is effective when administered alone or in combination to inhibit endothelial lipase and/or to prevent or treat the disorders listed herein. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the preventive or therapeutic effect, whether administered in combination, serially, or simultaneously.

BIOLOGICAL ACTIVITY

[00155] Endothelial lipase (EL) and hepatic lipase (HL) activities were measured using a fluorescent substrate, A10070, (Invitrogen, CA) doped into an artificial vesicle containing DMPG (Avanti Polar Lipids) as the excipient. Vesicles were prepared by



combining 571 μL of 29 mM DMPG in a 1:1 mixture of MeOH and CHCl_3 with 2000 μL of 1 mM A10070 in a 1:1 mixture of MeOH and CHCl_3 . The mixture was dried under nitrogen in multiple vials then resuspended in 20 mL total volume of 50 mM HEPES pH 8.0 buffer containing 50 mM NaCl and 0.2 mM EDTA. The sample was allowed to sit at room temperature for 15 min and then was sonicated 3 x 4 mins on ice with a Branson Sonicator using duty cycle 1. This preparation provides vesicles with a mole fraction of 0.11 for the FRET substrate.

[00156] The enzymatic assay was measured using 384-well white Optiplates. Each well contained 20 μL of assay buffer (50 mM HEPES pH 8.0, 50 mM NaCl and 1 mM CaCl_2) and 0.25 μL of a DMSO solution containing a compound of interest. EL or HL (10 μL) was added and allowed to incubate with the compound for 30 min at 37 °C. The source of EL was conditioned media obtained from HT-1080 cells that were transformed using RAGE technology (Athersys) to overexpress endogenous EL, and HL was partially purified from conditioned media obtained from COS cells overexpressing HL. The reaction was started by the addition of 10 μL of a 1:10 dilution of vesicles. The final total reaction volume was 20.25 μL . The reaction rates were measured on a Gemini plate reader with an excitation wavelength of 490 nm and an emission wavelength of 530 nm. Readings were taken over a period of 60 minutes, and the slope between 300 and 900 secs of the readout was used to calculate the rate of the reaction.

REFERENCE COMPOUNDS

[00157] The following reference compounds and their preparations are described below. The EL IC_{50} values were measured using the EL assay described above.

Compound No.	Structure	EL IC_{50} (nM)
Reference 1		9400

Compound No.	Structure	EL IC ₅₀ (nM)
Reference 2		>62000
Reference 3		>62000

[00158] The exemplified compounds, Example A1 to Example A9 and Example B1 to Example 205 and Example 207 to Example B397, disclosed in the present invention were tested in the EL assay described above. Surprisingly, Examples A1-A9 B1-B205, and
5 B207- B397 were found having a range of EL IC₅₀ values of $\leq 0.3 \mu\text{M}$ (300 nM), as shown below.

[00159] Accordingly, the compounds of the present invention can be administered to mammals, preferably humans, for the treatment of a variety of conditions and disorders, including, but not limited to, atherosclerosis, coronary heart disease, coronary artery
10 disease, coronary vascular disease, cerebrovascular disorders, Alzheimer's disease, venous thrombosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension,
15 vascular complications of diabetes, obesity or endotoxemia.

VI. PHARMACEUTICAL COMPOSITIONS, FORMULATIONS AND COMBINATIONS

[00160] The compounds of this invention can be administered for any of the uses
20 described herein by any suitable means, for example, orally, such as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders,

granules, elixirs, tinctures, suspensions, (including nanosuspensions, microsuspensions, spray-dried dispersions), syrups, and emulsions; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques (*e.g.*, as sterile injectable aqueous or non-aqueous solutions or suspensions);
5 nasally, including administration to the nasal membranes, such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories. They can be administered alone, but generally will be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

- 10 **[00161]** The term "pharmaceutical composition" means a composition comprising a compound of the invention in combination with at least one additional pharmaceutically acceptable carrier. A "pharmaceutically acceptable carrier" refers to media generally accepted in the art for the delivery of biologically active agents to animals, in particular, mammals, including, *i.e.*, adjuvant, excipient or vehicle, such as diluents, preserving
15 agents, fillers, flow regulating agents, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, perfuming agents, anti-bacterial agents, anti-fungal agents, lubricating agents and dispensing agents, depending on the nature of the mode of administration and dosage forms. Pharmaceutically acceptable carriers are formulated according to a number of factors well within the
20 purview of those of ordinary skill in the art. These include, without limitation: the type and nature of the active agent being formulated; the subject to which the agent-containing composition is to be administered; the intended route of administration of the composition; and the therapeutic indication being targeted. Pharmaceutically acceptable carriers include both aqueous and non-aqueous liquid media, as well as a variety of solid
25 and semi-solid dosage forms. Such carriers can include a number of different ingredients and additives in addition to the active agent, such additional ingredients being included in the formulation for a variety of reasons, *e.g.*, stabilization of the active agent, binders, etc., well known to those of ordinary skill in the art. Descriptions of suitable pharmaceutically acceptable carriers, and factors involved in their selection, are found in
30 a variety of readily available sources such as, for example, Allen, L. V. Jr. *et al.* *Remington: The Science and Practice of Pharmacy (2 Volumes)*, 22nd Edition (2012), Pharmaceutical Press.

[00162] The dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired.

[00163] By way of general guidance, the daily oral dosage of each active ingredient, when used for the indicated effects, will range between about 0.01 to about 5000 mg per day, preferably between about 0.1 to about 1000 mg per day, and most preferably

between about 0.1 to about 250 mg per day. Intravenously, the most preferred doses will range from about 0.01 to about 10 mg/kg/minute during a constant rate infusion.

Compounds of this invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily.

[00164] The compounds are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as pharmaceutical carriers) suitably selected with respect to the intended form of administration, *e.g.*, oral tablets, capsules, elixirs, and syrups, and consistent with conventional pharmaceutical practices.

[00165] Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 milligram to about 2000 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.1-95% by weight based on the total weight of the composition.

[00166] A typical capsule for oral administration contains at least one of the compounds of the present invention (250 mg), lactose (75 mg), and magnesium stearate (15 mg). The mixture is passed through a 60 mesh sieve and packed into a No. 1 gelatin capsule.

[00167] A typical injectable preparation is produced by aseptically placing at least one of the compounds of the present invention (250 mg) into a vial, aseptically freeze-drying and sealing. For use, the contents of the vial are mixed with 2 mL of physiological saline, to produce an injectable preparation.

[00168] The present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, a therapeutically effective amount of at least one of the compounds of the present invention, alone or in combination with a pharmaceutical carrier. Optionally, compounds of the present invention can be used alone, in

5 combination with other compounds of the invention, or in combination with one or more, preferably one to three, other therapeutic agent(s), *e.g.*, HMG-CoA reductase inhibitors or other pharmaceutically active material.

[00169] The compounds of the present invention may be employed in combination with other EL inhibitors or one or more, preferably one to three, other suitable therapeutic agents useful in the treatment of the aforementioned disorders including:

10 anti-atherosclerotic agents, anti-dyslipidemic agents, anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-thrombotic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, anti-pancreatic agents, lipid lowering agents, anorectic agents, memory enhancing agents, anti-dementia agents, cognition promoting agents, appetite suppressants, treatments for heart failure, treatments for peripheral arterial disease, treatment for malignant tumors, and anti-inflammatory agents.

20 [00170] The compounds of the present invention may be employed in combination with additional therapeutic agent(s) selected from one or more, preferably one to three, of the following therapeutic agents in treating atherosclerosis: anti-hyperlipidemic agents, plasma HDL-raising agents, anti-hypercholesterolemic agents, cholesterol biosynthesis inhibitors (such as HMG CoA reductase inhibitors), acyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitors, LXR agonist, probucol, raloxifene, nicotinic acid, niacinamide, cholesterol absorption inhibitors, bile acid sequestrants (such as anion exchange resins, or quaternary amines (*e.g.*, cholestyramine or colestipol)), low density lipoprotein receptor inducers, clofibrate, fenofibrate, benzofibrate, ciprofibrate, gemfibrozil, vitamin B₆, vitamin B₁₂, anti-oxidant vitamins, β -blockers, anti-diabetes agents, angiotensin II antagonists, angiotensin converting enzyme inhibitors, platelet aggregation inhibitors, fibrinogen receptor antagonists, aspirin or fibric acid derivatives.

25
30

[00171] The compounds of the present invention may be employed in combination with additional therapeutic agent(s) selected from one or more, preferably one to three, of the following therapeutic agents in treating cholesterol biosynthesis inhibitor, particularly an HMG-CoA reductase inhibitor. Examples of suitable HMG-CoA reductase inhibitors include, but are not limited to, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, and rivastatin.

[00172] The term HMG-CoA reductase inhibitor is intended to include all pharmaceutically acceptable salt, ester, free acid and lactone forms of compounds which have HMG-CoA reductase inhibitory activity and, therefore, the use of such salts, esters, free acids and lactone forms is included within the scope of this invention. Compounds which have inhibitory activity for HMG-CoA reductase can be readily identified using assays well-known in the art.

[00173] The compounds of the invention may be used in combination with one or more, preferably one to three, of the following anti-diabetic agents depending on the desired target therapy. Studies indicate that diabetes and hyperlipidemia modulation can be further improved by the addition of a second agent to the therapeutic regimen. Examples of anti-diabetic agents include, but are not limited to, sulfonylureas (such as chlorpropamide, tolbutamide, acetohexamide, tolazamide, glyburide, gliclazide, glynase, glimepiride, and glipizide), biguanides (such as metformin), thiazolidinediones (such as ciglitazone, pioglitazone, troglitazone, and rosiglitazone), and related insulin sensitizers, such as selective and non-selective activators of PPAR α , PPAR β and PPAR γ ; dehydroepiandrosterone (also referred to as DHEA or its conjugated sulphate ester, DHEA-SO₄); anti-glucocorticoids; TNF α inhibitors; α -glucosidase inhibitors (such as acarbose, miglitol, and voglibose), pramlintide (a synthetic analog of the human hormone amylin), other insulin secretagogues (such as repaglinide, gliquidone, and nateglinide), insulin, as well as the therapeutic agents discussed above for treating atherosclerosis.

[00174] The compounds of the invention may be used in combination with one or more, preferably one to three, of the following anti-obesity agents selected from phenylpropanolamine, phentermine, diethylpropion, mazindol, fenfluramine, dexfenfluramine, phentiramine, β_3 -adrenoreceptor agonist agents; sibutramine, gastrointestinal lipase inhibitors (such as orlistat), and leptins. Other agents used in treating obesity or obesity-related disorders include neuropeptide Y, enterostatin,

cholecystokinin, bombesin, amylin, histamine H₃ receptors, dopamine D₂ receptor modulators, melanocyte stimulating hormone, corticotrophin releasing factor, galanin and gamma amino butyric acid (GABA).

5 [00175] The above other therapeutic agents, when employed in combination with the compounds of the present invention may be used, for example, in those amounts indicated in the *Physicians' Desk Reference*, as in the patents set out above, or as otherwise determined by one of ordinary skill in the art.

10 [00176] Particularly when provided as a single dosage unit, the potential exists for a chemical interaction between the combined active ingredients. For this reason, when the compound of the present invention and a second therapeutic agent are combined in a single dosage unit they are formulated such that although the active ingredients are combined in a single dosage unit, the physical contact between the active ingredients is minimized (that is, reduced). For example, one active ingredient may be enteric coated. By enteric coating one of the active ingredients, it is possible not only to minimize the
15 contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines. One of the active ingredients may also be coated with a material that affects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between
20 the combined active ingredients. Furthermore, the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a low viscosity grade of
25 hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components. The polymer coating serves to form an additional barrier to interaction with the other component.

[00177] These as well as other ways of minimizing contact between the components of combination products of the present invention, whether administered in a single dosage
30 form or administered in separate forms but at the same time by the same manner, will be readily apparent to those skilled in the art, once armed with the present disclosure.

[00178] The compounds of the present invention can be administered alone or in combination with one or more, preferably one to three, additional therapeutic agents. By "administered in combination" or "combination therapy" it is meant that the compound of the present invention and one or more, preferably one to three, additional therapeutic agents are administered concurrently to the mammal being treated. When administered in combination, each component may be administered at the same time or sequentially in any order at different points in time. Thus, each component may be administered separately but sufficiently closely in time so as to provide the desired therapeutic effect.

[00179] The compounds of the present invention are also useful as standard or reference compounds, for example as a quality standard or control, in tests or assays involving the endothelial lipase. Such compounds may be provided in a commercial kit, for example, for use in pharmaceutical research involving endothelial lipase or HDL activity. For example, a compound of the present invention could be used as a reference in an assay to compare its known activity to a compound with an unknown activity. This would ensure the experimenter that the assay was being performed properly and provide a basis for comparison, especially if the test compound was a derivative of the reference compound. When developing new assays or protocols, compounds according to the present invention could be used to test their effectiveness. The compounds of the present invention may also be used in diagnostic assays involving endothelial lipase.

[00180] The present invention also encompasses an article of manufacture. As used herein, article of manufacture is intended to include, but not be limited to, kits and packages. The article of manufacture of the present invention, comprises: (a) a first container; (b) a pharmaceutical composition located within the first container, wherein the composition, comprises: a first therapeutic agent, comprising: a compound of the present invention or a pharmaceutically acceptable salt form thereof; and, (c) a package insert stating that the pharmaceutical composition can be used for the treatment and/or prophylaxis of dyslipidemias and the sequelae thereof. In another embodiment, the package insert states that the pharmaceutical composition can be used in combination (as defined previously) with a second therapeutic agent for the treatment and/or prophylaxis of dyslipidemias and the sequelae thereof. The article of manufacture can further comprise: (d) a second container, wherein components (a) and (b) are located within the second container and component (c) is located within or outside of the second container.

Located within the first and second containers means that the respective container holds the item within its boundaries.

[00181] The first container is a receptacle used to hold a pharmaceutical composition. This container can be for manufacturing, storing, shipping, and/or individual/bulk selling.

5 First container is intended to cover a bottle, jar, vial, flask, syringe, tube (*e.g.*, for a cream preparation), or any other container used to manufacture, hold, store, or distribute a pharmaceutical product.

[00182] The second container is one used to hold the first container and, optionally, the package insert. Examples of the second container include, but are not limited to,

10 boxes (*e.g.*, cardboard or plastic), crates, cartons, bags (*e.g.*, paper or plastic bags), pouches, and sacks. The package insert can be physically attached to the outside of the first container via tape, glue, staple, or another method of attachment, or it can rest inside the second container without any physical means of attachment to the first container. Alternatively, the package insert is located on the outside of the second container. When
15 located on the outside of the second container, it is preferable that the package insert is physically attached via tape, glue, staple, or another method of attachment. Alternatively, it can be adjacent to or touching the outside of the second container without being physically attached.

[00183] The package insert is a label, tag, marker, etc. that recites information relating
20 to the pharmaceutical composition located within the first container. The information recited will usually be determined by the regulatory agency governing the area in which the article of manufacture is to be sold (*e.g.*, the United States Food and Drug Administration). Preferably, the package insert specifically recites the indications for which the pharmaceutical composition has been approved. The package insert may be
25 made of any material on which a person can read information contained therein or thereon. Preferably, the package insert is a printable material (*e.g.*, paper, plastic, cardboard, foil, adhesive-backed paper or plastic, etc.) on which the desired information has been formed (*e.g.*, printed or applied).

[00184] Other features of the invention should become apparent in the course of the
30 above descriptions of exemplary embodiments that are given for illustration of the invention and are not intended to be limiting thereof.


EXAMPLES

[00185] The following Examples have been prepared, isolated and characterized using the methods disclosed herein. The following examples demonstrate a partial scope of the invention and are not meant to be limiting of the scope of the invention.

5

Example A1

N-(1-(6-(6-Fluoropyridin-3-yl)benzo[d]thiazol-2-yl)-2-oxo-2-((2-sulfamoyl)ethyl)amino)ethyl)-4-(trifluoromethyl)benzamide



10

Compound A1a. 2-(6-Bromobenzo[d]thiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide

[00186] Ethyl 2-(6-bromobenzo[d]thiazol-2-yl)acetate (described in WO2011/074560, 250 mg, 0.83 mmol) in THF (4 mL) was treated with sodium hydroxide (1N NaOH, 0.92 mL, 0.92 mmol). After 2 hours, the reaction mixture was concentrated to dryness under reduced pressure, and the residue was co-evaporated with toluene (5 mL), re-dissolved in DMF (4 mL), and treated with 2-aminoethanesulfonamide hydrochloride (201 mg, 1.30 mmol), TEA (1.2 mL, 8.3 mmol) and HATU (475 mg, 1.30 mmol). After 16 hours, the reaction mixture was diluted with water (20 mL), extracted with DCM (3 X 10 mL), dried over Na₂SO₄, and concentrated under reduced pressure. The residue was dissolved in

15

DMF/methanol and purified using reverse phase HPLC (Phenomemex Luna AXIA 5 micron C18, 21.2X100 mm, 30 to 100% B over 15 minutes with 10 minute hold time, solvent A: 90% water/ACN/0.1%TFA, solvent B:90% ACN/water/0.1%TFA, Flow rate 20 mL/min; detector at 254). The pooled fractions were lyophilized to Compound A1a, (170 mg, 45 % yield) as a white solid. HPLC: RT = 0.75 (LCMS Method O). MS (ES): $m/z = 379.7 [M+H]^+$. ^1H NMR (400MHz, DMF- d_7) δ 8.40 (d, $J=2.0$ Hz, 1H), 7.92 (d, $J=8.8$ Hz, 1H), 7.69 (dd, $J=8.8, 2.0$ Hz, 1H), 6.97 (s, 2H), 3.82 - 3.61 (m, 2H), 3.46 (s, 3H), 3.33 (dd, $J=7.9, 6.4$ Hz, 3H).

Compound A1b. 2-(6-(6-Fluoropyridin-3-yl)benzo[d]thiazol-2-yl)-N-(2-sulfamoylethyl)acetamide

[00187] $PdCl_2(dppf) \cdot CH_2Cl_2$ (21.6 mg, 0.026 mmol) was added to a solution of Compound A1a (100 mg, 0.26 mmol), potassium phosphate (84 mg, 0.40 mmol) and 2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (88 mg, 0.40 mmol) in dioxane (4 mL). The reaction mixture was purged with argon, and the reaction vessel was sealed and heated at 110°C for 18 hrs. The reaction mixture was allowed to cool to room temperature, diluted with water (20 mL), extracted with DCM (3 X 15 mL), dried over Na_2SO_4 , and concentrated under reduced pressure. The residue was purified using reverse phase HPLC (Waters Sunfire 5 micron 19x10 mm; 15min. Gradient, Flow rate 20 mL / min. ; wavelength at 220 nm; start % B = 20 & final % B = 100); Solvent A = 10% MeOH - 90% H_2O - 0.1% NH_4OAc : Solvent B = 90% MeOH - 10% H_2O - 0.1% NH_4OAc). The fractions containing product were combined and concentrated under reduced pressure to give Compound A1b (34 mg, 33 % yield) as a white solid. HPLC: RT = 0.76 (LCMS Method O). MS (ES): $m/z = 395.1 [M+H]^+$. ^1H NMR (400MHz, DMF- d_7) δ 8.76 - 8.68 (m, 1H), 8.54 - 8.49 (m, 1H), 8.48 - 8.36 (m, 1H), 8.12 - 8.07 (m, 2H), 7.96 - 7.85 (m, 1H), 7.41 - 7.30 (m, 1H), 7.05 - 6.94 (m, 1H), 5.83 (s, 1H), 4.22 (s, 2H), 3.80 - 3.67 (m, 2H), 3.38 - 3.32 (m, 2H).

Compound A1c. (E)-2-(6-(6-Fluoropyridin-3-yl)benzo[d]thiazol-2-yl)-2-(hydroxyimino)-N-(2-sulfamoylethyl)acetamide



[00188] To a suspension of Compound A1b (100 mg, 0.25 mmol) in acetic acid (4 mL) and water (0.4 mL) was added sodium nitrite (21 mg, 0.30 mmol), and the reaction



stirred at room temperature for 2 hours. A precipitate formed and the reaction mixture was filtered, the solids were washed successively with water, dichloromethane, ether and dried under reduced pressure to give Compound A1c (93 mg, 87 % yield) as a yellow solid. HPLC: RT = 0.77 (LCMS Method O). MS (ES): $m/z = 424.1$ $[M+H]^+$. ^1H NMR (400MHz, DMF- d_7) δ 8.71 (d, $J=2.5$ Hz, 1H), 8.59 - 8.36 (m, 2H), 8.18 (d, $J=8.5$ Hz, 1H), 7.95 (dd, $J=8.4$, 1.6 Hz, 1H), 7.34 (dd, $J=8.5$, 3.0 Hz, 1H), 4.04 (br. s., 1H), 3.93 - 3.76 (m, 1H), 3.64 - 3.34 (m, 2H).




Example A1

- 10 [00189] To a suspension of Compound A1c (34 mg, 0.080 mmol) in MeOH (10 mL) was added 4-(trifluoromethyl)benzoic anhydride (116 mg, 0.320 mmol) and 10% Pd/C (3 mg, 0.05mmol). The reaction mixture was degassed with argon and stirred under hydrogen atmosphere (ballon) for 2 hours at room temperature. The reaction mixture was diluted with DMF (2 mL), filtered, concentrated under reduced pressure and purified by
- 15 preparatory HPLC (Sunfire 5 μ 19 x100mm; 25 min. gradient; inj. vol. 2 mL, Flow rate 20mL/min. ; wavelength 220 nm; start % B = 20, final % B = 100, Solvent A = 10 % MeOH - 90 % H₂O - 0.1% TFA, Solvent B = 90% MeOH - 10%H₂O - 0.1% TFA) to give Example A1 (13 mg, 27 % yield). HPLC: RT = 0.9 (LCMS Method O). MS (ES): $m/z = 581.9$ $[M+H]^+$. ^1H NMR (400MHz, DMSO- d_6) δ 9.78 (s, 1H), 8.64 (d, $J=2.5$ Hz, 1H), 8.49 (d, $J=1.8$ Hz, 1H), 8.37 (d, $J=2.8$ Hz, 1H), 8.17 (d, $J=8.0$ Hz, 2H), 8.09 (d, $J=8.5$ Hz, 1H), 7.95 - 7.80 (m, 3H), 7.32 (dd, $J=8.7$, 2.9 Hz, 1H), 6.93 (s, 2H), 6.14 (d, $J=7.8$ Hz, 1H), 3.57 (t, $J=6.5$ Hz, 2H), 3.26 - 3.09 (m, 2H). EL IC₅₀ 35 nM.
- 20

- [00190] The following compounds, Example A2 to Example A8 were prepared by the
- 25 general procedures described for Example A1.


Ex #	Structure	Name	¹ H NMR (400MHz, DMSO-d ₆ , unless indicated otherwise)	LC/MS RT (min) Method M+H	EL IC ₅₀ (nM)
A2		N-(1-(6-(6-fluoropyridin-3-yl)benzo[d]thiazol-2-yl)-2-oxo-2-((2-sulfamoyl)ethyl)amino)ethyl)nicotinamide	δ 9.83 (d, J=7.8 Hz, 1H), 9.14 (d, J=1.5 Hz, 1H), 8.82 - 8.72 (m, 2H), 8.63 (d, J=2.5 Hz, 1H), 8.49 (d, J=1.8 Hz, 1H), 8.37 (dt, J=4.1, 1.9 Hz, 2H), 8.09 (d, J=8.5 Hz, 1H), 7.87 (dd, J=8.5, 1.8 Hz, 1H), 7.61 (s, 1H), 7.35 - 7.28 (m, 1H), 6.94 (br. s., 2H), 6.15 (d, J=7.8 Hz, 1H), 3.64 - 3.53 (m, 2H), 3.20 (dd, J=8.4, 6.4 Hz, 2H)	0.7 O 515.0	<10
A3		N-(1-(6-(6-fluoropyridin-3-yl)benzo[d]thiazol-2-yl)-2-oxo-2-((2-sulfamoyl)ethyl)amino)ethyl)butyramide	δ 9.00 (d, J=7.8 Hz, 1H), 8.75 (s, 1H), 8.64 (d, J=2.5 Hz, 1H), 8.49 (d, J=1.5 Hz, 1H), 8.45 - 8.31 (m, 1H), 8.07 (d, J=8.3 Hz, 1H), 7.88 (dd, J=8.5, 1.8 Hz, 1H), 7.33 (dd, J=8.5, 2.8 Hz, 1H), 6.93 (s, 2H), 5.92 (d, J=7.8 Hz, 1H), 3.65 - 3.49 (m, 2H), 3.17 (t, J=7.4 Hz, 2H), 2.37 - 2.19	0.79 O 480.0	<10

				(m, 2H), 1.57 (qd, $J=7.4$, 1.8 Hz, 2H), 0.96 - 0.81 (m, 3H)		
A4		2-(2,2-difluoroacetamido)-2-((6-(6-fluoropyridin-3-yl)benzo[d]thiazol-2-yl)-N-(2-sulfamoylethyl)acetamide		δ 10.06 - 9.93 (m, 1H), 8.90 - 8.80 (m, 1H), 8.67 - 8.60 (m, 1H), 8.54 - 8.49 (m, 1H), 8.42 - 8.34 (m, 1H), 8.16 - 8.08 (m, 1H), 7.95 - 7.85 (m, 1H), 7.40 - 7.29 (m, 1H), 7.26 - 7.16 (m, 1H), 7.11 - 7.04 (m, 1H), 6.98 - 6.89 (m, 3H), 6.59 - 6.24 (m, 1H), 6.05 - 5.91 (m, 1H), 5.79 - 5.71 (m, 1H), 3.59 - 3.48 (m, 2H), 3.21 - 3.10 (m, 2H)	0.8 O 488.0	<10
A5		N-(1-(6-(4-(morpholine-4-carbonyl)phenyl)benzo[d]thiazol-2-yl)-2-oxo-2-((2-sulfamoylethyl)amino)ethyl)butyramide		δ 8.99 (d, $J=7.7$ Hz, 1H), 8.75 (s, 1H), 8.46 (d, $J=1.5$ Hz, 1H), 8.04 (d, $J=8.6$ Hz, 1H), 7.89 - 7.79 (m, 3H), 7.59 - 7.48 (m, 2H), 6.93 (d, $J=10.1$ Hz, 2H), 5.91 (d, $J=7.9$ Hz, 1H), 3.71 - 3.44 (m, 10H), 3.16 (t, $J=7.5$ Hz, 2H), 2.36 - 2.15 (m, 2H), 1.56 (dd, $J=7.3$, 1.5 Hz, 2H), 0.95 - 0.76 (m, 3H)	0.7 O 574.0	<10

A6		N-(1-(6-(4-(morpholine-4-carbonyl)phenyl)benzo[d]thiazol-2-yl)-2-oxo-2-((2-sulfamoylethyl)amino)ethyl)nicotinamide	δ 9.80 (d, $J=7.9$ Hz, 1H), 9.13 (dd, $J=2.3$, 0.8 Hz, 1H), 8.82 - 8.71 (m, 1H), 8.55 - 8.42 (m, 1H), 8.40 - 8.22 (m, 1H), 8.09 (d, $J=8.6$ Hz, 1H), 7.92 - 7.75 (m, 2H), 7.64 - 7.49 (m, 2H), 6.95 (s, 1H), 6.15 (d, $J=7.7$ Hz, 1H), 4.08 (q, $J=5.3$ Hz, 1H), 3.75 - 3.50 (m, 5H), 3.31 (s, 2H), 3.25 - 3.12 (m, 2H)	0.6 O 609.2	<10
A7		4-carbonylphenyl)benzo[d]thiazol-2-yl)-2-oxo-2-((2-sulfamoylethyl)amino)ethyl)-4-(trifluoromethyl)benzamide	δ 9.80 (d, $J=7.7$ Hz, 1H), 8.86 - 8.72 (m, 1H), 8.48 (d, $J=1.5$ Hz, 1H), 8.19 (d, $J=8.1$ Hz, 1H), 8.09 (d, $J=8.6$ Hz, 1H), 8.00 - 7.80 (m, 3H), 7.60 - 7.48 (m, 1H), 7.01 - 6.89 (m, 1H), 6.18 - 5.72 (m, 2H), 3.73 - 3.54 (m, 4H), 3.28 - 3.15 (m, 2H)	0.9 O 676.2	<10
A8		2-acetamido-2-(6-(4-fluorophenyl)benzo[d]thiazol-2-yl)-N-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)acetamide	δ 9.32 (t, $J=5.8$ Hz, 1H), 9.09 (d, $J=8.0$ Hz, 1H), 8.41 - 8.38 (m, 1H), 8.02 (d, $J=8.5$ Hz, 1H), 7.83 - 7.76 (m, 4H), 7.37 - 7.29 (m, 3H), 5.99 (d, $J=8.0$ Hz, 1H), 4.65 - 4.48 (m, 2H), 2.44 (s, 3H), 2.01 - 1.99 (m, 3H)	0.8 O 440.2	<10

Example A9

2-(3-Benzylureido)-2-(6-(4-fluorophenyl)benzo[d]thiazol-2-yl)-N-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)acetamide



5

Compound A9a. 2-(6-(4-Fluorophenyl)benzo[d]thiazol-2-yl)-N-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)acetamide

[00191] Ethyl 2-(6-(4-fluorophenyl)benzo[d]thiazol-2-yl)acetate (described in WO2011/074560, 500 mg, 1.59 mmol) in THF (4 mL) was treated with sodium

10 hydroxide (1N NaOH, 1.9 mL, 1.9 mmol). After 2 hours, the reaction mixture was concentrated to dryness under reduced pressure. The residue was co-evaporated with toluene (5 mL), re-dissolved in DMF (4 mL), and treated with (5-methyl-1,3,4-oxadiazol-2-yl)methanamine hydrochloride (284 mg, 1.90 mmol), TEA (2.2 mL, 16 mmol) and PyBOP (990 mg, 1.9 mmol). After 16 hours, the reaction mixture was diluted with water

15 (20 mL), extracted with DCM (3 X 10 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel (eluting with 0-20% DCM/MeOH) to give Compound A9a (485 mg, 80.0 % yield) as an oil.

HPLC: RT = 0.88 (LCMS Method O). MS (ES): m/z = 383.2 [M+H]⁺. ¹H NMR (400MHz, DMF-d₇) δ 9.12 (br. s., 1H), 8.41 (d, J=1.8 Hz, 1H), 7.93 - 7.76 (m, 3H), 7.43 - 7.27 (m, 2H), 4.69 (d, J=5.8 Hz, 2H), 4.28 (s, 2H), 2.50 (s, 3H).

20

Compound A9b. (Z)-2-(6-(4-Fluorophenyl)benzo[d]thiazol-2-yl)-2-(hydroxyimino)-N-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)acetamide


[00192] Compound A9b) 50 mg, 47% yield) was prepared from Compound A9a as described in the general procedure given for Compound A1c. HPLC: RT = 0.93 (LCMS Method O). MS (ES): $m/z = 412.2 [M+H]^+$. ^1H NMR (400MHz, DMF- d_7) δ 8.34 - 8.27 (m, 1H), 7.98 - 7.93 (m, 1H), 7.89 - 7.84 (m, 2H), 7.82 - 7.78 (m, 1H), 7.41 - 7.28 (m, 2H), 5.04 - 4.95 (m, 2H), 2.54 (s, 3H).

Example A9

[00193] To a suspension of Compound A9b (50 mg, 0.12 mmol) in EtOH (10 mL) was added (isocyanatomethyl) benzene (16 mg, 0.12 mmol) and 10% Pd/C (3 mg, 0.05 mmol). The mixture was degassed with argon and stirred under hydrogen atmosphere (balloon) at room temperature for 2 hours. The reaction mixture was diluted with DMF (2 mL), filtered, concentrated under reduced pressure and purified by preparatory HPLC (Phenomenex AXIA Luna 5 μ 75 x 30mm; 35 min. gradient; inj. vol. 2 mL, Flow rate 40 mL / min. ; wavelength 220nm; start %B = 20, final %B = 100) Solvent A = 10% MeOH - 90% H₂O - 0.1% TFA : Solvent B = 90% MeOH - 10% H₂O - 0.1% TFA) to give Example A9 (10 mg, 15 % yield). HPLC: RT = 0.95 (LCMS Method O). MS (ES): $m/z = 531.2 [M+H]^+$. ^1H NMR (400MHz, DMSO- d_6) δ 8.41 (d, $J=1.8$ Hz, 1H), 8.02 (d, $J=8.5$ Hz, 1H), 7.86 - 7.74 (m, 3H), 7.40 - 7.23 (m, 9H), 6.98 (s, 1H), 5.87 (d, $J=8.0$ Hz, 1H), 4.65 - 4.48 (m, 2H), 4.27 (d, $J=5.8$ Hz, 2H), 2.42 (s, 3H). EL IC₅₀ 50 nM.

Example B1

2-(Methylsulfonyl)-2-(6-phenylbenzo[d]thiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide



Compound B1a. Ethyl 2-(methylsulfonyl)-2-(6-phenylbenzo[d]thiazol-2-yl)acetate


[00194] Ethyl 2-(6-phenylbenzo[d]thiazol-2-yl)acetate (described in WO2011/074560, 550 mg, 1.9 mmol) was dissolved in DMF (10 mL) and cooled to 0 °C. DBU (0.61 mL, 4.1 mmol) was added. After 10 minutes, methanesulfonyl chloride (0.2 mL, 3 mmol) was added dropwise. The reaction mixture was removed from the ice bath and stirred at room temperature. After 4 hours, the reaction mixture was cooled back to 0 °C, and additional methane sulfonyl chloride (0.11 mL, 1.4 mmol) was added. Following addition, the reaction mixture was removed from ice bath and stirred at room temperature. After 3 days, the reaction mixture was quenched by the addition of water (20 mL), and the resulting solid was collected by filtration. The solids were dissolved in DCM, washed with aqueous 10 % LiCl, 1N HCl, brine, dried over MgSO₄, concentrated under reduced pressure, and purified by silica gel chromatography (eluting with 0-20% DCM/MeOH) to give Compound B1a (250 mg, 36 % yield) as a yellow oil. HPLC: RT = 1.03 min (LCMS Method O). MS (ES): m/z = 376.0 [M+H]⁺. ¹H NMR (400MHz, pyridine-d₅) δ 8.07 (br. s., 1H), 7.79 - 7.64 (m, 4H), 7.51 (t, J=7.7 Hz, 2H), 7.40 (s, 1H), 4.39 (d, J=7.0 Hz, 2H), 3.49 (s, 3H), 1.29 (t, J=7.0 Hz, 3H).

Example B1

[00195] Compound B1a (110 mg, 0.29 mmol) was dissolved in dioxane (1 mL) and TEA (1 mL). 2-Aminoethanesulfonamide hydrochloride (94 mg, 0.59 mmol) was added, and the reaction mixture was sealed in a pressure vessel and heated at 135 °C for 18 hours. Additional 2-aminoethanesulfonamide hydrochloride (94 mg, 0.59 mmol) was added, and the reaction mixture was heated for an additional 3 hours at 165 °C. The reaction mixture was allowed to cool to room temperature, concentrated under reduced pressure, and the residue dissolved in DMF and purified by reverse phase HPLC (Waters Sunfire 5μ 19x100mm; 10min. Gradient/5-75mg; inj. vol. 2mL, Flow rate 20mL/min. ; wavelength 220nm; start %B = 80 & final %B = 100) Solvent A = 10% MeOH - 90% H₂O - 0.1% NH₄OAc : Solvent B = 90% MeOH - 10% H₂O - 0.1% NH₄Oac) to give Example B1 (20 mg, 15 % yield) as a white solid. HPLC: RT = 0.86 (LCMS Method O). MS (ES): m/z = 453.9 [M+H]⁺. ¹H NMR (400MHz, pyridine-d₅) δ 10.14 (s, 2H), 9.63 (br. s., 1H), 9.33 - 9.12 (m, 3H), 9.09 (s, 1H), 8.98 (t, J=7.7 Hz, 2H), 8.87 (d, J=7.3 Hz, 1H), 5.76 (d, J=6.0 Hz, 2H), 5.34 (t, J=6.3 Hz, 2H), 5.01 (br. s., 2H). EL IC₅₀ <10 nM.

Example B2

2-(Allylsulfonyl)-2-(6-phenylbenzo[d]thiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide



- 5 Compound B2a. 2-(6-Phenylbenzo[d]thiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide
 [00196] Pd(PPh₃)₄ (51 mg, 0.044 mmol) was added to dioxane (2 mL) / 2M Na₂CO₃ (1 mL) solution of Compound A1a (73 mg, 0.15 mmol) and phenylboronic acid (27 mg, 0.22 mmol). The reaction mixture was purged with argon gas and heated at 100 °C. After 90 minutes, the reaction mixture was diluted with water (20 mL), extracted with
 10 DCM (3 X 15 mL), and the combined organic portions dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was dissolved in DMF/methanol and purified using reverse phase HPLC (Phenomemex Luna AXIA 5 micron C18, 21.2 X 100 mm, 30 to 100% B over 15 minutes with 10 minute hold time, solvent A: 90% water/ACN/0.1%TFA, solvent B: 90% ACN/water/0.1%TFA, Flow rate 20 mL/min;
 15 detector at 254). The pooled fractions were diluted with saturated NaHCO₃ (20 mL), extracted with DCM (3 X 15 mL), dried over Na₂SO₄, and concentrated under reduced pressure to give Compound B2a (23 mg, 41 % yield) as a white solid. HPLC: RT = 0.83 min (LCMS Method M). MS (ES): m/z = 375.9 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.44 - 8.68 (1 H, m), 8.36 (1 H, d, J=1.93 Hz), 7.88 (1 H, d, J=8.80 Hz), 7.56 - 7.70
 20 (1 H, m), 6.90 (2 H, s), 4.06 (2 H, s), 3.43 - 3.62 (2 H, m), 3.07 - 3.22, (2 H, m).

Example B2



- [00197] Compound B2a (22 mg, 0.059 mmol) was dissolved in DMF (1 mL) and treated with NaH (60% in nujol, 11.7 mg, 0.300 mmol) at 0 °C. The reaction mixture
 25 was maintained at 0 °C for 2 minutes, allowed to reach room temperature for 3 minutes, and cooled back to 0 °C. After 2 minutes, prop-2-ene-1-sulfonyl chloride (12.4 mg,




0.0900 mmol) was added. After 20 minutes, the reaction mixture was quenched by the addition of 0.1 mL acetic acid, diluted with DMF/methanol and purified using reverse phase HPLC (Phenomenex Luna AXIA 5 micron C18, 21.2 X 100 mm, 30 to 100% B over 15 minutes with 10 minute hold time, solvent A: 90% water/ACN/0.1%TFA, solvent
5 B: 90% ACN/water/0.1%TFA, Flow rate 20 mL/min; detector at 254). The fractions containing product were lyophilized to yield Example B2 (8.1 mg, 29 % yield) as an off-white solid. HPLC: RT = 0.93 min (LCMS Method M). MS (ES): $m/z = 479.8$ $[M+H]^+$. ^1H NMR (500MHz, DMSO- d_6) δ 9.16 - 8.93 (m, 1H), 8.48 (d, $J=1.4$ Hz, 1H), 8.15 (d, $J=8.5$ Hz, 1H), 7.88 (d, $J=1.7$ Hz, 1H), 7.77 (dd, $J=8.3, 1.1$ Hz, 2H), 7.51 (d, $J=8.0$ Hz,
10 2H), 7.50 - 7.31 (m, 1H), 6.95 (s, 2H), 6.06 (s, 1H), 5.91 - 5.74 (m, 1H), 5.64 - 5.45 (m, 2H), 4.30 - 4.13 (m, 2H), 3.65 - 3.51 (m, 2H), 3.19 (d, $J=1.4$ Hz, 2H). EL $IC_{50} < 10$ nM




[00198] The following compounds, Example B3 to Example B22 were prepared as described in the general procedure given for Example B2.




15




Ex #	Structure	Name	¹ H NMR (500MHz, DMSO-d ₆ , unless indicated otherwise)	LC/MS RT (min) Method M+H	EL IC ₅₀ (nM)
B3		2-(6-(6-fluoro-3-pyridinyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoylethyl)acetamide	¹ H NMR (400MHz, DMSO-d ₆) δ 8.97 (s, 1H), 8.65 (d, J=1.8 Hz, 1H), 8.55 (d, J=1.5 Hz, 1H), 8.38 (d, J=2.5 Hz, 1H), 8.18 (d, J=8.5 Hz, 1H), 7.92 (dd, J=8.5, 1.8 Hz, 1H), 7.33 (dd, J=8.5, 2.8 Hz, 1H), 6.93 (s, 2H), 6.04 (s, 1H), 3.60 (d, J=6.3 Hz, 2H), 3.23 (s, 3H), 3.21 - 3.16 (m, 2H)	0.75 O 473.0	<10
B4		2-(6-(3,5-dimethyl-1-isoxazolyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoylethyl)acetamide	¹ H NMR (400MHz, DMSO-d ₆) δ 8.98 (s, 1H), 8.21 (d, J=1.3 Hz, 1H), 8.15 (d, J=8.5 Hz, 1H), 7.56 (dd, J=8.5, 1.8 Hz, 1H), 6.94 (s, 2H), 6.04 (s, 1H), 3.25 - 3.16 (m, 8H), 2.44 (s, 4H), 2.26 (s, 4H)	0.74 O 472.9	13
B5		2-(6-(6-fluoro-3-pyridinyl)-1,3-benzothiazol-2-yl)-2-(phenylsulfonyl)-N-(2-sulfamoylethyl)acetamide	¹ H NMR (400MHz, DMSO-d ₆) δ 9.09 - 8.96 (m, 1H), 8.66 (d, J=2.5 Hz, 1H), 8.56 (d, J=1.8 Hz, 2H), 8.39 (td, J=8.2, 2.6 Hz, 1H), 8.22 (d, J=8.5 Hz, 1H), 8.13 (s, 1H),	0.89 O 548.9	<10




			7.93 (dd, $J=8.5, 2.0$ Hz, 1H), 7.41 - 7.37 (m, 6H), 7.36 - 7.23 (m, 6H), 6.94 (s, 4H), 6.10 (s, 1H), 4.85 - 4.51 (m, 3H), 3.60 (q, $J=6.4$ Hz, 2H), 3.29 - 3.10 (m, 2H)		
B6		2-(6-(6-fluoro-3-pyridinyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoylethyl)-2-((4-(trifluoromethyl)benzyl)sulfonyl)acetamide	¹ H NMR (400MHz, DMSO-d ₆) δ 9.02 (s, 1H), 8.65 (d, $J=2.5$ Hz, 1H), 8.54 (d, $J=1.5$ Hz, 2H), 8.38 (d, $J=2.5$ Hz, 1H), 8.20 (d, $J=8.5$ Hz, 1H), 8.13 (d, $J=1.5$ Hz, 1H), 7.93 (dd, $J=8.7, 1.9$ Hz, 1H), 7.73 (d, $J=8.5$ Hz, 2H), 7.68 - 7.51 (m, 5H), 7.34 (dd, $J=8.8, 2.8$ Hz, 2H), 6.94 (s, 4H), 6.12 (s, 1H), 4.88 (d, $J=3.0$ Hz, 2H), 3.60 (d, $J=6.3$ Hz, 3H), 3.22 - 3.15 (m, 2H)	0.95 O 616.9	<10
B7		2-(6-(6-fluoropyridin-3-yl)benzo[d]thiazol-2-yl)-N-(2-sulfamoylethyl)-2-((3,3,3-trifluoropropyl)sulfonyl)acetamide	¹ H NMR (400MHz, DMSO-d ₆) δ 8.95 (d, $J=4.8$ Hz, 1H), 8.65 (br. s., 1H), 8.57 (br. s., 2H), 8.39 (d, $J=3.3$ Hz, 1H), 8.24 - 8.15 (m, 2H), 7.94 (d, $J=6.3$ Hz, 1H), 7.76 (br. s., 1H), 7.33 (d, $J=6.0$ Hz, 2H), 6.94 (br. s., 3H), 6.27 (d, $J=5.5$ Hz, 1H), 3.88 - 3.50 (m, 4H), 3.27 - 2.66 (m, 5H)	0.89 O 554.9	13

B8		2-(6-(2-fluoro-4-pyridinyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoylethyl)acetamide	δ 9.00 (s, 1H), 8.75 (d, J=1.9 Hz, 1H), 8.37 (d, J=5.2 Hz, 1H), 8.23 (d, J=8.5 Hz, 1H), 8.07 (dd, J=8.8, 1.9 Hz, 1H), 7.82 (d, J=5.2 Hz, 1H), 7.65 (s, 1H), 6.96 (s, 2H), 6.07 (s, 1H), 3.69 - 3.55 (m, 3H), 3.28 - 3.23 (m, 3H), 3.23 - 3.09 (m, 2H)	0.74 M 472.8	<10
B9		2-(6-(2-chloro-4-pyridinyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoylethyl)acetamide	δ 9.00 (s, 1H), 8.74 (d, J=1.7 Hz, 1H), 8.53 (d, J=5.2 Hz, 1H), 8.22 (d, J=8.5 Hz, 1H), 8.06 (dd, J=8.5, 1.9 Hz, 1H), 7.98 (d, J=1.1 Hz, 1H), 7.87 (dd, J=5.4, 1.5 Hz, 1H), 6.96 (s, 1H), 6.52 (s, 1H), 6.07 (s, 1H), 3.65 - 3.58 (m, 2H), 3.25 (s, 3H), 3.23 - 3.18 (m, 2H)	0.77 M 488.7	<10
B10		2-(6-(6-chloro-3-pyridinyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoylethyl)acetamide	δ 8.92 (s, 1H), 8.81 - 8.73 (m, 1H), 8.53 (d, J=1.9 Hz, 1H), 8.20 (dd, J=8.4, 2.6 Hz, 1H), 8.13 (d, J=8.5 Hz, 1H), 7.88 (dd, J=8.8, 1.9 Hz, 1H), 7.60 (d, J=8.3 Hz, 1H), 6.88 (s, 2H), 5.98 (s, 1H), 3.58 - 3.50 (m, 2H), 3.17 (s, 3H), 3.15 - 3.08 (m, 2H)	0.79 M 488.7	<10

B11		2-(methylsulfonyl)-N-(2-sulfamoyl-ethyl)-2-(6-(6-(trifluoromethyl)-3-pyridinyl)-1,3-benzothiazol-2-yl)acetamide	δ 9.21 (d, $J=2.2$ Hz, 1H), 9.00 (t, $J=5.8$ Hz, 1H), 8.70 (d, $J=1.7$ Hz, 1H), 8.48 (dd, $J=8.1, 2.1$ Hz, 1H), 8.25 (d, $J=8.5$ Hz, 1H), 8.09 - 8.00 (m, 2H), 6.96 (s, 2H), 6.07 (s, 1H), 3.65 - 3.58 (m, 2H), 3.27 - 3.24 (m, 3H), 3.24 - 3.17 (m, 2H)	0.84 M 527.7	<10
B12		2-(6-(6-fluoro-3-pyridinyl)-1,3-benzothiazol-2-yl)-2-(isopropylsulfonyl)-N-(2-sulfamoyl-ethyl)acetamide	^1H NMR (400MHz, DMSO- d_6) δ 9.04 (t, $J=5.5$ Hz, 1H), 8.64 (d, $J=2.3$ Hz, 1H), 8.61 - 8.50 (m, 1H), 8.38 (td, $J=8.2, 2.5$ Hz, 1H), 8.30 (br. s., 1H), 8.16 (d, $J=8.5$ Hz, 1H), 8.05 - 7.82 (m, 1H), 7.72 (d, $J=7.3$ Hz, 1H), 7.40 - 7.19 (m, 1H), 6.94 (br. s., 1H), 6.18 (s, 1H), 3.95 - 3.35 (m, 3H), 3.29 - 3.10 (m, 2H), 1.42 - 1.17 (m, 6H)	0.83 M 500.9	<10
B13		2-(methylsulfonyl)-2-(6-(4-(4-morpholinylmethyl)phenyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl-ethyl)acetamide	δ 9.14 - 8.95 (m, 1H), 8.23 - 8.09 (m, 1H), 7.66 (s, 1H), 7.30 (s, 1H), 7.03 (d, $J=1.9$ Hz, 3H), 6.86 - 6.69 (m, 2H), 6.10 (s, 2H), 3.62 - 3.48 (m, 2H), 3.18 - 3.05 (m, 2H), 2.73 (d, $J=6.1$ Hz, 5H), 2.37 (s, 6H)	0.58 M 552.9	<10


			3H), 2.35 - 2.20 (m, 6H)		
B14		2-(allylsulfonyl)-2-(6-(4-(4-morpholinylmethyl)phenyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl-ethyl)acetamide	δ 7.98 - 7.82 (m, 2H), 7.67 - 7.57 (m, 2H), 7.51 - 7.42 (m, 2H), 7.39 - 7.30 (m, 2H), 6.95 - 6.78 (m, 2H), 5.91 - 5.65 (m, 1H), 5.25 - 5.05 (m, 2H), 4.28 - 4.09 (m, 2H), 3.59 (d, $J=3.9$ Hz, 6H), 3.24 - 3.09 (m, 2H), 2.45 - 2.30 (m, 6H)	0.64 M 578.9	<10
B15		2-(6-(2-fluoro-4-pyridinyl)-1,3-benzothiazol-2-yl)-2-(propylsulfonyl)-N-(2-sulfamoyl-ethyl)acetamide	δ 9.05 - 8.98 (m, 1H), 8.74 (d, $J=1.7$ Hz, 1H), 8.37 (d, $J=5.2$ Hz, 1H), 8.22 (d, $J=8.5$ Hz, 1H), 8.06 (dd, $J=8.5, 1.9$ Hz, 1H), 7.82 (d, $J=5.2$ Hz, 1H), 7.65 (s, 1H), 6.96 (s, 2H), 6.09 (s, 1H), 3.66 - 3.56 (m, 3H), 3.43 - 3.38 (m, 2H), 3.23 - 3.12 (m, 2H), 1.82 - 1.70 (m, 2H), 1.00 (t, $J=7.4$ Hz, 3H)	0.83 M 500.8	<10
B16		2-(6-(4-acetamidophenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl-ethyl)acetamide	^1H NMR (500MHz, METHANOL- d_4) δ 8.28 - 8.13 (m, 1H), 8.08 - 7.95 (m, 1H), 7.81 - 7.69 (m, 1H), 7.59 (m, 4H), 3.86 - 3.61 (m, 2H), 3.32 - 3.23 (m, 2H), 3.12 (s, 3H), 2.06 (s, 3H)	0.69 M 511.1	40

B17		2-(6-(4-(dimethylsulfonyl)phenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)ethylacetamide	δ 9.08 - 8.92 (m, 1H), 8.61 (d, J =1.7 Hz, 1H), 8.20 (d, J =8.5 Hz, 1H), 8.04 (d, J =8.5 Hz, 2H), 7.97 (d, J =1.9 Hz, 1H), 7.87 (d, J =8.5 Hz, 2H), 6.95 (s, 2H), 3.60 (m, 2H), 3.24 (s, 3H), 3.19 (d, J =2.2 Hz, 2H), 2.75 - 2.60 (s, 6H)	0.78 M 561.1	<10
B18		2-(6-(4-(methylamino)phenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)ethylacetamide	δ 9.06 - 8.91 (m, 1H), 8.39 - 8.28 (m, 1H), 8.11 - 8.04 (m, 1H), 7.83 - 7.75 (m, 1H), 7.65 - 7.50 (m, 2H), 7.46 - 7.36 (m, 1H), 6.95 (s, 2H), 6.78 - 6.64 (m, 2H), 3.22 (m, 7H), 2.74 (s, 3H)	0.61 M 483.1	13
B19		2-(6-(6-methoxy-3-pyridinyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)ethylacetamide	δ 9.02 - 8.96 (m, 1H), 8.60 (d, J =2.8 Hz, 1H), 8.49 (d, J =1.9 Hz, 1H), 8.19 - 8.09 (m, 2H), 7.88 (dd, J =8.7, 1.8 Hz, 1H), 7.00 - 6.90 (m, 3H), 6.03 (s, 1H), 3.95 - 3.89 (m, 3H), 3.64 - 3.58 (m, 2H), 3.24 (s, 3H), 3.22 - 3.15 (m, 3H)	0.76 M 484.9	<10

B20		2-(methylsulfonyl)-2-(6-(4-(4-morpholinyl)phenyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide	δ 8.98 (t, J=5.6 Hz, 1H), 8.41 (d, J=1.4 Hz, 1H), 8.10 (d, J=8.5 Hz, 1H), 7.83 (dd, J=8.8, 1.9 Hz, 1H), 7.67 (d, J=8.8 Hz, 2H), 7.08 (d, J=9.1 Hz, 2H), 6.96 (s, 2H), 6.01 (s, 1H), 3.81 - 3.75 (m, 4H), 3.65 - 3.57 (m, 3H), 3.24 (s, 3H), 3.19 (t, J=5.0 Hz, 6H)	0.76 M 538.9	<10
B21		2-(methylsulfonyl)-2-(6-(4-(1H-pyrazol-1-yl)phenyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide	δ 8.97 - 8.86 (m, 1H), 8.54 - 8.44 (m, 1H), 8.10 (d, J=8.5 Hz, 1H), 7.96 - 7.89 (m, 2H), 7.88 - 7.79 (m, 2H), 7.79 - 7.65 (m, 2H), 6.88 (s, 2H), 6.56 - 6.47 (m, 1H), 3.58 - 3.50 (m, 2H), 3.21 - 3.15 (m, 3H), 3.15 - 3.08 (m, 2H)	0.84 M 519.9	<10
B22		methyl 4-(2-(1-(methylsulfonyl)-2-oxo-2-((2-sulfamoyl)ethyl)amino)ethyl)-1,3-benzothiazol-6-yl)phenyl)carbamate	δ 9.72 (s, 1H), 8.95 - 8.87 (m, 1H), 8.36 (d, J=1.7 Hz, 1H), 8.04 (d, J=8.8 Hz, 1H), 7.77 (dd, J=8.8, 1.9 Hz, 1H), 7.64 (d, J=8.8 Hz, 2H), 7.52 (d, J=8.5 Hz, 2H), 6.88 (s, 1H), 5.94 (s, 1H), 3.64 - 3.61 (m, 2H), 3.57 - 3.49 (m, 3H), 3.17 - 3.14 (m, 3H), 3.14 - 3.08 (m, 2H)	0.76 M 526.9	<10

Example B23

2-(6-(2-Fluoro-4-pyridinyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-(methylsulfonyl)ethyl)acetamide



- 5 Compound B23a. Ethyl 2-(6-(2-fluoropyridin-4-yl)benzo[d]thiazol-2-yl)acetate
[00199] SiliaCat DPP-Pd (0.26 mmol/g loading, from Silicycle, 100 mg, 0.67 mmol), ethyl 2-(6-bromobenzo[d]thiazol-2-yl)acetate (described in WO2011/074560, 200 mg, 0.67 mmol), potassium phosphate (348 mg, 2.00 mmol) and (2-fluoropyridin-4-yl)boronic acid (141 mg, 1.00 mmol) in dioxane (5 mL)/water (0.2 mL) were purged with
 10 argon for 5 minutes and then heated at 90 °C. After 4 hours, the reaction mixture was diluted with water (50 mL), extracted with DCM (3 X 50 mL), dried over MgSO₄, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0 to 100% ethyl acetate/hexanes over 15 minutes) to give Compound B23a (120 mg, 57 % yield) as a brown solid. HPLC: RT = 0.95 min (LCMS Method M).
 15 MS (ES): m/z = 316.9 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 8.68 (d, J=1.7 Hz, 1H), 8.35 (d, J=5.2 Hz, 1H), 8.12 (d, J=8.5 Hz, 1H), 8.02 (dd, J=8.5, 1.9 Hz, 1H), 7.81 (d, J=5.2 Hz, 1H), 7.64 (s, 1H), 4.38 (s, 2H), 4.19 (q, J=7.1 Hz, 2H), 1.24 (t, J=7.0 Hz, 3H).

Compound B23b. 2-(6-(2-Fluoropyridin-4-yl)benzo[d]thiazol-2-yl)-N-(2-(methylsulfonyl)ethyl)acetamide

- 20 (methylsulfonyl)ethyl)acetamide
[00200] Compound B23b (16 mg, 16 % yield) was prepared from Compound B23a as described in the general procedure given for Compound A1a. HPLC: RT = 0.73 min (LCMS Method M). MS (ES): m/z = 393.8 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 8.69 - 8.62 (m, 2H), 8.34 (d, J=5.5 Hz, 1H), 8.08 (d, J=8.5 Hz, 1H), 8.00 (dd, J=8.5, 1.9
 25 Hz, 1H), 7.81 (d, J=5.2 Hz, 1H), 7.64 (s, 1H), 4.13 (s, 2H), 3.58 - 3.51 (m, 2H), 3.31 (t, J=6.9 Hz, 2H), 3.03 (s, 3H).

Example B23

Example B23 (2.3 mg, 9.6 % yield) was prepared from Compound B23b as described in the general procedure given for Example B2. HPLC: RT = 0.76 min (LCMS Method M).


- 5 MS (ES): $m/z = 471.7$ $[M+H]^+$. ^1H NMR (500MHz, DMSO- d_6) δ 9.08 (s, 1H), 8.75 (d, $J=1.7$ Hz, 1H), 8.37 (d, $J=5.5$ Hz, 1H), 8.23 (d, $J=8.5$ Hz, 1H), 8.07 (dd, $J=8.7, 1.8$ Hz, 1H), 7.86 - 7.79 (m, 1H), 7.65 (s, 1H), 6.09 (s, 1H), 3.65 (d, $J=5.8$ Hz, 2H), 3.37 - 3.32 (m, 2H), 3.26 (s, 3H), 3.04 (s, 3H). EL IC₅₀ 210 nM.

- 10 **[00201]** The following compounds, Example B24 and Example B25 were prepared as described in the general procedure given for Example B24.

Ex #	Structure	Name	¹ H NMR (500MHz, DMSO-d ₆)	LC/MS RT (min) Method M+H	EL IC ₅₀ (nM)
B24		2-(6-(2-fluoro-4-pyridinyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-(phenylsulfonyl)ethyl)acetamide	δ 8.75 - 8.68 (m, 1H), 8.66 (d, J=1.4 Hz, 1H), 8.34 (d, J=5.5 Hz, 1H), 8.08 (d, J=8.5 Hz, 1H), 8.00 (dd, J=8.5, 1.9 Hz, 1H), 7.81 (dd, J=5.4, 1.8 Hz, 1H), 7.64 (s, 1H), 7.57 - 7.46 (m, 4H), 4.13 (s, 1H), 3.87 (t, J=6.9 Hz, 2H), 3.64 (d, J=5.8 Hz, 2H), 3.53 (s, 3H)	0.89 M 548.7	35
B25		N-(2-((4-fluorophenyl)sulfonyl)ethyl)-2-(6-(2-fluoropyridin-4-yl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)acetamide	δ 9.04 - 8.95 (m, 1H), 8.74 (d, J=1.4 Hz, 1H), 8.37 (d, J=5.5 Hz, 1H), 8.22 (d, J=8.5 Hz, 1H), 8.07 (dd, J=8.7, 1.8 Hz, 1H), 7.99 - 7.93 (m, 2H), 7.82 (d, J=5.5 Hz, 1H), 7.66 (s, 1H), 7.44 - 7.36 (m, 2H), 5.96 (s, 1H), 3.62 - 3.47 (m, 4H), 3.22 (s, 2H)	0.74 M 472.8	110

Example B26

2-(4-Fluoro-6-phenylbenzo[d]thiazol-2-yl)-N-(2-sulfamoyl-ethyl)-2-((3,3,3-trifluoropropyl)sulfonyl)acetamide



5

Compound B26a. Ethyl 3-((4-bromo-2,6-difluorophenyl)amino)-3-oxopropanoate

[00202] To a solution of 4-bromo-2,6-difluoroaniline (10 g, 48 mmol) in DCM (15 mL) was added ethyl 3-chloro-3-oxopropanoate (6.8 mL, 53 mmol) and DIEA (9.2 mL, 53 mmol) at room temperature. After 1 hour, the reaction mixture was partitioned between H_2O and DCM. The organic phase was washed with saturated NH_4Cl , H_2O , dried over Na_2SO_4 , and filtered. The filtrate was concentrated under reduced pressure to give Compound B26a (10 g, 65 % yield). HPLC: RT = 1.6 (LCMS Method Q). MS (ES): $m/z = 321.9$ $[\text{M}+\text{H}]^+$. ^1H NMR (500MHz, CHLOROFORM-d) δ 8.89 (br. s., 1H), 7.20 - 7.15 (m, 2H), 4.29 (q, $J=7.2$ Hz, 2H), 3.54 (s, 2H), 1.36 - 1.31 (m, 3H).

15

Compound B26b. Ethyl 2-(6-bromo-4-fluorobenzo[d]thiazol-2-yl)acetate

[00203] To a solution of Compound B26a (2.0 g, 6.2 mmol) in toluene (20 mL) was added Lawesson's reagent (1.5 g, 3.7 mmol), and the reaction mixture was heated at reflux. After 3 hours, Cs_2CO_3 (5.1 g, 16 mmol) was added, and the reaction mixture was heated at reflux. After 16 hours, the reaction mixture was filtered, concentrated under reduced pressure and purified using silica gel chromatography (eluting with 0 to 100%

20

EtOAc in hexanes) to give Compound B26b (1.2 g, 61 % yield). HPLC: RT = 2.02 (LCMS Method Q). MS (ES): $m/z = 319.9$ $[M+H]^+$. ^1H NMR (500 MHz, CHLOROFORM- d) δ ppm 7.93 (1 H, d), 7.66 (1 H, d, $J=1.7$ Hz), 4.28 (2 H, q, $J=7.2$ Hz), 4.22 - 4.24 (2 H, m), 1.33 (3 H, t, $J=7.2$ Hz).

5

Compound B26c. Ethyl 2-(4-fluoro-6-phenylbenzo[d]thiazol-2-yl)acetate

[00204] To a solution of Compound B26b (1.0 g, 3.1 mmol) in dioxane (20 mL) was added phenylboronic acid (460 mg, 3.8 mmol), potassium phosphate, (1.7 g, 7.9 mmol), and $Pd(PPh_3)_4$ (730 mg, 0.63 mmol). The reaction mixture was purged with argon and

10 heated at 105 °C for 16 hours. The reaction mixture was allowed to cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure and purified by silica gel chromatography (30 minutes gradient from 0 to 100% EtOAc in DCM) to give Compound B26c (810 mg, 82 % yield). HPLC: RT = 2.2 min (LCMS Method Q). MS (ES): $m/z = 316$ $[M+H]^+$. ^1H NMR (500 MHz, CHLOROFORM- d) δ ppm 7.88 (1 H, d, $J=1.4$ Hz), 7.61 - 7.67 (2 H, m), 7.47 - 7.54 (2 H, m), 7.39 - 7.47 (2 H, m), 4.30 (2 H, q, $J=7.2$ Hz), 4.26 (2 H, s), 1.33 - 1.38 (3 H, m).

15

Compound B26d. 2-(4-Fluoro-6-phenylbenzo[d]thiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide

20 **[00205]** Compound B26d (14.5 mg, 45 % yield) was prepared from Compound B26c as described in the general procedure given for Compound A1a. HPLC: RT = 1.81 min (LCMS Method Q). MS (ES): $m/z = 394.9$ $[M+H]^+$. ^1H NMR (500MHz, METHANOL- d_4) δ 8.12 (d, $J=1.4$ Hz, 1H), 7.81 - 7.70 (m, 2H), 7.59 (dd, $J=11.8, 1.7$ Hz, 1H), 7.52 (t, $J=7.7$ Hz, 2H), 7.44 (d, $J=7.4$ Hz, 1H), 4.17 (s, 2H), 3.71 (t, $J=6.7$ Hz, 2H), 2.64 (dt, $J=3.8, 1.8$ Hz, 2H).

25




Example B26

Example B26 (2.6 mg, 18 % yield) was prepared from Compound B26d as described in the general procedure given for Example B2. HPLC: RT = 2.0 (LCMS Method Q). MS (ES): $m/z = 554.1$ $[M+H]^+$. ^1H NMR (500MHz, METHANOL- d_4) δ 8.18 - 8.15 (m, 1H), 7.77 - 7.72 (m, 2H), 7.70 - 7.66 (m, 1H), 7.63 (dd, $J=11.8, 1.4$ Hz, 1H), 7.54 - 7.48

30


(m, 2H), 7.46 - 7.39 (m, 1H), 3.82 (td, $J=6.7, 4.4$ Hz, 2H), 3.77 (dt, $J=9.8, 5.9$ Hz, 2H), 3.40 - 3.35 (m, 2H), 2.88 - 2.74 (m, 2H). EL IC₅₀ <10 nM.

- [00206] The following compounds, Example B27 to Example B29 were prepared as
- 5 described in the general procedure given for Example B26.

Ex #	Structure	Name	¹ H NMR (400 MHz, METHANOL-d ₄)	LC/MS RT (min) Method M+H	EL IC ₅₀ (nM)
B27		4-(2-(1-(benzylsulfonyl)-2-oxo-2-(((3R)-2-oxo-3-pyrrolidinylamino)ethyl)-5-fluoro-1,3-benzothiazol-6-yl)benzamide	δ 6.67-8.44 (m, 12H), 4.70-5.02 (m, 1H), 4.27-4.66 (m, 2H), 3.35-3.59 (m, 2H), 2.56 (br. s., 1H), 1.82-2.16 (m, 1H).	1.75 Q 566.9	93
B28		2-(benzylsulfonyl)-N-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-2-(5-methyl-6-phenyl-1,3-benzothiazol-2-yl)acetamide	δ 6.40-8.60 (m, 13H), 3.51-4.72 (m, 4H), 1.73-2.84 (m, 6H)	2.18 Q 533.0	12
B29		2-(6-(4-chlorophenyl)-1,3-benzothiazol-2-yl)-N-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)acetamide	δ 6.52-8.81 (m, 13H), 3.48-4.77 (m, 4H), 2.17-2.94 (m, 3H).	2.12 Q 536.0	131

Example B30

2-(6-(2-Fluoro-4-pyridinyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-((2,2,2-trifluoroethyl)sulfamoyl)ethyl)acetamide



5

Compound B30a. Benzyl (2-(N-(2,2,2-trifluoroethyl)sulfamoyl)ethyl)carbamate

[00207] To a dioxane (1 mL) solution of 2,2,2-trifluoroethanamine (80 mg, 0.81 mmol) and DIEA (0.28 mL, 1.6 mmol) at 0 °C was added benzyl (2-

(chlorosulfonyl)ethyl)carbamate (150 mg, 0.54 mmol) in acetonitrile (1 mL). The

10 reaction was allowed to reach room temperature over a period of 20 minutes. The reaction mixture was concentrated under reduced pressure, and the residue purified using reverse phase HPLC (YMC Sunfire 5u (C18) 30 x 100 mm, 0-100% ACN (90% in H₂O, 0.1% TFA) using gradient over 16 min with flow rate 40 mL/min and UV detection at 220 nm) to give Compound B30a (95 mg, 39 % yield). HPLC: RT = 3.84 (LCMS

15 Method M). MS (ES): m/z = 340.9 [M+H]⁺. ¹H NMR (500MHz, CHLOROFORM-d) δ 7.43 - 7.34 (m, 5H), 5.28 (br. s., 2H), 5.15 (s, 2H), 3.86 - 3.68 (m, 4H), 3.35 - 3.24 (m, 2H).

Compound B30b. 2-Amino-N-(2,2,2-trifluoroethyl)ethanesulfonamide

[00208] HBr (1 mL, 33% solution in acetic acid) was added to Compound B30a (95 mg, 0.28 mmol) at room temperature. After 5 minutes, the reaction mixture was diluted with diethyl ether (5 mL), and the resulting solid, Compound B30b (42 mg, 41%) was isolated by filtration. HPLC: RT = 0.39 (LCMS Method M). MS (ES): $m/z = 207.0$ $[M+H]^+$. ^1H NMR (500MHz, DMSO- d_6) δ 8.46 (br. s, 1H), 7.87 (br. s., 2H), 3.87 (td, $J=6.3, 3.0$ Hz, 2H), 3.40 (t, $J=7.4$ Hz, 2H), 3.17 (br. s., 2H)

Compound B30c. 2-(6-(2-Fluoropyridin-4-yl)benzo[d]thiazol-2-yl)-N-(2-(N-(2,2,2-trifluoroethyl)sulfamoyl)ethyl)acetamide


[00209] Compound B30c (10 mg, 11%) was prepared from Compound B30b and Compound B23a as described in the general procedure given for Compound A1a. HPLC: RT = 0.83 (LCMS Method M). MS (ES): $m/z = 476.8$ $[M+H]^+$. ^1H NMR (500MHz, DMSO- d_6) δ 8.66 (d, $J=1.9$ Hz, 1H), 8.58 (s, 1H), 8.34 (d, $J=5.2$ Hz, 1H), 8.17 (t, $J=6.7$ Hz, 1H), 8.08 (d, $J=8.5$ Hz, 1H), 8.03 - 7.98 (m, 1H), 7.83 - 7.78 (m, 1H), 7.64 (s, 1H), 4.13 (s, 2H), 3.82 (dd, $J=9.6, 6.9$ Hz, 2H), 3.54 - 3.47 (m, 2H), 3.30 - 3.26 (m, 2H).

Example B30

[00210] Example B31 (2.0 mg, 18 % yield) was prepared from Compound B31c as described in the general procedure given for Example B2. HPLC: RT = 0.83 (LCMS Method M). MS (ES): $m/z = 476.8$ $[M+H]^+$. ^1H NMR (500MHz, DMSO- d_6) δ 8.66 (d, $J=1.9$ Hz, 1H), 8.58 (s, 1H), 8.34 (d, $J=5.2$ Hz, 1H), 8.17 (t, $J=6.7$ Hz, 1H), 8.08 (d, $J=8.5$ Hz, 1H), 8.03 - 7.98 (m, 1H), 7.83 - 7.78 (m, 1H), 7.64 (s, 1H), 4.13 (s, 2H), 3.82 (dd, $J=9.6, 6.9$ Hz, 2H), 3.54 - 3.47 (m, 2H), 3.30 - 3.26 (m, 2H). EL IC₅₀ 277 nM.

Example B31

N-*tert*-Butyl-4-(2-(1-(methylsulfonyl)-2-oxo-2-((2-sulfamoyl)ethyl)amino)ethyl)-1,3-benzothiazol-6-yl)benzamide



Compound B31a. Ethyl 2-(6-bromobenzo[d]thiazol-2-yl)-2-(methylsulfonyl)acetate

[00211] 1 M NaHMDS in THF (0.40 mL, 0.40 mmol) was added dropwise to a cooled (-20 °C) DMF (3 mL) solution of Compound A1a (100 mg, 0.26 mmol). After 3 minutes, methanesulfonyl chloride (0.03 mL, 0.40 mmol) was added. After 5 minutes, the reaction was quenched with acetic acid (0.2 mL), diluted with methanol (0.5 mL), and purified using reverse HPLC (Phenomomenex Luna AXIA 5 micron C18, 21.2X100, UV at 220 nm, 10 to 70% B over 15 minutes with 10 minute hold time, solvent A: 90%

10 water/ACN/0.1%TFA, solvent B:90% ACN/water/0.1%TFA, Flow rate 20 mL/min; detector at 254) to isolate Compound B31a (43 mg, 36% yield) as a white solid.

HPLC: Rt = 0.80 min (LCMS Method M). MS (ES): m/z = 457.6 [M+H]⁺.

¹H NMR (500MHz, DMSO-d₆) δ 8.97 (t, *J*=5.8 Hz, 1H), 8.47 (d, *J*=1.9 Hz, 1H), 8.02 (d, *J*=8.5 Hz, 1H), 7.72 (dd, *J*=8.8, 1.9 Hz, 1H), 6.94 (s, 2H), 6.01 (s, 1H), 3.78 - 3.48 (m, 2H), 3.21 (s, 3H), 3.20 - 3.13 (m, 2H).

Example B31

[00212] Example B31 (14 mg, 45% yield) was prepared from Compound B31a as described in the general procedure given for Compound B2a. EL IC₅₀ < 10 nM. HL IC₅₀



20 257 nM. HPLC: RT = 0.86 min (LCMS Method M). MS (ES): m/z = 552.8 [M+H]⁺.

¹H NMR (500MHz, DMSO-d₆) δ 8.98 (t, *J*=5.8 Hz, 1H), 8.55 (d, *J*=1.4 Hz, 1H), 8.17 (d, *J*=8.8 Hz, 1H), 8.00 - 7.90 (m, 3H), 7.88 - 7.77 (m, 3H), 6.95 (s, 2H), 6.03 (s, 1H), 3.61 (q, *J*=6.8 Hz, 2H), 3.24 (s, 3H), 3.22 - 3.15 (m, 2H), 1.47 - 1.33 (m, 9H).

[00213] Example B32 to Example B97 were prepared as described in the general procedure given for Example B31.

Example B98

- 5 2-(Methylsulfonyl)-2-(6-(1-(4-piperidiny)-1H-pyrazol-4-yl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)acetamide




Example B98

- [00214] A mixture of Compound B31a, (1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)boronic acid (15.5 mg, 0.0530 mmol) and Pd(PPh₃)₄ (12.2 mg, 10.5 μmol) in dioxane (2 mL) and 2M Na₂CO₃ (1 mL) was purged with argon and heated at 90 °C for 2 hours. The reaction mixture was concentrated under reduced pressure, dissolved in DMF (2 mL) and filtered. The filtrate was concentrated under reduced pressure, dissolved in DCM (1 mL) and treated with TFA (1 mL). After 16 hours, the reaction mixture was concentrated under reduced pressure, dissolved in DMF/methanol and purified by reverse phase HPLC (Column: Waters X Bridge C18, 19 x 200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10-mM ammonium acetate; Gradient: 0-25% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min) to give Example B98 (12.4 mg, 54.0 % yield). EL IC₅₀ <10 nM. HL IC₅₀ 464 nM. HPLC: RT = 1.0 min (LCMS Method N). MS (ES): m/z = 527.2 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 9.38 - 8.85 (m, 1H), 8.51 - 8.13 (m, 2H), 8.13 - 7.67 (m, 2H), 7.40 (br. s., 1H), 6.88 (br. s., 2H),

4.42 (br. s., 1H), 3.66 - 3.58 (m, 3H), 3.19 (br. s., 5H), 2.97 (br. s., 2H), 2.90 (br. s., 1H), 2.18 (d, $J=12.1$ Hz, 2H), 2.06 (d, $J=10.5$ Hz, 2H).

Example B99

- 5 4-(2-(1-(Benzylsulfonyl)-2-oxo-2-((2-sulfamoyl)ethyl)amino)ethyl)-1,3-benzothiazol-6-yl)-N-(2-methoxyethyl)benzamide



- 10 Compound B99a. N-(2-Methoxyethyl)-4-(2-(2-oxo-2-((2-sulfamoyl)ethyl)amino)ethyl)benzo[d]thiazol-6-yl)benzamide

- [00215] Compound B99a (26 mg, 52% yield) was prepared from Compound A1a and (4-((2-methoxyethyl)carbamoyl)phenyl)boronic acid as described in the general procedure given for Compound B2a. HPLC: RT = 0.83 min (LCMS Method M). MS (ES): $m/z = 375.9$ $[\text{M}+\text{H}]^+$. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.44 - 8.68 (1 H, m), 8.36 (1 H, d, $J=1.93$ Hz), 7.88 (1 H, d, $J=8.80$ Hz), 7.56 - 7.70 (1 H, m), 6.90 (2 H, s), 4.06 (2 H, s), 3.43 - 3.62 (2 H, m), 3.07 - 3.22, (2 H, m).

Example B100

- [00216] Example B99 (10 mg, 31% yield) was prepared from Compound B99a and benzyl sulfonylchloride as described in the general procedure given for Compound B31a.


EL IC₅₀ < 10 nM. HL IC₅₀ 55 nM. HPLC: RT = 0.83 min (LCMS Method M). MS (ES): m/z = 630.8 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 9.02 (t, J=5.8 Hz, 1H), 8.65 - 8.50 (m, 1H), 8.25 - 8.13 (m, 1H), 7.99 (d, J=8.5 Hz, 1H), 7.95 (dt, J=8.5, 1.7 Hz, 1H), 7.88 (d, J=8.5 Hz, 1H), 7.78 (br. s., 1H), 7.40 (s, 2H), 7.37 - 7.14 (m, 2H), 7.00 - 6.90 (m, 2H), 6.10 (s, 1H), 4.74 (q, J=13.5 Hz, 1H), 4.68 - 4.51 (m, 1H), 3.71 - 3.56 (m, 2H), 3.52 - 3.42 (m, 4H), 3.29 - 3.27 (m, 3H), 3.24 - 3.08 (m, 2H).

[00217] Example B100 to Example B156 were prepared as described in the general procedure given for Example B99.

10

Example B157

2-{6-[4-(4-Morpholinylcarbonyl)phenyl]-1,3-benzothiazol-2-yl}-2-{[2-(4-morpholinyl)ethyl]sulfonyl}-N-(2-sulfamoyl)ethyl)acetamide



15

Compound B157a. Benzyl (2-((1-(6-bromobenzo[d]thiazol-2-yl)-2-oxo-2-((2-sulfamoylethyl)amino)ethyl)sulfonyl)ethyl)carbamate

[00218] Compound B157a (260 mg, 46% yield) was prepared from Compound A1a as described in the general procedure given for Compound B31a. HPLC: RT = 1.12 min

5 (LCMS Method M). MS (ES): $m/z = 619.1$ $[M+H]^+$. ^1H NMR (400MHz, DMSO- d_6) δ 8.96 (s, 1H), 8.48 (d, $J=2.0$ Hz, 1H), 8.02 (d, $J=8.6$ Hz, 1H), 7.73 (dd, $J=8.6, 2.0$ Hz, 1H), 7.47 (br. s., 1H), 7.40 - 7.22 (m, 5H), 6.90 (s, 2H), 5.03 (s, 2H), 3.74 - 3.34 (m, 6H), 3.25 - 3.02 (m, 2H).

10 Compound B157b. 2-((2-Aminoethyl)sulfonyl)-2-(6-bromobenzo[d]thiazol-2-yl)-N-(2-sulfamoylethyl)acetamide hydrobromide

[00219] To Compound B157a (253 mg, 0.41 mmol) was added 33% HBr in AcOH (4 mL). After 1 h, the reaction mixture was diluted with Et₂O (~50 mL) generating a white precipitate, which was filtered and dried under reduced pressure to give Compound

15 B157b (230 mg, 100 % yield) as a brown solid. HPLC: RT = 0.84 min (LCMS Method M). MS (ES): $m/z = 487.0$ $[M+H]^+$. ^1H NMR (400MHz, DMF) δ 9.52 (t, $J=5.6$ Hz, 1H), 8.56 (d, $J=2.0$ Hz, 1H), 8.06 - 8.03 (m., 1H), 7.80 (dd, $J=8.6, 2.0$ Hz, 1H), 7.33 (s, 2H), 7.05 (s, 3H), 6.74 (s, 1H), 4.27 - 4.10 (m, 2H), 3.86 - 3.77 (m, 2H), 3.77 - 3.66 (m, 4H), 3.47 - 3.33 (m, 2H).

20

Compound B157c. 2-(6-Bromobenzo[d]thiazol-2-yl)-2-((2-morpholinoethyl)sulfonyl)-N-(2-sulfamoylethyl)acetamide

[00220] To a solution of Compound B157b (105 mg, 0.190 mmol) in acetonitrile (7 mL) was added 2,2'-dibromodiethyl ether (0.027 mL, 0.20 mmol) followed by K₂CO₃

25 (130 mg, 0.93 mmol), and the reaction mixture heated at 65 °C for 2 days. The reaction mixture was concentrated under reduced pressure and purified by silica gel chromatography eluting with 0.5 to 10% MeOH/DCM to give Compound B157c (31 mg, 30 % yield) as a white solid. HPLC: RT = 1.39 min (LCMS Method B). MS (ES): $m/z = 557.0$ $[M+H]^+$. ^1H NMR (400MHz, DMF) δ 8.80 (br. s., 1H), 8.43 (br. s., 1H), 8.00 (d, $J=8.6$ Hz, 1H), 7.72 (d, $J=7.9$ Hz, 1H), 7.03 (br. s., 2H), 3.82 (d, $J=5.9$ Hz, 2H), 3.66 (d, $J=6.4$ Hz, 2H), 3.65 - 3.44 (m, 4H), 3.44 - 3.31 (m, 2H), 2.89 - 2.81 (m, 2H), 2.48 (br. s., 4H).

30

Example B157

[00221] Example B157 (18 mg, 49% yield) was prepared from Compound B157c and 4-(morpholine-4-carbonyl)phenylboronic acid as described in the general procedure

5 given for Compound B2a. EL IC₅₀ <10 nM. HL IC₅₀ 147 nM


HPLC: RT = 1.36 min (LCMS Method B). MS (ES): m/z = 666.1 [M+H]⁺. ¹H NMR (400MHz, METHANOL-d₄) δ 8.00 (br. s., 1H), 7.76 (s, 6H), 7.55 (d, J=8.1 Hz, 1H), 4.09 - 3.47 (m, 25H).

10 **[00222]** Example B158 to Example B161 were prepared as described in the general procedure given for Example B157.

Example B162

2-(6-(1-(2-Methoxyethyl)-1H-pyrazol-4-yl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)acetamide

15



Compound B162a. 1-(2-Methoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

20 **[00223]** 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (100 mg, 0.52 mmol), 1-chloro-2-methoxyethane (0.056 mL, 0.62 mmol) and cesium carbonate (252 mg, 0.73 mmol) in DMF (1 mL) were heated in microwave reactor at 160 °C for 30 min. The reaction mixture was concentrated under reduced pressure and purified by silica gel chromatography (ISCO, hexanes/ethyl acetate 0-100% over 15 min) to isolate Compound

B162a (130 mg, 100% yield). HPLC: RT = 1.0 min (LCMS Method M). MS (ES): m/z = 253.0 $[M+H]^+$. ^1H NMR (500MHz, CHLOROFORM- d) δ 8.04 (s, 1H), 7.83 (d, $J=18.4$ Hz, 1H), 4.37 (t, $J=5.2$ Hz, 1H), 3.78 (t, $J=5.2$ Hz, 1H), 3.38 - 3.31 (m, 2H), 2.98 (s, 3H), 2.90 (s, 3H), 1.34 (s, 6H), 1.26 (s, 3H).

5

Example B162


[00224] Example B162 (9 mg, 50% yield) was prepared from Compound B162a and Compound B31a as described in the general procedure given for Example B2a. EL IC_{50} <10 nM. HL IC_{50} 995 nM. HPLC: RT = 0.7 min (LCMS Method M). MS (ES): m/z = 501.8 $[M+H]^+$. ^1H NMR (500MHz, DMSO- d_6) δ 8.97 (s, 1H), 8.36 (d, $J=1.4$ Hz, 1H), 8.27 (s, 1H), 8.05 (d, $J=8.5$ Hz, 1H), 8.00 (d, $J=0.6$ Hz, 1H), 7.79 (dd, $J=8.5, 1.9$ Hz, 1H), 6.95 (s, 2H), 5.99 (s, 1H), 4.30 (t, $J=5.2$ Hz, 3H), 3.74 (t, $J=5.4$ Hz, 3H), 3.65 - 3.56 (m, 6H), 3.28 - 3.24 (m, 4H), 3.21 - 3.15 (m, 3H).

[00225] Example B163 to Example B165 were prepared as described in the general procedure given for Example B162.

Example B166

2-(6-(4-(3,3-Difluoroazetidine-1-carbonyl)phenyl)benzo[d]thiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl-ethyl)acetamide

20



Compound B166a. (3,3-Difluoroazetidin-1-yl)(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanone

[00226] A mixture of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (490 mg, 2.0 mmol), 3,3-difluoroazetidine hydrochloride (260 mg, 2.00 mmol), DIPEA (0.686 mL, 3.93 mmol) and HATU (900 mg, 2.4 mmol) in DMF (4 mL) was stirred at room temperature for 3 days. The reaction mixture was diluted with EtOAc, the organic portion washed successively with water and brine, dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with 0-100% EtOAc/hexane) to give Compound B166a (360 mg, 57 % yield) as a white solid. HPLC: RT = 1.9 min (LCMS Method Q). MS (ES): $m/z = 324.0$ $[M+H]^+$. ^1H NMR (400MHz, CHLOROFORM- d) δ 7.87 (s, 2H), 7.62 (d, $J=8.1$ Hz, 2H), 4.53 (t, $J=12.0$ Hz, 4H), 1.36 (s, 12H).

Compound B166b. 2-(6-(4-(3,3-difluoroazetidine-1-carbonyl)phenyl)benzo[d]thiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide

[00227] A mixture of Compound B166a (140 mg, 0.37 mmol), Compound A1a (144 mg, 0.44 mmol), K_3PO_4 (196 mg, 0.93 mmol) and chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (2nd generation X-Phos precatalyst, 29 mg, 0.037 mmol) in dioxane (3 mL) and water (1 mL) was purged with argon gas and heated at 95 °C for 1 hour. The reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with 0-10% MeOH/DCM) to give Compound B166b (116 mg, 62.0% yield) as a white solid. HPLC: RT = 1.6 min (LCMS Method Q). MS (ES): $m/z = 495$ $[M+H]^+$. ^1H NMR (400MHz, DMSO- d_6) δ 8.55 (t, $J=5.4$ Hz, 1H), 8.48 (d, $J=1.5$ Hz, 1H), 8.05 (d, $J=8.6$ Hz, 1H), 7.90 - 7.85 (m, 3H), 7.83 (s, 2H), 6.92 (s, 2H), 5.05 - 4.33 (m, 4H), 4.15 - 4.09 (m, 2H), 3.60 - 3.44 (m, 2H), 3.18 (d, $J=5.3$ Hz, 2H).

Example B166


[00228] Example B166 (16.4 mg, 30% yield) was prepared from Compound B166b as described in the general procedure given for Compound B31a. EL $IC_{50} < 10$ nM. HL IC_{50} 13 nM. HPLC: RT = 1.4 min (LCMS Method O). MS (ES): $m/z = 573.0$ $[M+H]^+$.

¹H NMR (500MHz, DMSO-d₆) δ 8.98 (t, *J*=5.6 Hz, 1H), 8.57 (s, 1H), 8.18 (d, *J*=8.5 Hz, 1H), 7.97 - 7.90 (m, 2H), 7.89 - 7.85 (m, 2H), 7.85 - 7.81 (m, 2H), 6.98 - 6.82 (m, 2H), 6.04 (s, 1H), 3.61 (q, *J*=6.9 Hz, 2H), 3.25 - 3.23 (m, 3H), 3.22 - 3.16 (m, 2H).

- 5 **[00229]** Example B167 to Example B171 were prepared as described in the general procedure given for Example B166.

Example B172

- 10 N-(2-Methoxyethyl)-N-methyl-4-(2-(1-(methylsulfonyl)-2-oxo-2-((2-sulfamoyl)ethyl)amino)ethyl)-1,3-benzothiazol-6-yl)benzamide



Compound B172a. N-(2-methoxyethyl)-N-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

- 15 **[00230]** EDC (310 mg, 1.6 mmol) was added to DMF (4 mL) solution of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (200 mg, 0.81 mmol), 2-methoxy-N-methylethanamine (144 mg, 1.6 mmol), TEA (0.23 mL, 1.6 mmol) and HOBT hydrate (247 mg, 1.60 mmol). After 3 days at room temperature, the reaction mixture was diluted in water (15 mL), extracted with DCM (3 X 10 mL), the combined organic portions dried over Na₂SO₄, filtered, concentrated under reduced pressure and purified by reverse phase HPLC (Phenomemex Luna AXIA 5 micron C18, 21.2X100, UV at 220 nm, 10 to 70% B over 30 minutes with 10 minute hold time, solvent A: 90% water/ACN/0.1%TFA, solvent B: 90% ACN/water/0.1%TFA, Flow rate 20 mL/min; detector at 254) to isolate Compound B172a (47 mg, 18 % yield) as a clear oil. HPLC: RT = 0.96 min (LCMS
- 20
- 25 Method M). MS (ES): *m/z* = 319.7 [M+H]⁺. ¹H NMR (500MHz, CHLOROFORM-d) δ


9.45 - 8.71 (m, 1H), 7.85 (d, $J=7.2$ Hz, 2H), 7.40 (d, $J=8.0$ Hz, 2H), 3.89 - 3.64 (m, 2H), 3.42 (d, $J=12.1$ Hz, 3H), 3.34 - 3.12 (m, 3H), 3.04 (s, 2H), 1.36 (s, 12H).

Example B172

- 5 **[00231]** Example B172 (2.2 mg, 7% yield) was prepared from Compound B172a as described in the general procedure given for Compound B2a. EL $IC_{50} < 10$ nM. HL IC_{50} 77 nM. HPLC: RT = 1.22 min (LCMS Method N). MS (ES): $m/z = 569.1$ $[M+H]^+$. ^1H NMR (500MHz, DMSO- d_6) δ 9.02 (br. s., 1H), 8.54 (s, 1H), 8.17 (d, $J=8.5$ Hz, 1H), 7.99 - 7.88 (m, 1H), 7.83 (br. s., 2H), 7.52 (d, $J=7.7$ Hz, 2H), 6.97 (s, 2H), 6.04 (s, 1H),
10 3.67 - 3.55 (m, 4H), 3.44 (br. s., 5H), 3.31 (br. s., 2H), 3.22 - 3.14 (m, 3H), 3.00 (br. s., 3H)

Example B173

- 15 4-(2-(1-(Methylsulfonyl)-2-oxo-2-(2-sulfamoyl ethylamino)ethyl)benzo[d]thiazol-6-yl)benzoic acid




- [00232]** To a solution of Example B157 (101 mg, 0.18 mmol) in DCM (2.0 mL) was added TFA (1.0 mL, 13 mmol). The mixture was stirred at room temperature for 3 hours.
- 20 The mixture was concentrated under reduced pressure. The residue was dissolved in DMF (2 mL), filtered and purified by preparative HPLC (Column: Waters XBridge C18, 19 x 200 mm, 5- μ m particles; Mobile Phase A: 5:95 acetonitrile:water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10-mM ammonium acetate; Gradient: 0-30% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20
- 25 mL/min). Fractions containing the desired product were combined and dried via centrifugal evaporation to give Example B173 (79 mg, 87% yield). EL $IC_{50} < 10$ nM. HL IC_{50} 274 nM. HPLC: RT = 1.1 min (LCMS Method O). MS (ES): $m/z = 498.0$ $[M+H]^+$. ^1H NMR (500MHz, DMSO- d_6) δ 13.05 (br. s., 1H), 9.03 (br. s., 1H), 8.60 (br. s., 1H),

8.20 (d, $J=7.7$ Hz, 1H), 8.10 - 8.04 (m, 2H), 7.97 - 7.89 (m, 3H), 6.99 (br. s., 2H), 6.06 (br. s., 1H), 3.62 (br. s., 2H), 3.26 (br. s., 3H), 3.22 - 3.17 (m, 2H).

Example B174

- 5 2-(6-(4-(3-Hydroxy-3-methylazetidine-1-carbonyl)phenyl)benzo[d]thiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)acetamide





- [00233] Example B174 (15 mg, 55%) was prepared from Example B173 and 3-methylazetidin-3-ol hydrochloride as described in the general procedure given for
 10 Example B166. EL $IC_{50} < 10$ nM. HL IC_{50} 402 nM. HPLC: RT = 1.0 min (LCMS Method O). MS (ES): $m/z = 567.0$ $[M+H]^+$. ^1H NMR (500MHz, DMSO- d_6) δ 9.00 (br. s., 1H), 8.56 (br. s., 1H), 8.19 (d, $J=8.5$ Hz, 1H), 7.99 - 7.90 (m, 2H), 7.86 (d, $J=7.2$ Hz, 2H), 7.77 (d, $J=6.6$ Hz, 2H), 6.96 (br. s., 2H), 6.06 (br. s., 1H), 5.70 (br. s., 1H), 4.20 (d, $J=16.5$ Hz, 2H),
 15 4.00 - 3.85 (m, 4H), 3.62 (br. s., 2H), 3.27 - 3.24 (m, 3H), 3.23 - 3.17 (m, 2H).

[00234] Example B175 to Example B179 were prepared as described in the general procedure given for Example B174.

20

Example B180

2-(Methylsulfonyl)-2-(6-(2-oxo-2,3-dihydro-1H-indol-5-yl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)acetamide



[00235] Example B180 (3.8 mg, 14%) was prepared from Compound B31a and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one as described in the general procedure given for Example 166. EL IC₅₀ < 10 nM. HL IC₅₀ 170 nM.


HPLC: RT = 1.1 min (LCMS Method Q). MS (ES): m/z = 509.1 [M+H]⁺.

¹H NMR (500MHz, DMSO-d₆) δ 10.54 (br. s., 1H), 9.02 (br. s., 1H), 8.41 (br. s., 1H), 8.12 (d, J=8.5 Hz, 1H), 7.82 (d, J=8.5 Hz, 1H), 7.69 - 7.56 (m, 2H), 7.03 - 6.97 (m, 2H), 6.03 (br. s., 1H), 3.92 (br. s., 1H), 3.64 - 3.54 (m, 4H), 3.30 - 3.10 (m, 5H).

[00236] Example B181 to Example B186 were prepared as described in the general procedure given for Example B180.

Example B187

2-(Methylsulfonyl)-2-(6-(6-oxo-1,6-dihydro-3-pyridinyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoylethyl)acetamide




[00237] A mixture of Example B19 (12 mg, 0.025 mmol), NaI (11 mg, 0.074 mmol) and TMS-Cl (0.016 mL, 0.12 mmol) in acetonitrile (1.5 mL) was stirred at 80 °C for 2 hours. The reaction mixture was quenched with water and purified by reverse phase

preparative HPLC (method A) to give Example B187 (6 mg, 50% yield). EL IC₅₀ 16 nM. HL IC₅₀ 155 nM. HPLC: RT = 1.2 min (LCMS Method Q). MS (ES): m/z = 471.0 [M+H]⁺. ¹H NMR (400MHz, DMSO-d₆) δ 11.97 (br. s., 1H), 9.01 (t, J=5.6 Hz, 1H), 8.39 (s, 1H), 8.18 - 8.06 (m, 1H), 7.98 - 7.92 (m, 1H), 7.88 - 7.82 (m, 1H), 7.79 (dd, J=8.6, 1.8 Hz, 1H), 6.99 (s, 2H), 6.02 (s, 1H), 3.66 - 3.56 (m, 2H), 3.23 (s, 3H), 3.21 - 3.13 (m, 2H).

[00238] Example B188 to Example B195 were prepared as described in the general procedure given for Example B187.

10 Example B196

tert-Butyl 2-(2-oxo-2-((2-sulfamoyl)ethyl)amino)-1-((3,3-trifluoropropyl)sulfonyl)ethyl)benzo[d]thiazole-6-carboxylate



15 Compound B196a. *tert*-Butyl 2-chlorobenzo[d]thiazole-6-carboxylate

[00239] To a solution of di-*tert*-butyl dicarbonate (1.2 mL, 5.0 mmol) and 2-chlorobenzo[d]thiazole-6-carboxylic acid (530 mg, 2.5 mmol) in anhydrous *t*-butanol (10 mL) was added dimethylaminopyridine (91 mg, 0.74 mmol) at room temperature. After 1 hour, the reaction mixture was concentrated under reduced pressure and purified by silica gel chromatography (ISCO: 0-50% EtOAc/Hexane) to afford Compound B196a (560 mg, 84 % yield) as a clear oil. HPLC: RT = 2.22 min (LCMS Method B). MS (ES): m/z = 270.0 [M+H]⁺. ¹H NMR (400MHz, CHLOROFORM-d) δ 8.45 (d, J=1.5 Hz, 1H), 8.12 (dd, J=8.6, 1.8 Hz, 1H), 7.97 (d, J=8.6 Hz, 1H), 1.55 - 1.42 (m, 9H).

25 Compound B196b. *tert*-Butyl 2-(2-ethoxy-2-oxoethyl)benzo[d]thiazole-6-carboxylate

[00240] Ethyl acetate (0.26 mL, 2.67 mmol) was added to cooled (-78° C) solution of NaHMDS (1 M in THF, 4.9 mL, 4.9 mmol) in toluene (10 mL) over a period of 15 minutes. After one hour, Compound B196a (0.6 g, 2.2 mmol in toluene (5 mL) was added over a period of 15 minutes. After one hour, the reaction mixture was warmed to -5° C over a period of 90 minutes. The reaction mixture was diluted with 1N HCl (50 mL) and extracted with ethyl acetate (3 X 50 mL). The organic phase was washed with brine (100 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0 to 50% ethyl acetate/hexanes) to isolate Compound B196b (480 mg, 67% yield) as a white solid. HPLC: RT = 2.13 min (LCMS Method B). MS (ES): m/z = 322.0 [M+H]⁺. ¹H NMR (400MHz, CHLOROFORM-d) δ 8.57 - 8.52 (m, 1H), 8.11 (dd, J=8.6, 1.5 Hz, 1H), 8.04 - 7.98 (m, 1H), 4.32 - 4.25 (m, 2H), 4.20 (s, 2H), 1.63 (s, 9H), 1.32 (t, J=7.2 Hz, 3H).

Compound B196c. *tert*-Butyl 2-(2-oxo-2-((2-sulfamoyl)ethyl)amino)ethyl)benzo[d]thiazole-6-carboxylate


[00241] Compound B196c (810 mg, 76% yield) was prepared from Compound B196b as described in the general procedure given for Compound A1a. HPLC: RT = 1.88 min (LCMS Method B). MS (ES): m/z = 399.9 [M+H]⁺. ¹H NMR (400MHz, CHLOROFORM-d) δ 8.51 - 8.47 (m, 1H), 8.07 (dd, J=8.6, 1.5 Hz, 1H), 7.97 (dd, J=8.6, 0.4 Hz, 1H), 4.11 (s, 2H), 3.83 (m, 2H), 3.39 (m, 2H), 1.62 (s, 9H).

Example B196

[00242] Example B196 (120 mg, 48% yield) was prepared from Compound B196c as described in the general procedure given for Compound B31a. EL IC₅₀ 65 nM. HL IC₅₀ 379 nM. HPLC: RT = 2.16 min (LCMS Method B). MS (ES): m/z = 560.0 [M+H]⁺. ¹H NMR (400MHz, CHLOROFORM-d) δ 7.78 - 7.74 (m, 1H), 7.33 (dd, J=8.6, 1.5 Hz, 1H), 7.23 (dd, J=8.6, 0.4 Hz, 1H), 3.37 (s, 2H), 3.09 (m, 2H), 2.96 (m, 2H), 0.88 (s, 9H).

Example B197

2-(6-(3,3-Difluoropyrrolidine-1-carbonyl)benzo[d]thiazol-2-yl)-N-(2-sulfamoyl)ethyl)-2-((3,3,3-trifluoropropyl)sulfonyl)acetamide




[00243] Example B197 (6.2 mg, 21% yield) was prepared from Example B196 as described in the general procedure given for Example B174. EL IC₅₀ < 10 nM. HL IC₅₀ 10,100 nM. HPLC: RT = 2.16 (LCMS Method O). MS (ES): m/z = 593.05 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 8.15 (d, *J*=8.5 Hz, 1H), 6.99 (m, 2H), 4.04 - 3.53 (m, 8H), 3.27 - 3.13 (m, 2H), 2.94 - 2.80 (m, 2H), 2.50 - 2.35 (m, 2H).

[00244] Example B198 to Example B201 were prepared as described in the general procedure given for Example B197.

10 Example B202

N-(2-methoxyethyl)-3-(2-(2-oxo-2-((2-sulfamoyl)ethyl)amino)-1-((3,3,3-trifluoropropyl)sulfonyl)ethyl)benzo[d]thiazol-6-yl)benzamide




15

[00245] Example B202 (1.7 mg, 5.0 % yield) was prepared from Compound B202a as described in the general procedure given for Example B99. EL IC₅₀ 24 nM. HL IC₅₀ 170 nM. HPLC: RT = 1.51 (LCMS Method O). MS (ES): m/z = 637.1 [M+H]⁺. ¹H NMR

(500MHz, DMSO- d_6) δ 8.19 - 8.09 (m, 2H), 7.92 - 7.80 (m, 3H), 7.58 - 7.48 (m, 2H), 3.55 (m, 4H), 3.41 (m, 4H), 3.21 (s, 3H), 3.10-3.13 (m, 2H), 2.81 - 2.75 (m, 2H).

Example B203

- 5 2-(5-methyl-6-(1-methyl-1H-pyrazol-4-yl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl-ethyl)acetamide



- 10 [00246] Example B203 (4.1 mg, 14.3 % yield) was prepared from Compound B203a as described in the general procedure given for Example B99. EL IC_{50} 10 nM. HL IC_{50} 141 nM. HPLC: RT = 0.70 (LCMS Method M). MS (ES): m/z = 472.8 $[\text{M}+\text{H}]^+$. ^1H NMR (500 MHz, METHANOL- d_4) δ 7.98 (s, 1H), 7.95 (s, 1H), 7.90 (s, 1H), 7.76 (d, $J=0.55$ Hz, 1H), 5.49 (s, 1H), 3.97-4.00 (m, 3H), 3.80 (d, $J=2.75$ Hz, 1H), 3.59 (d, $J=7.98$ Hz, 1H), 3.19-3.22 (m, 2H), 3.17 (s, 3H), 2.44-2.55 (m, 3H).

15

[00247] Example B204 to Example B205 were prepared as described in the general procedure given for Example B2.

[00248] Example B207 to Example B281 were prepared as described in the general procedure given for Example B31.

- 20 [00249] Example B282 to Example B312 were prepared as described in the general procedure given for Example B99.

[00250] Example B313 to Example B316 were prepared as described in the general procedure given for Example B157.

[00251] Example B317 was prepared as described in the general procedure given for Example B162.

[00252] Example B318 to Example B324 were prepared as described in the general procedure given for Example B166.

5 [00253] Example B325 to Example B327 were prepared as described in the general procedure given for Example B173.

[00254] Example B328 to Example B351 were prepared as described in the general procedure given for Example B174.

10 [00255] Example B352 to Example B374 were prepared as described in the general procedure given for Example B180.


[00256] Example B375 to Example B385 were prepared as described in the general procedure given for Example B187.

[00257] Example B386 was prepared as described in the general procedure given for Example B31.

15

Example B387

2-{6-[1-(2-Hydroxy-2-methylpropyl)-2-oxo-1,2-dihydropyridin-4-yl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl-ethyl)-2-{[4-(trifluoromethyl)phenyl]methanesulfonyl}acetamide



20

Compound B387a. 5-bromo-1-(2-hydroxy-2-methylpropyl)pyridin-2(1H)-one

[00258] A mixture of 5-bromopyridin-2(1H)-one (600 mg, 3.5 mmol), 2,2-dimethyloxirane (750 mg, 10 mmol) and K₂CO₃ (960 mg, 6.9 mmol) in DMF (3 mL) was heated at 100 °C for 2 hours. The reaction mixture was allowed to cool to room temperature. The reaction mixture was diluted with ethyl acetate (80 mL), washed with water, brine, and dried over MgSO₄. The organic layer was filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with 10 to 50% EtOAc/hexane) to give Compound B387a (650 mg, 76% yield). ¹H NMR (400MHz, CHLOROFORM-d) δ 7.50 (d, *J*=2.6 Hz, 1H), 7.40 (dd, *J*=9.6, 2.8 Hz, 1H), 6.54 (d, *J*=9.7 Hz, 1H), 3.99 (s, 2H), 3.57 - 3.39 (s, 1H), 1.27 (s, 6H).

Compound B387b. 1-(2-hydroxy-2-methylpropyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one

[00259] To a solution of Compound B387a (500 mg, 2.0 mmol) was added bis(pinacolato)diboron (1.0 g, 4.1 mmol), PdCl₂(dppf)-CH₂Cl₂ adduct (166 mg, 0.200 mmol) and potassium acetate (995 mg, 10.1 mmol). The reaction mixture was heated at 100 °C for 16 hours. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with 0-10% MeOH) to give Compound B387b (360 mg, 1.2 mmol, 60 % yield). ¹H NMR (400MHz, CHLOROFORM-d) δ 7.83 - 7.59 (m, 2H), 6.59 (d, *J*=9.0 Hz, 1H), 4.10 - 3.94 (m, 2H), 1.46 - 1.19 (m, 18H).


Example B387

[00260] Example B387 (2.2 mg, 9.0% yield) was prepared from Compound B387c (prepared as described in the general procedure given for Example B31) and Compound B387b as described in the general procedure given for Example B180. EL IC₅₀ 13.6 nM. HL IC₅₀ 6544 nM. HPLC: RT = 1.4 min (LCMS Method Q). MS (ES): *m/z* = 687.1 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 14.04 and 11.46 and 6.15 (s, 1H), 9.12 - 9.02 and 8.61 (1H), 8.19 (br. s., 1H), 7.97 (s, 1H), 7.82 - 7.55 (m, 6H), 6.97 (br. s., 2H), 6.82 and 6.64 - 6.56 (1H), 6.77 - 6.66 (m, 1H), 6.53 (s, 1H), 6.15 (s, 1H), 4.93 - 4.71 (m, 2H), 4.03 - 3.91 (m, 2H), 3.68 - 3.57 (m, 2H), 3.25 - 3.14 (m, 2H), 1.13 (d, *J*=6.9 Hz, 6H).

[00261] Example B388 to Example B390 were prepared as described in the general procedure given for Example B388.

5 Example B391

tert-Butyl 2-(1-(methylsulfonyl)-2-oxo-2-((2-sulfamoyl)ethyl)amino)ethyl)-1,3-benzothiazole-5-carboxylate



10 Compound B391b. *tert*-Butyl 2-(2-ethoxy-2-oxoethyl)benzo[d]thiazole-5-carboxylate

[00262] To a solution of Compound B391a (1.49 mmol, 395 mg, prepared as described in the general procedure given for Example B26) in dichloromethane (20 mL) was added *tert*-butyl 2,2,2-trichloroacetimidate (1.6 g, 7.4 mmol). Boron trifluoride etherate (38 mL, 0.30 mmol) was added, and the mixture was stirred at room temperature. After 7

15 hours, the mixture was loaded onto Celite and purified by ISCO flash chromatography (120 g silica gel cartridge, 0-50% ethyl acetate – hexane gradient over 24 min., 85 mL/min.). The fractions containing the product were combined, and the solvent removed under reduced pressure to provide Compound B391b (184 mg, 38.0% yield). HPLC: RT = 2.07 min (LCMS Method B). MS (ES): $m/z = 322$ $[M+H]^+$. ¹H NMR (400MHz, CHLOROFORM-*d*) δ 8.64 (d, $J=1.1$ Hz, 1H), 8.03 (dd, $J=8.4, 1.5$ Hz, 1H), 7.90 (d, $J=8.4$ Hz, 1H), 4.27 (q, $J=7.3$ Hz, 2H), 4.19 (s, 2H), 1.63 (s, 9H), 1.31 (t, $J=7.2$ Hz, 3H).

20

Compound B391c. *tert*-Butyl 2-(2-oxo-2-((2-sulfamoyl)ethyl)amino)ethyl)benzo[d]thiazole-5-carboxylate

[00263] Compound B391b (184 mg, 0.570 mmol) was dissolved in THF (2 mL) and sodium hydroxide (0.57 mL, 0.57 mmol., 1.0 M) was added. After 1 hour, the solvent was removed under reduced pressure, and the residue dried *in vacuo*. The residue was dissolved in DMF (2 mL) and 2-aminoethanesulfonamide HCl salt was added.

5 Diisopropylethyl amine (0.20 mL, 1.2 mmol) and HATU (240 mg, 0.63 mmol) were added, and the mixture was stirred at room temperature for 7 hours. DMF was removed *in vacuo*, and the residue was purified by ISCO flash chromatography (12 g silica gel cartridge, 0-100% acetonitrile – dichloromethane gradient over 11 min., 30 mL/min.).

The fractions containing the product were combined, and the solvent removed to provide

10 Compound B391c (131 mg, 53.0% yield). HPLC: RT = 1.71 min (LCMS Method B). MS (ES): $m/z = 400$ $[M+H]^+$. ^1H NMR (400MHz, CHLOROFORM- d) δ 8.61 (d, $J=0.9$ Hz, 1H), 8.05 (dd, $J=8.4$, 1.5 Hz, 1H), 7.90 (dd, $J=8.4$, 0.4 Hz, 1H), 7.68 (br. s., 1H), 5.05 (br. s., 2H), 4.10 (s, 2H), 3.87 (q, $J=6.1$ Hz, 2H), 3.40 - 3.31 (m, 2H), 1.64 (s, 9H).

15 Example B391


[00264] Compound B391c (28 mg, 0.070 mmol) was dissolved in DMF (2 mL), and the mixture was cooled to -25 °C. Sodium bis(trimethylsilyl)amide (0.10 mL, 0.10 mmol, 1.0 M in THF) was added dropwise. After 10 min, methanesulfonyl chloride (8 μ L, 0.1 mmol) was added. After 30 min., the reaction was quenched by the addition of

20 acetic acid, and the solvent was removed *in vacuo*. The residue was purified by ISCO flash chromatography (4 g silica gel cartridge, 0-100% acetonitrile – dichloromethane gradient over 11 min., 18 mL/min.). The fractions containing the product were combined and the solvent removed to provide Example B391 (10 mg, 28% yield). EL IC₅₀ 25 nM. HL IC₅₀ 53.4 nM. HPLC: RT = 1.72 min (LCMS Method B). MS (ES): $m/z = 478$

25 $[M+H]^+$. ^1H NMR (400MHz, DMSO- d_6) δ 8.98 (t, $J=5.7$ Hz, 1H), 8.57 - 8.54 (m, 1H), 8.30 (d, $J=8.4$ Hz, 1H), 8.02 (dd, $J=8.4$, 1.5 Hz, 1H), 6.96 (s, 2H), 6.08 (s, 1H), 3.64 - 3.57 (m, 2H), 3.24 (s, 3H), 3.22 - 3.16 (m, 2H), 1.60 (s, 9H).

Example B392

30 2-(1-(Methylsulfonyl)-2-oxo-2-((2-sulfamoyl)ethyl)amino)ethyl)benzo[d]thiazole-5-carboxylic acid



Compound B392a. 2-(1-(Methylsulfonyl)-2-oxo-2-((2-sulfamoyl)ethyl)amino)ethyl benzo[d]thiazole-5-carboxylic acid

- 5 **[00265]** Compound B392a was synthesized by cleaving the *tert*-butyl ester of Example B391 using the procedure described for Example B197. HPLC: RT = 1.14 min (LCMS Method B). MS (ES): $m/z = 421.9$ $[M+H]^+$. The product was used without further purification or characterization assuming 100% yield.


10 **Example B392**

- [00266]** Example B392 (5.9 mg, 43 % yield) was prepared from Compound B392a and (3-isopropylisoxazol-5-yl)methanamine as described in the general procedure given for Example B197. EL IC₅₀ 3.1 nM. HL IC₅₀ 92.7 nM. HPLC: RT = 1.24 min. (LCMS Method N). MS (ES): $m/z = 478$ $[M+H]^+$. ¹H NMR (500MHz, DMSO-*d*₆) δ 9.35 (br. s., 1H), 8.99 (br. s., 1H), 8.63 (s, 1H), 8.29 (d, $J=8.3$ Hz, 1H), 8.03 (d, $J=8.3$ Hz, 1H), 7.97 (s, 1H), 6.96 (s, 2H), 6.37 (s, 1H), 6.09 (s, 1H), 4.63 (d, $J=5.0$ Hz, 2H), 3.62 (m, 2H), 3.25 (s, 3H), 3.21 (br. m., 2H), 3.03 - 2.93 (m, 1H), 1.22 (d, $J=6.9$ Hz, 6H).
- 15

- [00267]** Example B393 to Example B394 were prepared as described in the general procedure given for Example B392.
- 20

Example B395


2-(6-(5-(4-Fluorophenyl)-1,3,4-oxadiazol-2-yl)benzo[d]thiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)ethyl)acetamide



[00268] Compound B395a (prepared following the general procedure given for Example B197) and 4-fluorobenzohydrazide (10 mg, 0.065 mmol) were dissolved in dioxane (1.0 mL) and treated with DIEA (0.036 mL, 0.21 mmol) and 1-propanephosphonic acid cyclic anhydride (0.12 mL, 0.21 mmol, 50% in ethyl acetate). The reaction mixture was heated at 70° C for 1 hour, allowed to cool to room temperature and concentrated under reduced pressure. The material was purified via preparative HPLC (Column: Waters XBridge C18, 19 x 200 mm, 5- μ m particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1% TFA; Mobile Phase B: 95:5 acetonitrile:water with 0.1% TFA; Gradient: 10-55% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min). Fractions containing the desired product were combined and dried via centrifugal evaporation to afford Example B395 (1 mg, 3% yield) as a clear oil. EL IC₅₀ 148 nM. HL IC₅₀ 275.5 nM. HPLC: RT = 1.50 min (LCMS Method N). MS (ES): m/z = 540.15 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 9.08 - 8.99 (m, 1H), 8.31 (s, 1H), 8.29 - 8.21 (m, 2H), 7.58 - 7.45 (m, 2H), 6.95 (m, 1H), 3.68 - 3.56 (m, 2H), 3.26 (s, 3H), 3.23 - 3.16 (m, 2H).

Example B396

2-[6-(6-fluoropyridin-3-yl)-1,3-benzothiazol-2-yl]-2-(2-methoxyethanesulfonyl)-N-[(methylcarbamoyl)methyl]acetamide



Compound B396b. tert-butyl 2-(2-(6-(6-fluoropyridin-3-yl)benzo[d]thiazol-2-yl)acetamido)acetate

- 5 **[00269]** To a solution of Compound B396a (440 mg, 1.4 mmol, prepared as described in the general procedure given for Compound B23a) in THF (10 mL) at 0 °C was added 1N NaOH (1.5 mL, 1.5 mmol). The ice bath was removed and the mixture stirred for 4h. The mixture was evaporated under reduced pressure and the residue evaporated from toluene (2x) under reduced pressure. The residue was dissolved in DMF (7 mL) at 0 °C
- 10 then DIPEA (0.73 mL, 4.2 mmol) added followed by glycine tert-butyl ester hydrochloride (280 mg, 1.7 mmol) and HATU (690 mg, 1.8 mmol). The mixture was stirred for 1 h then poured into saturated NH₄Cl and extracted with EtOAc (3x). The combined organic extracts were washed with brine, dried (Na₂SO₄) filtered and concentrated under reduced pressure. The residue was purified by silica gel
- 15 chromatography eluting with 10 to 75% EtOAc/DCM to give Compound B396b (190 mg, 34 % yield) as a yellow solid. RT = 1.85 min (LCMS Method B). MS (ES): m/z = 403.1 [M+H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.48 (d, J=2.0 Hz, 1H), 8.12 (d, J=8.6 Hz, 1H),

8.07 - 7.97 (m, 2H), 7.65 (dd, $J=8.5$, 1.7 Hz, 1H), 7.45 (br. s., 1H), 7.05 (dd, $J=8.5$, 3.0 Hz, 1H), 4.14 (s, 2H), 4.01 (d, $J=5.1$ Hz, 2H), 1.47 (s, 9H).

Compound B396c. tert-butyl 2-(2-(6-(6-fluoropyridin-3-yl)benzo[d]thiazol-2-yl)-2-((2-methoxyethyl)sulfonyl)acetamido)acetate

[00270] To a solution of Compound B396b (190 mg, 0.47 mmol) in DMF (5 mL) at brine/ice bath temperature was added 1N NaHMDS in THF (0.71 mL, 0.71 mmol) and the mixture stirred for 2 min. A solution of 2-methoxyethanesulfonyl chloride (113 mg, 0.710 mmol) in DMF (0.5 mL) was added dropwise and the reaction stirred for 5 min.

The reaction was quenched by the addition of saturated NH_4Cl and extracted with 50% EtOAc/hexanes (3x). The combined organic extracts were washed with brine then dried (Na_2SO_4) filtered and concentrated. The residue was purified by silica gel

chromatography eluting with 5 to 50% EtOAc/DCM to give Compound B396c (100 mg, 41 % yield) as a brown solid. RT = 1.93 min (LCMS Method B). MS (ES): $m/z = 524.1$

$[\text{M}+\text{H}]^+$. ^1H NMR (400MHz, CDCl_3) δ 14.41 (s, 1H), 8.42 (d, $J=2.6$ Hz, 1H), 8.13 (t, $J=5.3$ Hz, 1H), 8.00 - 7.90 (m, 1H), 7.78 - 7.71 (m, 1H), 7.57 - 7.49 (m, 1H), 7.44 - 7.36 (m, 1H), 7.03 (dd, $J=8.8$, 2.9 Hz, 1H), 4.09 - 3.96 (m, 2H), 3.84 (t, $J=6.2$ Hz, 2H), 3.55 - 3.47 (m, 2H), 3.28 (s, 3H), 1.50 (s, 9H).

Compound B396d. 2-(2-(6-(6-fluoropyridin-3-yl)benzo[d]thiazol-2-yl)-2-((2-methoxyethyl)sulfonyl)acetamido)acetic acid

[00271] To a flask charged with Compound B396c (95 mg, 0.18 mmol) was added 50% TFA in DCM (1 mL) and the mixture stirred for 1h. The mixture was evaporated under reduced pressure and the residue evaporated from toluene (2x) under reduced

pressure to give Compound B396d (84 mg, 99 % yield) as a brown solid. RT = 1.60 min (LCMS Method B). MS (ES): $m/z = 468.0$ $[\text{M}+\text{H}]^+$. ^1H NMR (400MHz, $\text{DMSO}-d_6$) δ 9.09 (t, $J=5.6$ Hz, 1H), 8.66 (d, $J=2.4$ Hz, 1H), 8.56 (d, $J=1.8$ Hz, 1H), 8.39 (td, $J=8.2$, 2.5 Hz, 1H), 8.20 (d, $J=8.6$ Hz, 1H), 7.95 - 7.90 (m, 1H), 7.35 (dd, $J=8.4$, 2.9 Hz, 1H), 6.19 (s, 1H), 3.98 (dd, $J=10.8$, 5.7 Hz, 2H), 3.80 - 3.70 (m, 4H), 3.28 (s, 3H).


Example B396

[00272] To a solution of Compound B396d (15 mg, 0.032 mmol) in DMF (0.5 mL) was added methylamine hydrochloride (3.3 mg, 0.048 mmol) followed by DIEA (0.017 mL, 0.10 mmol) and HATU (16 mg, 0.042 mmol) and the mixture stirred for 1.5h.



- 5 Reaction mixture was diluted with DMF and filtered. The material was purified via preparative HPLC (Column : Phenomex Axia Luna C18, 30 x 100mm, 5- μ m particles; Mobile Phase A: 10:90 acetonitrile:water with 0.1% TFA; Mobile Phase B: 90:10 acetonitrile:water with 0.1% TFA; Gradient: 20-100% B over 20 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min). The fractions containing product were
- 10 combined and concentrated under reduced pressure to give Example 396 (10 mg, 64 % yield) as a yellow solid. RT = 1.56 min (LCMS Method B). MS (ES): m/z = 481.0 [M+H]⁺. ¹H NMR (400MHz, DMSO-d₆) δ 9.03 (t, *J*=5.4 Hz, 1H), 8.66 (d, *J*=2.2 Hz, 1H), 8.57 (d, *J*=1.5 Hz, 1H), 8.40 (td, *J*=8.1, 2.6 Hz, 1H), 8.20 (d, *J*=8.6 Hz, 1H), 7.95 - 7.91 (m, 2H), 7.35 (dd, *J*=8.6, 2.6 Hz, 1H), 6.21 (s, 1H), 3.87 (dd, *J*=15.5, 5.6 Hz, 2H),
- 15 3.82 - 3.75 (m, 2H), 3.75 - 3.69 (m, 2H), 3.28 (s, 3H), 2.62 (d, *J*=4.6 Hz, 3H).




Example B397




N-[(ethylcarbamoyl)methyl]-2-[6-(6-fluoropyridin-3-yl)-1,3-benzothiazol-2-yl]-2-(2-methoxyethanesulfonyl)acetamide




- [00273] Example B397 was prepared from Compound B396d as described in the general procedure given for Example B396 (8 mg, 49%). EL IC₅₀ 109 nM. HL IC₅₀ 460 nM. RT = 1.63 min (LCMS Method B). MS (ES): m/z = 495.1 [M+H]⁺. ¹H NMR (400MHz, DMSO-d₆) δ 9.02 (t, *J*=5.6 Hz, 1H), 8.66 (d, *J*=2.4 Hz, 1H), 8.57 (d, *J*=1.8
- 25 Hz, 1H), 8.40 (td, *J*=8.1, 2.6 Hz, 1H), 8.20 (d, *J*=8.6 Hz, 1H), 7.95 - 7.91 (m, 2H), 7.35 (dd, *J*=8.7, 2.8 Hz, 1H), 6.22 (s, 1H), 3.89 - 3.84 (m, 2H), 3.78 (dt, *J*=5.0, 2.7 Hz, 2H), 3.75 - 3.69 (m, 2H), 3.28 (s, 3H), 3.16 - 3.05 (m, 2H), 1.03 (t, *J*=7.3 Hz, 3H).



Ex #	Structure	Name	¹ H NMR (500MHz, DMSO-d ₆ , unless indicated otherwise)	LC/MS RT (min) Method M+H	EL IC ₅₀ (nM)	HL IC ₅₀ (nM)
B32		2-(6-(3-chloro-4-(4-morpholinylcarbonyl)phenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)ethyl)acetamide	δ 8.99 (t, J=5.8 Hz, 1H), 8.58 (d, J=1.7 Hz, 1H), 8.17 (d, J=8.8 Hz, 1H), 8.01 - 7.91 (m, 2H), 7.83 (dd, J=8.0, 0.8 Hz, 1H), 7.53 (d, J=8.0 Hz, 1H), 6.95 (s, 2H), 6.05 (s, 1H), 3.76 - 3.51 (m, 8H), 3.25 (s, 3H), 3.22 - 3.09 (m, 4H)	0.75 M 600.8	<10	923
B33		2-(6-(6-fluoro-5-methyl-3-pyridinyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)ethyl)acetamide	δ 9.06 - 8.91 (m, 1H), 8.61 - 8.51 (m, 1H), 8.48 - 8.41 (m, 1H), 8.36 - 8.24 (m, 1H), 8.21 - 8.14 (m, 1H), 7.97 - 7.83 (m, 1H), 7.02 - 6.91 (m, 2H), 6.09 - 5.99 (m, 1H), 3.68 - 3.56 (m, 2H), 3.24 (s, 3H), 3.22 - 3.14 (m, 2H)	0.81 M 486.8	14	22



B34		2-(methylsulfonyl)-2-(6-(1-(2-(4-morpholinylethyl)ethyl)-1H-pyrazol-4-yl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide	δ 8.98 (s, 1H), 8.38 (d, J=5.5 Hz, 2H), 8.13 (br. s., 1H), 8.09 (d, J=8.5 Hz, 1H), 7.81 (d, J=8.5 Hz, 1H), 6.96 (s, 2H), 6.01 (s, 1H), 4.59 (br. s., 2H), 4.04 (q, J=7.2 Hz, 2H), 3.67 (br. s., 6H), 3.61 (dd, J=12.7, 6.3 Hz, 2H), 3.24 (s, 3H), 3.22 - 3.17 (m, 2H)	0.55 M 556.9	<10	313
B35		<i>N</i> -(2-methoxyethyl)-4-(2-{1-(methylsulfonyl)-2-oxo-2-[(2-sulfamoyl)ethyl]amino}ethyl)-1,3-benzothiazol-6-yl)benzamide	^1H NMR (500MHz, METHANOL- d_4) δ 8.49 - 8.29 (m, 1H), 8.23 - 8.08 (m, 1H), 8.01 - 7.70 (m, 5H), 3.92 - 3.70 (m, 2H), 3.60 (s, 3H), 3.40 (m, 6H), 3.22 (s, 3H)	0.70 M 554.9	<10	43
B36		2-(6-(4-fluorophenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)ethyl)acetamide	δ 9.13 - 8.87 (m, 1H), 8.54 - 8.41 (m, 1H), 8.23 - 8.07 (m, 1H), 7.93 - 7.73 (m, 3H), 7.42 - 7.26 (m, 2H), 7.12 - 6.81 (m, 2H), 3.65 - 3.53 (m, 2H), 3.27 (s, 3H), 3.22 - 3.13 (m, 2H)	0.89 M 471.9	<10	<10




B37		2-(6-(3-fluorophenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)ethyl)acetamide	δ 9.21 - 8.85 (m, 1H), 8.67 - 8.47 (m, 1H), 8.26 - 8.11 (m, 1H), 8.00 - 7.88 (m, 1H), 7.71 - 7.60 (m, 2H), 7.59 - 7.50 (m, 2H), 7.35 - 7.18 (m, 1H), 6.95 (s, 2H), 3.66 - 3.52 (m, 2H), 3.24 (s, 3H), 3.22 - 3.12 (m, 2H)	0.88 M 471.9	<10	<10
B38		2-(6-(1,3-benzodioxol-5-yl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)ethyl)acetamide	δ 9.13 - 8.91 (m, 1H), 8.40 (s, 1H), 8.17 - 8.06 (m, 1H), 7.95 (s, 1H), 7.87 - 7.75 (m, 1H), 7.35 (s, 1H), 7.28 - 7.20 (m, 1H), 7.09 - 7.01 (m, 1H), 6.95 (s, 2H), 6.08 (s, 2H), 6.01 (s, 1H), 3.66 - 3.53 (m, 2H), 3.23 (s, 3H), 3.18 (m., 2H)	1.43 N 498.1	<10	<10
B39		2-(methylsulfonyl)-N-(2-sulfamoyl)ethyl)-2-(6-(4-(trifluoromethoxy)phenyl)-1,3-benzothiazol-2-yl)acetamide	¹ H NMR (500MHz, METHANOL-d ₄) δ 8.32 (br. s., 1H), 8.20 - 8.08 (m, 1H), 7.91 - 7.31 (m, 8H), 5.49 (s, 1H), 3.90 - 3.74 (m, 2H), 3.33-3.36 (m, 2H), 3.22 (s, 3H)	0.98 M 537.8	<10	<10



B40		N-(2-hydroxyethyl)-4-(2-(1-(methylsulfonyl)-2-oxo-2-((2-sulfamoyl)ethyl)-1,3-aminoethyl)-6-yl) benzamide	δ 9.05 - 8.94 (m, 1H), 8.62 - 8.55 (m, 1H), 8.54 - 8.42 (m, 1H), 8.24 - 8.12 (m, 1H), 7.98 (s, 3H), 7.88 (s, 3H), 6.95 (s, 2H), 6.04 (s, 1H), 3.69 - 3.57 (m, 2H), 3.56 - 3.48 (m, 2H), 3.42 - 3.34 (m, 2H), 3.24 (s, 3H), 3.22 - 3.14 (m, 2H)	0.63 M 540.8	<10	19
B41		4-(2-(1-(methylsulfonyl)-2-oxo-2-((2-sulfamoyl)ethyl)-1,3-aminoethyl)-6-yl)-N-(2,2,2-trifluoroethyl) benzamide	^1H NMR (400MHz, DMSO-d ₆) δ 9.51 - 9.10 (m, 1H), 9.05 - 8.93 (m, 1H), 8.64 - 8.52 (m, 1H), 8.29 - 8.13 (m, 1H), 8.03 (d, $J=8.6$ Hz, 2H), 7.92 (d, $J=8.6$ Hz, 3H), 6.95 (s, 2H), 6.04 (s, 1H), 4.33 - 4.05 (m, 2H), 3.70 - 3.53 (m, 2H), 3.24 (s, 3H), 3.22 - 3.15 (m, 2H)	0.83 M 578.7	<10	17
B42		2-(methylsulfonyl)-2-(6-(4-(2-(1-piperidinyloxy)ethoxy)phenyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl acetamide	δ 9.05 - 8.92 (m, 1H), 8.48 - 8.38 (m, 1H), 8.15 - 8.02 (m, 1H), 7.87 - 7.80 (m, 1H), 7.78 - 7.71 (m, 2H), 7.19 - 7.09 (m, 2H), 6.99 - 6.88 (m, 2H), 6.11 - 5.94 (m, 1H),	0.66 M 580.8	<10	10



			4.46 - 4.34 (m, 2H), 3.65 - 3.57 (m, 2H), 3.57 - 3.47 (m, 4H), 3.22 (s, 3H), 3.21 - 3.13 (m, 2H), 3.08 - 2.96 (m, 2H), 2.68 - 2.59 (m, 1H), 2.39 - 2.31 (m, 1H), 1.92 - 1.79 (m, 2H), 1.76 - 1.62 (m, 3H), 1.47 - 1.31 (m, 1H)			
B43	 2-(6-{4-[(4-methyl-1-piperidinyl)carbonyl]phenyl}-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-<i>N</i>-(2-sulfamoyl)ethyl acetamide		δ 9.10 - 8.82 (m, 1H), 8.77 - 8.43 (m, 1H), 8.23 - 8.11 (m, 1H), 7.98 - 7.87 (m, 1H), 7.86 - 7.75 (m, 2H), 7.59 - 7.40 (m, 3H), 7.04 - 6.86 (m, 2H), 6.19 - 5.96 (m, 1H), 4.64 - 4.37 (m, 2H), 3.69 - 3.55 (m, 2H), 3.23 (s, 3H), 3.21 - 3.13 (m, 2H), 3.11 - 2.91 (m, 1H), 2.87 - 2.69 (m, 1H), 1.78 - 1.52 (m, 3H), 1.18 - 1.03 (m, 2H), 0.98 - 0.86 (m, 3H).	0.83 M 578.7	<10	<10




B44		2-(6-(4-acetamidophenyl)-1,3-benzothiazol-2-yl)-2-(benzylsulfonyl)-N-(2-sulfamoyl)ethyl)acetamide	δ 10.07 (s, 1H), 9.22 - 8.82 (m, 1H), 8.44 (d, <i>J</i>=1.7 Hz, 1H), 8.15 (d, <i>J</i>=8.5 Hz, 1H), 7.95 (s, 1H), 7.90 - 7.83 (m, 1H), 7.72 (s, 2H), 7.66 (s, 2H), 7.39 (s, 3H), 7.36 - 7.17 (m, 2H), 6.95 (s, 2H), 6.08 (s, 1H), 4.74 (d, <i>J</i>=14.0 Hz, 1H), 4.67 - 4.48 (m, 1H), 3.60 (br. s., 2H), 3.20 (s, 2H), 2.50 (s, 3H)	1.46 N 587.1	<10	148
B45		4-(2-(2-oxo-2-((2-sulfamoyl)ethyl)amino)-1-((3,3,3-trifluoropropyl)sulfonyl)ethyl)-1,3-benzothiazol-6-yl)-N-(2,2,2-trifluoroethyl)benzamide	δ 9.23 - 9.06 (m, 1H), 8.99 - 8.85 (m, 1H), 8.69 - 8.51 (m, 1H), 8.19 - 8.13 (m, 1H), 8.08 - 7.75 (m, 5H), 7.76 - 7.38 (m, 2H), 7.17 - 6.80 (m, 2H), 6.50 - 6.08 (m, 1H), 4.25 - 4.00 (m, 2H), 3.84 - 3.51 (m, 4H), 3.23 - 3.14 (m, 2H), 2.96 - 2.78 (m, 2H)	0.83 M 660.8	<10	38



B46		N-(2-hydroxyethyl)-4-(2- (2-oxo-2-((2- sulfamoyl)ethyl)amino)-1- ((3,3,3-trifluoropropyl) sulfonyl)ethyl)-1,3- benzothiazol-6-yl) benzamide	δ 9.03 - 8.87 (m, 1H), 8.66 - 8.55 (m, 1H), 8.55 - 8.41 (m, 1H), 8.23 - 8.10 (m, 1H), 8.05 - 7.91 (m, 3H), 7.92 - 7.83 (m, 2H), 7.83 - 7.72 (m, 1H), 6.95 (s, 2H), 6.26 (s, 1H), 4.83 - 4.58 (m, 1H), 3.88 - 3.58 (m, 4H), 3.58 - 3.45 (m, 2H), 3.42 - 3.32 (m, 2H), 3.26 - 3.09 (m, 2H), 2.93 - 2.68 (m, 2H)	0.77 M 622.8	<10	520
B47		2-(6-(4-(2- hydroxyethyl)phenyl)-1,3- benzothiazol-2-yl)-2- (methylsulfonyl)-N-(2- sulfamoyl)ethyl)acetamide	δ 9.05 - 8.86 (m, 1H), 8.53 - 8.41 (m, 1H), 8.24 - 8.08 (m, 1H), 7.95 - 7.82 (m, 1H), 7.73 - 7.64 (m, 2H), 7.44 - 7.33 (m, 2H), 6.95 (s, 2H), 6.10 - 5.96 (m, 1H), 4.83 - 4.61 (m, 1H), 3.79 - 3.46 (m, 4H), 3.24 (s, 3H), 3.22 - 3.13 (m, 2H), 2.89 - 2.74 (m, 2H)	0.72 M 497.8	<10	35



B48		2-(6-(4-(2-methoxyethoxy)phenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)ethylacetamide	δ 9.08 - 8.85 (m, 1H), 8.41 (s, 1H), 8.17 - 8.08 (m, 1H), 7.88 - 7.79 (m, 1H), 7.70 (d, $J=8.0$ Hz, 2H), 7.08 (d, $J=8.3$ Hz, 2H), 6.95 (s, 2H), 6.01 (s, 1H), 4.16 (br. s., 2H), 3.69 (br. s., 2H), 3.59 (br. s., 2H), 3.31 (s, 3H), 3.23 (s, 3H), 3.19 (br. s., 2H)	1.55 N 528.1	<10	11
B49		N-(2-methoxyethyl)-3-(2-(1-(methylsulfonyl)-2-oxo-2-((2-sulfamoyl)ethyl)-1,3-amino)ethyl)-1,3-benzothiazol-6-yl)benzamide	δ 9.06 - 8.93 (m, 1H), 8.73 - 8.65 (m, 1H), 8.55 (br. s., 1H), 8.24 (br. s., 1H), 8.21 - 8.16 (m, 1H), 7.95 (br. s., 4H), 7.67 - 7.56 (m, 1H), 6.95 (br. s., 2H), 6.04 (br. s., 1H), 3.67 - 3.57 (m, 2H), 3.48 (d, $J=1.7$ Hz, 4H), 3.28 (br. s., 3H), 3.24 (br. s., 3H), 3.19 (br. s., 2H)	1.29 N 555.1	<10	152
B50		2-(6-(4-cyanophenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)ethylacetamide	δ 9.05 - 8.88 (m, 1H), 8.60 (br. s., 1H), 8.29 - 8.13 (m, 1H), 8.05 - 7.90 (m, 6H), 6.95 (br. s., 2H), 6.05 (br. s., 1H), 3.61 (d, $J=5.5$	1.48 N 479.1	<10	14



				Hz, 2H), 3.24 (br. s., 3H), 3.19 (br. s., 2H)			
B51		2-(6-(3-cyanophenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)acetamide	δ 9.03 - 8.91 (m, 1H), 8.59 (br. s., 1H), 8.27 (br. s., 1H), 8.22 - 8.16 (m, 1H), 8.16 - 8.05 (m, 1H), 7.95 (br. s., 2H), 7.91 - 7.83 (m, 1H), 7.78 - 7.67 (m, 1H), 6.95 (br. s., 2H), 6.05 (br. s., 1H), 3.61 (d, $J=5.2$ Hz, 2H), 3.24 (br. s., 3H), 3.19 (br. s., 2H)	1.51 N 479.1	<10	<10	
B52		2-(6-(3-acetamidophenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)acetamide	δ 10.06 (br. s., 1H), 9.10 - 8.81 (m, 1H), 8.40 (br. s., 1H), 8.23 - 8.11 (m, 1H), 7.97 (d, $J=16.8$ Hz, 2H), 7.83 - 7.72 (m, 1H), 7.65 - 7.52 (m, 1H), 7.41 (br. s., 2H), 6.95 (br. s., 2H), 6.03 (br. s., 1H), 3.68 - 3.53 (m, 2H), 3.24 (br. s., 3H), 3.19 (br. s., 2H), 2.08 (br. s., 3H)	1.28 N 511.1	<10	66	



B53		2-(6-(4-(2-hydroxyethyl)phenyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl-2-((3,3,3-trifluoropropyl)sulfonyl)acetamide	δ 8.94 (br. s., 1H), 8.46 (br. s., 1H), 8.13 (d, $J=8.3$ Hz, 1H), 7.86 (d, $J=8.3$ Hz, 1H), 7.67 (d, $J=6.9$ Hz, 2H), 7.35 (d, $J=7.2$ Hz, 2H), 6.95 (br. s., 2H), 6.25 (br. s., 1H), 4.65 (br. s., 1H), 3.65 (br. s., 6H), 3.18 (br. s., 2H), 2.93 - 2.69 (m, 4H)	1.63 N 580.1	<10	152
B54		2-(6-(4-(2-(piperidinylethoxy)phenyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)-2-((3,3,3-trifluoropropyl)sulfonyl)acetamide	δ 9.57 - 9.28 (m, 1H), 9.09 - 8.95 (m, 1H), 8.45 (br. s., 1H), 8.29 - 8.08 (m, 1H), 7.76 (d, $J=8.0$ Hz, 3H), 7.15 (d, $J=8.3$ Hz, 2H), 6.98 (br. s., 2H), 6.26 (br. s., 1H), 4.41 (br. s., 2H), 3.53 (br. s., 8H), 3.18 (br. s., 2H), 3.10 - 2.96 (m, 2H), 2.89 (br. s., 2H), 1.83 (br. s., 2H), 1.70 (d, $J=11.3$ Hz, 3H), 1.52 - 1.32 (m, 1H)	1.48 N 663.2	<10	23



B55		2-(6-(4-acetamidophenyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl-2-yl)-N-((3,3,3-trifluoropropyl)sulfonyl)acetamide	δ 10.09 (br. s., 1H), 8.98 (br. s., 1H), 8.46 (br. s., 1H), 8.12 (d, $J=7.7$ Hz, 1H), 7.85 (d, $J=8.0$ Hz, 1H), 7.76 - 7.59 (m, 4H), 6.98 (br. s., 2H), 6.25 (br. s., 1H), 3.85 - 3.46 (m, 4H), 3.18 (br. s., 2H), 2.85 (d, $J=9.4$ Hz, 2H), 2.07 (br. s., 3H)	1.45 N 593.2	<10	55
B56		2-(6-(4-(hydroxymethyl)phenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl-2-yl)-acetamide	δ 9.01 (t, $J=5.6$ Hz, 1H), 8.48 (d, $J=1.4$ Hz, 1H), 8.14 (d, $J=8.5$ Hz, 1H), 7.87 (dd, $J=8.8, 1.7$ Hz, 1H), 7.73 (d, $J=8.3$ Hz, 2H), 7.45 (d, $J=8.3$ Hz, 2H), 6.97 (s, 2H), 6.12 - 5.92 (m, 1H), 4.65 - 4.50 (m, 2H), 3.60 (q, $J=6.8$ Hz, 2H), 3.27 - 3.21 (m, 3H), 3.22 - 3.13 (m, 2H)	1.22 N 484.1	<10	122
B57		2-(6-(4-((2-hydroxyethyl)sulfamoyl)phenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl-2-yl)-acetamide	δ 9.08 - 8.93 (m, 1H), 8.59 (d, $J=1.7$ Hz, 1H), 8.20 (d, $J=8.5$ Hz, 1H), 8.04 - 7.87 (m, 5H), 7.71 (s, 1H), 6.97 (s, 2H), 6.05 (s, 1H),	1.15 N 577.1	<10	144



B58		2-(6-(3-(2-hydroxyethyl)phenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoylethyl)acetamide	4.72 (s, 1H), 3.60 (d, $J=6.1$ Hz, 2H), 3.39 (d, $J=5.8$ Hz, 2H), 3.24 (s, 3H), 3.19 (d, $J=1.9$ Hz, 2H), 2.83 (d, $J=6.1$ Hz, 2H)		
B59		4-(2-(1-((cyclopropylmethyl)sulfonyl)-2-oxo-2-((2-sulfamoylethyl)amino)ethyl)-1,3-benzothiazol-6-yl)-N-(2-hydroxyethyl)benzamide	δ 9.16 - 8.89 (m, 1H), 8.56 (br. s., 2H), 8.23 - 8.10 (m, 1H), 8.05 - 7.62 (m, 6H), 6.97 (br. s., 1H), 6.94 - 6.84 (m, 1H), 6.06 (br. s., 1H), 4.75 (br. s., 1H), 3.60 (br. s., 2H), 3.53 (d, $J=4.4$ Hz, 2H), 3.45 - 3.37 (m, 2H), 3.28 (br. s., 2H),	1.26 N 581.1	<10



				3.18 (br. s., 2H), 1.16 - 0.89 (m, 1H), 0.63 (br. s., 1H), 0.40 (br. s., 2H), 0.31 - 0.03 (m, 1H)			
B60		2-((cyclopropylmethyl)sulfonyl)-2-(6-(4-(2-hydroxyethyl)phenyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide	δ 9.16 - 8.97 (m, 1H), 8.54 - 8.38 (m, 1H), 8.17 - 8.06 (m, 1H), 7.95 (br. s., 1H), 7.90 - 7.79 (m, 1H), 7.70 - 7.54 (m, 2H), 7.35 (br. s., 2H), 6.96 (br. s., 2H), 6.16 - 5.99 (m, 1H), 4.79 - 4.62 (m, 1H), 3.63 (br. s., 4H), 3.27 (br. s., 2H), 3.18 (br. s., 2H), 2.77 (br. s., 2H), 1.15 - 0.88 (m, 1H), 0.71 - 0.56 (m, 1H), 0.40 (br. s., 2H), 0.29 - 0.08 (m, 1H)	1.53 N 538.1	<10	61	
B61		2-(6-(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)ethyl)acetamide	δ 9.16 - 8.96 (m, 1H), 8.40 - 8.31 (m, 1H), 8.13 - 7.99 (m, 1H), 7.84 - 7.70 (m, 1H), 7.28 - 7.20 (m, 1H), 7.14 - 7.07 (m, 1H), 7.02 - 6.92 (m, 2H), 6.86 - 6.74 (m, 1H), 6.19 - 5.90 (m, 1H), 4.43 - 4.21	1.63 N 525.1	<10	50	




				(m, 2H), 3.62 - 3.53 (m, 2H), 3.31 - 3.25 (m, 2H), 3.25 - 3.22 (m, 3H), 3.20 - 3.14 (m, 2H), 2.89 (s, 3H)			
B62		2-(methylsulfonyl)-2-(6-(3-(1-pyrrolidinyl)phenyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl acetamide	δ 9.00 (t, $J=5.6$ Hz, 1H), 8.45 (s, 1H), 8.13 (s, 1H), 7.84 (d, $J=8.5$ Hz, 1H), 7.27 (t, $J=7.8$ Hz, 1H), 7.05 - 6.90 (m, 3H), 6.83 (s, 1H), 6.58 (d, $J=8.0$ Hz, 1H), 6.02 (s, 1H), 3.60 (q, $J=6.6$ Hz, 2H), 3.31 (t, $J=6.1$ Hz, 4H), 3.23 (s, 3H), 3.18 (t, $J=7.2$ Hz, 2H), 1.98 (br. s., 4H)	1.92 N 523.1	1.2	1	
B63		2-(6-(4-(methoxymethyl)phenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)ethyl acetamide	δ 9.01 (t, $J=5.6$ Hz, 1H), 8.49 (s, 1H), 8.15 (d, $J=8.5$ Hz, 1H), 7.88 (s, 1H), 7.76 (d, $J=7.7$ Hz, 2H), 7.45 (d, $J=7.7$ Hz, 2H), 6.97 (s, 2H), 6.03 (s, 1H), 4.56 - 4.43 (m, 2H), 3.60 (q, $J=6.6$ Hz, 2H), 3.32 (s, 3H), 3.24 (s, 3H), 3.19 (t, $J=7.2$	1.48 N 498.1	0.5	2.6	



			Hz, 2H)			
B64		2-methoxyethyl 4-(2-(1-(methylsulfonyl)-2-oxo-2-((2-sulfamoyl)ethyl)amino)ethyl)-1,3-benzothiazol-6-yl)phenyl)carbamate	δ 9.92 (br. s., 1H), 9.00 (s, 1H), 8.43 (s, 1H), 8.11 (d, $J=8.5$ Hz, 1H), 7.84 (d, $J=8.5$ Hz, 1H), 7.71 (d, $J=8.3$ Hz, 2H), 7.60 (d, $J=8.3$ Hz, 2H), 6.97 (s, 2H), 6.01 (s, 1H), 4.37 - 4.16 (m, 2H), 3.70 - 3.52 (m, 4H), 3.29 (s, 3H), 3.23 (s, 3H), 3.18 (t, $J=7.2$ Hz, 2H)	1.32 N 571.1	0.5	1.9
B65		4-(2-(1-(4-fluorobenzyl)sulfonyl)-2-oxo-2-((2-sulfamoyl)ethyl)amino)ethyl)-1,3-benzothiazol-6-yl)-N-(2,2,2-trifluoroethyl)benzamide	δ 9.35 - 9.13 (m, 1H), 9.05 (br. s., 1H), 8.60 (s, 1H), 8.26 - 8.16 (m, 1H), 8.09 - 7.89 (m, 4H), 7.88 - 7.71 (m, 2H), 7.46 (t, $J=6.2$ Hz, 1H), 7.39 (br. s., 1H), 7.24 (t, $J=8.3$ Hz, 1H), 7.17 - 7.07 (m, 1H), 7.06 - 6.90 (m, 2H), 6.08 (s, 1H), 4.75 (br. s., 1H), 4.67 - 4.52 (m, 1H), 4.12 (d, $J=7.2$ Hz, 2H), 3.70 - 3.53 (m, 2H), 3.27 - 3.11 (m, 2H)	1.73 N 673.1	<10	61


B66		4-(2-(1-(4-fluorobenzyl)sulfonyl)-2-oxo-2-((2-sulfamoyl)ethyl)amino)ethyl)-1,3-benzothiazol-6-yl)-N-(2-hydroxyethyl)benzamide	δ 8.62 - 8.45 (m, 2H), 8.28 - 8.12 (m, 1H), 8.05 - 7.85 (m, 5H), 7.84 - 7.67 (m, 2H), 7.56 - 7.44 (m, 1H), 7.38 (br. s., 1H), 7.24 (t, $J=8.3$ Hz, 1H), 7.18 - 7.05 (m, 1H), 7.04 - 6.89 (m, 2H), 6.07 (s, 1H), 4.75 (br. s., 2H), 4.65 (br. s., 1H), 3.60 (d, $J=6.1$ Hz, 2H), 3.53 (t, $J=5.4$ Hz, 2H), 3.36 (d, $J=5.8$ Hz, 2H), 3.19 (t, $J=7.2$ Hz, 2H)	1.87 N 555.1	<10	103
B67		2-[6-(1-isobutyl-1H-pyrazol-4-yl)-1,3-benzothiazol-2-yl]-2-(methylsulfonyl)-N-(2-sulfamoyl)acetamide	δ 9.03 - 8.96 (m, 1H), 8.36 (d, $J=1.7$ Hz, 1H), 8.29 (s, 1H), 8.05 (d, $J=8.5$ Hz, 1H), 8.00 (s, 1H), 7.80 (dd, $J=8.5, 1.7$ Hz, 1H), 6.98 (s, 2H), 5.99 (s, 1H), 3.96 (d, $J=7.2$ Hz, 2H), 3.60 (dd, $J=13.2, 6.9$ Hz, 4H), 3.23 (s, 3H), 3.21 - 3.15 (m, 2H), 0.92 - 0.86 (m, 6H)	0.81 M 499.8	<10	41




B68		2-[6-(1-benzyl-1H-pyrazol-4-yl)-1,3-benzothiazol-2-yl]-2-(methylsulfonyl)-N-(2-sulfamoyl)ethyl)acetamide	δ 8.39 (d, J=13.8 Hz, 1H), 8.21 (s, 1H), 8.08 - 8.00 (m, 1H), 7.88 (s, 1H), 7.82 (br. s., 1H), 7.36 (t, J=7.2 Hz, 3H), 7.34 - 7.26 (m, 2H), 6.95 (s, 1H), 6.86 (s, 1H), 5.38 (s, 1H), 5.33 (s, 1H), 3.65 - 3.55 (m, 3H), 3.25 - 3.13 (m, 5H)	0.82 M 533.8	<10	<10
B69		2-(6-(1-(2-(4-morpholinyl)ethyl)-1H-pyrazol-4-yl)-1,3-benzothiazol-2-yl)-2-(2-sulfamoyl)ethyl)-2-((3,3,3-trifluoropropyl)sulfonyl)acetamide	¹ H NMR (500MHz, ACETONITRILE-d ₃) δ 8.25 (d, J=1.4 Hz, 1H), 8.10 (t, J=4.1 Hz, 1H), 8.03 - 7.97 (m, 1H), 7.96 - 7.88 (m, 1H), 7.79 (dd, J=8.5, 1.9 Hz, 1H), 7.66 - 7.57 (m, 1H), 5.58 - 5.45 (m, 2H), 4.69 - 4.58 (m, 2H), 3.91 (br. s., 3H), 3.87 - 3.69 (m, 2H), 3.65 - 3.43 (m, 3H), 3.37 - 3.29 (m, 2H), 3.23 (br. s., 2H), 2.84 - 2.66 (m, 2H)	0.69 M 638.9	<10	612




B70		<i>tert</i>-butyl 4-(2-(1-((2-methoxyethyl)sulfonyl)-2-oxo-2-((2-sulfamoyl)ethyl)-1,3-benzothiazol-6-yl)phenyl)carbamate	δ 9.49 (s, 1H), 8.95 (t, J=5.5 Hz, 1H), 8.43 (s, 1H), 8.12 (d, J=8.5 Hz, 1H), 7.84 (d, J=8.8 Hz, 1H), 7.69 (d, J=8.5 Hz, 1H), 7.63 - 7.52 (m, 2H), 6.96 (s, 2H), 6.02 (s, 1H), 3.81 - 3.73 (m, 1H), 3.70 - 3.65 (m, 2H), 3.60 (q, J=6.8 Hz, 2H), 3.28 (s, 3H), 3.23 - 3.15 (m, 2H), 2.90 (s, 1H), 2.74 (s, 1H), 1.54 - 1.48 (m, 9H)	1.81 N 613.3	<10	<10
B71		methyl 4-(2-(1-((2-methoxyethyl)sulfonyl)-2-oxo-2-((2-sulfamoyl)ethyl)-1,3-benzothiazol-6-yl)phenyl)carbamate	δ 9.80 (s, 1H), 8.95 (s, 1H), 8.44 (s, 1H), 8.12 (d, J=8.5 Hz, 1H), 7.93 - 7.80 (m, 1H), 7.72 (d, J=8.5 Hz, 2H), 7.60 (d, J=8.5 Hz, 2H), 6.96 (s, 2H), 6.02 (s, 1H), 3.83 - 3.73 (m, 2H), 3.73 - 3.65 (m, 5H), 3.60 (q, J=6.6 Hz, 2H), 3.28 (s, 3H), 3.24 - 3.16 (m, 2H)	1.34 N 571.1	<10	<10




B72		2-(6-(2-fluoro-4-pyridinyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl-ethyl)-2-((3,3,3-trifluoropropyl)sulfonyl)acetamide	δ 8.97 (t, J=5.6 Hz, 1H), 8.75 (d, J=1.7 Hz, 1H), 8.36 (d, J=5.2 Hz, 1H), 8.22 (d, J=8.8 Hz, 1H), 8.07 (dd, J=8.7, 1.8 Hz, 1H), 7.92 (br. s., 1H), 7.81 (d, J=5.5 Hz, 1H), 7.64 (s, 1H), 6.96 (s, 2H), 6.29 (s, 1H), 3.82 - 3.59 (m, 5H), 3.22 - 3.16 (m, 3H)	1.55 N 555.1	<10	68
B73		2-(6-(1-(2-(4-morpholinyl)ethyl)-1H-pyrazol-4-yl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl-ethyl)-2-((4-(trifluoromethyl)benzyl)sulfonyl)acetamide	^1H NMR (400MHz, DMSO- d_6) δ 9.02 (s, 1H), 8.38 (s, 1H), 8.11 (d, J=8.6 Hz, 1H), 7.96 (s, 1H), 7.82 (d, J=9.0 Hz, 1H), 7.76 (d, J=8.6 Hz, 2H), 7.64 (d, J=8.1 Hz, 2H), 7.59 (s, 2H), 6.96 (s, 2H), 6.09 (s, 1H), 4.89 (d, J=2.2 Hz, 2H), 3.79 - 3.56 (m, 12H), 3.25 - 3.15 (m, 6H)	0.76 M 700.7	<10	15860
B74		2-(6-(1-(4-fluorophenyl)-1H-pyrazol-4-yl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-	^1H NMR (400MHz, DMSO- d_6) δ 9.05 (s, 1H), 8.93 (s, 1H), 8.43 (s, 1H), 8.27 (s, 1H), 8.06 (d, J=8.6 Hz, 1H), 7.87 (dt, J=8.8, 2.4 Hz,	0.91 M 537.7	<10	<10




		sulfamoyl)ethyl)acetamide	2H), 7.34 (t, J=8.8 Hz, 2H), 6.91 (s, 1H), 5.95 (s, 1H), 5.69 (s, 1H), 3.58 - 3.47 (m, 2H), 3.17 (s, 3H), 3.15 - 3.07 (m, 3H)			
B75		2-((4-fluorobenzyl) sulfonyl)-2-(6-(1-(2-(4-morpholinyl)ethyl)-1H-pyrazol-4-yl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide	¹ H NMR (400MHz, DMSO-d ₆) δ 8.93 (t, J=5.7 Hz, 1H), 8.36 - 8.27 (m, 1H), 8.17 (br. s., 1H), 8.03 (d, J=8.6 Hz, 1H), 7.98 - 7.85 (m, 1H), 7.74 (dd, J=8.6, 1.8 Hz, 1H), 7.50 (s, 1H), 7.38 (dd, J=8.9, 5.4 Hz, 2H), 7.16 (t, J=8.9 Hz, 1H), 7.02 (br. s., 1H), 6.88 (s, 2H), 5.96 (s, 1H), 4.71 - 4.62 (m, 2H), 4.49 (br. s., 3H), 3.52 (dd, J=13.1, 6.7 Hz, 7H), 3.12 (dd, J=8.8, 6.6 Hz, 5H)	0.70 M 650.8	<10	25000
B76		<i>tert</i> -butyl 4-(4-(2-(1-(methylsulfonyl)-2-oxo-2-((2-sulfamoyl)amino)ethyl)-1,3-	¹ H NMR (400MHz, DMSO-d ₆) δ 8.97 (s, 1H), 8.43 - 8.33 (m, 2H), 8.09 - 7.98 (m, 2H), 7.81 (dd, J=8.6, 1.8 Hz, 1H), 6.95 (s, 2H),	0.88 M 626.7	<10	21




B77		2-[(cyclopropylmethyl)sulfonyl]-2-(6-{1-[2-(4-morpholinyl)ethyl]-1 <i>H</i> -pyrazol-4-yl}-1,3-benzothiazol-2-yl)- <i>N</i> -(2-sulfamoyl)ethyl)acetamide	5.99 (s, 1H), 4.40 (s, 1H), 4.06 (d, J=12.8 Hz, 3H), 3.68 - 3.52 (m, 5H), 3.22 - 3.14 (m, 6H), 2.14 - 1.99 (m, 2H), 1.90 - 1.75 (m, 2H), 1.44 (s, 9H)			
		¹ H NMR (400MHz, ACETONITRILE-d ₃) δ 8.22 (d, J=1.3 Hz, 1H), 8.14 - 8.02 (m, 1H), 7.98 (d, J=5.3 Hz, 1H), 7.91 - 7.84 (m, 1H), 7.76 (dd, J=8.6, 1.8 Hz, 1H), 7.61 - 7.52 (m, 1H), 5.82 (s, 1H), 5.53 (br. s., 2H), 4.63 (dt, J=8.3, 6.1 Hz, 2H), 3.92 (br. s., 4H), 3.85 - 3.72 (m, 2H), 3.64 (q, J=6.2 Hz, 2H), 3.38 - 3.25 (m, 4H), 3.22 - 3.10 (m, 2H), 1.28 - 0.99 (m, 1H), 0.75 - 0.69 (m, 1H), 0.57 - 0.43 (m, 2H), 0.31 (d, J=4.6 Hz, 1H)	0.64 M 596.8	<10	2261	



B78		2-(methylsulfonyl)-N-(2-sulfamoyl-ethyl)-2-(6-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3-benzothiazol-2-yl)acetamide	¹ H NMR (400MHz, DMSO-d ₆) δ 13.85 (br. s., 1H), 9.06 - 8.93 (m, 1H), 8.29 (s, 1H), 8.21 (d, J=1.5 Hz, 1H), 8.14 (d, J=8.4 Hz, 1H), 7.60 (dd, J=8.7, 1.7 Hz, 1H), 6.95 (s, 2H), 6.52 (s, 1H), 6.04 (s, 1H), 3.67 - 3.54 (m, 2H), 3.25 (s, 3H), 3.22 - 3.15 (m, 2H)	0.72 M 511.7	<10	68
B79		2-(6-(3-methoxyphenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl-ethyl)acetamide	δ 9.10 - 8.84 (m, 1H), 8.49 (br. s., 1H), 8.20 - 8.09 (m, 1H), 7.95 (br. s., 1H), 7.91 - 7.84 (m, 1H), 7.47 - 7.38 (m, 1H), 7.29 (br. s., 2H), 7.06 - 6.95 (m, 2H), 6.95 (br. s., 2H), 6.03 (br. s., 1H), 3.85 (br. s., 3H), 3.66 - 3.56 (m, 2H), 3.23 (br. s., 3H), 3.19 (br. s., 2H)	1.63 N 484.9	<10	<10
B80		2-[6-(6-fluoro-3-pyridinyl)-5-methyl-1,3-benzothiazol-2-yl]-N-[(5-methyl-1,3,4-	δ 9.51 (t, J=5.50 Hz, 1H), 8.30 (s, 1H), 8.08 (s, 2H), 7.32 (dd, J=2.20, 8.25 Hz, 1H), 6.08 (s, 1H), 4.68 (d, J=5.78 Hz, 2H), 3.26 (s,	1.6 O 476.1	<10	<10




		oxadiazol-2-yl)methyl]-2-(methylsulfonyl)acetamide	3H), 2.47 (s, 3H), 2.37 (s, 3H).			
B81		2-{5-methyl-6-[4-(4-morpholinyl)carbonyl]phenyl]-1,3-benzothiazol-2-yl}-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-2-(methylsulfonyl)acetamide	δ 9.51 (t, J =5.64 Hz, 1H), 8.04 (d, J =11.83 Hz, 2H), 7.45-7.52 (m, 3H), 6.07 (s, 1H), 4.68 (d, J =5.78 Hz, 2H), 3.64 (br. s., 4H), 3.26 (s, 3H), 2.90 (s, 1H), 2.74 (s, 1H), 2.47 (s, 3H), 2.38 (s, 3H)	1.60 O 570.1	14	196
B82		N-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-2-(5-methyl-6-phenyl-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)acetamide	¹ H NMR (500 MHz, METHANOL-d ₄) δ 7.98 (d, J =13.48 Hz, 1H), 7.84 (d, J =8.80 Hz, 1H), 7.43-7.48 (m, 2H), 7.36-7.40 (m, 3H), 5.01 (s, 1H), 4.74 (d, J =4.13 Hz, 2H), 3.23 (s, 3H), 2.50-2.54 (m, 3H), 2.35-2.41 (m, 3H)	3.36 B 457.1	85	177
B83		2-(5-methyl-6-(1-(2-(4-morpholinyl)ethyl)-1H-pyrazol-4-yl)-1,3-benzothiazol-2-yl)-N-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-2-(methylsulfonyl)acetamide	δ 8.15-8.20 (m, 2H), 8.01 (s, 1H), 7.89 (br. s., 1H), 6.05 (s, 1H), 4.67 (d, J =6.05 Hz, 2H), 4.58 (br. s., 2H), 3.87-4.09 (m, 2H), 3.68 (d, J =17.61 Hz, 6H), 3.25 (s, 3H),	0.61 O 560.9	77	229




		y)methyl)-2-((methylsulfonyl)acetamide	2.90 (s, 1H), 2.74 (s, 1H), 2.54 (s, 3H), 2.47 (s, 3H)			
B84		N-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-2-(5-methyl-6-(4-(piperazin-1-yl)phenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)acetamide	δ 7.29 (d, $J=8.25$ Hz, 1H), 7.05 (d, $J=8.53$ Hz, 1H), 5.19 (s, 1H), 4.61 (br. s., 2H), 3.17 (s, 3H), 3.04-3.14 (m, 6H), 2.90 (s, 1H), 2.74 (s, 1H), 2.48 (s, 3H), 2.38 (s, 3H)	0.66 O 541.1	34	350
B85		N-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-2-(5-methyl-6-(2-oxo-1,2,3,4-tetrahydro-6-quinoliny)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)acetamide	δ 7.96 (d, $J=4.68$ Hz, 1H), 7.11-7.21 (m, 1H), 6.06 (s, 1H), 4.60-4.70 (m, 2H), 3.45 (m, 1H), 3.26 (s, 3H), 3.18 (m, 1H), 2.92-2.99 (m, 2H), 2.47 (s, 3H)	1.31 O 526.1	11	124
B86		2-(methylsulfonyl)-2-(5-(4-(4-morpholinyl)carbonyl)phenyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide	δ 9.00 (br. s., 1H), 8.42 (s, 1H), 8.28 (d, $J=8.3$ Hz, 1H), 7.89 (d, $J=6.9$ Hz, 3H), 7.56 (d, $J=7.2$ Hz, 2H), 6.96 (br. s., 2H), 6.07 (s, 1H), 3.92 (s, 2H), 3.62 (d, $J=6.1$ Hz,	1.28 O 567.1	<10	494




B87		2-(5-(6-methoxy-3-pyridinyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)ethyl)acetamide	δ 9.03 (t, J=5.6 Hz, 1H), 8.64 (d, J=2.5 Hz, 1H), 8.39 (d, J=0.8 Hz, 1H), 8.26 (d, J=8.5 Hz, 1H), 8.17 (dd, J=8.5, 2.5 Hz, 1H), 7.85 (dd, J=8.5, 1.4 Hz, 1H), 7.01 - 6.93 (m, 3H), 6.06 (s, 1H), 3.97 - 3.87 (m, 3H), 3.61 (q, J=6.7 Hz, 2H), 3.26 (s, 3H), 3.23 - 3.17 (m, 2H)	1.2 O 485	0.5	2.6			
B88		2-(5-(2-methoxy-4-pyridinyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)ethyl)acetamide	δ 9.02 (t, J=5.8 Hz, 1H), 8.52 (s, 1H), 8.35 - 8.25 (m, 2H), 8.00 - 7.90 (m, 2H), 7.48 (d, J=5.2 Hz, 1H), 6.99 (s, 2H), 6.07 (s, 1H), 3.93 (s, 3H), 3.62 (q, J=6.8 Hz, 2H), 3.26 (s, 3H), 3.23 - 3.18 (m, 2H)	1.1 O 485.1	0.5	2.2			
B89		2-(5-(2-(methylsulfonyl)-2-(5-(5-pyrimidinyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide	δ 9.30 (s, 1H), 9.24 (s, 1H), 9.02 (t, J=5.5 Hz, 1H), 8.59 (s, 1H), 8.35 (d, J=8.5 Hz, 1H), 7.99 (d, J=8.3 Hz, 1H), 6.99 (s, 2H), 6.08	1.0 O 456.0	4.4	70			



			(s, 1H), 3.62 (q, J=6.5 Hz, 2H), 3.27 (s, 3H), 3.21 (t, J=7.2 Hz, 2H)			
B90		2-(5-(1-(2-methoxyethyl)-1H-pyrazol-4-yl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)acetamide	¹ H NMR (400MHz, DMSO-d ₆) δ 8.13 (s, 1H), 8.09 (s, 1H), 7.93 (d, J=8.4 Hz, 1H), 7.86 (s, 1H), 7.59 (m, 1H), 4.15 (m, 2H), 3.61 - 3.54 (m, 4H), 3.21 (m, 2H), 3.12 (s, 3H), 3.09 - 3.06 (s, 3H)	1.4 B 502.0	<10	100
B91		2-(methylsulfonyl)-2-(5-(1-(2-(4-morpholinyl)ethyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)acetamide	¹ H NMR (400MHz, METHANOL-d ₄) δ 8.24 (d, J=1.3 Hz, 1H), 8.21 (s, 1H), 8.05 (d, J=0.7 Hz, 1H), 8.03 - 7.99 (m, 1H), 7.71 (dd, J=8.5, 1.7 Hz, 1H), 4.15 - 3.88 (m, 4H), 3.87 - 3.66 (m, 8H), 3.35 (m, 4H), 3.23 (s, 3H)	1.14 B 557.0	<10	1800
B92		2-(methylsulfonyl)-2-(5-phenyl-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)acetamide	¹ H NMR (400MHz, DMSO-d ₆) δ 8.95 (t, J=5.6 Hz, 1H), 8.29 (s, 1H), 8.18 (d, J=8.4 Hz, 1H), 7.80 - 7.70 (m, 3H), 7.45 (t, J=7.5 Hz,	1.71 B 454.0	<10	<10



					2H), 7.36 (d, J=7.5 Hz, 1H), 6.92 (s, 2H), 5.98 (s, 1H), 3.53 (q, J=6.5 Hz, 2H), 3.12 (t, J=7.0 Hz, 2H).			
B93		N-(2-methoxyethyl)-4-(2-((1-(methylsulfonyl)-2-oxo-2-((2-sulfamoyl)ethyl)-1,3-benzothiazol-5-yl) benzamide	δ 8.63 (t, J=5.1 Hz, 1H), 8.46 (s, 1H), 8.29 (d, J=8.5 Hz, 1H), 8.02 - 7.90 (m, 5H), 6.99 (s, 2H), 6.07 (s, 1H), 3.62 (q, J=6.8 Hz, 2H), 3.52 - 3.45 (m, 4H), 3.30 (s, 3H), 3.27 (s, 3H), 3.20 (t, J=7.3 Hz, 2H).	1.17 N 555.2	0.5	7.1		
B94		N-(2-hydroxyethyl)-4-(2-((1-(methylsulfonyl)-2-oxo-2-((2-sulfamoyl)ethyl)-1,3-benzothiazol-5-yl) benzamide	δ 9.02 (t, J=5.8 Hz, 1H), 8.54 (t, J=5.6 Hz, 1H), 8.46 (d, J=1.1 Hz, 1H), 8.29 (d, J=8.3 Hz, 1H), 8.04 - 7.86 (m, 6H), 6.99 (s, 2H), 6.07 (s, 1H), 4.78 (t, J=5.6 Hz, 1H), 3.62 (d, J=6.3 Hz, 2H), 3.55 (q, J=5.9 Hz, 2H), 3.37 (d, J=6.1 Hz, 2H), 3.24 - 3.16 (m, 2H)	1.71 O 541.1	<10	123		



B95		2-[5-(2-fluoro-4-pyridinyl)-1,3-benzothiazol-2-yl]-2-(methylsulfonyl)-N-(2-sulfamoyl-ethyl)acetamide	δ 9.02 (br. s., 1H), 8.64 (br. s., 1H), 8.36 (br. s., 2H), 8.09 - 7.94 (m, 1H), 7.88 (br. s., 1H), 7.73 (br. s., 1H), 6.99 (br. s., 2H), 6.09 (br. s., 1H), 3.62 (br. s., 2H), 3.27 (br. s., 3H), 3.20 (br. s., 2H)	1.35 N 473.1	<10	70
B96		2-(benzylsulfonyl)-2-(5-methyl-6-(4-(4-morpholinylcarbonyl)phenyl)-1,3-benzothiazol-2-yl)-N-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)acetamide	δ 8.30 - 7.84 (m, 2H), 7.69 - 7.09 (m, 9H), 5.09 - 4.26 (m, 4H), 3.98 - 3.46 (m, 7H), 2.99 - 2.65 (m, 3H), 2.49 - 2.20 (m, 5H).	1.55 Q 646.2	27	251
B97		2-(benzylsulfonyl)-2-(6-(6-methoxy-3-pyridinyl)-5-methyl-1,3-benzothiazol-2-yl)-N-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)acetamide	^1H NMR (400MHz, CHLOROFORM-d) δ 8.35 - 6.59 (m, 10H), 4.64 - 4.26 (m, 3H), 4.09 - 3.85 (m, 3H), 3.74 - 3.01 (m, 2H), 2.67 - 2.49 (m, 3H), 2.45 - 2.13 (m, 3H)	3.79 L 564.1	24	57



B100		2-((2-methoxyethylsulfonyl)sulfonyl)-2-(6-(4-morpholinyl)carbonyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)acetamide	δ 8.60 - 8.49 (m, 1H), 8.23 - 8.14 (m, 1H), 7.84 (m, 4H), 7.62 - 7.43 (m, 3H), 6.95 (s, 2H), 3.81 - 3.53 (m, 14H), 3.27 (s, 3H), 3.24 - 3.13 (m, 2H)	0.74 M 610.9	<10	1236
B101		2-((6-(4-morpholinyl)carbonyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)acetamide	^1H NMR (400MHz, DMSO- d_6) 8.97 (s, 1H), 8.53 (s, 1H), 8.17 (d, $J=8.6$ Hz, 1H), 7.91 (d, $J=8.4$ Hz, 1H), 7.85 (d, $J=7.9$ Hz, 2H), 7.55 (d, $J=7.9$ Hz, 2H), 6.94 (s, 2H), 6.04 (s, 1H), 3.61 (d, $J=5.5$ Hz, 5H), 3.52 (br. s., 2H), 3.19 (t, $J=7.2$ Hz, 2H)	0.77 M 567.2	<10	63
B102		2-((6-(4-morpholinyl)carbonyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)acetamide	δ 9.03 (s, 1H), 8.54 (d, $J=1.7$ Hz, 1H), 8.23 (br. s., 1H), 7.97 - 7.83 (m, 2H), 7.76 (br. s., 2H), 7.60 - 7.47 (m, 2H), 7.40 (m, 3H), 7.37 - 7.14 (m, 2H), 7.04 - 6.87 (m, 2H), 4.89 - 4.69 (m, 1H), 4.67 - 4.52	0.83 M 642.8	18	5288




				(m, 1H), 3.77 - 3.52 (m, 10H), 3.20 (t, $J=7.6$ Hz, 2H)			
B103		2-((2-methoxyethyl)sulfonyl)-2-(6-phenyl-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl-ethyl)acetamide		¹ H NMR (500MHz, CHLOROFORM-d) δ 7.78 (s, 1H), 7.60 (dd, $J=17.5$, 8.1 Hz, 3H), 7.52 - 7.43 (m, 2H), 7.40 (d, $J=7.4$ Hz, 2H), 4.03 - 3.89 (m, 2H), 3.83 (t, $J=5.6$ Hz, 2H), 3.49 (m, 3H), 3.41 (t, $J=5.6$ Hz, 2H), 3.26 (m, 2H).	0.92 M 497.8	<10	<10
B104		2-(benzylsulfonyl)-2-(6-phenyl-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl-ethyl)acetamide		¹ H NMR (500MHz, METHANOL-d ₄) δ 7.97 - 7.13 (m, 13H), 4.54 (br. s., 2H), 3.90 - 3.68 (m, 2H), 3.29-3.31 (m., 2H)	1.0 M 529.8	<10	<10
B105		2-(ethylsulfonyl)-2-(6-phenyl-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl-ethyl)acetamide		δ 9.09 - 8.93 (m, 1H), 8.47 (d, $J=1.1$ Hz, 1H), 8.14 (d, $J=8.8$ Hz, 1H), 7.87 (d, $J=1.9$ Hz, 1H), 7.76 (d, $J=7.7$ Hz, 2H), 7.60 - 7.37 (m, 3H), 6.95 (s, 2H), 6.07 (s, 1H),	1.61 M 468.1	<10	<10



				3.60 (d, $J=6.3$ Hz, 2H), 3.36-3.38 (m, 2H), 3.20 (d, $J=6.3$ Hz, 2H), 1.27 (t, $J=7.4$ Hz, 3H)			
B106		2-(isobutylsulfonyl)-2-(6-phenyl-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl acetamide		δ 9.15 - 8.93 (m, 1H), 8.58 - 8.40 (m, 1H), 8.22 - 8.07 (m, 1H), 7.91 - 7.82 (m, 1H), 7.76 (s, 2H), 7.51 (s, 2H), 7.47 - 7.34 (m, 1H), 6.95 (s, 2H), 6.02 (s, 1H), 3.75 - 3.54 (m, 2H), 3.29 - 3.12 (m, 4H), 2.32 - 2.19 (m, 1H), 1.03 (d, $J=6.9$ Hz, 6H)	1.93 N 496.1	<10	<10
B107		2-(6-phenyl-1,3-benzothiazol-2-yl)-2-(propylsulfonyl)-N-(2-sulfamoyl)ethyl acetamide		^1H NMR (500MHz, METHANOL- d_4) δ 8.40 - 8.25 (m, 1H), 8.18 - 8.07 (m, 1H), 8.00 - 7.92 (m, 1H), 7.88 - 7.80 (m, 1H), 7.75 - 7.69 (m, 1H), 7.70 - 7.59 (m, 1H), 7.53 - 7.30 (m, 3H), 3.91 - 3.73 (m, 2H), 3.35 (br. s., 4H), 1.99 - 1.72 (m, 2H), 1.05 (d, $J=12.1$ Hz, 3H)	0.96 M 481.8	<10	<10



B108		2-(6-(4-(4-morpholinyl carbonyl)phenyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl-2-yl)-N-(2-((3,3,3-trifluoropropyl)sulfonyl)acetamide	δ 9.25 - 8.84 (m, 1H), 8.71 - 8.50 (m, 1H), 8.34 - 8.10 (m, 1H), 7.97 - 7.89 (m, 1H), 7.89 - 7.83 (m, 2H), 7.81 - 7.69 (m, 1H), 7.63 - 7.38 (m, 2H), 7.09 - 6.85 (m, 2H), 6.41 - 6.11 (m, 1H), 3.88 - 3.45 (m, 12H), 3.25 - 3.11 (m, 2H), 2.94 - 2.72 (m, 2H)	0.84 M 648.8	<10	23
B109		2-(isobutylsulfonyl)-2-(6-(4-(4-morpholinyl carbonyl)phenyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl-2-yl)-N-(2-((3,3,3-trifluoropropyl)sulfonyl)acetamide	δ 9.08 - 8.94 (m, 1H), 8.59 - 8.51 (m, 1H), 8.24 - 8.13 (m, 1H), 7.95 - 7.88 (m, 1H), 7.88 - 7.80 (m, 2H), 7.63 - 7.48 (m, 2H), 7.02 - 6.88 (m, 2H), 6.15 - 5.99 (m, 1H), 3.76 - 3.50 (m, 8H), 3.28 - 3.13 (m, 4H), 2.30 - 2.18 (m, 1H), 1.09 - 0.98 (m, 6H)	0.82 M 608.8	<10	191



B110		N-(2-methoxyethyl)-4-(2-(2-oxo-2-((2-sulfamoyl ethyl)amino)-1-((3,3,3-trifluoropropyl)sulfonyl)ethyl)-1,3-benzothiazol-6-yl)benzamide	¹ H NMR (400MHz, DMSO-d ₆) δ 9.05 - 8.88 (m, 1H), 8.63 - 8.56 (m, 2H), 8.20 - 8.13 (m, 1H), 8.03 - 7.97 (m, 2H), 7.97 - 7.92 (m, 1H), 7.90 - 7.85 (m, 2H), 7.84 - 7.72 (m, 1H), 7.04 - 6.92 (m, 2H), 6.32 - 6.24 (m, 1H), 3.84 - 3.56 (m, 4H), 3.52 - 3.40 (m, 4H), 3.29 - 3.27 (m, 3H), 3.22 - 3.12 (m, 2H), 2.92 - 2.77 (m, 2H)	0.85 M 636.9	<10	180
B111		2-((cyclopropylmethyl) sulfonyl)-2-(6-(4-(4-morpholinyl)carbonyl)phenyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl ethyl)acetamide	δ 9.14 - 8.92 (m, 1H), 8.52 (br. s., 1H), 8.30 - 8.10 (m, 1H), 8.01 - 7.81 (m, 4H), 7.80 - 7.66 (m, 1H), 7.55 (d, J=7.7 Hz, 2H), 6.94 (br. s., 2H), 3.59-3.62 (m., 10H), 3.28 (br. s., 2H), 3.19 (br. s., 2H), 1.21 - 0.93 (m, 1H), 0.63 (d, J=7.2 Hz, 1H), 0.55 - 0.34 (m, 2H), 0.31 - 0.20 (m, 1H)	1.64 N 607.1	<10	1460



B112		4-(2-(1-(4-fluorobenzyl)sulfonyl)-2-oxo-2-((2-sulfamoyl)ethyl)-1,3-benzothiazol-6-yl)-N-(2-methoxyethyl)benzamide	δ 9.09 - 8.96 (m, 1H), 8.66 - 8.49 (m, 1H), 8.27 - 8.12 (m, 1H), 7.95 (d, $J=5.2$ Hz, 3H), 7.89 (br. s., 3H), 7.53 - 7.43 (m, 1H), 7.42 - 7.33 (m, 1H), 7.28 - 7.19 (m, 1H), 7.17 - 7.05 (m, 1H), 6.95 (br. s., 2H), 6.14 - 6.04 (m, 1H), 4.83 - 4.71 (m, 1H), 4.68 - 4.53 (m, 1H), 3.71 - 3.58 (m, 2H), 3.47 (br. s., 4H), 3.28 (br. s., 3H), 3.24 - 3.12 (m, 2H)	1.58 N 649.1	<10	8333
B113		N-(2-methoxyethyl)-4-(2-(2-oxo-2-((2-sulfamoyl)ethyl)amino)-1-(4-(trifluoromethoxy)benzyl)sulfonyl)ethyl)-1,3-benzothiazol-6-ylbenzamide	δ 9.05 (t, $J=5.6$ Hz, 1H), 8.77 - 8.46 (m, 2H), 8.29 - 8.10 (m, 1H), 8.07 - 7.84 (m, 4H), 7.87 - 7.65 (m, 2H), 7.59 - 7.36 (m, 3H), 7.32 - 7.20 (m, 1H), 7.10 - 6.87 (m, 2H), 6.11 (s, 1H), 4.89 - 4.74 (m, 1H), 4.75 - 4.58 (m, 1H), 3.72 - 3.54 (m, 2H), 3.54 - 3.41 (m, 5H), 3.28 (d, $J=2.5$ Hz, 3H), 3.25 - 3.11	1.69 N 715.1	0.7	48.2



		(m, 2H)			
B114		4-(2-(1-((cyclopropylsulfonyl)-2-oxo-2-methylsulfonyl)ethyl)amino)ethyl)-1,3-benzothiazol-6-yl)-N-(2-methoxyethyl)benzamide	δ 8.82 (t, $J=5.5$ Hz, 1H), 8.50 - 8.21 (m, 2H), 7.84 - 7.60 (m, 7H), 6.85 - 6.62 (m, 3H), 3.37 (q, $J=6.9$ Hz, 2H), 3.29 - 3.17 (m, 5H), 3.08 (s, 3H), 3.00 - 2.87 (m, 3H), 0.47 - 0.31 (m, 2H), 0.34 - 0.10 (m, 3H)	1.35 N 593.12	0.8 119
B115		2-((3-cyanobenzyl)sulfonyl)-2-(6-phenyl-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide	δ 9.05 (t, $J=5.5$ Hz, 1H), 8.70 - 8.48 (m, 1H), 8.20 (d, $J=8.5$ Hz, 1H), 8.07 - 7.35 (m, 10H), 7.08 - 6.90 (m, 2H), 4.86 (s, 1H), 4.79 - 4.59 (m, 1H), 3.60 (d, $J=6.1$ Hz, 2H), 3.52 - 3.42 (m, 4H), 3.28 (s, 3H), 3.19 (t, $J=7.0$ Hz, 2H)	1.41 N 656.1	1.2 107
B116		N-(2-methoxyethyl)-4-(2-(2-oxo-2-((2-sulfamoyl)ethyl)amino)-1-((4-(trifluoromethyl)benzyl)sulfonyl)ethyl)-1,3-benzothiazol-6-yl)	δ 9.06 (t, $J=5.2$ Hz, 1H), 8.69 - 8.49 (m, 1H), 8.25 - 8.13 (m, 1H), 8.05 - 7.86 (m, 5H), 7.82 - 7.70 (m, 3H), 7.70 - 7.50 (m, 4H), 7.05 - 6.91 (m, 2H), 6.12 (s, 1H), 4.89 (d, $J=3.0$ Hz, 1H), 4.81 - 4.68 (m,	1.64 N 699.2	<10 182




		benzamide	1H), 3.61 (d, $J=6.3$ Hz, 2H), 3.52 - 3.42 (m, 4H), 3.28 (s, 3H), 3.26 - 3.12 (m, 2H)			
B117		4-(2-(1-(3-fluorobenzyl)sulfonyl)-2-oxo-2-((2-sulfamoyl)ethyl)-1,3-aminoethyl)-1,3-benzothiazol-6-yl)-N-(2-methoxyethyl)benzamide	δ 9.06 (br. s., 1H), 8.68 - 8.55 (m, 2H), 8.26 - 8.15 (m, 1H), 8.04 - 7.86 (m, 4H), 7.85 - 7.72 (m, 2H), 7.45 (d, $J=7.2$ Hz, 1H), 7.37 - 7.17 (m, 3H), 7.04 - 6.91 (m, 2H), 6.10 (s, 1H), 4.79 (d, $J=3.9$ Hz, 1H), 4.71 - 4.55 (m, 1H), 3.60 (d, $J=6.1$ Hz, 2H), 3.51 - 3.41 (m, 4H), 3.28 (s, 3H), 3.25 - 3.08 (m, 2H)	1.50 N 649.1	<10	176
B118		2-((cyclopropylmethyl)sulfonyl)-2-(6-phenyl-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide	δ 9.04 (br. s., 1H), 8.47 (s, 1H), 8.14 (d, $J=8.8$ Hz, 1H), 7.86 (d, $J=8.5$ Hz, 1H), 7.76 (d, $J=7.4$ Hz, 1H), 7.68 (br. s., 1H), 7.58 - 7.35 (m, 3H), 7.03 - 6.81 (m, 2H), 6.05 (s, 1H), 3.59 (br. s., 2H), 3.39 (d, $J=6.9$ Hz, 1H), 3.30 - 3.22 (m, 1H), 3.22 - 3.13 (m, 2H), 1.10 (br.	1.78 N 494.09	<10	10



				s., 1H), 0.62 (d, $J=7.7$ Hz, 1H), 0.53 - 0.36 (m, 2H), 0.26 (br. s., 1H)			
B119		2-((4-fluorobenzyl)sulfonyl)-2-(6-phenyl-1,3-benzothiazol-2-yl)-N-(2-sulfamoylethyl)acetamide	δ 9.04 (br. s., 1H), 8.49 (s, 1H), 8.18 (d, $J=8.5$ Hz, 1H), 7.88 (d, $J=8.3$ Hz, 1H), 7.77 (d, $J=7.2$ Hz, 1H), 7.68 (br. s., 1H), 7.59 - 7.32 (m, 5H), 7.24 (t, $J=8.3$ Hz, 1H), 7.10 (br. s., 1H), 7.05 - 6.88 (m, 2H), 6.06 (s, 1H), 4.75 (d, $J=5.8$ Hz, 1H), 4.69 - 4.50 (m, 1H), 3.60 (d, $J=6.1$ Hz, 2H), 3.26 - 3.09 (m, 2H)	1.96 N 548.1	<10	11	
B120		2-((3-cyanobenzyl)sulfonyl)-2-(6-phenyl-1,3-benzothiazol-2-yl)-N-(2-sulfamoylethyl)acetamide	δ 9.04 (br. s., 1H), 8.49 (s, 1H), 8.23 - 8.06 (m, 1H), 7.98 - 7.58 (m, 7H), 7.56 - 7.31 (m, 3H), 7.12 - 6.86 (m, 2H), 6.10 (s, 1H), 4.86 (br. s., 1H), 4.77 - 4.57 (m, 1H), 3.61 (br. s., 2H), 3.19 (t, $J=6.2$ Hz, 2H)	1.87 N 555.1	<10	15	



B121		N-(2-(bis(4-methoxybenzyl)sulfamoyl)ethyl)-2-(methylsulfonyl)-2-(6-phenyl-1,3-benzothiazol-2-yl)acetamide	δ 9.04 (t, J=5.8 Hz, 1H), 8.48 (d, J=1.4 Hz, 1H), 8.16 (s, 1H), 7.94 - 7.84 (m, 1H), 7.77 (d, J=7.4 Hz, 2H), 7.53 (t, J=7.7 Hz, 2H), 7.46 - 7.39 (m, 1H), 7.13 (d, J=8.5 Hz, 4H), 6.88 - 6.80 (m, 4H), 6.07 (s, 1H), 4.19 (s, 4H), 3.71 (s, 6H), 3.67 - 3.60 (m, 2H), 3.58 (s, 3H), 3.26 (s, 3H)	1.15 M 694.0	80	11
B122		2-(benzylsulfonyl)-2-(6-{1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl}-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide	δ 9.02 (s, 1H), 8.44 - 8.34 (m, 1H), 8.12 (d, J=8.5 Hz, 1H), 7.96 (s, 1H), 7.82 (dd, J=8.5, 1.7 Hz, 1H), 7.40 (s, 3H), 7.33 (s, 2H), 6.96 (s, 2H), 6.07 (s, 1H), 5.76 (s, 1H), 4.85 - 4.67 (m, 2H), 4.66 - 4.41 (m, 2H), 3.61 (dd, J=13.1, 7.0 Hz, 8H), 3.23 - 3.01 (m, 6H)	0.69 M 632.9	44	631




B123		2-(isobutylsulfonyl)-2-((6-{1-[2-(4-morpholinyl)-1H-pyrazol-4-yl]-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl}acetamide	0.67 M 599.0	18	400
B124		2-(6-bromo-1,3-benzothiazol-2-yl)-2-((2-methoxyethyl)sulfonyl)-N-(2-sulfamoyl)ethylacetamide	0.83 M 499.7	26	830




B125		2-(6-bromo-1,3-benzothiazol-2-yl)-N-(2-sulfamoylethyl)-2-((3,3,3-trifluoropropyl)sulfonyl)acetamide	δ 8.94 (s, 1H), 8.50 (d, J=1.9 Hz, 1H), 8.03 (d, J=8.8 Hz, 1H), 7.76 - 7.69 (m, 1H), 6.95 (s, 2H), 6.24 (s, 1H), 3.72 (dd, J=16.6, 8.1 Hz, 2H), 3.61 (dt, J=12.6, 6.5 Hz, 3H), 3.21 - 3.14 (m, 2H), 2.85 (dd, J=10.6, 7.8 Hz, 2H)	0.95 M 537.5	99	300
B126		2-(benzylsulfonyl)-2-(6-(2-fluoro-4-pyridinyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoylethyl)acetamide	¹ H NMR (500MHz, ACETONITRILE-d ₃) δ 8.41 - 8.22 (m, 1H), 8.05 (dd, J=3.7, 1.8 Hz, 1H), 8.00 - 7.90 (m, 1H), 7.89 - 7.76 (m, 1H), 7.75 - 7.61 (m, 1H), 7.61 - 7.51 (m, 1H), 7.51 - 7.43 (m, 1H), 7.43 - 7.38 (m, 2H), 7.35 - 7.29 (m, 2H), 7.27 (t, J=7.7 Hz, 1H), 5.58 - 5.42 (m, 2H), 4.55 (s, 1H), 4.49 (s, 1H), 3.84 - 3.74 (m, 1H), 3.71 (d, J=6.1 Hz, 1H), 3.41 - 3.17 (m, 2H)	0.90 M 548.8	<10	51



B127		2-(6-(1-(2-(4-morpholinyl)ethyl)-1H-pyrazol-4-yl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl-ethyl)-2-((4,4-trifluorobutyl)sulfonyl)acetamide	δ 9.01 (t, J=5.8 Hz, 1H), 8.43 - 8.33 (m, 2H), 8.12 (br. s., 1H), 8.07 (d, J=8.5 Hz, 1H), 7.81 (dd, J=8.7, 1.8 Hz, 1H), 7.01 - 6.90 (m, 2H), 6.10 (s, 1H), 3.71 - 3.57 (m, 6H), 3.56 - 3.46 (m, 6H), 3.19 (dq, J=9.4, 7.1 Hz, 5H), 2.00 - 1.90 (m, 3H)	0.71 M 652.8	<10	933
B128		2-(5-methyl-6-(1-methyl-1H-pyrazol-4-yl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-((methylsulfonyl)sulfamoyl)ethyl)acetamide	^1H NMR (500 MHz, METHANOL- d_4) δ 7.99 (s, 1H), 7.96 (s, 1H), 7.90 (s, 1H), 7.76 (d, J=0.55 Hz, 1H), 5.49 (s, 1H), 3.95-4.01 (m, 3H), 3.80 (d, J=2.48 Hz, 1H), 3.57 (d, J=7.15 Hz, 1H), 3.19-3.25 (m, 3H), 3.16 (s, 2H), 2.44-2.57 (m, 3H)	0.64 M 571.9	28	290
B129		2-(6-(6-fluoro-3-pyridinyl)-5-methyl-1,3-benzothiazol-2-yl)-2-methyl-N-(2-sulfamoyl)	^1H NMR (500 MHz, METHANOL- d_4) δ 8.31 (d, J=2.48 Hz, 1H), 8.06-8.11 (m, 2H), 8.03 (s, 1H), 7.26 (dd, 2H)	0.80 M 486.7	<10	<10




		ethyl)acetamide	$J=2.61, 8.39 \text{ Hz, 1H), 4.62-4.62 (m, 1H), 3.78-3.83 (m, 2H), 3.37 (dt, } J=2.89, 6.81 \text{ Hz, 3H), 3.29 (s, 3H), 3.16-3.22 (m, 1H), 2.46 (s, 3H)$		
B130		2-(6-(6-fluoro-3-pyridinyl)-5-methyl-1,3-benzothiazol-2-yl)-2-(3,3,3-trifluoropropylsulfonyl)-N-(2-sulfamoyl)ethyl)acetamide	$^1\text{H NMR (500 MHz, Acetone) } \delta$ 8.19-8.29 (m, 1H), 7.96-8.06 (m, 2H), 7.65-7.75 (m, 1H), 7.14-7.23 (m, 1H), 6.28 (d, $J=3.58 \text{ Hz, 2H)$, 3.77-3.91 (m, 3H), 3.49-3.57 (m, 1H), 3.31-3.40 (m, 2H), 2.76 (td, $J=11.24, 16.30 \text{ Hz, 2H)$, 2.31-2.42 (m, 3H)	1.87 B 569.1	<10 13
B131		2-(6-(6-fluoro-3-pyridinyl)-5-methyl-1,3-benzothiazol-2-yl)-2-(isobutylsulfonyl)-N-(2-sulfamoyl)ethyl)acetamide	$^1\text{H NMR (500 MHz, Acetone) } \delta$ 8.20-8.30 (m, 1H), 7.96-8.09 (m, 2H), 7.63-7.78 (m, 1H), 7.15-7.27 (m, 1H), 6.20-6.32 (m, 1H), 3.49-3.94 (m, 2H), 3.31-3.40 (m, 2H), 3.15-3.29 (m, 2H), 2.31-2.43 (m, 3H), 2.27 (td, $J=6.33, 12.65 \text{ Hz, 3H)$	0.93 M 528.9	<10 12



B134		2-(4-fluoro-6-phenyl-1,3-benzothiazol-2-yl)-2-((2-methoxyethyl)sulfonyl)-N-(2-sulfamoylethyl)acetamide	¹ H NMR (400 MHz, Acetone) δ 8.26 (d, $J=1.54$ Hz, 1H), 7.79-7.83 (m, 2H), 7.66 (dd, $J=1.65$, 11.99 Hz, 1H), 7.51-7.56 (m, 2H), 7.42-7.48 (m, 1H), 6.29 (d, $J=3.74$ Hz, 1H), 3.82-3.97 (m, 5H), 3.71-3.78 (m, 2H), 3.42 (s, 3H), 3.37-3.41 (m, 2H)	0.86 M 516.0	<10	18
B135		benzyl (2-((1-(5-fluoro-6-phenyl-1,3-benzothiazol-2-yl)-2-oxo-2-((2-sulfamoyl)amino)ethyl)sulfonyl)ethyl)carbamate	¹ H NMR (500MHz, METHANOL-d ₄) δ 8.13 (dd, $J=13.3$, 7.3 Hz, 1H), 7.92 - 7.76 (m, 1H), 7.65 - 7.57 (m, 2H), 7.54 - 7.37 (m, 5H), 7.37 - 7.27 (m, 4H), 5.12 - 5.04 (m, 2H), 3.84 - 3.73 (m, 2H), 3.65 (s, 3H), 3.58 - 3.51 (m, 1H), 3.45 (t, $J=1.7$ Hz, 1H), 3.20 - 3.15 (m, 1H)	0.95 M 634.4	<10	56



B136		2-(5-fluoro-6-phenyl-1,3-benzothiazol-2-yl)-N-(2-sulfamoylethyl)-2-[(3,3,3-trifluoropropyl)sulfonyl]acetamide	¹ H NMR (400MHz, Chloroform-d containing Methanol-d ₄) δ 8.00 (br. s., 1H), 7.85 - 7.64 (m, 4H), 7.55 (d, J=8.1 Hz, 2H), 3.96 - 3.85 (m, 5H), 3.84 - 3.73 (m, 5H), 3.72 - 3.64 (m, 3H), 3.61 (t, J=8.1 Hz, 3H), 3.58 - 3.49 (m, 2H), 3.41 - 3.35 (m, 4H), 3.35 - 3.25 (m, 2H).	2.12 Q 554.0	<10	11
B137		N-((2-amino-1,3-thiazol-4-yl)methyl)-2-(6-(4-(methylsulfonyl)-2-(4-(4-morpholinylcarbonyl)phenyl)-1,3-benzothiazol-2-yl)acetamide	δ 9.22 (t, J=5.4 Hz, 1H), 8.55 (d, J=1.7 Hz, 1H), 8.19 (d, J=8.5 Hz, 1H), 7.97 (s, 1H), 7.93 (dd, J=8.7, 1.8 Hz, 2H), 7.86 (d, J=8.3 Hz, 2H), 7.57 (d, J=8.3 Hz, 2H), 6.52 (s, 1H), 6.09 (s, 1H), 4.36 - 4.21 (m, 2H), 3.26 (s, 3H)	1.25 N 572	<10	17480
B138		2-(benzylsulfonyl)-2-(5-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoylethyl)acetamide	¹ H NMR (400MHz, METHANOL-d ₄) δ 8.48 - 7.71 (m, 3H), 7.55 - 6.94 (m, 6H), 4.98 - 4.41 (m, 2H), 4.08 - 3.88 (m, 3H), 3.84 - 3.58 (m, 2H), 3.48 -	1.79 Q 552.0	<10	142





B139		2-(6-(5-Pyrimidinyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoylethyl)-2-((3,3,3-trifluoropropyl)sulfonyl)acetamide	3.16 (m, 2H) δ 9.31 - 9.23 (m, 1H), 9.22 - 9.15 (m, 1H), 9.04 - 8.94 (m, 1H), 8.72 - 8.64 (m, 1H), 8.27 - 8.21 (m, 1H), 8.08 - 8.00 (m, 1H), 7.04 - 6.93 (m, 2H), 6.34 - 6.25 (m, 1H), 3.83 - 3.59 (m, 4H), 3.25 - 3.16 (m, 3H), 2.89 - 2.82 (m, 2H).	1.4 Q 538	16	2090	
B140		2-(benzylsulfonyl)-2-(6-(5-pyrimidinyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoylethyl)acetamide	^1H NMR (400MHz, DMSO- d_6) δ 9.27 (s, 2H), 9.21 - 9.14 (m, 2H), 8.72 - 8.66 (m, 1H), 8.28 (d, $J=8.6$ Hz, 2H), 7.41 (s, 5H), 7.08 - 6.97 (m, 2H), 6.14 (s, 1H), 4.84 - 4.68 (m, 2H), 3.65 - 3.56 (m, 2H), 3.28 - 3.04 (m, 2H)	1.7 Q 532	13.7	8789	
B141		2-((2-methoxyethyl)sulfonyl)-2-(6-(5-pyrimidinyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoylethyl)acetamide	^1H NMR (400MHz, DMSO- d_6) δ 9.34 - 9.15 (m, 4H), 9.00 (t, $J=5.5$ Hz, 1H), 8.68 (d, $J=1.5$ Hz, 1H), 8.25 (d, $J=8.4$ Hz, 1H), 8.09 - 8.01 (m, 1H), 6.99 (s, 3H), 6.07 (s, 1H),	1.4 Q 500	14.7	2211	




				3.90 - 3.47 (m, 4H), 3.28 (s, 3H), 3.22 - 3.16 (m, 2H)			
B142		2-(6-(5-fluoro-2-methoxy-4-pyridinyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoylethyl)acetamide		¹ H NMR (400MHz, DMSO-d ₆) δ 9.02 (t, J=5.5 Hz, 1H), 8.51 (s, 1H), 8.35 - 8.29 (m, 1H), 8.26 - 8.19 (m, 1H), 7.90 - 7.80 (m, 1H), 7.17 - 7.09 (m, 1H), 7.05 - 6.94 (m, 2H), 6.13 - 5.96 (m, 1H), 3.91 (s, 3H), 3.65 - 3.57 (m, 2H), 3.25 (s, 3H), 3.22 - 3.16 (m, 2H)	1.8 Q 503	>10	77
B143		2-((4-fluorobenzyl)sulfonyl)-2-(6-(5-pyrimidinyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoylethyl)acetamide		¹ H NMR (400MHz, DMSO-d ₆) δ 9.30 - 9.23 (m, 2H), 9.22 - 9.14 (m, 2H), 8.69 (d, J=1.8 Hz, 1H), 8.28 (d, J=8.4 Hz, 1H), 7.53 - 7.44 (m, 1H), 7.31 - 7.22 (m, 2H), 6.99 (s, 2H), 6.11 (s, 1H), 4.92 - 4.32 (m, 2H), 3.71 - 3.54 (m, 2H), 3.29 - 3.07 (m, 4H)	0.9 M 550	18	4735



B144		2-(6-(2-methoxy-4-pyridinyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl-2-((3,3,3-trifluoropropyl)sulfonyl)acetamide	δ 8.97 (s, 1H), 8.67 (s, 1H), 8.29 (d, $J=5.5$ Hz, 1H), 8.20 (d, $J=8.5$ Hz, 1H), 8.00 (d, $J=8.5$ Hz, 1H), 7.44 - 7.39 (m, 1H), 7.23 (s, 1H), 6.97 (s, 3H), 6.29 (s, 1H), 3.92 (s, 3H), 3.68 - 3.60 (m, 2H), 3.23 - 3.17 (m, 2H), 2.89 - 2.82 (m, 2H)	1.5 O 567	<10	33
B145		2-(6-(1-methyl-2-oxo-1,2-dihydro-4-pyridinyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl-2-((3,3,3-trifluoropropyl)sulfonyl)acetamide	δ 8.96 (t, $J=5.6$ Hz, 1H), 8.61 (d, $J=1.4$ Hz, 1H), 8.16 (d, $J=8.5$ Hz, 1H), 7.96 - 7.90 (m, 1H), 7.86 - 7.81 (m, 1H), 7.02 - 6.91 (m, 2H), 6.85 - 6.77 (m, 1H), 6.71 - 6.64 (m, 1H), 6.34 - 6.25 (m, 1H), 3.66 - 3.57 (m, 2H), 3.49 (s, 3H), 3.46 (s, 2H), 3.24 - 3.15 (m, 2H), 2.90 - 2.81 (m, 2H)	1.3 O 567	<10	362
B146		2-(6-(5-pyrimidinyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl-2-((3,3,3-trifluoropropyl)sulfonyl)acetamide	¹ H NMR (400MHz, DMSO-d ₆) δ 9.33 - 9.21 (m, 1H), 9.07 - 8.96 (m, 1H), 8.68 (d, $J=1.5$ Hz, 1H), 8.33 - 8.19 (m, 1H), 8.03 (dd,	0.7 M 456.1	<10	916



				$J=8.6, 1.8 \text{ Hz, 1H}, 6.97 \text{ (s, 2H)}, 6.07 \text{ (s, 1H)}, 3.65 - 3.58 \text{ (m, 2H)}, 3.57 - 3.46 \text{ (m, 2H)}, 3.25 \text{ (s, 3H)}, 3.20 \text{ (dd, } J=8.0, 6.5 \text{ Hz, 2H)}$			
B147		2-(6-(2-methoxy-4-pyridinyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl ethyl)acetamide		$^1\text{H NMR (400MHz, DMSO-d}_6\text{) } \delta$ 8.97 (t, $J=5.8 \text{ Hz, 1H}$), 8.60 (d, $J=1.5 \text{ Hz, 1H}$), 8.27 - 8.18 (m, 1H), 8.16 - 8.08 (m, 1H), 7.96 - 7.89 (m, 1H), 7.40 - 7.32 (m, 1H), 7.20 - 7.15 (m, 1H), 6.95 - 6.88 (m, 2H), 6.06 - 5.96 (m, 1H), 3.86 (s, 3H), 3.61 - 3.44 (m, 2H), 3.23 - 3.17 (m, 3H), 3.15 - 3.10 (m, 2H)	0.9 M 485	<10	<10
B148		2-((2-methoxyethyl)sulfonyl)-2-(6-(2-methoxy-4-pyridinyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl ethyl)acetamide		$^1\text{H NMR (400MHz, DMSO-d}_6\text{) } \delta$ 8.99 (t, $J=5.6 \text{ Hz, 1H}$), 8.66 (d, $J=1.5 \text{ Hz, 1H}$), 8.32 - 8.26 (m, 1H), 8.22 - 8.16 (m, 1H), 8.02 - 7.96 (m, 1H), 7.48 - 7.41 (m, 1H), 7.25 - 7.20 (m, 1H), 7.02 - 6.93 (m, 2H), 6.06 (s, 1H), 3.95 - 3.92	1.4 Q 529	<10	13



			(m, 3H), 3.71 - 3.44 (m, 6H), 3.28 (s, 3H), 3.21 - 3.16 (m, 2H)			
B149		2-(6-(3-fluoro-2-methoxy-4-pyridinyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl-ethyl)acetamide	¹ H NMR (400MHz, DMSO- d ₆) d 9.00 (t, J=5.7 Hz, 1H), 8.50 (s, 1H), 8.22 (d, J=8.6 Hz, 1H), 8.09 (d, J=5.3 Hz, 1H), 7.82 (dt, J=8.5, 1.7 Hz, 1H), 7.26 (t, J=5.2 Hz, 1H), 6.96 (s, 2H), 6.07 (s, 1H), 4.08 - 3.90 (m, 3H), 3.62 (d, J=6.4 Hz, 2H), 3.25 (s, 3H), 3.22 - 3.16 (m, 2H)	1.0 O 503.1	<10	64
B150		2-(5-Fluoro-6-phenyl-1,3-benzothiazol-2-yl)-N-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-2-((3,3,3-trifluoropropyl)sulfonyl)acetamide	¹ H NMR (400MHz, METHANOL-d ₄) δ 8.33 - 7.23 (m, 7H), 4.77 - 4.68 (m, 2H), 4.25 - 3.50 (m, 2H), 3.13 - 2.66 (m, 2H), 2.60 - 2.32 (m, 3H)	2.18 Q 543.0	<10	84



B151		2-(ethylsulfonyl)-2-(5-fluoro-6-phenyl-1,3-benzothiazol-2-yl)-N-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)acetamide	¹ H NMR (400MHz, METHANOL-d ₄) δ 8.36 - 6.98 (m, 7H), 4.80 - 4.53 (m, 2H), 3.65 - 3.32 (m, 2H), 2.51 (m, 3H), 1.63 - 1.12 (m, 3H)	2.01 Q 475.0	<10	47
B152		2-(5-fluoro-6-phenyl-1,3-benzothiazol-2-yl)-2-(isobutylsulfonyl)-N-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)acetamide	¹ H NMR (400MHz, METHANOL-d ₄) δ 8.22 - 7.28 (m, 7H), 4.81 - 4.55 (m, 2H), 3.68 - 3.26 (m, 2H), 2.68 - 2.43 (m, 3H), 2.39 - 2.08 (m, 1H), 1.28 - 0.76 (m, 6H)	2.25 Q 503.1	<10	39
B153		2-(benzylsulfonyl)-2-(5-fluoro-6-phenyl-1,3-benzothiazol-2-yl)-N-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)acetamide	¹ H NMR (400MHz, METHANOL-d ₄) δ 8.47 - 7.57 (m, 2H), 7.56 - 7.31 (m, 8H), 7.27 - 6.95 (m, 2H), 4.80 - 4.41 (m, 4H), 2.75 - 2.20 (m, 3H)	2.17 Q 537.1	<10	39
B154		2-(5-fluoro-6-phenyl-1,3-benzothiazol-2-yl)-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-2-	¹ H NMR (400MHz, METHANOL-d ₄) δ 8.27 - 7.08 (m, 7H), 4.82 - 4.51 (m, 2H), 3.27 - 3.07 (m, 3H), 2.64 - 2.29 (m, 3H)	1.93 Q 461.0	<10	11

		(methylsulfonyl)acetamide				
B155		2-(5-fluoro-6-phenyl-1,3-benzothiazol-2-yl)-2-[(2-methoxyethyl)sulfonyl]-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]acetamide	¹ H NMR (400MHz, METHANOL-d ₄) δ 8.43 - 6.86 (m, 7H), 4.73 (m, 2H), 4.10 - 3.51 (m, 4H), 3.39-3.19 (m, 3H), 2.69 - 2.07 (m, 3H)	1.99 Q 505.0	<10	<10
B156		<i>tert</i> -butyl 4-(2-(1-(methylsulfonyl)-2-oxo-2-(2-sulfamoyl)ethylamino)ethyl)benzo [d]thiazol-6-yl)benzoate	¹ H NMR (400MHz, DMSO-d ₆) δ 9.02 (br. s., 1H), 8.59 (br. s., 1H), 8.30 - 8.16 (m, 1H), 8.12 - 7.75 (m, 5H), 6.99 (br. s., 2H), 6.06 (br. s., 1H), 3.62 (br. s., 2H), 3.32 - 3.11 (m, 5H), 1.59 (br. s., 9H).	2.0 Q 554.1	<10	<10
B158		benzyl 2-((1-(6-(4-(4-morpholinylcarbonyl)phenyl)-1,3-benzothiazol-2-yl)-2-oxo-2-((2-sulfamoyl)ethylamino)ethyl)sulfonyl)ethyl)carbamate	¹ H NMR (400MHz, DMF) δ 9.15 - 9.05 (m, 1H), 8.63 - 8.57 (m, 1H), 8.34 - 8.23 (m, 1H), 8.22 - 8.15 (m, 1H), 8.00 - 7.96 (m, 2H), 7.94 (d, J=8.3 Hz, 2H), 7.89 - 7.82 (m, 1H), 7.63 (d, J=8.5 Hz, 3H), 7.43 - 7.35 (m, 5H), 7.03 (s, 3H),	0.86 M 730.2	<10	31



B159		2-((2-aminoethyl)sulfonyl)-2-(6-phenyl-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide	¹ H NMR (400MHz, DMSO-d ₆) δ 9.15 - 8.99 (m, 1H), 8.52 (d, <i>J</i> =1.3 Hz, 1H), 8.17 (d, <i>J</i> =8.4 Hz, 1H), 7.96 (br. s., 2H), 7.91 (dd, <i>J</i> =8.6, 2.0 Hz, 2H), 7.82 - 7.75 (m, 3H), 7.59 - 7.48 (m, 3H), 7.44 (d, <i>J</i> =7.3 Hz, 1H), 7.25 (s, 3H), 7.12 (s, 3H), 7.01 - 6.89 (m, 5H), 6.31 - 6.21 (m, 1H), 3.92 - 3.67 (m, 2H), 3.63 (br. s., 3H), 3.27 (d, <i>J</i> =5.5 Hz, 2H), 3.20 (t, <i>J</i> =7.0 Hz, 2H)	0.93 M 596.2	<10	22
B160		2-(5-fluoro-6-phenyl-1,3-benzothiazol-2-yl)-2-((2-(4-morpholinyl)ethyl)sulfonyl)-N-(2-sulfamoyl)ethyl)acetamide	¹ H NMR (500MHz, Acetone) δ 7.69 - 7.60 (m, 3H), 7.52 (t, <i>J</i> =7.6 Hz, 3H), 7.47 - 7.40 (m, 2H), 3.90 (br. s., 7H), 3.66 - 3.55 (m, 3H), 3.40 (br. s., 3H), 3.31 (d, <i>J</i> =12.7 Hz, 3H)	0.73 O 571.1	<10	20



B161		2-((2-aminoethyl)sulfonyl)-2-(6-phenyl-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)acetamide	¹ H NMR (400MHz, DMSO-d ₆) δ 9.15 - 8.99 (m, 1H), 8.52 (d, J=1.3 Hz, 1H), 8.17 (d, J=8.4 Hz, 1H), 7.96 (br. s., 2H), 7.91 (dd, J=8.6, 2.0 Hz, 2H), 7.82 - 7.75 (m, 3H), 7.59 - 7.48 (m, 3H), 7.44 (d, J=7.3 Hz, 1H), 7.25 (s, 3H), 7.12 (s, 3H), 7.01 - 6.89 (m, 5H), 6.31 - 6.21 (m, 1H), 3.92 - 3.67 (m, 2H), 3.63 (br. s., 3H), 3.27 (d, J=5.5 Hz, 2H), 3.20 (t, J=7.0 Hz, 2H)	0.88 M 483.1	<10	22
B163		2-((4-fluorobenzyl)sulfonyl)-2-(6-(1-(2-methoxyethyl)-1H-pyrazol-4-yl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)acetamide	¹ H NMR (400MHz, DMSO-d ₆) δ 9.00 (s, 1H), 8.37 (d, J=1.1 Hz, 1H), 8.28 (s, 1H), 8.08 (d, J=8.8 Hz, 1H), 8.01 (d, J=0.7 Hz, 1H), 7.85 - 7.77 (m, 2H), 7.46 (dd, J=8.9, 5.6 Hz, 1H), 7.24 (t, J=8.8 Hz, 1H), 6.95 (s, 2H), 6.03 (s, 1H), 4.75 (d, J=3.7 Hz, 1H), 4.34 - 4.24 (m, 2H), 3.77 - 3.69 (m, 3H), 3.60	0.83 M 596.8	28	2554




				(d, J=5.5 Hz, 4H), 3.26 (s, 1H), 3.23 - 3.15 (m, 2H)			
B164		2-(6-(1-(2-methoxyethyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl)-2-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)acetamide		δ 9.00 (br. s., 1H), 8.27 (br. s., 1H), 8.21 (br. s., 1H), 8.15 (d, J=8.5 Hz, 1H), 7.97 (br. s., 1H), 7.59 (d, J=8.5 Hz, 1H), 6.96 (br. s., 1H), 6.05 (br. s., 1H), 4.43 (br. s., 1H), 3.79 (br. s., 1H), 3.66 - 3.57 (m, 1H), 3.29 (br. s., 3H), 3.25 (br. s., 3H), 3.20 (t, J=6.5 Hz, 1H), 2.91 (s, 2H), 2.75 (s, 2H)	1.52 N 572.1	<10	199
B165		2-((cyclopropylmethyl)sulfonyl)-2-(6-(1-(2-methoxyethyl)-1H-pyrazol-4-yl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)acetamide		δ 9.13 - 8.93 (m, 1H), 8.39 - 8.32 (m, 1H), 8.29 - 8.23 (m, 1H), 8.08 - 7.97 (m, 2H), 7.82 - 7.73 (m, 1H), 6.96 (s, 2H), 6.16 - 5.94 (m, 1H), 4.34 - 4.25 (m, 2H), 3.82 - 3.68 (m, 2H), 3.63 - 3.55 (m, 2H), 3.44 - 3.37 (m, 1H), 3.25 (s, 4H), 3.21 - 3.13 (m, 2H), 1.17 - 1.02 (m, 1H), 0.70 - 0.58 (m, 2H), 0.52	1.31 N 542.1	37	317




B167		2-(6-(4-((3,3-difluoro-1-azetidiny) carbonyl) phenyl)-1,3-benzothiazol-2-yl)-2-((2-methoxyethyl) sulfonyl)-N-(2-sulfamoyl)acetamide	- 0.34 (m, 2H) δ 8.96 (t, <i>J</i>=4.8 Hz, 1H), 8.58 (s, 1H), 8.19 (d, <i>J</i>=8.5 Hz, 1H), 7.99 - 7.92 (m, 1H), 7.91 - 7.87 (m, 2H), 7.86 - 7.79 (m, 3H), 6.96 (s, 2H), 6.06 (s, 1H), 3.82 - 3.74 (m, 2H), 3.72 - 3.67 (m, 2H), 3.65 - 3.56 (m, 2H), 3.29 (s, 3H), 3.23 - 3.17 (m, 2H)	1.4 O 617.1	<10	79
B168		2-(6-(4-((3,3-difluoro-1-pyrrolidiny) carbonyl) phenyl)-1,3-benzothiazol-2-yl)-2-((2-methoxyethyl) sulfonyl)-N-(2-sulfamoyl)acetamide	¹H NMR (400MHz, DMSO-d₆) δ 9.09 - 8.87 (m, 1H), 8.57 (s, 1H), 8.19 (d, <i>J</i>=8.8 Hz, 1H), 7.99 - 7.85 (m, 4H), 7.82 - 7.63 (m, 3H), 6.96 (s, 2H), 3.94 (d, <i>J</i>=19.3 Hz, 2H), 3.82 - 3.74 (m, 4H), 3.72 - 3.66 (m, 2H), 3.61 (d, <i>J</i>=6.3 Hz, 2H), 3.29 (s, 3H), 3.24 - 3.17 (m, 3H)	1.5 O 631.1	<10	60



B169		2-(6-(4-((3,3-difluoro-1-pyrrolidinyl)carbonyl)phenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoylethyl)acetamide	δ 9.00 (t, J =5.4 Hz, 1H), 8.57 (s, 1H), 8.19 (d, J =8.5 Hz, 1H), 7.97 - 7.91 (m, 1H), 7.90 - 7.84 (m, 2H), 7.75 - 7.69 (m, 2H), 6.96 (s, 2H), 6.06 (s, 1H), 4.07 - 3.85 (m, 3H), 3.77 (t, J =7.2 Hz, 2H), 3.62 (q, J =6.4 Hz, 2H), 3.26 (s, 3H), 3.21 (t, J =7.0 Hz, 2H)	1.4 O 587.1	<10	91
B170		2-(6-(4-((3,3-difluoro-1-pyrrolidinyl)carbonyl)phenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoylpropyl)acetamide	δ 8.97 (t, J =5.5 Hz, 1H), 8.59 (s, 1H), 8.19 (d, J =8.3 Hz, 1H), 7.99 - 7.91 (m, 1H), 7.88 (d, J =7.7 Hz, 2H), 7.74 - 7.69 (m, 2H), 6.97 (s, 2H), 6.28 (s, 1H), 4.03 - 3.90 (m, 3H), 3.80 - 3.73 (m, 5H), 3.68 - 3.59 (m, 2H), 3.21 (t, J =7.2 Hz, 2H), 2.90 - 2.82 (m, 2H)	1.7 O 669.1	<10	32
B171		2-(6-(4-((4,4-difluoro-1-piperidinyl)carbonyl)phenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoylpropyl)acetamide	^1H NMR (400MHz, DMSO- d_6) δ 9.01 (t, J =5.8 Hz, 1H), 8.56 (d, J =1.5 Hz, 1H), 8.18 (d, J =8.6 Hz, 1H), 7.93 (dd, J =8.6, 1.8 Hz, 1H),	1.0 M 601.2		



		N-(2-sulfamoylethyl) acetamide	7.86 (d, $J=8.4$ Hz, 2H), 7.60 (d, $J=8.4$ Hz, 2H), 6.97 (s, 2H), 6.05 (s, 1H), 3.62 (dd, $J=13.1$, 6.9 Hz, 6H), 3.25 (s, 3H), 3.20 (t, $J=7.2$ Hz, 2H), 2.09 (s, 4H)		<10	19
B175		2-(6-(4-((3-methoxy-1-azetidinyl)carbonyl)phenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoylethyl)acetamide	δ 9.03 (br. s., 1H), 8.57 (br. s., 1H), 8.19 (d, $J=8.5$ Hz, 1H), 7.96 - 7.90 (m, 1H), 7.90 - 7.84 (m, 2H), 7.81 - 7.76 (m, 2H), 6.99 (br. s., 2H), 6.06 (br. s., 1H), 4.52 (br. s., 1H), 4.28 (br. s., 3H), 3.90 (d, $J=16.0$ Hz, 1H), 3.62 (br. s., 2H), 3.25 (br. s., 4H), 3.20 (br. s., 2H)	1.2 O 567.1	<10	118
B176		2-(6-(4-(4-hydroxy-4-methyl-1-piperidinyl)carbonyl)phenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoylethyl)acetamide	δ 9.03 (br. s., 1H), 8.55 (br. s., 1H), 8.18 (d, $J=8.0$ Hz, 1H), 8.01 - 7.89 (m, 2H), 7.86 - 7.80 (m, 2H), 7.52 (d, $J=7.4$ Hz, 2H), 6.99 (br. s., 2H), 6.06 (br. s., 1H), 4.11 (br. s., 1H), 3.92 (br. s., 1H), 3.68 - 3.31 (m, 4H), 3.30 - 3.10 (m, 5H),	1.1 O 595.2	<10	92




B177		2-(6-(4-(4-hydroxy-1-piperidinyl)carbonyl)phenyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)ethyl)acetamide	1.70 - 1.34 (m, 4H), 1.18 (br. s., 3H)	δ 9.00 (br. s., 1H), 8.55 (br. s., 1H), 8.18 (d, $J=8.5$ Hz, 1H), 8.00 - 7.87 (m, 2H), 7.87 - 7.79 (m, 2H), 7.57 - 7.49 (m, 2H), 6.96 (br. s., 2H), 6.05 (br. s., 1H), 4.81 (br. s., 1H), 4.05 (br. s., 1H), 3.92 (br. s., 1H), 3.77 (br. s., 1H), 3.62 (br. s., 2H), 3.29 - 3.15 (m, 6H), 2.91 (br. s., 2H), 2.75 (br. s., 2H)	1.0 O 581.0	<10	495
B178		4-(2-(1-(methylsulfonyl)-2-oxo-2-((2-sulfamoyl)ethyl)-1,3-amino)ethyl)-1,3-benzothiazol-6-yl)-N-3-oxetanylbenzamide	¹ H NMR (400MHz, DMSO- d ₆) δ	8.99 (t, $J=5.7$ Hz, 1H), 8.60 (d, $J=1.5$ Hz, 1H), 8.19 (d, $J=8.6$ Hz, 1H), 8.07 - 8.01 (m, 2H), 7.98 - 7.93 (m, 3H), 6.96 (s, 3H), 6.05 (s, 1H), 4.70 - 4.53 (m, 1H), 4.43 (br. s., 2H), 3.69 - 3.58 (m, 4H), 3.25 (s, 3H), 3.21 (d, $J=8.1$ Hz, 2H)	1.2 Q 553.0	<10	91



B179		N-(2-Methoxyethyl)-3-(2-(2-oxo-2-((2-sulfamoyl ethyl)amino)-1-((3,3,3-trifluoropropyl)sulfonyl)ethyl)benzo[d]thiazol-6-yl)benzamide	δ 8.58 (s, 1H), 8.14 (d, J =8.5 Hz, 2H), 7.86 (d, J =8.8 Hz, 2H), 4.88 - 4.48 (m, 4H), 3.81 - 3.52 (m, 4H), 3.18 (s, 2H), 2.89 (m, 2H)	1.5 O 637.1	24	170
B181		2-(6-(3-oxo-2,3-dihydro-1H-isoindol-5-yl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl ethyl)acetamide	δ 9.03 (br. s., 1H), 8.73 - 8.66 (m, 1H), 8.62 - 8.52 (m, 1H), 8.21 - 8.12 (m, 1H), 8.03 - 7.99 (m, 2H), 7.98 - 7.92 (m, 1H), 7.76 - 7.71 (m, 1H), 6.99 (br. s., 2H), 6.06 (br. s., 1H), 4.46 (br. s., 2H), 3.62 (br. s., 2H), 3.26 (br. s., 3H), 3.21 (br. s., 2H)	1.0 O 509.1	<10	145
B182		2-(6-(1-oxo-2,3-dihydro-1H-isoindol-5-yl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl ethyl)acetamide	δ 9.03 (br. s., 1H), 8.65 (br. s., 1H), 8.59 - 8.56 (m, 1H), 8.23 - 8.18 (m, 1H), 7.97 (br. s., 3H), 7.83 - 7.78 (m, 1H), 6.99 (br. s., 2H), 6.06 (br. s., 1H), 4.48 (br. s., 2H), 3.62 (br. s., 2H), 3.26 (br. s., 2H)	1.4 O 509	<10	36




B183		2-(6-(2-methoxy-2-oxo-2,3-dihydro-1H-indol-6-yl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide	3H), 3.23 - 3.17 (m, 2H) δ 9.04 (t, <i>J</i> =5.6 Hz, 1H), 8.45 (s, 1H), 8.21 - 8.12 (m, 1H), 7.96 (s, 2H), 7.82 (d, <i>J</i> =8.5 Hz, 1H), 7.39 - 7.30 (m, 2H), 6.99 (s, 2H), 6.05 (s, 1H), 3.65 - 3.58 (m, 2H), 3.57 - 3.53 (m, 2H), 3.25 (s, 3H), 3.22 - 3.16 (m, 2H)	1.2 O 509	<10	139		
B184		2-(6-(2-methoxy-3-pyridinyl)-1,3-benzothiazol-2-yl)-N-(2-(methylsulfonyl)-N-(2-sulfamoyl)ethyl)acetamide	δ 9.02 (br. s., 1H), 8.35 (br. s., 1H), 8.27 - 8.22 (m, 1H), 8.18 - 8.09 (m, 1H), 7.99 - 7.93 (m, 1H), 7.88 - 7.81 (m, 1H), 7.80 - 7.69 (m, 1H), 7.20 - 7.12 (m, 1H), 7.04 - 6.93 (m, 2H), 6.11 - 5.94 (m, 1H), 3.91 (br. s., 3H), 3.31 - 3.13 (m, 5H)	1.5 O 485	<10	65		
B185		2-(6-(6-methoxy-2-pyridinyl)-1,3-benzothiazol-2-yl)-N-(2-(methylsulfonyl)-N-(2-sulfamoyl)ethyl)acetamide	δ 9.02 - 8.98 (m, 1H), 8.95 - 8.89 (m, 1H), 8.37 - 8.27 (m, 1H), 8.23 - 8.14 (m, 1H), 8.01 - 7.95 (m, 1H), 7.90 - 7.82 (m, 1H), 7.74 -	1.6 O 485				




		sulfamoyl)ethyl)acetamide	7.68 (m, 1H), 6.96 (br. s., 2H), 6.09 - 6.02 (m, 1H), 4.02 (br. s., 3H), 3.68 - 3.57 (m, 2H), 3.29 - 3.24 (m, 3H), 3.23 - 3.18 (m, 2H)	<10	<10
B186		2-(6-(1-(2-hydroxy-2-methylpropyl)-6-oxo-1,3-dihydro-3-pyridinyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoyl)ethyl)acetamide	δ 9.01 (t, J=5.6 Hz, 1H), 8.35 (s, 1H), 8.20 - 8.06 (m, 2H), 8.02 - 7.88 (m, 2H), 7.75 (d, J=8.5 Hz, 1H), 7.03 - 6.89 (m, 2H), 6.57 (d, J=9.4 Hz, 1H), 4.88 (s, 1H), 4.03 (s, 2H), 3.61 (q, J=6.6 Hz, 2H), 3.24 (s, 3H), 3.20 (t, J=7.2 Hz, 2H), 1.13 (s, 6H)	1.0 O 543.1	1.1 10000
B188		2-(6-(2-(methylsulfonyl)-2-(6-(6-oxo-1,6-dihydro-2-pyridinyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide	δ 9.03 (br. s., 1H), 8.57 (br. s., 1H), 8.19 (d, J=8.5 Hz, 1H), 7.96 - 7.90 (m, 1H), 7.90 - 7.84 (m, 2H), 7.81 - 7.76 (m, 2H), 6.99 (br. s., 2H), 6.06 (br. s., 1H), 4.52 (br. s., 1H), 4.28 (br. s., 3H), 3.90 (d, J=16.0 Hz, 1H), 3.62 (br. s., 2H), 3.25 (br. s., 4H), 3.20 (br. s., 2H)	1.2 Q 471.1	<10 398



B189		2-((2-methylsulfonyl)-2-(6-(2-oxo-1,2-dihydro-4-pyridinyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl ethyl)acetamide	δ 11.66 (br. s., 1H), 9.00 (t, $J=5.4$ Hz, 1H), 8.57 (s, 1H), 8.16 (d, $J=8.8$ Hz, 1H), 7.89 (dd, $J=8.5, 1.7$ Hz, 1H), 7.51 (d, $J=6.9$ Hz, 1H), 6.96 (s, 2H), 6.71 (s, 1H), 6.65 - 6.54 (m, 1H), 6.06 (s, 1H), 3.68 - 3.56 (m, 2H), 3.27 - 3.23 (m, 3H), 3.20 (t, $J=7.2$ Hz, 2H)	0.9 O 471.0	<10	13
B190		2-((2-methoxyethyl)-2-(6-(2-oxo-1,2-dihydro-4-pyridinyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl ethyl)acetamide	δ 11.66 (br. s., 1H), 8.96 (t, $J=5.5$ Hz, 1H), 8.57 (s, 1H), 8.16 (d, $J=8.5$ Hz, 1H), 7.89 (dd, $J=8.5, 1.4$ Hz, 1H), 7.54 - 7.47 (m, 1H), 6.99 - 6.90 (m, 3H), 6.74 - 6.68 (m, 1H), 6.67 - 6.58 (m, 2H), 6.15 - 6.00 (m, 1H), 3.71 - 3.66 (m, 2H), 3.64 - 3.57 (m, 2H), 3.28 (s, 3H), 3.22 - 3.16 (m, 2H)	0.9 O 515.1	<10	272




B191		2-(6-(2-oxo-1,2-dihydro-4-pyridinyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoylethyl)-2-((3,3,3-trifluoropropyl)sulfonyl)acetamide	δ 11.78 - 11.27 (m, 1H), 8.96 (s, 1H), 8.69 - 8.43 (m, 1H), 8.20 - 8.13 (m, 1H), 8.00 - 7.86 (m, 2H), 7.56 - 7.49 (m, 1H), 6.97 (s, 3H), 6.71 (s, 1H), 6.66 - 6.58 (m, 1H), 6.28 (s, 1H), 3.66 - 3.59 (m, 2H), 3.20 (s, 2H), 2.90 - 2.82 (m, 2H)	1.3 O 553.1	<10	445
B192		2-(6-(5-fluoro-2-oxo-1,2-dihydro-4-pyridinyl)-1,3-benzothiazol-2-yl)-2-(methylsulfonyl)-N-(2-sulfamoylethyl)acetamide	^1H NMR (400MHz, DMSO- d_6) δ 9.02 (t, $J=5.5$ Hz, 1H), 8.51 (s, 1H), 8.35 - 8.29 (m, 1H), 8.26 - 8.19 (m, 1H), 7.90 - 7.80 (m, 1H), 7.17 - 7.09 (m, 1H), 7.05 - 6.94 (m, 2H), 6.13 - 5.96 (m, 1H), 3.65 - 3.57 (m, 2H), 3.25 (s, 3H), 3.22 - 3.16 (m, 2H).	0.7 M 489.0	<10	20600
B193		2-[6-(3-fluoro-2-hydroxy-4-pyridinyl)-1,3-benzothiazol-2-yl]-2-(methylsulfonyl)-N-(2-sulfamoylethyl)acetamide	δ 12.25 (br. s., 1H), 9.02 (t, $J=5.5$ Hz, 1H), 8.46 (s, 1H), 8.21 (d, $J=8.5$ Hz, 1H), 7.78 (d, $J=8.5$ Hz, 1H), 7.37 (d, $J=6.6$ Hz, 1H), 6.98 (s, 2H), 6.40 (t, $J=6.3$ Hz, 1H),	0.93 O 489.0	0.5	238



				6.07 (s, 1H), 3.61 (q, J=6.6 Hz, 2H), 3.25 (s, 2H), 3.20 (t, J=7.0 Hz, 2H)			
B194		2-(methylsulfonyl)-2-(5-(2-oxo-1,2-dihydro-4-pyridinyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide		δ 11.68 (br. s., 1H), 9.02 (t, J=5.5 Hz, 1H), 8.41 (s, 1H), 8.28 (d, J=8.5 Hz, 1H), 7.86 (d, J=8.5 Hz, 1H), 7.50 (d, J=6.9 Hz, 1H), 6.99 (s, 2H), 6.82 - 6.71 (m, 1H), 6.69 - 6.63 (m, 1H), 6.07 (s, 1H), 3.61 (q, J=6.4 Hz, 2H), 3.26 (s, 3H), 3.20 (t, J=7.2 Hz, 2H)	0.94 O 471.0	2	95
B195		2-(methylsulfonyl)-2-(5-(6-(4-hydroxypyridin-2-yl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide		δ 11.94 (br. s., 1H), 9.01 (t, J=5.5 Hz, 1H), 8.39 - 8.23 (m, 1H), 8.22 - 8.17 (m, 1H), 8.02 - 7.95 (m, 2H), 7.93 - 7.84 (m, 1H), 7.79 - 7.68 (m, 1H), 6.99 (s, 2H), 6.52 - 6.40 (m, 1H), 3.61 (q, J=6.4 Hz, 2H), 3.25 (s, 3H), 3.20 (t, J=7.0 Hz, 2H)	0.95 O 471.0	1	105



B198		N-(2-(1H-imidazol-4-yl)ethyl)-2-(2-oxo-2-((2-sulfamoyl)ethyl)amino)-1-((3,3,3-trifluoropropyl)sulfonyl)ethyl)-1,3-benzothiazole-6-carboxamide	δ 9.00 - 8.70 (m, 1H), 8.56 - 8.26 (m, 2H), 8.19 - 7.87 (m, 3H), 7.70 (d, $J=8.5$ Hz, 1H), 7.29 - 7.15 (m, 1H), 6.88 (s, 2H), 3.62 (d, $J=6.3$ Hz, 8H), 2.92 - 2.82 (m, 4H)	1.1 O 597.0	148	3933
B199		N-((3-isopropyl-5-isoxazolyl)methyl)-2-(2-oxo-2-((2-sulfamoyl)ethyl)amino)-1-((3,3,3-trifluoropropyl)sulfonyl)ethyl)-1,3-benzothiazole-6-carboxamide	δ 8.58 (s, 1H), 8.14 (d, $J=8.5$ Hz, 2H), 7.86 (d, $J=8.8$ Hz, 2H), 4.88 - 4.48 (m, 4H), 3.81 - 3.52 (m, 4H), 3.18 (s, 2H), 2.89 (m, 2H)	1.74 O 626.1	166	3671
B200		2-(6-((3,3-difluoro-1-azetidyl)carbonyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)-2-((3,3,3-trifluoropropyl)sulfonyl)ethyl)-1,3-benzothiazole-6-carboxamide	δ 8.58 (s, 1H), 8.14 (d, $J=8.5$ Hz, 2H), 7.86 (d, $J=8.8$ Hz, 2H), 4.88 - 4.48 (m, 4H), 3.81 - 3.52 (m, 4H), 3.18 (s, 2H), 2.89 (m, 2H)	1.43 O 579.1	26	10,000



		acetamide					
B201		2-(6-(3,4-dihydro-2(1H)-isoquinolinylcarbonyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl-2-((3,3,3-trifluoropropyl)sulfonyl)acetamide	δ 8.33 (m, 1H), 8.15 (d, $J=8.5$ Hz, 1H), 7.86 (m, 1H), 7.19 (m, 3H), 6.96 (m, 1H), 4.85 - 4.54 (m, 2H), 3.93 - 3.52 (m, 6H), 3.22 - 3.14 (m, 2H), 2.92 - 2.83 (m, 4H)	1.43 O 619.0	23	311	
B204		2-(2-methoxyethane sulfonyl)-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-2-(6-phenyl-1,3-benzothiazol-2-yl)acetamide	δ 9.54 (br. s., 1H), 8.51 (br. s., 1H), 8.17 (d, $J=8.5$ Hz, 1H), 7.89 (d, $J=8.3$ Hz, 1H), 7.78 (m, 2H), 7.53 (t, $J=7.0$ Hz, 2H), 7.44 (d, $J=6.9$ Hz, 1H), 6.10 (br. s., 1H), 4.68 (m., 2H), 3.82 - 3.68 (m, 4H), 3.28 (br. s., 3H), 2.47 (br. s., 3H)	1.8 N 486.9	23.7	17.5	
B205		methyl 3-([(5-methyl-1,3,4-oxadiazol-2-yl)methyl]carbamoyl) (6-phenyl-1,3-benzothiazol-2-yl)methanesulfonyl)propanoate	δ 9.56 (m., 1H), 8.52 (br. s., 1H), 8.24 - 8.10 (m, 1H), 7.98 - 7.64 (m, 3H), 7.58 - 7.35 (m, 3H), 6.21 (br. s., 1H), 4.78 - 4.62 (m, 2H), 3.84 - 3.65 (m, 2H), 3.63 (br. s., 3H), 2.90 - 2.75 (m, 2H), 2.47	1.7 N 515.3	205.0	100.6	



			(m., 3H)				
B207		2-[6-(4-chlorophenyl)-1,3-benzothiazol-2-yl]-2-methanesulfonyl-N-(2-sulfamoylethyl)acetamide	δ 9.01 (t, J=5.6 Hz, 1H), 8.51 (d, J=1.5 Hz, 1H), 8.16 (d, J=8.5 Hz, 1H), 7.88 (dd, J=8.5, 1.8 Hz, 1H), 7.84 - 7.75 (m, 2H), 7.64 - 7.51 (m, 2H), 6.97 (s, 2H), 6.05 (s, 1H), 3.67 - 3.55 (m, 2H), 3.24 (s, 3H), 3.22 - 3.14 (m, 2H)	2.56 R 488.1	1.4	2.8	
B208		2-[6-(3-chlorophenyl)-1,3-benzothiazol-2-yl]-2-methanesulfonyl-N-(2-sulfamoylethyl)acetamide	δ 9.01 (t, J=5.5 Hz, 1H), 8.55 (s, 1H), 8.17 (d, J=8.5 Hz, 1H), 8.00 - 7.88 (m, 1H), 7.85 (s, 1H), 7.76 (d, J=7.9 Hz, 1H), 7.55 (t, J=7.9 Hz, 1H), 7.48 (d, J=8.2 Hz, 1H), 6.97 (s, 2H), 6.05 (s, 1H), 3.61 (q, J=6.6 Hz, 2H), 3.25 (s, 3H), 3.20 (t, J=7.3 Hz, 2H)	2.5 R 488.1	0.8	0.8	




B209		2-[6-(3-chloro-5-fluorophenyl)-1,3-benzothiazol-2-yl]-2-methanesulfonyl-N-(2-sulfamoyl-ethyl)acetamide	δ 9.02 (t, J=5.5 Hz, 1H), 8.61 (s, 1H), 8.17 (d, J=8.5 Hz, 1H), 8.01 - 7.92 (m, 1H), 7.75 (s, 1H), 7.49 (d, J=8.2 Hz, 2H), 6.97 (s, 2H), 6.06 (s, 1H), 3.66 - 3.57 (m, 2H), 3.25 (s, 3H), 3.23 - 3.17 (m, 2H)	2.6 R 506.1	8.0	13.9
B210		2-methanesulfonyl-2-[6-(3-phenoxyphenyl)-1,3-benzothiazol-2-yl]-N-(2-sulfamoyl-ethyl)acetamide	δ 9.01 (s, 1H), 8.50 (s, 1H), 8.14 (d, J=8.5 Hz, 1H), 7.86 (d, J=7.0 Hz, 1H), 7.61 - 7.46 (m, 3H), 7.46 - 7.38 (m, 3H), 7.23 - 7.13 (m, 2H), 7.10 (d, J=7.6 Hz, 2H), 7.03 (d, J=7.6 Hz, 1H), 6.97 (s, 2H), 6.04 (s, 1H), 3.61 (d, J=6.7 Hz, 2H), 3.24 (s, 3H), 3.22 - 3.13 (m, 2H)	2.83 R 541.1	0.6	1.9
B211		N-(3-hydroxypropyl)-4-(2-{methanesulfonyl}[(2-sulfamoyl-ethyl)carbamoyl]methyl)-1,3-benzothiazol-6-yl)benzamide	δ 9.07 - 8.97 (m, 1H), 8.57 (d, J=1.8 Hz, 1H), 8.53 (t, J=5.6 Hz, 1H), 8.18 (d, J=8.5 Hz, 1H), 8.01 - 7.92 (m, 4H), 7.88 (d, J=8.5 Hz, 2H), 6.97 (s, 2H), 6.05 (s, 1H),	1.53 R	0.7	57.0



			4.50 (t, J=5.2 Hz, 1H), 3.62 (q, J=6.7 Hz, 2H), 3.53 - 3.43 (m, 2H), 3.39 - 3.35 (m, 2H), 3.25 (s, 3H), 3.22 - 3.17 (m, 2H), 1.71 (t, J=6.9 Hz, 2H)	554.1		
B212		2-fluoro-4-(2-{methanesulfonyl}[(2-sulfamoylethyl)carbamoyl]methyl}-1,3-benzothiazol-6-yl)-N,N-dimethylbenzamide	δ 9.03 (t, J=5.5 Hz, 1H), 8.60 (d, J=1.8 Hz, 1H), 8.18 (d, J=8.5 Hz, 1H), 8.01 - 7.90 (m, 1H), 7.79 - 7.66 (m, 2H), 7.53 (t, J=7.6 Hz, 1H), 6.97 (s, 2H), 6.06 (s, 1H), 3.66 - 3.55 (m, 2H), 3.25 (s, 3H), 3.20 (t, J=7.5 Hz, 2H), 3.07 - 3.00 (m, 3H), 2.91 (s, 3H)	1.86 R 542.1	1.2	87.9
B213		2-{6-[3-(difluoromethoxy)phenyl]-1,3-benzothiazol-2-yl}-2-methanesulfonyl-N-(2-sulfamoylethyl)acetamide	δ 9.01 (t, J=5.8 Hz, 1H), 8.55 (s, 1H), 8.18 (d, J=8.5 Hz, 1H), 7.92 (d, J=8.5 Hz, 1H), 7.67 (d, J=7.9 Hz, 1H), 7.62 - 7.48 (m, 2H), 7.23 (d, J=5.5 Hz, 1H), 6.97 (s, 2H), 6.05 (s, 1H), 3.66 - 3.56 (m, 2H), 3.25 (s, 3H), 3.20 (t, J=7.0 Hz, 2H)	2.40 R 519.0	2.8	3.0



B214		4-(2-((methanesulfonyl)carbamoyl)sulfamoyl)ethyl)carbamoyl]-1,3-benzothiazol-6-yl)benzamide	δ 9.01 (t, J=5.8 Hz, 1H), 8.57 (d, J=1.5 Hz, 1H), 8.18 (d, J=8.5 Hz, 1H), 8.06 (br. s., 1H), 8.04 - 7.99 (m, 2H), 7.99 - 7.92 (m, 2H), 7.87 (d, J=8.2 Hz, 2H), 7.42 (br. s., 1H), 6.97 (s, 2H), 6.05 (s, 1H), 3.66 - 3.57 (m, 2H), 3.25 (s, 3H), 3.22 - 3.16 (m, 2H)	1.5 R 497.1	1.6	159.9
B215		2-methanesulfonyl-2-([3-(methoxymethyl)phenyl]-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide	δ 9.01 (t, J=5.8 Hz, 1H), 8.50 (d, J=1.5 Hz, 1H), 8.16 (d, J=8.5 Hz, 1H), 7.96 (s, 1H), 7.88 (dd, J=8.5, 1.8 Hz, 1H), 7.75 - 7.67 (m, 2H), 7.67 - 7.59 (m, 1H), 7.59 - 7.53 (m, 1H), 7.50 (t, J=7.6 Hz, 1H), 7.37 (d, J=7.6 Hz, 1H), 6.97 (s, 2H), 6.04 (s, 1H), 4.52 (s, 2H), 3.61 (q, J=6.7 Hz, 2H), 3.35 (br. s., 3H), 3.25 (br. s., 3H) 3.20 (t, J=7.3 Hz, 2H)	2.2 R 498.2	4.4	3.6



B216		N-cyclopropyl-4-(2-{methanesulfonyl}[(2-sulfamoylethyl)carbamoyl]methyl)-1,3-benzothiazol-6-yl)benzamide	δ 9.02 (t, J=5.8 Hz, 1H), 8.57 (d, J=1.5 Hz, 1H), 8.52 (d, J=4.0 Hz, 1H), 8.18 (d, J=8.5 Hz, 1H), 8.01 - 7.89 (m, 3H), 7.89 - 7.77 (m, 2H), 6.97 (s, 2H), 6.05 (s, 1H), 3.61 (q, J=6.7 Hz, 2H), 3.25 (s, 3H), 3.23 - 3.15 (m, 2H), 2.89 - 2.85 (m, 1H), 0.76 - 0.68 (m, 2H), 0.64 - 0.58 (m, 2H)	1.8 R 537.2	2.1	154.9
B217		2-{6-[3-chloro-4-(propan-2-yloxy)phenyl]-1,3-benzothiazol-2-yl}-2-methanesulfonyl-N-(2-sulfamoylethyl)acetamide	δ 9.00 (t, J=5.8 Hz, 1H), 8.48 (d, J=1.5 Hz, 1H), 8.12 (d, J=8.9 Hz, 1H), 7.86 - 7.82 (m, 1H), 7.70 (dd, J=8.5, 2.4 Hz, 1H), 7.30 (d, J=8.9 Hz, 1H), 6.97 (s, 2H), 6.03 (s, 1H), 4.76 (dt, J=12.1, 6.2 Hz, 1H), 3.61 (q, J=6.7 Hz, 2H), 3.24 (s, 3H), 3.20 (t, J=7.5 Hz, 2H), 1.37 - 1.30 (m, 6H)	2.8 R 546.1	2.3	3.6



B218		2-[6-(3,5-difluoro-4-methoxyphenyl)-1,3-benzothiazol-2-yl]-2-methanesulfonyl-N-(2-sulfamoylethyl)acetamide	δ 9.01 (t, J=5.6 Hz, 1H), 8.60 (s, 1H), 8.17 (d, J=8.5 Hz, 1H), 8.02 - 7.89 (m, 3H), 7.57 (d, J=8.5 Hz, 2H), 6.97 (s, 2H), 6.05 (s, 1H), 5.31 (t, J=5.6 Hz, 1H), 4.55 (d, J=5.2 Hz, 2H), 3.61 (q, J=6.6 Hz, 2H), 3.24 (s, 3H), 3.20 (t, J=7.3 Hz, 2H)	1.84 R 519.0	1.7	5.2
B219		2-methanesulfonyl-N-(2-[6-(3-sulfamoylphenyl)-1,3-benzothiazol-2-yl]acetamide	δ 9.01 (t, J=5.5 Hz, 1H), 8.56 (d, J=1.5 Hz, 1H), 8.26 - 8.17 (m, 2H), 8.01 (d, J=7.6 Hz, 1H), 7.96 (s, 2H), 7.91 (dd, J=8.5, 1.8 Hz, 1H), 7.87 (d, J=7.9 Hz, 1H), 7.72 (t, J=7.8 Hz, 1H), 7.45 (s, 2H), 6.97 (s, 2H), 6.06 (s, 1H), 3.62 (q, J=6.9 Hz, 2H), 3.26 (s, 3H), 3.23 - 3.15 (m, 2H)	1.62 R 532.0	2.2	141.8



B220		tert-butyl 3-(2-{methanesulfonyl}[(2-sulfamoylethyl)carbamoyl]methyl)-1,3-benzothiazol-6-yl)-1H-pyrrole-1-carboxylate	δ 9.00 (br. s., 1H), 8.48 (br. s., 1H), 8.05 (d, $J=8.3$ Hz, 1H), 7.90 (d, $J=8.5$ Hz, 1H), 7.85 (br. s., 1H), 7.38 (br. s., 1H), 6.98 (br. s., 2H), 6.86 (br. s., 1H), 6.01 (br. s., 1H), 3.68 - 3.54 (m, 2H), 3.24 (br. s., 3H), 3.19 (br. s., 2H), 1.61 (br. s., 9H)	1.8 N 543.2	51.4	2.8
B221		2-methanesulfonyl-N-(2-sulfamoylethyl)-2-[6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1,3-benzothiazol-2-yl]acetamide	δ 8.98 (t, $J=5.6$ Hz, 1H), 8.43 - 8.31 (m, 2H), 8.12 - 8.00 (m, 2H), 7.79 (dd, $J=8.5$, 1.7 Hz, 1H), 6.96 (s, 2H), 6.00 (s, 1H), 4.44 (t, $J=6.9$ Hz, 2H), 3.61 (q, $J=6.6$ Hz, 2H), 3.27 - 3.22 (m, 3H), 3.22 - 3.14 (m, 2H), 3.02 - 2.87 (m, 2H)	1.4 N 540.1	78.1	308.1
B222		2-methanesulfonyl-N-(2-sulfamoylethyl)-2-[6-(1,3-thiazol-5-yl)-1,3-benzothiazol-2-yl]acetamide	δ 9.15 (s, 1H), 9.01 (s, 1H), 8.55 (d, $J=1.7$ Hz, 1H), 8.44 (s, 1H), 8.15 (d, $J=8.8$ Hz, 1H), 7.92 (dd, $J=8.5$, 1.7 Hz, 1H), 6.96 (s, 2H), 6.05 (s, 1H), 3.66 - 3.56 (m, 2H),	1.1 N 461	12.3	31.6



B223		2-{6-[4-(5-amino-1,3,4-thiadiazol-2-yl)phenyl]-1,3-benzothiazol-2-yl}-2-methanesulfonyl-N-(2-sulfamoyl-ethyl)acetamide	3.25 (s, 3H), 3.23 - 3.14 (m, 2H) δ 9.02 (t, J=5.8 Hz, 1H), 8.58 (s, 1H), 8.19 (d, J=8.5 Hz, 1H), 8.00 - 7.92 (m, 1H), 7.90 (s, 3H), 7.48 (br. s., 2H), 6.97 (s, 2H), 6.06 (s, 1H), 3.92 (s, 1H), 3.67 - 3.60 (m, 2H), 3.26 (s, 3H), 3.24 - 3.14 (m, 2H)	1.2 N 553.1	1.2	7.7
B224		2-methanesulfonyl-2-{6-[4-(1,3-oxazol-2-yl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl-ethyl)acetamide	δ 9.01 (br. s., 1H), 8.60 (s, 1H), 8.40 (d, J=9.4 Hz, 1H), 8.29 (d, J=6.3 Hz, 1H), 8.22 - 8.01 (m, 4H), 7.97 (d, J=7.2 Hz, 2H), 7.45 (d, J=6.1 Hz, 1H), 7.02 (s, 1H), 6.97 (s, 1H), 3.62 (d, J=6.1 Hz, 2H), 3.46 (s, 2H), 3.21 (d, J=6.9 Hz, 3H)	1.5 N 521.1	8.4	10.0




B225		2-methanesulfonyl-2-yl- [4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]- 1,3-benzothiazol-2-yl}-N-(2-sulfamoyl-ethyl) acetamide	δ 9.03 (s, 1H), 8.63 (s, 1H), 8.21 (d, J=8.5 Hz, 1H), 8.15 - 8.09 (m, J=8.3 Hz, 2H), 8.07 - 8.01 (m, J=8.3 Hz, 2H), 7.98 (d, J=9.6 Hz, 1H), 6.97 (s, 2H), 6.07 (s, 1H), 3.63 (q, J=6.6 Hz, 2H), 3.26 (s, 3H), 3.21 (t, J=7.0 Hz, 2H), 2.63 (s, 3H)	1.3 N 536.2	4.9	15.4
B226		N-cyclopropyl-4-(2- sulfamoyl-ethyl)carbamoyl- [4-(trifluoromethoxy) phenyl]methanesulfonyl methyl}-1,3-benzothiazol- 6-yl)benzamide	δ 9.05 (br. s., 1H), 8.50 (d, J=18.7 Hz, 1H), 8.26 - 8.10 (m, 1H), 8.01 - 7.90 (m, 2H), 7.90 - 7.82 (m, 1H), 7.78 (d, J=11.0 Hz, 1H), 7.55 (d, J=7.7 Hz, 1H), 7.52 - 7.44 (m, 1H), 7.40 (d, J=7.7 Hz, 1H), 7.27 (br. s., 1H), 6.97 (br. s., 2H), 4.89 - 4.78 (m, 1H), 4.76 - 4.59 (m, 1H), 3.63 (d, J=5.5 Hz, 2H), 3.27 - 3.13 (m, 2H), 2.91 (br. s., 1H), 0.73 (br. s., 2H), 0.62 (br. s., 2H)	1.6 N 697.1	0.5	74.0



B227		4-(2-{[(2-sulfamoyl)ethyl] carbamoyl}[[4-(trifluoromethoxy) phenyl]methanesulfonyl methyl]-1,3-benzothiazol-6-yl)benzamide	δ 9.05 (br. s., 1H), 8.09 - 8.00 (m, 2H), 8.00 - 7.93 (m, 2H), 7.88 (d, J=7.7 Hz, 1H), 7.77 (br. s., 2H), 7.56 (d, J=8.0 Hz, 1H), 7.49 (d, J=7.7 Hz, 1H), 7.40 (d, J=8.5 Hz, 2H), 6.97 (br. s., 2H), 4.83 (d, J=5.8 Hz, 1H), 4.75 - 4.57 (m, 1H), 3.63 (d, J=6.1 Hz, 2H), 3.22 (t, J=6.9 Hz, 2H)	1.5 N 657.2	0.5	80.8
B228		4-(2-{[(2-sulfamoyl)ethyl] carbamoyl}[[3,3,3-trifluoro propanesulfonyl)methyl]-1,3-benzothiazol-6-yl] benzamide	δ 8.98 (br. s., 1H), 8.60 (s, 1H), 8.19 (d, J=8.5 Hz, 1H), 8.10 - 8.01 (m, 2H), 8.01 - 7.93 (m, 2H), 7.88 (d, J=8.0 Hz, 2H), 7.80 (d, J=6.6 Hz, 1H), 7.42 (br. s., 1H), 6.97 (s, 2H), 6.29 (s, 1H), 3.86 - 3.67 (m, 2H), 3.67 - 3.57 (m, 2H), 3.21 (t, J=7.0 Hz, 2H), 2.87 (d, J=9.1 Hz, 2H)	1.3 N 579.15	9.2	249.6




B229		2-fluoro-N,N-dimethyl-4-(2-[(2-sulfamoyl)ethoxy]carbamoyl)[4-(trifluoromethoxy)phenyl]methanesulfonylmethyl}-1,3-benzothiazol-6-yl) benzamide	δ 8.26 - 8.12 (m, 1H), 8.01 - 7.95 (m, 1H), 7.94 - 7.79 (m, 1H), 7.78 - 7.69 (m, 1H), 7.68 - 7.58 (m, 1H), 7.58 - 7.51 (m, 1H), 7.48 (br. s., 1H), 7.40 (d, J=7.7 Hz, 1H), 7.28 (d, J=9.1 Hz, 1H), 7.22 (br. s., 1H), 7.11 (br. s., 1H), 7.01 (br. s., 1H), 6.97 (br. s., 1H), 4.92 - 4.76 (m, 1H), 4.75 - 4.60 (m, 1H), 3.63 (d, J=5.5 Hz, 2H), 3.26 - 3.17 (m, 2H), 3.05 (br. s., 3H), 2.95 - 2.88 (m, 3H)	1.67 N 703.1	29.2	242.3
B230		2-fluoro-N,N-dimethyl-4-(2-[(2-sulfamoyl)ethoxy]carbamoyl)(3,3,3-trifluoropropanesulfonylmethyl)-1,3-benzothiazol-6-yl) benzamide	δ 9.00 (br. s., 1H), 8.62 (s, 1H), 8.19 (d, J=8.3 Hz, 1H), 8.02 - 7.93 (m, 1H), 7.78 - 7.70 (m, 1H), 7.65 (br. s., 1H), 7.57 - 7.43 (m, 1H), 6.97 (br. s., 2H), 6.29 (s, 1H), 3.86 - 3.69 (m, 2H), 3.68 - 3.56 (m, 2H), 3.21 (t, J=7.6 Hz, 2H), 3.05 (br. s., 3H), 2.92 (d, J=6.6 Hz,	1.4 N 625.1	4.6	37.4



B231		4-{2-[methanesulfonyl ({[3-(propan-2-yl)-1,2- oxazol-5-yl]methyl} carbamoyl)methyl]- 1,3-benzothiazol-6-yl}-N- (2-methoxyethyl) benzamide	4H), 2.89 - 2.81 (m, 1H) δ 9.40 (t, J=5.8 Hz, 1H), 8.56 (t, J=5.2 Hz, 1H), 8.53 (d, J=1.7 Hz, 1H), 8.14 (d, J=8.5 Hz, 1H), 7.98 - 7.92 (m, J=8.5 Hz, 2H), 7.92 - 7.88 (m, 1H), 7.86 - 7.78 (m, J=8.3 Hz, 2H), 6.30 (s, 1H), 6.02 (s, 1H), 4.61 - 4.41 (m, 2H), 3.51 - 3.39 (m, 4H), 3.25 - 3.23 (m, 3H), 3.20 (s, 3H), 2.92 (quin, J=6.9 Hz, 1H), 1.15 (s, 3H), 1.13 (s, 3H)	1.50 N 573.2	290.9	18.5		
B232		2-(2-methoxyethane sulfonyl)-2-(6-phenyl-1,3- benzothiazol-2-yl)-N-{[3- (propan-2-yl)-1,2-oxazol- 5-yl]methyl}acetamide	δ 9.43 (s, 1H), 8.50 (d, J=1.7 Hz, 1H), 8.17 (d, J=8.8 Hz, 1H), 7.89 (dd, J=8.5, 1.9 Hz, 1H), 7.82 - 7.74 (m, 2H), 7.53 (t, J=7.7 Hz, 2H), 7.44 (d, J=7.4 Hz, 1H), 6.34 (s, 1H), 6.08 (s, 1H), 4.56 (dd, J=5.5, 3.3 Hz, 2H), 3.83 - 3.72 (m, 2H), 3.72 - 3.64 (m, 2H), 3.28 (s, 3H), 3.02 - 2.92 (m, 1H), 1.23 - 1.17	2.09 N 514.25	45.9	0.8		



			(m, 6H)				
B233		2-methanesulfonyl-N-[(3-methyl-1,2-oxazol-5-yl)methyl]-2-(6-phenyl-1,3-benzothiazol-2-yl)acetamide	δ 9.44 (s, 1H), 8.50 (d, J=1.4 Hz, 1H), 8.18 (d, J=8.5 Hz, 1H), 7.89 (dd, J=8.5, 1.9 Hz, 1H), 7.81 - 7.75 (m, 2H), 7.53 (t, J=7.7 Hz, 2H), 7.44 (d, J=7.2 Hz, 1H), 6.26 (s, 1H), 6.06 (s, 1H), 4.57 (dd, J=8.0, 5.8 Hz, 2H), 3.25 (s, 3H), 2.21 (s, 3H)	1.79 N 442.1	31.6	3.6	
B234		2-(2-methoxyethane sulfonyl)-N-[(3-methyl-1,2-oxazol-5-yl)methyl]-2-(6-phenyl-1,3-benzothiazol-2-yl)acetamide	δ 9.47 (s, 1H), 8.50 (d, J=1.7 Hz, 1H), 8.17 (d, J=8.5 Hz, 1H), 7.89 (dd, J=8.7, 1.8 Hz, 1H), 7.83 - 7.74 (m, 2H), 7.53 (t, J=7.7 Hz, 2H), 7.44 (d, J=7.4 Hz, 1H), 6.26 (s, 1H), 6.09 (s, 1H), 4.64 - 4.45 (m, 2H), 3.85 - 3.70 (m, 2H), 3.70 - 3.62 (m, 2H), 3.27 (s, 3H), 2.21 (s, 3H)	1.89 N 486.15	4.9	0.5	



B235		2-methanesulfonyl-2-[(1-methyl-1H-pyrazol-5-yl)-1,3-benzothiazol-2-yl]-N-(2-sulfamoyl)ethyl)acetamide	δ 9.00 (t, J=5.6 Hz, 1H), 8.44 - 8.34 (m, 1H), 8.19 (d, J=8.5 Hz, 1H), 7.77 - 7.67 (m, 1H), 7.52 (d, J=1.7 Hz, 1H), 6.96 (s, 2H), 6.51 (d, J=1.9 Hz, 1H), 6.06 (s, 1H), 3.91 (s, 3H), 3.65 - 3.57 (m, 2H), 3.25 (s, 3H), 3.22 - 3.16 (m, 2H)	0.64 M 457.7	5.1	3051.0
B236		2-[6-(4-acetamidophenyl)-1,3-benzothiazol-2-yl]-N-(2-sulfamoyl)ethyl)acetamide	δ 10.25 - 9.93 (m, 1H), 9.09 - 8.88 (m, 1H), 8.53 - 8.41 (m, 1H), 8.21 - 8.08 (m, 1H), 7.97 - 7.83 (m, 1H), 7.71 (s, 4H), 6.95 (s, 2H), 6.39 - 6.13 (m, 1H), 3.84 - 3.48 (m, 4H), 3.25 - 3.11 (m, 2H), 2.95 - 2.76 (m, 2H), 2.08 (s, 3H)	1.42 N 593.1	0.8	55.3
B237		4-(2-{cyclopropylmethane sulfonyl}[(2-sulfamoyl ethyl)carbamoyl]methyl)-1,3-benzothiazol-6-yl)-N-(2-hydroxyethyl) benzamide	δ 9.21 - 8.89 (m, 1H), 8.55 (d, J=1.4 Hz, 2H), 8.15 (d, J=8.8 Hz, 1H), 8.04 - 7.66 (m, 5H), 6.94 (s, 2H), 6.05 (s, 1H), 4.91 - 4.65 (m, 1H), 3.53 (d, J=5.5 Hz, 4H), 3.35 (d, J=5.8 Hz, 3H), 3.18 (br. s.,	0.69 O 476.7	3.7	499.2



				3H), 1.14 - 0.97 (m, 1H), 0.61 (s, 3H), 0.43 - 0.14 (m, 1H)			
B238		2-[(4-fluorophenyl)methanesulfonyl]-2-(6-{4-[(2-hydroxyethyl)sulfamoyl]phenyl}-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)acetamide	δ 8.29 - 8.12 (m, 1H), 8.04 - 7.83 (m, 6H), 7.73 - 7.64 (m, 1H), 7.46 (br. s., 1H), 7.38 (br. s., 1H), 7.24 (t, $J=8.3$ Hz, 1H), 7.09 (br. s., 1H), 7.04 - 6.91 (m, 2H), 6.08 (s, 1H), 4.73 (d, $J=15.1$ Hz, 2H), 4.68 - 4.54 (m, 1H), 3.59 (br. s., 2H), 3.39 (br. s., 2H), 3.23 - 3.10 (m, 2H), 2.83 (br. s., 2H)	1.42 N 671.1	9.8	233.8	
B239		2-{6-[4-(methoxymethyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl)ethyl)-2-(3,3,3-trifluoropropanesulfonyl)acetamide	δ 8.83 (s, 1H), 8.58 (s, 1H), 8.47 (d, $J=1.4$ Hz, 1H), 8.03 (d, $J=8.5$ Hz, 1H), 8.00 - 7.93 (m, 2H), 7.92 - 7.80 (m, 3H), 4.51 - 4.13 (m, 2H), 4.05 - 3.84 (m, 2H), 3.64 (s, 2H), 3.53 - 3.41 (m, 4H), 3.33 - 3.21 (m, 3H)	1.79 N 580.1	9.4	7.3	



B240		2-[(4-fluorophenyl)methanesulfonyl]-2-{6-[(2-hydroxyethyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl)ethyl)acetamide	δ 8.24 - 7.97 (m, 1H), 7.88 - 7.57 (m, 3H), 7.52 - 7.10 (m, 5H), 6.97 (br. s., 2H), 4.85 - 4.52 (m, 3H), 3.72 - 3.53 (m, 4H), 3.25 - 3.08 (m, 2H), 2.87 - 2.68 (m, 2H)	1.55 N 592.1	25.7	76.6
B241		N-(2-hydroxy-2-methylpropyl)-4-(2-{methanesulfonyl}[(2-sulfamoyl)ethyl]carbamoyl)methyl)-1,3-benzothiazol-6-yl)benzamide	δ 9.13 - 8.90 (m, 1H), 8.62 - 8.49 (m, 1H), 8.44 - 8.31 (m, 1H), 8.25 - 8.15 (m, 1H), 8.07 - 7.84 (m, 4H), 7.24 - 6.93 (m, 2H), 6.15 - 5.95 (m, 1H), 4.75 - 4.52 (m, 1H), 3.65 - 3.54 (m, 2H), 3.32 - 3.13 (m, 8H), 1.12 (br. s., 6H)	1.11 N 569.1	6.4	607.0
B242		4-{2-[(4-fluorophenyl)methanesulfonyl]-(2-sulfamoyl)ethyl}carbamoyl]-1,3-benzothiazol-6-yl)-N-(2-hydroxy-2-methylpropyl)benzamide	δ 8.44 - 8.12 (m, 2H), 8.06 - 7.76 (m, 5H), 7.46 (br. s., 2H), 7.26 - 6.95 (m, 5H), 6.08 (s, 1H), 4.75 (d, $J=5.5$ Hz, 1H), 4.57 (br. s., 1H), 3.60 (d, $J=6.1$ Hz, 2H), 3.29 (br. s., 2H), 3.20 (d, $J=6.9$ Hz, 2H), 1.13 (br. s., 6H)	1.42 N 663.1	2.7	109.3




B243		2-[6-(3-chlorophenyl)-1,3-benzothiazol-2-yl]-2-[(4-fluorophenyl)methanesulfonyl]-N-(2-sulfamoyl)ethyl acetamide	δ 8.25 - 8.03 (m, 1H), 7.98 - 7.65 (m, 4H), 7.59 - 7.09 (m, 6H), 6.95 (s, 2H), 6.07 (s, 1H), 4.75 (d, $J=5.2$ Hz, 2H), 3.60 (d, $J=6.1$ Hz, 2H), 3.19 (t, $J=6.9$ Hz, 2H)	2.05 N 582.0	4.8	2.4
B244		4-(2-{cyclopropylmethanesulfonyl}[(2-sulfamoyl)ethyl]carbonyl)methyl}-1,3-benzothiazol-6-yl)-N-(2-methoxy-2-methylpropyl)benzamide	δ 9.02 - 8.80 (m, 1H), 8.49 - 8.37 (m, 1H), 8.25 - 8.12 (m, 1H), 8.07 - 7.98 (m, 1H), 7.93 - 7.72 (m, 4H), 7.70 - 7.57 (m, 1H), 6.89 - 6.70 (m, 2H), 6.06 - 5.85 (m, 1H), 3.88 - 3.64 (m, 1H), 3.58 - 3.42 (m, 2H), 3.33 - 3.21 (m, 3H), 3.17 - 3.11 (m, 6H), 3.09 - 2.99 (m, 5H), 0.98 - 0.93 (m, 1H), 0.58 - 0.35 (m, 2H), 0.36 - 0.11 (m, 2H)	1.43 N 623.2	0.9	12.0



B245		2-[(4-fluorophenyl)methanesulfonyl]-2-{6-[4-(hydroxymethyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl-6-(4-fluorophenyl)methyl)acetamide	δ 9.02 (s, 1H), 8.48 (d, $J=1.7$ Hz, 1H), 8.17 (d, $J=8.5$ Hz, 1H), 7.88 (dd, $J=8.5, 1.9$ Hz, 1H), 7.74 (d, $J=8.3$ Hz, 2H), 7.64 (br. s., 1H), 7.50 - 7.32 (m, 4H), 7.23 (t, $J=8.8$ Hz, 1H), 7.16 - 7.07 (m, 1H), 6.95 (s, 2H), 5.42 - 5.10 (m, 1H), 4.75 (d, $J=6.9$ Hz, 1H), 4.67 - 4.50 (m, 3H), 3.79 - 3.57 (m, 2H), 3.25 - 3.12 (m, 2H)	1.49 N 578.1	2.1	130.4
B246		2-fluoro-4-(2-{methanesulfonyl}[(2-sulfamoyl-6-(4-(4-fluorophenyl)-2-methanesulfonylphenyl)-1,3-benzothiazol-2-yl)-N-(2-methoxyethyl)-N-methyl]benzamide	δ 9.09 - 8.95 (m, 1H), 8.47 - 8.39 (m, 1H), 8.24 - 8.17 (m, 1H), 7.81 - 7.75 (m, 1H), 7.73 - 7.65 (m, 1H), 7.51 - 7.31 (m, 2H), 7.05 - 6.91 (m, 2H), 6.29 - 5.98 (m, 1H), 3.74 - 3.58 (m, 4H), 3.52 - 3.42 (m, 2H), 3.29 - 3.24 (m, 5H), 3.23 - 3.12 (m, 3H), 3.09 - 2.96 (m, 3H)	1.17 N 587.1	2.8	94.4




B247		4-(2-{cyclopropylmethane sulfonyl}[(2-sulfamoyl ethyl)carbamoyl]methyl}-1,3-benzothiazol-6-yl)-2-fluoro-N-(2-methoxy ethyl)-N-methylbenzamide	δ 9.16 - 8.89 (m, 1H), 8.62 - 8.29 (m, 1H), 8.23 - 7.53 (m, 4H), 7.46 - 7.19 (m, 2H), 7.05 - 6.81 (m, 2H), 6.15 - 5.99 (m, 1H), 3.81 - 3.53 (m, 4H), 3.52 - 3.37 (m, 3H), 3.28 - 3.11 (m, 6H), 3.00 (br. s., 3H), 1.21 - 1.00 (m, 1H), 0.75 - 0.45 (m, 2H), 0.45 - 0.08 (m, 2H)	1.39 N 627.1	6.1 127.3
B248		4-(2-{cyclopropylmethane sulfonyl}[(2-sulfamoyl ethyl)carbamoyl]methyl}-1,3-benzothiazol-6-yl)-N-(1-methoxy-2-methyl propan-2-yl)benzamide	δ 9.12 - 8.91 (m, 1H), 8.54 (d, J=1.7 Hz, 1H), 8.16 (d, J=8.8 Hz, 1H), 8.01 - 7.90 (m, 3H), 7.83 (d, J=8.5 Hz, 1H), 7.76 - 7.63 (m, 1H), 7.00 - 6.89 (m, 2H), 6.05 (s, 1H), 3.90 (s, 1H), 3.72 - 3.57 (m, 3H), 3.57 - 3.51 (m, 1H), 3.45 - 3.31 (m, 4H), 3.32 - 3.27 (m, 3H), 3.27 - 3.12 (m, 4H), 1.10 (s, 1H), 0.70 - 0.49 (m, 2H), 0.40 (dd, J=4.8, 1.5 Hz, 2H)	1.65 N 623.17	7.5 17.6



B249		N-(1-methoxy-2-methylpropan-2-yl)-4-(2-{{(2-sulfamoyl)ethyl}carbamoylethyl}carbamoylethyl)phenylmethanesulfonylmethyl}-1,3-benzothiazol-6-yl)benzamide	δ 8.64 - 8.51 (m, 1H), 8.24 - 8.11 (m, 1H), 7.99 - 7.82 (m, 3H), 7.73 (s, 2H), 7.53 (s, 1H), 7.51 - 7.45 (m, 1H), 7.43 - 7.36 (m, 1H), 7.32 - 7.21 (m, 1H), 6.98 (s, 2H), 6.11 (s, 1H), 4.87 - 4.76 (m, 1H), 4.75 - 4.57 (m, 1H), 3.68 - 3.58 (m, 2H), 3.54 (d, $J=4.4$ Hz, 2H), 3.29 (d, $J=2.8$ Hz, 3H), 3.24 - 3.13 (m, 2H), 1.35 (d, $J=4.4$ Hz, 6H)	1.98 N 743.2	8.3	29.4
B250		N-[(2S)-1-methoxypropan-2-yl]-4-(2-{{(2-sulfamoyl)ethyl}carbamoylethyl}carbamoylethyl)phenylmethanesulfonylmethyl}-1,3-benzothiazol-6-yl)benzamide	δ 9.19 - 8.98 (m, 1H), 8.40 - 8.12 (m, 2H), 8.05 - 7.85 (m, 4H), 7.83 - 7.67 (m, 2H), 7.63 - 7.35 (m, 3H), 7.34 - 7.17 (m, 1H), 7.06 - 6.88 (m, 2H), 6.31 - 5.97 (m, 1H), 5.05 - 4.76 (m, 1H), 4.74 - 4.57 (m, 1H), 4.35 - 4.17 (m, 1H), 3.71 - 3.57 (m, 2H), 3.51 - 3.40 (m, 2H), 3.28 (d, $J=2.5$ Hz, 3H), 3.24 - 3.09 (m, 2H), 1.29 - 1.10 (m, 3H)	1.73 N 729.1	5.3	38.4



B251		2-cyclopropylmethane sulfonyl-2-(6-{4-[(2S)-2- methylmorpholine-4- carbonyl]phenyl}-1,3- benzothiazol-2-yl)-N-(2- sulfamoyl-ethyl)acetamide	δ 9.05 (s, 1H), 8.53 (d, $J=1.7$ Hz, 1H), 8.15 (d, $J=8.5$ Hz, 1H), 7.90 (d, $J=1.7$ Hz, 1H), 7.84 (d, $J=8.0$ Hz, 1H), 7.79 - 7.63 (m, 1H), 7.52 (d, $J=8.3$ Hz, 2H), 6.97 (s, 2H), 6.06 (s, 1H), 3.88 - 3.77 (m, 1H), 3.90 (s, 1H), 3.73 - 3.50 (m, 4H), 3.48 - 3.37 (m, 4H), 3.28 (d, $J=7.4$ Hz, 2H), 3.19 (d, $J=7.4$ Hz, 2H), 1.27 (d, $J=6.6$ Hz, 3H), 1.14 - 0.96 (m, 1H), 0.62 (d, $J=8.0$ Hz, 2H), 0.44 - 0.15 (m, 2H)	1.46 N 621.1	2.6	362.7
B252		2-methanesulfonyl-2-(6-(phenyl-1,3-benzothiazol-2-yl)-N-([3-(propan-2-yl)-1,2-oxazol-5-yl]methyl)acetamide	δ 9.44 (t, $J=5.8$ Hz, 1H), 8.51 (d, $J=1.4$ Hz, 1H), 8.17 (d, $J=8.5$ Hz, 1H), 7.90 (dd, $J=8.5$, 1.9 Hz, 1H), 7.81 - 7.75 (m, 2H), 7.59 - 7.50 (m, 2H), 7.47 - 7.38 (m, 1H), 6.35 (s, 1H), 6.06 (s, 1H), 4.58 (dd, $J=8.3$, 5.8 Hz, 2H), 3.26 (s, 3H), 3.04 - 2.93 (m, 1H), 1.27 - 1.12	1.6 N 697.1	21.5	1.4




			(m, 6H)				
B253		2-[6-(4-fluorophenyl)-1,3-benzothiazol-2-yl]-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-2-phenylmethanesulfonylacetamide	δ 7.58-10.10 (m, 5H), 5.84-7.52 (m, 9H), 4.79 (m, 1H), 4.64-4.72 (m, 2H), 4.60 (m., 1H), 2.48 ppm (m, 3H)	3.85 R 537.2	42.2	9.4	
B254		2-[6-(4-hydroxyphenyl)-1,3-benzothiazol-2-yl]-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-2-phenylmethanesulfonylacetamide	δ 7.38-10.00 (m, 11H), 6.00-7.35 (m, 4H), 4.19-5.01 (m, 4H), 2.48 ppm (m, 3H)	2.36 R 535.3	293.6	259.3	
B255		2-{6-[3-(dimethylamino)phenyl]-1,3-benzothiazol-2-yl}-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-2-phenylmethanesulfonylacetamide	δ 7.36-14.64 (m, 7H), 5.69-7.31 (m, 7H), 4.23-5.14 (m, 4H), 3.00 (s, 3H), 2.97 (s, 3H), 2.49 ppm (m, 3H)	3.04 R 562.3	225.2	43.5	




B256		2-methanesulfonyl-2-(6-phenyl-1,3-benzothiazol-2-yl)-N-[(3-sulfamoylphenyl)methyl]acetamide	δ 9.27 (t, J=5.9 Hz, 1H), 8.39 (d, J=1.7 Hz, 1H), 8.07 (d, J=8.5 Hz, 1H), 7.78 (dd, J=8.7, 1.8 Hz, 1H), 7.72 - 7.59 (m, 4H), 7.51 - 7.38 (m, 4H), 7.37 - 7.28 (m, 1H), 7.25 (s, 2H), 5.95 (s, 1H), 4.44 (dd, J=10.0, 5.9 Hz, 2H), 3.14 (br. s, 3H)	1.71 N 516.1	189.7	14.7
B257		2-{6-[4-(3,3-difluoroazetidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-2-methanesulfonyl-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]acetamide	δ 9.54 (t, J=5.6 Hz, 1H), 8.59 (d, J=1.7 Hz, 1H), 8.20 (d, J=8.5 Hz, 1H), 7.99 - 7.92 (m, 1H), 7.91 - 7.87 (m, 2H), 7.87 - 7.82 (m, 2H), 6.11 (s, 1H), 4.84 (br. s., 2H), 4.69 (d, J=6.1 Hz, 2H), 4.64 - 4.46 (m, 2H), 3.29 (s, 3H), 2.50 - 2.46 (m, 3H)	1.41 N 562.2	32.0	53.3




B258		4-{5-fluoro-2-[(2-methoxyethanesulfonyl)([(5-methyl-1,3,4-oxadiazol-2-yl)methyl]carbamoyl)methyl]-1,3-benzothiazol-6-yl}-N-(2-methoxyethyl)benzamide	δ 9.52 (t, J=5.5 Hz, 1H), 8.69 - 8.54 (m, 1H), 8.43 (d, J=7.2 Hz, 1H), 8.11 (d, J=11.0 Hz, 1H), 8.04 - 7.90 (m, 2H), 7.72 (d, J=8.0 Hz, 2H), 6.12 (s, 1H), 4.71 - 4.63 (m, 2H), 3.89 - 3.62 (m, 2H), 3.53 - 3.42 (m, 2H), 3.29 (m, 3H), 2.50 - 2.42 (m, 3H)	1.36 N 606.2	57.2	888.7
B259		2-fluoro-4-{5-fluoro-2-[(2-methoxyethanesulfonyl)([(5-methyl-1,3,4-oxadiazol-2-yl)methyl]carbamoyl)methyl]-1,3-benzothiazol-6-yl}-N,N-dimethylbenzamide	δ 9.53 (br. s., 1H), 8.46 (d, J=7.2 Hz, 1H), 8.13 (d, J=11.3 Hz, 1H), 7.81 - 7.68 (m, 1H), 7.63 - 7.46 (m, 2H), 6.13 (s, 1H), 4.71 - 4.64 (m, 2H), 3.82 - 3.65 (m, 4H), 3.29 (s, 3H), 3.05 (m, 3H), 2.92 (m, 3H), 2.48 (d, J=31.6 Hz, 3H)	1.38 N 594.2	121.3	207.7
B260		2-{5-fluoro-6-[4-(3-hydroxy-3-methylazetidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-2-(2-methoxyethane	δ 9.56 - 9.49 (m, 1H), 8.43 (d, J=7.7 Hz, 1H), 8.12 (d, J=11.3 Hz, 1H), 7.82 - 7.62 (m, 5H), 6.13 (s, 1H), 4.71 - 4.65 (m, 2H), 4.25 - 4.13 (m, 2H), 3.99 - 3.89 (m, 3H),	1.21 N 618.2	67.0	1345.0




			sulfonyl)-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]acetamide	3.82 - 3.66 (m, 4H), 3.16 - 3.14 (m, 2H), 3.29 (s, 3H), 2.50 - 2.43 (m, 3H)			
B261			2-{5-fluoro-6-[3-fluoro-4-(pyrrolidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-2-(2-methoxyethanesulfonyl)-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]acetamide	δ 9.54 (t, J=5.0 Hz, 1H), 8.47 (m, 1H), 8.14 (m, 1H), 7.66 - 7.45 (m, 3H), 6.13 (s, 1H), 4.68 (m, 2H), 3.85 - 3.59 (m, 2H), 3.57 - 3.48 (m, 4H), 3.32 - 3.23 (m, 4H), 3.29 (s, 3H), 2.50 - 2.45 (m, 3H), 2.04 - 1.79 (m, 2H)	1.49 N 620.2	101.4	764.6
B262			2-{5-fluoro-6-[4-(pyrrolidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-2-(2-methoxyethanesulfonyl)-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]acetamide	δ 9.61 - 9.45 (m, 1H), 8.42 (d, J=7.4 Hz, 1H), 8.11 (d, J=11.3 Hz, 1H), 7.69 (m, 4H), 6.13 (s, 1H), 4.85 - 4.50 (m, 2H), 3.86 - 3.63 (m, 4H), 3.58 - 3.43 (m, 4H), 3.29 (s, 3H), 2.50 - 2.45 (m, 3H), 1.96 - 1.76 (m, 2H)	1.42 N 602.15	101.5	373.7



B263		2-{6-[4-(3-hydroxy-3-methylazetidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-2-methanesulfonyl-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]acetamide	δ 9.54 (t, J=5.6 Hz, 1H), 8.62 - 8.51 (m, 1H), 8.25 - 8.15 (m, 1H), 7.99 - 7.91 (m, 1H), 7.86 (d, J=8.5 Hz, 2H), 7.77 (m, 2H), 6.11 (s, 1H), 4.69 (d, J=6.1 Hz, 2H), 4.25 - 4.13 (m, 2H), 3.98 - 3.92 (m, 2H), 3.32 - 3.26 (m, 3H), 2.47 (s, 3H), 1.42 (s, 3H)	1.17 N 556.2	77.0	10000.0
B264		4-{2-[(2-methoxyethanesulfonyl)-{(5-methyl-1,3,4-oxadiazol-2-yl)methyl}carbamoyl)]-1,3-benzothiazol-6-yl}-N-(2-methoxyethyl)benzamide	δ 9.52 (t, J=5.2 Hz, 1H), 8.64 - 8.54 (m, 2H), 8.19 (d, J=8.5 Hz, 1H), 8.06 - 7.93 (m, 4H), 7.92 - 7.84 (m, 1H), 6.11 (s, 1H), 4.68 (t, J=5.1 Hz, 2H), 3.82 - 3.69 (m, 3H), 3.54 - 3.43 (m, 4H), 3.30 (s, 3H), 3.29 (s, 3H), 2.50 - 2.45 (m, 3H)	1.34 N 588.1	93.0	184.5



B265		2-{6-[4-(3-hydroxy-3-methylazetidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-2-(2-methoxyethanesulfonyl)-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]acetamide	δ 9.52 (t, J=5.4 Hz, 1H), 8.57 (s, 1H), 8.19 (d, J=8.5 Hz, 1H), 8.00 - 7.90 (m, 2H), 7.89 - 7.83 (m, 1H), 7.81 - 7.73 (m, 2H), 6.11 (s, 1H), 4.71 - 4.61 (m, 2H), 4.20 (m, 2H), 3.84 - 3.74 (m, 2H), 3.74 - 3.61 (m, 4H), 3.28 (s, 3H), 2.47 (s, 3H), 1.42 (br. s., 3H)	1.19 N 600.2	59.0 634.0
B266		4-{5-fluoro-2-[methanesulfonyl]({[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]carbonyl})methyl}-1,3-benzothiazol-6-yl)-N-(2-methoxyethyl)benzamide	δ 9.55 (t, J=5.6 Hz, 1H), 8.63 (t, J=5.2 Hz, 1H), 8.53 - 8.32 (m, 1H), 8.21 - 8.07 (m, 1H), 8.06 - 7.91 (m, 2H), 7.80 - 7.62 (m, 2H), 6.12 (s, 1H), 4.69 (d, J=5.8 Hz, 2H), 3.59 - 3.42 (m, 4H), 3.31 - 3.26 (m, 3H), 2.50 - 2.42 (m, 3H)	1.22 N 562.15	39.1 947.5
B267		N-(2-methoxyethyl)-4-{2-[(propane-2-sulfonyl)](2-sulfamoyl)ethyl}carbonyl)-1,3-benzothiazol-6-yl}benzamide	δ 14.20 - 5.53 (m, 12H), 3.80 - 3.39 (m, 9H), 3.33 (m, 3H), 3.24 - 3.12 (m, 2H), 1.48 - 1.21 (m, 6H)	1.29 N 583.20	44.5 289.0



B268		2-{6-[4-(morpholine-4-carbonyl)phenyl]-5-(trifluoromethyl)-1,3-benzothiazol-2-yl}-2-(propane-2-sulfonyl)-N-(2-sulfamoylethyl)acetamide	δ 14.35 - 5.91 (m, 9H), 3.88 - 3.49 (m, 11H), 3.30 - 2.98 (m, 2H), 1.60 - 1.03 (m, 6H)	1.41 N 663.20	9.2	405.8
B269		N-(2-methoxyethyl)-4-{2-[(propane-2-sulfonyl)[(2-sulfamoylethyl)carbamoyl)methyl]-5-(trifluoromethyl)-1,3-benzothiazol-2-yl}-2-(propane-2-sulfonyl)-N-(2-sulfamoylethyl)acetamide	δ 14.33 - 5.35 (m, 10H), 3.85 - 3.45 (m, 9H), 3.30 (s, 3H), 3.25 - 3.17 (m, 2H), 1.49 - 1.16 (m, 6H)	1.45 N 651.15	10.0	312.1
B270		N-(3-[(2-methoxyethanesulfonamido)sulfonyl]phenyl)methyl)-2-(2-methoxyethanesulfonyl)-2-(5-phenyl-1,3-benzothiazol-2-yl)acetamide	δ 9.35 (t, J=5.6 Hz, 1H), 8.38 (s, 1H), 8.26 (d, J=8.5 Hz, 1H), 8.02 - 7.77 (m, 4H), 7.73 - 7.60 (m, 2H), 7.57 - 7.49 (m, 2H), 7.47 - 7.34 (m, 3H), 6.07 (s, 1H), 4.71 - 4.38 (m, 2H), 3.89 - 3.59 (m, 6H), 3.27 (s, 3H), 3.24 - 3.16 (m, 5H)	1.55 N 682.05	204.6	211.9



B271		2-{6-[4-(morpholine-4-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-2-(propane-2-sulfonyl)-N-(2-sulfamoyl-2-yl)acetamide	δ 14.71 - 7.66 (m, 6H), 7.69 - 5.91 (m, 5H), 3.81 - 3.50 (m, 5H), 3.27 - 3.00 (m, 2H), 1.65 - 1.11 (m, 6H)	1.55 N 682.05	7.5	1004.0
B272		N,N-dimethyl-3-{2-[(propane-2-sulfonyl)-N-(2-sulfamoyl-2-yl)-2-benzothiazol-6-yl]}benzamide	δ 14.21 - 7.64 (m, 6H), 7.63 - 5.94 (m, 5H), 3.82 - 3.50 (m, 3H), 3.30 - 3.15 (m, 2H), 3.04 (br. s., 3H), 2.98 (br. s., 3H), 1.56 - 1.19 (m, 6H)	1.35 N 553.15	35.3	611.6
B273		tert-butyl 4-(5-methyl-2-{phenylmethanesulfonyl}[(2-sulfamoyl-2-yl)-1,3-benzothiazol-6-yl])benzoate	δ 9.02 (t, J=5.64 Hz, 1H), 8.08 (s, 1H), 7.99-8.04 (m, 2H), 7.94 (d, J=7.15 Hz, 2H), 7.54 (d, J=7.98 Hz, 2H), 7.48 (d, J=7.70 Hz, 2H), 7.25 (br. s., 2H), 6.08 (s, 1H), 4.68-4.78 (m, 2H), 4.65 (br. s., 1H), 3.60 (q, J=6.69 Hz, 2H), 3.19 (t, J=7.29 Hz, 2H), 2.36 (s, 3H), 1.58 (s, 9H)	2.25 B 644.1	1.4	3.0



B274		tert-butyl 4-(2-{methanesulfonyl}[(2-sulfamoyl)ethyl]carbamoyl)methyl-5-methyl-1,3-benzothiazol-6-yl)benzoate	δ 8.98 (t, J=5.64 Hz, 1H), 8.04 (s, 1H), 8.01 (d, J=4.40 Hz, 2H), 7.99 (s, 1H), 7.53 (d, J=7.98 Hz, 2H), 6.02 (s, 1H), 3.60 (q, J=6.88 Hz, 2H), 3.22 (s, 3H), 3.18 (t, J=7.15 Hz, 2H), 1.58 (s, 9H)	0.96 M 568	1.7	5.1
B275		2-methanesulfonyl-2-{6-[4-(piperidin-1-yl)phenyl]-1,3-benzothiazol-2-yl}-N-[(2-sulfamoyl)phenyl]methyl]acetamide	δ 7.94-8.69 (m, 4H), 7.61-7.89 (m, 4H), 7.47-7.60 (m, 1H), 7.11-7.44 (m, 3H), 5.93 (s, 1H), 5.02 (d, J=5.23 Hz, 1H), 4.83 (d, J=5.23 Hz, 1H), 2.89 (s, 3H), 2.72-2.76 (m, 4H), 1.70 (d, J=19.53 Hz, 4H), 1.60 (br. s., 2H)	2.02 B 599.2	173.3	218.5
B276		tert-butyl 4-(2-{phenylmethanesulfonyl}[(2-sulfamoyl)ethyl]carbamoyl)methyl-5-methyl-1,3-benzothiazol-6-yl)benzoate	δ 8.58 (s, 1H), 8.22 (d, J=8.53 Hz, 1H), 8.02 (d, J=7.43 Hz, 2H), 7.95-7.99 (m, 2H), 7.90-7.94 (m, 2H), 7.78-7.85 (m, 2H), 7.32-7.36 (m, 2H), 7.27 (d, J=7.43 Hz, 2H), 6.11 (s, 1H), 4.74 (q, J=13.30 Hz, 2H), 4.54-4.65 (m, 1H), 3.58-3.64 (m, 1H)	2.16 B 630.1	1.1	0.8




			(m, 3H), 3.09-3.23 (m, 4H), 1.58 (s, 9H)			
B277	 2-phenylmethanesulfonyl-2-{6-[4-(pyrrolidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-N-[(3-sulfamoylphenyl)methyl]acetamide		δ 9.42 (br. s., 1H), 8.22 (d, J=8.80 Hz, 1H), 7.95 (s, 2H), 7.84 (d, J=7.70 Hz, 1H), 7.72 (br. s., 1H), 7.66 (d, J=7.43 Hz, 1H), 7.61 (d, J=7.43 Hz, 2H), 7.55 (br. s., 1H), 7.39 (s, 3H), 7.30-7.36 (m, 2H), 6.12 (s, 1H), 4.67-4.79 (m, 1H), 4.53 (d, J=3.85 Hz, 1H), 4.34-4.65 (m, 2H), 3.41-3.53 (m, 4H), 1.80-1.93 (m, 4H)	0.88 M 689	191.2 84.9	
B278	 2-[6-(3-chloropyridin-4-yl)-1,3-benzothiazol-2-yl]-2-phenylmethanesulfonyl-N-[(3-sulfamoylphenyl)methyl]acetamide		δ 9.41 (t, J=5.91 Hz, 1H), 8.63-8.68 (m, 1H), 8.26 (d, J=8.25 Hz, 1H), 7.70-7.76 (m, 2H), 7.59 (d, J=4.95 Hz, 1H), 7.53-7.57 (m, 2H), 7.37-7.42 (m, 5H), 7.33 (m, 3H), 6.15 (s, 1H), 4.66-4.83 (m, 1H), 4.50-4.57 (m, 1H)	0.86 M 627.1	157.8 355.1	



B279		tert-butyl 4-{2-[methanesulfonyl({[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]carbamoyl})methyl]-1,3-benzothiazol-6-yl} benzoate	δ 9.65 (t, J=5.78 Hz, 1H), 8.58 (d, J=1.65 Hz, 1H), 8.19 (d, J=8.53 Hz, 1H), 8.02 (d, J=8.25 Hz, 2H), 7.93 (dd, J=1.79, 8.67 Hz, 1H), 7.90 (d, J=8.25 Hz, 2H), 6.08 (s, 1H), 4.81 (d, J=6.05 Hz, 2H), 3.25 (s, 3H), 2.68 (s, 3H), 1.57 (br. s., 9H)	2.13 B 559.1	15.6	2.8
B280		tert-butyl 3-{4-fluoro-2-[(propane-2-sulfonyl)carbonyl]methyl-1,3-benzothiazol-6-yl} benzoate	δ 9.09 (t, J=5.78 Hz, 1H), 8.23 (s, 1H), 8.03 (d, J=7.70 Hz, 1H), 7.90-8.00 (m, 2H), 7.80 (d, J=12.10 Hz, 1H), 7.65 (t, J=7.84 Hz, 1H), 6.97 (s, 2H), 6.25 (s, 1H), 3.55-3.63 (m, 2H), 3.47-3.55 (m, 1H), 3.12-3.25 (m, 2H), 2.89 (s, 3H), 2.73 (s, 3H)	1.01 M 600.1	4.8	2.9



B281		2-[6-(6-fluoropyridin-3-yl)-1,3-benzothiazol-2-yl]-2-(2-methoxyethane sulfonyl)-N-(2-sulfamoyl ethyl)acetamide	δ 8.96 (t, J=5.8 Hz, 1H), 8.67 (d, J=2.5 Hz, 1H), 8.57 (d, J=1.7 Hz, 1H), 8.40 (td, J=8.2, 2.6 Hz, 1H), 8.20 (d, J=8.5 Hz, 1H), 8.00 - 7.89 (m, 2H), 7.36 (dd, J=8.7, 2.6 Hz, 1H), 6.97 (s, 2H), 3.84 - 3.73 (m, 2H), 3.72 - 3.66 (m, 2H), 3.64 - 3.58 (m, 2H), 3.29 (s, 3H), 3.22 - 3.17 (m, 2H)	1.25 N 517.2	17.9	109.7
B282		N-(2-methoxyethyl)-4-(2-{{[(2-sulfamoyl ethyl)carbamoyl][4-(trifluoromethoxy)phenyl]methanesulfonylmethyl}-1,3-benzothiazol-6-yl})benzamide	δ 9.05 (t, J=5.6 Hz, 1H), 8.77 - 8.46 (m, 2H), 8.29 - 8.10 (m, 1H), 8.07 - 7.84 (m, 4H), 7.87 - 7.65 (m, 2H), 7.59 - 7.36 (m, 3H), 7.32 - 7.20 (m, 1H), 7.10 - 6.87 (m, 2H), 6.11 (s, 1H), 4.89 - 4.74 (m, 1H), 4.75 - 4.58 (m, 1H), 3.72 - 3.54 (m, 2H), 3.54 - 3.41 (m, 5H), 3.28 (d, J=2.5 Hz, 3H), 3.25 - 3.11 (m, 2H)	1.69 N 715.1	2.6	306.1



B283		2-(cyclopropylmethanesulfonyl)-2-{6-[4-(morpholine-4-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoylethyl)acetamide	δ 9.14 - 8.92 (m, 1H), 8.52 (br. s., 1H), 8.30 - 8.10 (m, 1H), 8.01 - 7.81 (m, 4H), 7.80 - 7.66 (m, 1H), 7.55 (d, $J=7.7$ Hz, 2H), 6.94 (br. s., 2H), 3.59-3.62 (m., 10H), 3.28 (br. s., 2H), 3.19 (br. s., 2H), 1.21 - 0.93 (m, 1H), 0.63 (d, $J=7.2$ Hz, 1H), 0.55 - 0.34 (m, 2H), 0.31 - 0.20 (m, 1H)	1.64 N 607.1	53.8	364.6
B284		2-(6-phenyl-1,3-benzothiazol-2-yl)-N-(2-sulfamoylethyl)-2-(3,3,3-trifluoropropanesulfonyl)acetamide	δ 8.50 (s, 1H), 8.15 (d, $J=8.3$ Hz, 1H), 7.88 (d, $J=8.5$ Hz, 1H), 7.77 (d, $J=7.4$ Hz, 2H), 7.74 - 7.63 (m, 1H), 7.57 - 7.46 (m, 2H), 7.42 (d, $J=7.2$ Hz, 1H), 6.98 (br. s., 2H), 6.27 (s, 1H), 3.84 - 3.51 (m, 4H), 3.18 (t, $J=7.0$ Hz, 2H), 2.85 (d, $J=9.4$ Hz, 2H)	1.87 N 536.1	6.8	2.6




B285		2-{6-[4-(methoxymethyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl-ethyl)-2-[(4-(trifluoromethoxy)phenyl)methyl]methanesulfonyl acetamide	δ 8.49 (br. s., 1H), 8.22 - 8.05 (m, 1H), 7.89 (d, <i>J</i>=8.8 Hz, 1H), 7.76 (d, <i>J</i>=6.9 Hz, 1H), 7.65 (br. s., 1H), 7.54 (d, <i>J</i>=7.7 Hz, 1H), 7.51 - 7.36 (m, 4H), 7.27 (d, <i>J</i>=10.5 Hz, 1H), 6.97 (br. s., 2H), 4.81 (br. s., 1H), 4.72 - 4.59 (m, 1H), 4.46 (d, <i>J</i>=13.2 Hz, 2H), 3.60 (br. s., 2H), 3.19 (br. s., 2H)	2.0 N 658.1	5.4	126.4
B286		2-cyclopropylmethane sulfonyl-2-{6-[4-(methoxymethyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl-ethyl)acetamide	δ 9.04 (br. s., 1H), 8.48 (br. s., 1H), 8.13 (d, <i>J</i>=8.5 Hz, 1H), 7.86 (d, <i>J</i>=8.5 Hz, 1H), 7.75 (d, <i>J</i>=7.2 Hz, 1H), 7.67 (br. s., 1H), 7.55 - 7.34 (m, 2H), 6.97 (br. s., 2H), 4.75 - 4.32 (m, 2H), 3.59 (br. s., 2H), 3.39 (d, <i>J</i>=6.1 Hz, 1H), 3.29 - 3.04 (m, 3H), 1.09 (br. s., 1H), 0.62 (d, <i>J</i>=6.9 Hz, 2H), 0.40 (br. s., 2H)	1.71 N 538.1	3.9	55.5



B287		2-[6-(4-acetamidophenyl)-1,3-benzothiazol-2-yl]-N-(2-sulfamoyl-4-(4-(trifluoromethyl)phenyl)methyl)phenyl]methanesulfonyl}acetamide	δ 7.95 (s, 1H), 7.91 - 7.80 (m, 1H), 7.83 - 7.50 (m, 10H), 6.95 (s, 2H), 5.02 - 4.63 (m, 2H), 3.69 - 3.50 (m, 2H), 3.24 - 3.06 (m, 2H), 2.07 (d, $J=6.9$ Hz, 3H)	1.65 N 655.1	7.0	90.0
B288		N-(2-methoxyethyl)-N-methyl-4-(2-((2-sulfamoyl-4-(4-(4-(trifluoromethyl)phenyl)methyl)phenyl)methyl)phenyl)methyl)carbamoyl]benzamide	δ 8.33 - 7.38 (m, 11H), 7.07 - 6.88 (m, 2H), 6.19 - 6.05 (m, 1H), 4.98 - 4.84 (m, 1H), 4.81 - 4.62 (m, 1H), 3.77 - 3.52 (m, 4H), 3.55 - 3.39 (m, 3H), 3.27 - 3.10 (m, 4H), 3.00 (br. s., 3H)	1.73 N 713.14	0.8	123.5
B289		N-(2-methoxyethyl)-N-methyl-4-(2-((2-sulfamoyl-4-(4-(4-(trifluoromethoxy)phenyl)methyl)phenyl)methyl)phenyl)methyl)carbamoyl]benzamide	δ 8.65 - 8.43 (m, 1H), 8.26 - 8.04 (m, 1H), 8.01 - 7.63 (m, 4H), 7.59 - 7.16 (m, 6H), 7.03 - 6.84 (m, 2H), 6.27 - 6.03 (m, 1H), 4.98 - 4.74 (m, 1H), 4.77 - 4.55 (m, 1H), 3.73 - 3.52 (m, 4H), 3.52 - 3.39 (m, 3H), 3.23 - 3.10 (m, 4H), 3.00 (br. s., 3H)	1.78 N 729.13	3.1	21.7



B290		N-(2-methoxyethyl)-N-methyl-4-(2-[(2-sulfamoyl)ethyl]carbamoyl)-(3,3,3-trifluoropropyl)sulfonylmethyl-1,3-benzothiazol-6-yl benzamide	δ 9.04 - 8.90 (m, 1H), 8.69 - 8.47 (m, 1H), 8.32 - 8.11 (m, 1H), 8.03 - 7.66 (m, 4H), 7.61 - 7.43 (m, 2H), 6.95 (s, 2H), 6.49 - 6.12 (m, 1H), 4.00 - 3.51 (m, 5H), 3.57 - 3.38 (m, 2H), 3.27 - 3.10 (m, 4H), 3.00 (br. s., 3H), 2.92 - 2.80 (m, 2H)	1.51 N 651.1	12.1	114.5
B291		4-(2-{cyclopropylmethanesulfonyl}[(2-sulfamoyl)ethyl]carbamoyl)methyl-1,3-benzothiazol-6-yl)-N-(2-methoxyethyl)-N-methylbenzamide	δ 9.17 - 8.93 (m, 1H), 8.62 - 8.44 (m, 1H), 8.23 - 8.08 (m, 1H), 7.94 - 7.68 (m, 3H), 7.61 - 7.41 (m, 2H), 7.06 - 6.86 (m, 2H), 6.11 - 6.01 (m, 1H), 3.74 - 3.54 (m, 4H), 3.50 - 3.40 (m, 4H), 3.25 - 3.14 (m, 5H), 3.00 (br. s., 3H), 1.23 - 1.04 (m, 1H), 0.72 - 0.46 (m, 2H), 0.42 - 0.18 (m, 2H)	1.34 N 609.2	0.7	35.2



B292		4-{2-[(3,4-dichlorophenyl)methanesulfonyl]-(2-sulfamoyl)ethyl}carbamoyl methyl]-1,3-benzothiazol-6-yl}-N-(2-methoxyethyl) benzamide	δ 9.15 - 8.99 (m, 1H), 8.57 (d, $J=1.4$ Hz, 1H), 8.18 (d, $J=8.5$ Hz, 1H), 8.05 - 7.74 (m, 4H), 7.71 - 7.50 (m, 2H), 7.47 - 7.31 (m, 1H), 6.97 (s, 2H), 6.08 (s, 1H), 4.80 (s, 1H), 4.72 - 4.59 (m, 1H), 3.72 - 3.56 (m, 2H), 3.53 - 3.41 (m, 4H), 3.28 (d, $J=2.2$ Hz, 3H), 3.19 (s, 2H)	1.61 N 699.1	20.2	112.0
B293		2-{6-[4-(morpholine-4-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl)ethyl)-2-[[4-(trifluoromethyl)phenyl]methanesulfonyl} acetamide	δ 9.17 - 8.94 (m, 1H), 8.60 - 8.47 (m, 1H), 8.27 - 8.09 (m, 1H), 8.00 - 7.88 (m, 1H), 7.84 (s, 1H), 7.74 (br. s., 1H), 7.65 (s, 2H), 7.57 (s, 3H), 6.98 (s, 2H), 6.12 (s, 1H), 5.01 - 4.84 (m, 1H), 4.80 - 4.64 (m, 1H), 3.82 - 3.52 (m, 8H), 3.53 - 3.37 (m, 2H), 3.26 - 3.10 (m, 2H)	1.60 N 711.12	145.6	328.5



B294		2-{6-[4-(morpholine-4-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoylethyl)-2-{[4-(trifluoromethoxy)phenyl]methanesulfonyl}acetamide	δ 9.14 - 8.99 (m, 1H), 8.61 - 8.45 (m, 1H), 8.25 - 8.17 (m, 1H), 8.15 - 8.08 (m, 1H), 7.85 (d, $J=8.3$ Hz, 3H), 7.55 (t, $J=8.0$ Hz, 3H), 7.40 (s, 1H), 7.35 - 7.20 (m, 1H), 6.97 (s, 2H), 6.12 (s, 1H), 4.88 - 4.76 (m, 1H), 4.74 - 4.58 (m, 1H), 3.81 - 3.51 (m, 8H), 3.46 - 3.36 (m, 2H), 3.30 - 3.13 (m, 2H)	1.65 N 725.10	74.8	180.7
B295		4-{2-[(3,5-dichlorophenyl)methanesulfonyl]-(2-sulfamoylethyl)carbamoyl}methyl-1,3-benzothiazol-6-yl}-N-(2-methoxyethyl)benzamide	δ 9.15 - 8.93 (m, 1H), 8.68 - 8.53 (m, 2H), 8.28 - 8.16 (m, 1H), 8.07 - 7.76 (m, 7H), 7.55 - 7.37 (m, 3H), 7.06 - 6.91 (m, 2H), 6.23 - 6.06 (m, 1H), 4.91 - 4.76 (m, 1H), 4.75 - 4.57 (m, 1H), 3.75 - 3.56 (m, 2H), 3.53 - 3.41 (m, 4H), 3.28 (d, $J=1.9$ Hz, 3H), 3.25 - 3.12 (m, 2H)	1.64 N 699.06	20.9	140.4



B296		2-[(4-fluorophenyl)methanesulfonyl]-2-{6-[4-(morpholine-4-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl)ethyl)acetamide	δ 9.15 - 8.99 (m, 1H), 8.62 - 8.48 (m, 1H), 8.28 - 8.13 (m, 1H), 7.85 (d, $J=8.3$ Hz, 5H), 7.56 (d, $J=8.3$ Hz, 4H), 7.29 - 7.06 (m, 3H), 6.97 (s, 2H), 6.07 (s, 1H), 4.86 - 4.71 (m, 1H), 4.71 - 4.53 (m, 1H), 3.60 (d, $J=6.3$ Hz, 10H), 3.27 - 3.10 (m, 2H)	1.51 N 661.1	2.9	266.7
B297		2-[(3,4-dichlorophenyl)methanesulfonyl]-2-{6-[4-(morpholine-4-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl)ethyl)acetamide	δ 9.19 - 8.84 (m, 1H), 8.66 - 8.45 (m, 1H), 8.28 - 8.09 (m, 1H), 8.00 - 7.46 (m, 8H), 7.48 - 7.27 (m, 1H), 6.97 (s, 2H), 4.80 (s, 1H), 4.72 - 4.56 (m, 1H), 3.61 (dd, $J=13.2, 6.6$ Hz, 10H), 3.19 (s, 2H)	1.68 N 711.08	5.3	555.7
B298		2-methanesulfonyl-2-[6-(pyrimidin-2-yl)-1,3-benzothiazol-2-yl]-N-(2-sulfamoyl)ethyl)acetamide	δ 9.35 - 8.93 (m, 4H), 8.88 - 8.22 (m, 2H), 8.19 - 7.82 (m, 2H), 7.08 - 6.77 (m, 2H), 6.08 (br. s., 1H), 3.83 - 3.49 (m, 2H), 3.26 (br. s., 4H)	1.00 O 534.0	41.5	865.7



B299		2-{6-[4-(3-methoxy azetidine-1-carbonyl) phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl ethyl)-2-{[4-(trifluoromethyl) phenyl]methanesulfonyl} acetamide	¹ H NMR (400MHz, DMSO- d ₆) δ 9.17 - 8.53 (m, 1H), 8.27 - 8.10 (m, 1H), 7.85 (s, 3H), 7.76 (d, J=9.5 Hz, 4H), 7.67 - 7.58 (m, 2H), 6.96 (s, 1H), 4.93 - 4.70 (m, 2H), 4.51 (br. s., 1H), 4.33 - 4.11 (m, 3H), 3.88 (br. s., 1H), 3.62 (d, J=6.2 Hz, 2H), 3.29 (s, 2H), 3.25 (d, J=1.8 Hz, 3H), 3.21 (s, 1H)	1.90 B 711.0	5.6	74.2
B300		2-{6-[4-(3-methoxy azetidine-1-carbonyl) phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl ethyl)-2-{[4-(trifluoro methoxy)phenyl]methane sulfonyl} acetamide	δ 9.15 - 8.52 (m, 1H), 8.32 - 8.10 (m, 1H), 7.99 - 7.66 (m, 6H), 7.59 - 7.37 (m, 3H), 7.28 (dd, J=18.7, 6.9 Hz, 1H), 7.03 - 6.90 (m, 2H), 4.97 - 4.60 (m, 2H), 4.57 - 4.43 (m, 1H), 4.31 - 4.17 (m, 3H), 3.94 - 3.83 (m, 1H), 3.70 - 3.56 (m, 2H), 3.28 - 3.16 (m, 5H)	1.73 O 727.1	5.5	85.1



B301		2-{6-[4-(3-methoxyazetidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl ethyl)-2-(3,3,3-trifluoropropanesulfonyl)acetamide	δ 9.00 - 8.95 (m, 1H), 8.64 - 8.50 (m, 1H), 8.19 (d, J=8.5 Hz, 1H), 7.99 - 7.91 (m, 2H), 7.90 - 7.84 (m, 2H), 7.82 - 7.71 (m, 3H), 7.00 - 6.89 (m, 2H), 6.28 (s, 1H), 4.56 - 4.45 (m, 1H), 4.33 - 4.14 (m, 3H), 3.95 - 3.84 (m, 1H), 3.84 - 3.51 (m, 4H), 3.25 (s, 3H), 3.23 - 3.18 (m, 1H), 2.90 - 2.82 (m, 1H)	1.54 O 649.1 7.8 112.9
B302		2-[(4-fluorophenyl)methanesulfonyl]-2-{6-[(3-methoxyazetidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl)ethyl)acetamide	δ 9.22 - 8.54 (m, 1H), 8.34 - 8.16 (m, 1H), 7.87 (d, J=8.0 Hz, 2H), 7.83 - 7.71 (m, 3H), 7.48 (d, J=2.5 Hz, 2H), 7.25 (s, 2H), 6.96 (s, 2H), 6.09 (s, 1H), 4.81 - 4.56 (m, 2H), 4.54 - 4.45 (m, 1H), 4.34 - 4.17 (m, 3H), 3.94 - 3.84 (m, 2H), 3.71 - 3.56 (m, 2H), 3.26 - 3.15 (m, 5H)	1.55 O 661.1 7.2 52.0




B303		2-[6-(1-oxo-2,3-dihydro-1H-indol-5-yl)-1,3-benzothiazol-2-yl]-N-(2-sulfamoyl-ethyl)-2-[[4-(trifluoromethoxy)phenyl]methanesulfonyl]acetamide	δ 9.05 (t, J=5.5 Hz, 1H), 8.65 - 8.56 (m, 2H), 8.29 - 8.10 (m, 2H), 8.00 - 7.94 (m, 3H), 7.93 - 7.85 (m, 2H), 7.83 - 7.73 (m, 3H), 7.59 - 7.53 (m, 2H), 7.51 - 7.46 (m, 1H), 7.43 - 7.36 (m, 2H), 7.35 - 7.24 (m, 2H), 6.97 (s, 4H), 6.18 - 6.09 (m, 1H), 4.95 - 4.78 (m, 2H), 4.76 - 4.62 (m, 2H), 4.52 - 4.41 (m, 3H), 3.74 - 3.55 (m, 4H), 3.27 - 3.14 (m, 4H), 2.63 - 2.55 (m, 2H)	1.56 O 669.1	2.5 51.2
B304		2-(6-{4-[(3S)-3-methoxy-pyrrolidine-1-carbonyl]phenyl}-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl-ethyl)-2-(3,3,3-trifluoropropanesulfonyl)acetamide	δ 9.34 (br. s., 1H), 9.06 - 8.89 (m, 1H), 8.70 (s, 1H), 8.61 - 8.55 (m, 1H), 8.42 - 8.35 (m, 1H), 8.27 - 8.16 (m, 2H), 8.09 - 8.03 (m, 1H), 7.99 - 7.89 (m, 4H), 7.88 - 7.83 (m, 2H), 7.81 - 7.75 (m, 1H), 7.74 - 7.60 (m, 4H), 7.03 - 7.01 (m, 1H), 6.97 (br. s., 2H), 6.33 - 6.25 (m, 1H), 4.10 - 3.91 (m, 2H), 3.86	1.50 O 663.1	0.7 16.6



					- 3.40 (m, 1H), 3.30 (br. s., 4H), 3.20 (br. s., 4H), 2.57 (br. s., 8H), 2.02 (br. s., 4H).			
B305		2-[6-(2-fluorophenyl)-1,3-benzothiazol-2-yl]-2-methanesulfonyl-N-(2-sulfamoylethyl)acetamide		δ 9.07 - 8.95 (m, 1H), 8.38 (s, 1H), 8.23 - 8.15 (m, 1H), 7.81 - 7.72 (m, 1H), 7.66 - 7.61 (m, 1H), 7.45 - 7.33 (m, 3H), 6.97 (s, 2H), 6.16 - 6.02 (m, 1H), 3.65 - 3.58 (m, 2H), 3.29 - 3.24 (m, 3H), 3.21 (t, J=7.0 Hz, 2H).	1.52 O 471.9	3.0	1.0	
B306		2-(2-methoxyethane sulfonyl)-2-(6-{4-[(3S)-3-methoxypyrrolidine-1-carbonyl]phenyl}-1,3-benzothiazol-2-yl)-N-(2-sulfamoylethyl)acetamide		δ 8.98 (br. s., 1H), 8.56 (s, 1H), 8.18 (d, J=8.3 Hz, 1H), 8.01 - 7.90 (m, 2H), 7.88 - 7.83 (m, 2H), 7.81 - 7.73 (m, 1H), 7.70 - 7.61 (m, 3H), 7.22 (s, 1H), 7.12 (s, 1H), 7.02 (s, 1H), 6.99 - 6.91 (m, 3H), 6.10 - 6.04 (m, 1H), 4.10 - 3.95 (m, 2H), 3.92 (s, 1H), 3.39 (br. s., 32H), 3.25 - 3.17 (m, 6H), 2.05 - 1.84 (m, 4H)	1.20 N 625.1	3.8	149.3	



B307		2-[6-(2-fluorophenyl)-1,3-benzothiazol-2-yl]-N-(2-sulfamoylethyl)-2-(3,3,3-trifluoropropanesulfonyl)acetamide	δ 9.11 - 8.97 (m, 1H), 8.33 (m, 2H), 7.63 - 7.45 (m, 2H), 6.97 (m, 2H), 3.71 - 3.53 (m, 2H), 3.26 - 3.13 (m, 2H), 2.91 (s, 3H)	1.5 N 540.1	3.0	1.5
B308		2-[5-(6-fluoropyridin-3-yl)-1,3-benzothiazol-2-yl]-2-(2-methoxyethanesulfonyl)-N-(2-sulfamoylethyl)acetamide	δ 8.96 (t, J=5.8 Hz, 1H), 8.71 (d, J=2.5 Hz, 1H), 8.51 - 8.39 (m, 2H), 8.30 (d, J=8.3 Hz, 1H), 7.90 (dd, J=8.5, 1.9 Hz, 1H), 7.34 (dd, J=8.5, 2.5 Hz, 1H), 6.96 (s, 2H), 6.07 (s, 1H), 3.83 - 3.67 (m, 4H), 3.64 - 3.58 (m, 2H), 3.29 (s, 3H), 3.20 (td, J=7.1, 2.3 Hz, 2H).	1.32 N 517	1.3	194.0



B309		2-[5-(6-fluoropyridin-3-yl)-1,3-benzothiazol-2-yl]-N-(2-sulfamoylethyl)-2-{[4-(trifluoromethoxy)phenyl]methanesulfonyl}acetamide	δ 9.07 (t, J=5.8 Hz, 1H), 8.72 (d, J=2.5 Hz, 1H), 8.54 (br. s., 1H), 8.50 (d, J=1.4 Hz, 1H), 8.46 (td, J=8.3, 2.8 Hz, 1H), 8.31 (d, J=8.3 Hz, 2H), 8.21 - 8.03 (m, 1H), 7.97 - 7.81 (m, 3H), 7.57 (d, J=8.8 Hz, 3H), 7.51 - 7.21 (m, 7H), 6.99 (s, 4H), 6.14 (s, 1H), 4.90 - 4.78 (m, 2H), 4.75 - 4.62 (m, 2H), 3.72 - 3.55 (m, 4H), 3.28 - 3.14 (m, 4H).	1.91 O 633	0.5	67.0
B310		2-[(4-fluorophenyl)methanesulfonyl]-2-[5-(6-fluoropyridin-3-yl)-1,3-benzothiazol-2-yl]-N-(2-sulfamoylethyl)acetamide	δ 9.06 (t, J=5.6 Hz, 1H), 8.72 (d, J=2.2 Hz, 1H), 8.51 (d, J=1.4 Hz, 1H), 8.46 (td, J=8.1, 2.8 Hz, 1H), 8.32 (d, J=8.5 Hz, 1H), 7.91 (dd, J=8.3, 1.7 Hz, 1H), 7.48 (dd, J=8.5, 5.5 Hz, 1H), 7.43 - 7.32 (m, 2H), 7.25 (t, J=8.9 Hz, 1H), 7.17 - 7.06 (m, 1H), 6.99 (s, 2H), 6.10 (s, 1H), 4.83 - 4.73 (m, 2H), 4.70 - 4.56 (m, 1H), 3.65 - 3.55 (m, 2H),	1.67 N 567	1.0	51.4



B311		2-[5-(6-fluoropyridin-3-yl)-1,3-benzothiazol-2-yl]-N-(2-sulfamoyl-2-(3,3,3-trifluoropropyl)sulfonyl)acetamide	3.26 - 3.14 (m, 2H) δ 9.00 (t, J=5.6 Hz, 1H), 8.71 (d, J=2.2 Hz, 1H), 8.49 - 8.43 (m, 2H), 8.33 (d, J=8.3 Hz, 1H), 7.92 (dd, J=8.4, 1.5 Hz, 1H), 7.35 (dd, J=8.4, 2.6 Hz, 1H), 6.99 (s, 1H), 6.30 (s, 1H), 3.86 - 3.69 (m, 1H), 3.63 (dd, J=12.0, 6.2 Hz, 3H), 3.25 - 3.16 (m, 2H), 2.89 - 2.81 (m, 1H)	1.65 N 555	3.1	24.2		
B312		2-[5-(6-fluoropyridin-3-yl)-1,3-benzothiazol-2-yl]-N-(2-sulfamoyl-2-(propane-2-sulfonyl)acetamide	δ 9.08 (t, J=5.6 Hz, 1H), 8.71 (d, J=2.5 Hz, 1H), 8.49 - 8.40 (m, 2H), 8.30 (d, J=8.3 Hz, 2H), 7.90 (dd, J=8.4, 1.8 Hz, 1H), 7.35 (dd, J=8.5, 2.8 Hz, 1H), 6.98 (s, 2H), 6.22 (s, 1H), 3.71 - 3.51 (m, 3H), 3.28 - 3.13 (m, 2H), 1.39 (d, J=6.9 Hz, 3H), 1.28 (d, J=6.9 Hz, 3H)	1.45 N 501	6.2	152.7		



B313		2-[6-(6-fluoropyridin-3-yl)-1,3-benzothiazol-2-yl]-2-[2-(morpholin-4-yl)ethanesulfonyl]-N-(2-sulfamoylethyl)acetamide	δ 8.64 (br. s., 1H), 8.41 - 8.35 (m, 1H), 7.88 (d, J=7.4 Hz, 1H), 7.33 (dd, J=8.5, 2.2 Hz, 1H), 6.95 (s, 2H), 3.68 - 3.49 (m, 8H), 3.19 (t, J=6.9 Hz, 3H), 2.78 (br. s., 2H), 2.40 (br. s., 4H)	1.93 B 572.1	10.8	106.5
B314		2-{6-[4-(hydroxymethyl)phenyl]-1,3-benzothiazol-2-yl}-2-[2-(morpholin-4-yl)ethanesulfonyl]-N-(2-sulfamoylethyl)acetamide	δ 7.70 (br. s., 2H), 7.43 (d, J=7.2 Hz, 2H), 6.94 (br. s., 2H), 5.21 (br. s., 1H), 4.55 (d, J=5.5 Hz, 2H), 3.68 - 3.41 (m, 8H), 3.19 (t, J=6.9 Hz, 2H), 2.75 (br. s., 2H), 2.38 (br. s., 4H)	1.41 B 583.1	16.1	35.1
B315		2-[2-(morpholin-4-yl)ethanesulfonyl]-2-[6-(pyrimidin-5-yl)-1,3-benzothiazol-2-yl]-N-(2-sulfamoylethyl)acetamide	δ 9.23 (br. s., 2H), 8.63 (br. s., 1H), 8.19 (br. s., 1H), 8.07 - 7.91 (m, 2H), 7.04 - 6.90 (m, 2H), 3.90 - 3.31 (m, 16H)	1.24 B 555.1	55.6	10000.0




B316		2-[2-(morpholin-4-yl)ethanesulfonyl]-N-(2-sulfamoylethyl)-2-{6-[6-(trifluoromethyl)pyridin-3-yl]-1,3-benzothiazol-2-yl}acetamide	δ 9.20 (br. s., 1H), 8.66 (br. s., 1H), 8.47 (d, J =5.8 Hz, 1H), 8.22 (br. s., 1H), 8.06 (d, J =8.0 Hz, 2H), 7.01 - 6.97 (m, 2H), 3.70 - 3.31 (m, 12H), 3.22 (br. s., 4H)	1.63 B 622.1	145.4	399.1
B317		2-methanesulfonyl-2-(6-{1-[2-(oxan-4-yl)ethyl]-1H-pyrazol-4-yl}-1,3-benzothiazol-2-yl)-N-(2-sulfamoylethyl)acetamide	^1H NMR (400MHz, METHANOL- d_4) δ 8.23 (d, J =1.3 Hz, 1H), 8.14 (s, 1H), 8.07 - 8.01 (m, 1H), 7.96 - 7.89 (m, 1H), 7.77 (dd, J =8.6, 1.8 Hz, 1H), 4.27 - 4.23 (m, 2H), 3.91 (dd, J =10.9, 3.9 Hz, 3H), 3.81 - 3.74 (m, 1H), 3.42 - 3.36 (m, 2H), 3.35 - 3.32 (m, 3H), 3.20 (s, 3H), 1.86 (q, J =6.8 Hz, 3H), 1.67 (d, J =12.5 Hz, 2H), 1.39 - 1.27 (m, 2H)	0.68 M 556.1	13.0	391.3



B318		2-{6-[4-(3-hydroxy-3-methylazetidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-2-methanesulfonyl-N-(2-sulfamoyl)ethylacetamide	δ 9.00 (br. s., 1H), 8.56 (br. s., 1H), 8.19 (d, J=8.5 Hz, 1H), 8.01 - 7.91 (m, 1H), 7.89 - 7.81 (m, 2H), 7.80 - 7.71 (m, 2H), 7.01 - 6.89 (m, 2H), 6.12 - 5.98 (m, 1H), 5.85 - 5.63 (m, 1H), 4.31 - 4.13 (m, 2H), 4.00 - 3.87 (m, 3H), 3.67 - 3.55 (m, 2H), 3.29 - 3.16 (m, 4H), 1.50 - 1.40 (m, 3H)	1.06 O 567.0	1.8	910.9
B319		2-{5-[4-(3-hydroxy-3-methylazetidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-2-methanesulfonyl-N-(2-sulfamoyl)ethylacetamide	δ 9.03 (br. s., 1H), 8.53 - 8.36 (m, 1H), 8.29 (d, J=8.3 Hz, 1H), 7.93 - 7.84 (m, 3H), 7.77 (d, J=6.6 Hz, 2H), 6.99 (br. s., 2H), 6.06 (br. s., 1H), 4.29 - 4.11 (m, 2H), 4.01 - 3.84 (m, 3H), 3.66 - 3.57 (m, 2H), 3.26 (br. s., 3H), 3.20 (br. s., 2H), 1.42 (br. s., 3H)	1.14 O 567.1	4.8	1001.0




B320		2-{6-[4-(3-hydroxy-3-methylazetidino-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoylethyl)-2-(3,3,3-trifluoropropanesulfonyl)acetamide	δ 8.98 (br. s., 1H), 8.70 - 8.49 (m, 1H), 8.22 - 8.13 (m, 1H), 7.94 (d, J=8.3 Hz, 1H), 7.86 (d, J=7.7 Hz, 1H), 7.81 - 7.67 (m, 3H), 6.99 (br. s., 2H), 6.56 - 6.05 (m, 1H), 5.89 - 5.50 (m, 1H), 4.20 (d, J=18.7 Hz, 2H), 3.94 (br. s., 2H), 3.83 - 3.53 (m, 4H), 3.20 (br. s., 2H), 2.97 - 2.81 (m, 2H), 1.42 (br. s., 3H)	1.41 O 649.2	1.9	1264.0
B321		2-{5-[4-(3,3-difluoroazetidino-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-2-methanesulfonyl-N-(2-sulfamoylethyl)acetamide	δ 9.03 (br. s., 1H), 8.45 (br. s., 1H), 8.37 - 8.25 (m, 1H), 8.02 - 7.88 (m, 3H), 7.84 (d, J=7.7 Hz, 2H), 6.99 (br. s., 2H), 6.07 (br. s., 1H), 4.87 (br. s., 2H), 4.65 - 4.38 (m, 2H), 3.62 (br. s., 2H), 3.27 (br. s., 3H), 3.20 (br. s., 2H)	1.41 O 573.1	0.6	175.0




B322		2-{6-[4-(3-hydroxy-3-methylazetidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl-2-yl)-N-(2-(trifluoromethyl)phenyl)methanesulfonyl} acetamide	δ 9.11 - 8.54 (m, 1H), 8.30 - 8.10 (m, 1H), 8.04 - 7.89 (m, 1H), 7.88 - 7.84 (m, 1H), 7.76 (d, J=8.3 Hz, 4H), 7.68 - 7.56 (m, 3H), 7.15 - 6.65 (m, 2H), 5.82 - 5.48 (m, 1H), 5.03 - 4.45 (m, 2H), 4.31 - 4.13 (m, 2H), 4.03 - 3.82 (m, 3H), 3.67 - 3.53 (m, 2H), 3.26 - 3.13 (m, 2H), 1.42 (d, J=3.3 Hz, 3H)	1.51 O 711.1	2.4	37.4
B323		2-{6-[4-(3-hydroxy-3-methylazetidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl-2-yl)-N-(2-(trifluoromethoxy)phenyl)methanesulfonyl} acetamide	δ 9.19 - 8.51 (m, 1H), 8.21 (d, J=8.5 Hz, 1H), 7.86 (s, 2H), 7.82 - 7.69 (m, 4H), 7.55 (s, 3H), 7.32 - 7.22 (m, 1H), 6.97 (s, 2H), 5.69 (d, J=5.5 Hz, 1H), 5.05 - 4.53 (m, 2H), 4.33 - 4.09 (m, 2H), 4.02 - 3.83 (m, 3H), 3.69 - 3.51 (m, 2H), 3.22 (t, J=7.2 Hz, 2H), 1.42 (d, J=3.3 Hz, 3H)	1.59 O 727.1	2.6	81.7




B324		2-{6-[4-(3,3-difluoro pyrrolidine-1-carbonyl) phenyl]-1,3-benzothiazol- 2-yl}-N-(2-sulfamoyl ethyl)-2-{[4-(trifluoro methoxy)phenyl] methanesulfonyl} acetamide	δ 9.17 - 8.47 (m, 1H), 8.27 - 8.09 (m, 1H), 8.00 - 7.93 (m, 1H), 7.90 - 7.86 (m, 1H), 7.73 (br. s., 3H), 7.59 - 7.46 (m, 2H), 7.44 - 7.37 (m, 1H), 7.33 - 7.24 (m, 1H), 7.03 - 6.92 (m, 2H), 4.89 - 4.78 (m, 1H), 4.73 - 4.61 (m, 1H), 4.03 - 3.91 (m, 2H), 3.77 (q, J=6.8 Hz, 2H), 3.69 - 3.59 (m, 2H), 3.28 - 3.15 (m, 2H), 2.52 (br. s., 2H)	1.92 O 747.1	9.1	58.1
B325		4-(5-methyl-2-{phenyl methanesulfonyl}[(2- sulfamoyl)ethyl]carbonyl] methyl}-1,3-benzothiazol- 6-yl)benzoic acid	δ 8.03-8.07 (m, 2H), 8.00 (d, J=8.25 Hz, 1H), 7.55 (d, J=7.98 Hz, 1H), 7.48 (d, J=6.88 Hz, 1H), 7.40 (s, 3H), 7.30 (d, J=19.26 Hz, 2H), 6.95 (s, 2H), 6.08 (s, 1H), 4.68-4.79 (m, 1H), 4.62 (br. s., 1H), 3.60 (q, J=6.69 Hz, 2H), 3.07-3.21 (m, 2H), 2.24-2.40 (m, 3H)	1.85 B 588	1.2	104.0




B326		4-(2-{methanesulfonyl}[(2-sulfamoyl)ethyl]carbamoyl)methyl}-5-methyl-1,3-benzothiazol-6-yl)benzoic acid	δ 8.04 (d, J=7.70 Hz, 4H), 7.54 (d, J=7.98 Hz, 2H), 6.95 (s, 2H), 6.02 (s, 1H), 3.60 (q, J=6.60 Hz, 2H), 3.23 (s, 3H), 3.14-3.19 (m, 2H), 2.36 (s, 3H)	1.56 B 512	1.6	201.4
B327		4-(2-{phenylmethanesulfonyl}[(2-sulfamoyl)ethyl]carbamoyl)methyl}-1,3-benzothiazol-6-yl)benzoic acid	δ 8.59 (s, 1H), 8.22 (d, J=8.53 Hz, 1H), 8.07 (d, J=7.70 Hz, 2H), 8.02 (d, J=7.70 Hz, 1H), 7.95 (br. s., 1H), 7.91 (d, J=7.98 Hz, 2H), 7.79-7.84 (m, 1H), 7.32-7.36 (m, 1H), 7.27 (d, J=5.50 Hz, 1H), 6.96 (m, 1H), 6.95 (s, 2H), 6.11 (s, 1H), 4.69-4.80 (m, 1H), 4.55-4.66 (m, 1H), 3.61 (d, J=6.05 Hz, 2H), 3.20 (t, J=6.88 Hz, 2H)	1.45 B 572	3.0	1797.0
B328		2-(6-{4-[(3S)-3-hydroxy pyrrolidine-1-carbonyl]phenyl}-1,3-benzothiazol-2-yl)-2-methanesulfonyl-N-(2-sulfamoyl)ethyl	δ 9.02 (br. s., 1H), 8.56 (br. s., 1H), 8.19 (d, J=8.0 Hz, 1H), 7.97 - 7.90 (m, 1H), 7.88 - 7.81 (m, 2H), 7.73 - 7.63 (m, 2H), 6.99 (br. s., 2H), 6.05 (br. s., 1H), 4.40 - 4.20	1.06 O 567.1	4.0	2624.0




		acetamide	(m, 1H), 3.92 (br. s., 2H), 3.71 - 3.58 (m, 4H), 3.28 - 3.24 (m, 3H), 3.23 - 3.14 (m, 2H), 2.05 - 1.74 (m, 2H)			
B329		2-(6-{4-[(3R)-3-hydroxy pyrrolidine-1-carbonyl]phenyl}-1,3-benzothiazol-2-yl)-2-methanesulfonyl-N-(2-sulfamoyl)ethyl acetamide	δ 9.03 (br. s., 1H), 8.56 (br. s., 1H), 8.19 (d, J=9.1 Hz, 1H), 7.96 - 7.91 (m, 1H), 7.88 - 7.81 (m, 2H), 7.67 (br. s., 2H), 6.99 (br. s., 2H), 6.05 (br. s., 1H), 4.43 - 4.16 (m, 1H), 3.92 (br. s., 2H), 3.61 (br. s., 4H), 3.25 (br. s., 3H), 3.20 (br. s., 2H), 2.03 - 1.75 (m, 2H)	1.06 O 567.1	1.8	261.6
B330		2-{6-[4-(3-fluoroazetidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-2-methanesulfonyl-N-(2-sulfamoyl)ethyl acetamide	δ 9.02 (br. s., 1H), 8.58 (br. s., 1H), 8.19 (d, J=8.5 Hz, 1H), 7.99 - 7.91 (m, 2H), 7.90 - 7.85 (m, 2H), 7.83 - 7.78 (m, 2H), 6.99 (br. s., 2H), 6.06 (br. s., 1H), 5.56 - 5.38 (m, 1H), 4.59 - 4.38 (m, 2H), 4.21 - 4.03 (m, 1H), 3.65 - 3.56 (m, 2H), 3.25 (br. s., 3H), 3.20 (br. s., 2H)	1.23 O 555.1	0.7	46.7



			2H)			
B331		3-(2-{[(2-sulfamoyl)ethyl] carbamoyl}[(3,3,3-trifluoro propanesulfonyl)methyl]-1,3-benzothiazol-6-yl) benzamide	δ 8.98 (s, 1H), 8.58 (d, J=1.7 Hz, 1H), 8.29 (s, 1H), 8.20 (d, J=8.8 Hz, 1H), 8.14 (br. s., 1H), 8.01 - 7.86 (m, 3H), 7.61 (m, 1H), 7.47 (br. s., 1H), 3.64 (m, 4H), 2.86 (m, 2H)	1.36 N 579.1	72.5	214.2
B332		2-{6-[3-(4-hydroxy piperidine-1-carbonyl) phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl ethyl)-2-(3,3,3-trifluoro propanesulfonyl)acetamide	δ 8.99 (m, 1H), 8.57 (m, 1H), 8.17 (m, 1H), 7.98 - 7.84 (m, 2H), 7.75 (m, 1H), 7.59 (d, J=6.1 Hz, 1H), 7.41 (m, 1H), 4.05 (m, 1H), 3.85 - 3.53 (m, 8H), 3.21 (br. s., 4H), 1.91 - 1.66 (m, 2H), 1.54 - 1.28 (m, 2H)	1.37 N 663.1	1.5	136.5
B333		2-{6-[3-(morpholine-4-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl)ethyl)-2-(3,3,3-trifluoropropanesulfonyl) acetamide	δ 9.05 - 8.92 (m, 1H), 8.57 (d, J=1.7 Hz, 1H), 8.18 (d, J=8.8 Hz, 1H), 7.96 - 7.84 (m, 3H), 7.79 (m, 2H), 7.61 (m, 1H), 7.46 (d, J=7.7 Hz, 1H), 3.84 - 3.48 (m, 12H), 3.25 - 3.14 (m, 2H), 2.96 - 2.81	1.48 N 649.8	9.8	119.3



			(m, 2H)			
B334		2-{6-[3-(3,3-difluoroazetidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl ethyl)-2-(3,3,3-trifluoro propanesulfonyl)acetamide	δ 8.99 (m, 1H), 8.59 (d, J=1.7 Hz, 1H), 8.18 (d, J=8.5 Hz, 1H), 8.03 - 7.91 (m, 4H), 7.76 - 7.57 (m, 3H), 4.97 - 4.81 (m, 2H), 4.62 - 4.42 (m, 2H), 3.87 - 3.54 (m, 5H), 2.95 - 2.81 (m, 2H)	1.66 N 655.1	14.2	60.4
B335		2-{6-[3-(3,3-difluoro piperidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl ethyl)-2-(3,3,3-trifluoro propanesulfonyl)acetamide	δ 8.98 (m, 1H), 8.57 (s, 1H), 8.18 (d, J=8.5 Hz, 1H), 7.96 - 7.86 (m, 2H), 7.63 (m, 1H), 7.43 (d, J=7.7 Hz, 1H), 3.87 - 3.53 (m, 8H), 3.20 (m, 2H), 2.96 - 2.81 (m, 2H), 2.25 - 2.06 (m, 2H), 1.85 - 1.64 (m, 2H)	1.7 N 683.2	5.5	14.7
B336		2-{6-[3-(3-fluoroazetidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl ethyl)-2-(3,3,3-trifluoro propanesulfonyl)acetamide	δ 8.97 (s, 1H), 8.58 (s, 1H), 8.18 (d, J=8.5 Hz, 1H), 7.97 (m, 5H), 7.71 - 7.59 (m, 2H), 4.71 - 4.33 (m, 4H), 4.24 - 4.00 (m, 1H), 3.89 - 3.49 (m, 4H), 2.90 (m, 4H)	1.54 N 637	8.2	22.6



B337		N-(cyclobutyl-3-(2-[[2-sulfamoylethyl]carbamoyl](3,3,3-trifluoropropane sulfonyl)methyl}-1,3-benzothiazol-6-yl) benzamide	δ 8.98 (s, 1H), 8.75 (d, J=7.4 Hz, 1H), 8.58 (s, 1H), 8.26 - 8.16 (m, 2H), 7.97 (m, 4H), 7.67 - 7.49 (m, 1H), 4.56 - 4.40 (m, 1H), 3.90 - 3.53 (m, 5H), 3.27 - 3.14 (m, 2H), 2.93 - 2.79 (m, 2H), 2.34 - 2.19 (m, 2H), 2.18 - 2.06 (m, 2H), 1.83 - 1.62 (m, 2H)	1.71 N 633.1	6.8	28.4
B338		N-(2,2-difluoroethyl)-N-methyl-3-(2-[[2-sulfamoylethyl]carbamoyl](3,3,3-trifluoropropane sulfonyl)methyl}-1,3-benzothiazol-6-yl) benzamide	δ 8.57 (s, 1H), 8.18 (d, J=8.5 Hz, 1H), 7.98 - 7.86 (m, 2H), 7.80 (br. s., 1H), 7.62 (s, 1H), 7.51 - 7.35 (m, 1H), 3.92 (m, 3H), 3.85 - 3.57 (m, 4H), 3.24 - 3.16 (m, 1H), 3.07 (s., 3H), 2.90 (m, 2H)	1.66 N 657.1	26.9	99.7
B339		N-(2,2-difluoropropyl)-3-(2-[[2-sulfamoylethyl]carbamoyl](3,3,3-trifluoropropanesulfonyl)methyl}-1,3-benzothiazol-6-yl)	δ 9.07 - 8.92 (m, 2H), 8.20 (m, 2H), 8.01 - 7.84 (m, 3H), 7.71 - 7.46 (m, 2H), 3.86 - 3.54 (m, 6H), 3.26 - 3.14 (m, 2H), 1.74 - 1.56 (m, 3H)	1.68 N 657.1	9.7	49.2




		6-yl)benzamide				
B340		N,N-dimethyl-3-((2-[(2-sulfamoyl)ethyl]carbamoyl)(3,3,3-trifluoropropane sulfonyl)methyl)-1,3-benzothiazol-6-yl)benzamide	δ 9.01 - 8.92 (m, 1H), 8.57 (s, 1H), 8.17 (d, J=8.5 Hz, 1H), 7.99 - 7.91 (m, 2H), 7.89 - 7.81 (m, 2H), 7.81 - 7.72 (m, 2H), 7.64 - 7.55 (m, 1H), 3.83 - 3.57 (m, 6H), 3.20 (m, 2H), 3.04 (s, 3H), 2.98 (s, 3H)	1.54 N 607.1	14.6	79.5
B341		2-((6-((3-((4-hydroxy-4-methylpiperidin-1-yl)-1,3-carbonyl)phenyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)-2-(3,3,3-trifluoropropanesulfonyl)acetamide	δ 8.57 (s, 1H), 8.17 (s, 1H), 8.06 - 7.99 (m, 2H), 7.92 - 7.83 (m, 2H), 7.75 (m, 2H), 7.64 (m, 2H), 3.64 (m, 10H), 2.87 (m, 2H), 1.56 - 1.45 (m, 4H), 1.18 (s, 3H)	1.48 N 677.1	6.0	111.8
B342		2-((6-((3-[(3R)-3-hydroxy pyrrolidine-1-carbonyl]phenyl)-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)-2-(3,3,3-trifluoropropanesulfonyl)acetamide	δ 8.98 (m, 1H), 8.58 (s, 1H), 8.17 (d, J=8.5 Hz, 1H), 7.95 - 7.91 (m, 1H), 7.87 (m, 2H), 7.82 - 7.73 (m, 1H), 7.63 - 7.52 (m, 2H), 4.39 - 4.23 (m, 1H), 3.64 (m, 8H), 3.20 (s, 2H), 2.90 - 2.80 (m, 2H), 2.03 -	1.37 N 649.1	9.5	153.7


			1.74 (m, 2H)				
B343		2-{6-[3-(4,4-difluoro piperidine-1-carbonyl) phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl ethyl)-2-(3,3,3-trifluoro propanesulfonyl)acetamide	δ 8.98 (s, 1H), 8.57 (s, 1H), 8.19 (d, J=8.5 Hz, 1H), 7.85 (m, 5H), 7.66 - 7.55 (m, 1H), 7.50 (s, 1H), 3.90 - 3.43 (m, 8H), 3.25 - 3.16 (m, 2H), 2.91 - 2.81 (m, 2H), 2.17 - 2.00 (m, 4H)	1.76 N 683.1	13.5	38.1	
B344		2-(6-{3-[(3S)-3-hydroxy pyrrolidine-1-carbonyl] phenyl}-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl ethyl)-2-(3,3,3-trifluoro propanesulfonyl)acetamide	δ 8.97 (m, 1H), 8.58 (s, 1H), 8.18 (d, J=8.5 Hz, 1H), 7.99 - 7.91 (m, 1H), 7.88 (m, 2H), 7.78 (m, 2H), 7.57 - 7.49 (m, 2H), 4.26 (m, 1H), 3.64 (m, 9H), 3.21 (m, 2H), 2.90 - 2.81 (m, 2H), 2.02 - 1.79 (m, 2H)	1.38 O 649.1	13.1	22.2	
B345		N-(2-hydroxy-2-methyl propyl)-3-(2-{(2-sulfamoyl)ethyl)carbamoyl] (3,3,3-trifluoropropane sulfonyl)methyl}-1,3-benzothiazol-6-yl) benzamide	δ 9.00 (s, 1H), 8.59 (s, 1H), 8.49 - 8.41 (m, 1H), 8.26 (s, 1H), 8.20 (d, J=8.8 Hz, 1H), 8.01 - 7.89 (m, 4H), 7.66 - 7.56 (m, 1H), 3.64 (m, 5H), 3.21 (m, 2H), 2.90 - 2.81 (m, 2H), 1.15 (m, 6H)	1.46 N 651.1	1.0	213.0	



B346		2-{5-methyl-6-[4-(morpholine-4-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-2-phenylmethane sulfonyl-N-(2-sulfamoyl-ethyl)acetamide	1H NMR (400 MHz, Acetone) δ 7.86 (d, J=6.60 Hz, 1H), 7.75-7.81 (m, 1H), 7.53-7.59 (m, 3H), 7.45-7.51 (m, 4H), 7.33-7.43 (m, 3H), 4.64 (s, 2H), 3.75-3.83 (m, 1H), 3.58-3.72 (m, 1H), 2.38 (s, 3H)	0.69 M 656.7	5.3	400.4
B347		2-{6-[4-(3-hydroxy-3-methylazetidine-1-carbonyl)phenyl]-5-methyl-1,3-benzothiazol-2-yl}-2-phenylmethane sulfonyl-N-(2-sulfamoyl-ethyl)acetamide	δ 9.01 (t, J=5.78 Hz, 1H), 8.02-8.09 (m, 1H), 7.74 (d, J=8.25 Hz, 1H), 7.70 (d, J=8.25 Hz, 1H), 7.49 (d, J=7.98 Hz, 1H), 7.39-7.45 (m, 4H), 7.25-7.37 (m, 2H), 6.90-6.99 (m, 2H), 4.67-4.80 (m, 1H), 4.50-4.64 (m, 1H), 4.12-4.25 (m, 2H), 3.89-3.97 (m, 2H), 3.55-3.65 (m, 2H), 3.19 (t, J=7.43 Hz, 2H), 2.23-2.40 (m, 3H), 1.41 (d, J=3.03 Hz, 3H)	1.74 B 657	3.4	579.6



B348		2-{5-methyl-6-[4-(piperidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-2-phenylmethane sulfonyl-N-(2-sulfamoyl-ethyl)acetamide	δ 8.01-8.10 (m, 1H), 7.62-7.75 (m, 1H), 7.47 (s, 3H), 7.39-7.45 (m, 4H), 7.22-7.36 (m, 2H), 6.90-7.00 (m, 2H), 4.67-4.79 (m, 1H), 4.50-4.65 (m, 1H), 3.65-3.87 (m, 8H), 3.51-3.64 (m, 4H), 3.06-3.23 (m, 2H), 2.23-2.42 (m, 3H)	1.96 B 655.1	1.0	37.1
B349		2-{6-[4-(3-hydroxy-3-methylazetidine-1-carbonyl)phenyl]-5-methyl-1,3-benzothiazol-2-yl}-2-methanesulfonyl-N-(2-sulfamoyl-ethyl)acetamide	δ 8.03 (d, J=9.63 Hz, 1H), 7.95 (s, 1H), 7.73 (d, J=7.98 Hz, 2H), 7.47 (s, 2H), 6.95 (s, 2H), 6.02 (s, 1H), 5.69 (br. s., 1H), 4.19 (d, J=11.83 Hz, 2H), 3.93 (d, J=5.23 Hz, 2H), 3.55-3.64 (m, 2H), 3.23 (s, 3H), 3.16-3.20 (m, 2H), 2.34-2.38 (m, 3H), 1.41 (s, 3H)	1.44 B 581.1	2.3	347.2



B350		2-methanesulfonyl-2-({5-methyl-6-[4-(morpholine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl)ethyl)acetamide	δ 8.03 (s, 1H), 8.01 (s, 1H), 7.95 (s, 2H), 7.50-7.53 (m, 2H), 7.46-7.50 (m, 2H), 6.95 (s, 1H), 6.02 (s, 1H), 3.60 (td, J=6.81, 13.34 Hz, 10H), 3.22 (s, 3H), 3.18 (t, J=7.15 Hz, 2H), 2.37 (s, 3H)	1.48 B 581.1	3.2	90.5
B351		2-phenylmethanesulfonyl-2-({6-[4-(piperidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl)ethyl)acetamide	δ 8.54 (s, 1H), 8.20 (d, J=8.25 Hz, 1H), 7.95 (s, 1H), 7.92 (d, J=8.53 Hz, 1H), 7.84 (d, J=7.70 Hz, 2H), 7.51 (d, J=7.70 Hz, 2H), 7.46 (d, J=7.70 Hz, 1H), 7.33-7.36 (m, 1H), 6.95 (br. s., 2H), 6.10 (s, 1H), 4.69-4.81 (m, 1H), 4.54-4.65 (m, 1H), 3.61 (d, J=6.05 Hz, 4H), 3.17-3.23 (m, 2H), 3.11 (br. s., 2H), 1.63 (br. s., 2H), 1.52 (br. s., 5H)	1.63 B 641.2	6.2	14.9

B352		2-[5-(2-fluorophenyl)-1,3-benzothiazol-2-yl]-2-methanesulfonyl-N-(2-sulfamoylethyl)acetamide	δ 9.02 (br. s., 1H), 8.33 - 8.21 (m, 2H), 7.75 - 7.62 (m, 2H), 7.48 (br. s., 1H), 7.43 - 7.32 (m, 2H), 7.07 - 6.71 (m, 2H), 6.12 - 5.82 (m, 1H), 3.61 (br. s., 2H), 3.26 (br. s., 3H), 3.20 (br. s., 2H)	1.57 O 472.1	0.8	13.7
B353		2-[(4-fluorophenyl)methanesulfonyl]-2-{6-[4-(3-hydroxy-3-methylazetidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoylethyl)acetamide	δ 9.16 - 8.54 (m, 1H), 8.32 - 8.12 (m, 1H), 7.99 - 7.84 (m, 2H), 7.81 - 7.70 (m, 3H), 7.51 - 7.35 (m, 2H), 6.96 (s, 4H), 6.09 (s, 1H), 5.70 (d, J=5.5 Hz, 1H), 5.07 - 4.48 (m, 2H), 4.35 - 4.12 (m, 2H), 4.01 - 3.88 (m, 3H), 3.70 - 3.52 (m, 2H), 3.26 - 3.11 (m, 2H), 1.42 (d, J=3.0 Hz, 3H)	1.43 N 661.1	2.0	18.5
B354		2-(6-{4-[(3R)-3-methoxypyrrolidine-1-carbonyl]phenyl}-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl)ethyl)-2-{[4-(trifluoroethyl)-2-yl]-N-(2-sulfamoyl)ethyl}-2-{[4-(trifluoroethyl)-2-yl]-N-(2-sulfamoyl)ethyl}	δ 9.05 (t, J=5.5 Hz, 1H), 8.56 (s, 1H), 8.21 (s, 1H), 8.16 - 8.10 (m, 1H), 8.01 - 7.90 (m, 2H), 7.88 - 7.83 (m, 2H), 7.78 - 7.60 (m, 6H), 7.56 (d, J=8.3 Hz, 2H), 7.52 - 7.46	1.73 O 741.1	3.8	552.8



			methoxy)phenyl]methane sulfonyl} acetamide	(m, 2H), 7.43 - 7.38 (m, 2H), 7.33 - 7.24 (m, 1H), 7.02 - 6.94 (m, 4H), 6.13 (s, 1H), 4.89 - 4.77 (m, 2H), 4.73 - 4.60 (m, 2H), 4.09 - 3.94 (m, 2H), 3.92 (s, 1H), 3.73 - 3.47 (m, 10H), 3.30 (s, 3H), 3.26 - 3.16 (m, 6H), 2.10 - 1.90 (m, 4H)			
B355		2-{6-[4-(3-fluoroazetidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl-ethyl)-2-[(4-(trifluoromethoxy)phenyl)methanesulfonyl] acetamide	δ 9.05 (t, J=5.6 Hz, 1H), 8.58 (s, 1H), 8.30 - 8.19 (m, 1H), 8.17 - 8.12 (m, 1H), 7.99 - 7.93 (m, 2H), 7.92 - 7.85 (m, 3H), 7.84 - 7.69 (m, 7H), 7.59 - 7.54 (m, 2H), 7.51 - 7.45 (m, 2H), 7.43 - 7.37 (m, 2H), 7.32 - 7.22 (m, 2H), 7.03 - 6.94 (m, 4H), 6.14 (s, 1H), 5.66 - 5.30 (m, 2H), 4.91 - 4.78 (m, 2H), 4.75 - 4.60 (m, 3H), 4.48 (br. s., 4H), 4.13 (d, J=11.3 Hz, 2H), 3.74 - 3.55 (m, 4H), 3.27 - 3.12 (m, 4H)	1.74 O 715.1	6.6	235.2	



B356		2-(6-{4-[(3S)-3-methoxy pyrrolidine-1-carbonyl] phenyl}-1,3-benzothiazol- 2-yl)-N-(2-sulfamoyl ethyl)-2-{[4-(trifluoro methoxy)phenyl]methane sulfonyl}acetamide	δ 14.04 and 11.48 (br. s., 1H), 9.05 (br. s., 1H), 8.56 (s, 1H), 8.24 - 8.19 (m, 1H), 8.17 - 8.11 (m, 1H), 7.98 - 7.60 (m, 11H), 7.58 - 7.53 (m, 2H), 7.49 (d, J=7.7 Hz, 2H), 7.41 (d, J=8.0 Hz, 2H), 7.35 - 7.24 (m, 2H), 7.04 - 6.93 (m, 3H), 6.13 (s, 1H), 4.88 - 4.78 (m, 2H), 4.74 - 4.60 (m, 2H), 4.11 - 3.94 (m, 2H), 3.92 (s, 2H), 3.73 - 3.38 (m, 16H), 3.35 - 3.28 (m, 3H), 3.25 - 3.20 (m, 3H), 2.02 (br. s., 4H)	1.74 O 741.1	2.7	26.7
B357		2-{6-[4-(3,3-difluoro azetidine-1-carbonyl) phenyl]-1,3-benzothiazol- 2-yl}-N-(2-sulfamoyl ethyl)-2-{[4- (trifluoromethyl)phenyl] methanesulfonyl}	δ 14.05 and 11.44 and 6.14 (s, 1H), 9.07 - 9.02 and 8.66 - 8.55 (m, 1H), 8.27 - 8.14 (m, 1H), 7.99 - 7.93 (m, 1H), 7.92 - 7.83 (m, 2H), 7.83 - 7.74 (m, 3H), 7.68 - 7.63 (m, 1H), 7.61 - 7.58 (m, 1H), 7.01 - 6.94 (m, 2H), 4.98 - 4.45	1.83 O 717.1	15.0	93.2



		acetamide	(m, 6H), 3.75 - 3.59 (m, 2H), 3.26 - 3.15 (m, 2H)			
B358		2-[6-(1-oxo-2,3-dihydro-1H-isindol-5-yl)-1,3-benzothiazol-2-yl]-N-(2-sulfamoylethyl)-2-{[4-(trifluoromethyl)phenyl]methanesulfonyl}acetamide	δ 9.05 and 8.62 (br. s., 1H), 8.57 (br. s., 1H), 8.28 - 8.20 and 8.19 - 8.11 (m, 1H), 8.00 - 7.93 (m, 2H), 7.91 - 7.85 (m, 1H), 7.83 - 7.75 (m, 2H), 7.69 - 7.56 (m, 2H), 6.97 (br. s., 2H), 6.53 (s, 1H), 4.95 - 4.66 (m, 2H), 4.47 (d, J=15.7 Hz, 2H), 3.63 (d, J=5.5 Hz, 2H), 3.25 - 3.11 (m, 2H)	1.55 O 653.1	3.7	67.6
B359		2-[6-[4-(3,3-difluoroazetidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl]-N-(2-sulfamoyl ethyl)-2-{[3-(trifluoromethyl)phenyl]methanesulfonyl}acetamide	δ 14.05 and 11.55 (br. s., 1H), 9.08 (br. s., 1H), 8.59 (s, 1H), 8.20 (d, J=8.8 Hz, 2H), 8.00 - 7.94 (m, 2H), 7.93 - 7.88 (m, 2H), 7.88 - 7.73 (m, 10H), 7.70 - 7.53 (m, 4H), 7.06 - 6.87 (m, 6H), 6.15 (s, 1H), 5.12 - 4.34 (m, 12H), 3.63 (br. s., 4H), 3.27 - 3.13 (m, 4H)	1.83 O 717.1	4.7	47.0




B360		2-{6-[4-(3-hydroxy-3-methylazetidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl-ethyl)-2-[(3-(trifluoromethyl)phenyl)methanesulfonyl]acetamide	δ 14.05 and 11.54 (br. s., 1H), 9.06 (br. s., 1H), 8.57 (s, 1H), 8.30 - 8.13 (m, 2H), 7.99 - 7.85 (m, 4H), 7.83 - 7.71 (m, 10H), 7.70 - 7.51 (m, 4H), 7.07 - 6.92 (m, 6H), 6.14 (s, 1H), 5.70 (d, J=3.9 Hz, 2H), 5.01 - 4.69 (m, 4H), 4.34 - 4.06 (m, 4H), 3.99 - 3.89 (m, 4H), 3.63 (br. s., 4H), 3.27 - 3.15 (m, 4H), 1.42 (br. s., 6H)	1.55 O 711.1	6.2	471.4
B361		2-[6-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1,3-benzothiazol-2-yl]-N-(2-sulfamoyl-ethyl)-2-[(4-(trifluoromethyl)phenyl)methanesulfonyl]acetamide	δ 14.03 and 11.41 (br. s., 1H), 9.54 - 8.69 (m, 1H), 8.47 - 8.33 (m, 1H), 8.33 - 8.25 (m, 1H), 8.19 - 8.09 (m, 2H), 8.00 - 7.92 (m, 2H), 7.86 - 7.80 (m, 2H), 7.78 - 7.74 (m, 2H), 7.70 - 7.51 (m, 5H), 7.26 - 7.18 and 7.13 - 7.09 (m, 1H), 6.97 (s, 4H), 6.62 - 6.44 (m, 2H), 6.12 (s, 1H), 4.97 - 4.85 (m, 2H), 4.82 - 4.61 (m, 2H), 3.92 (s, 2H)	1.41 O 629.1	121.1	1231.0



				1H), 3.70 - 3.59 (m, 4H), 3.53 (s, 2H), 3.26 - 3.13 (m, 4H), 2.52 (br. s., 6H)		
B362	 <chem>CN(C(=O)c1ccc(cc1C2=C(N3CC(O)C3)C=C2)C4=NC(=S)C5=CC=CC=C5C6=CC=CC=C6C(S(=O)(=O)CC7=CC=CC=C7OC(F)(F)F)=C8C(=O)N8</chem>	2-{6-[4-(3-hydroxy-3-methylazetidine-1-carbonyl)phenyl]-1,3-benzothiazol-2-yl}-2-{[4-(trifluoromethoxy)phenyl]methanesulfonyl} acetamide	δ 8.75 - 8.11 (m, 2H), 8.06 - 7.92 (m, 1H), 7.90 - 7.85 (m, 1H), 7.80 - 7.71 (m, 3H), 7.56 - 7.43 (m, 2H), 7.42 - 7.24 (m, 2H), 6.05 (s, 1H), 5.84 - 5.49 (m, 1H), 4.99 - 4.55 (m, 2H), 4.36 - 4.10 (m, 2H), 3.94 (br. s., 2H), 1.61 - 1.39 (m, 3H)	1.53 O 620.1	157.9	30.3
B363	 <chem>CN(C(=O)c1ccc(cc1C2=C(N3CC(O)C3)C=C2)C4=NC(=S)C5=CC=CC=C5C6=CC=CC=C6C(S(=O)(=O)CC7=CC=CC=C7OC(F)(F)F)=C8C(=O)N8</chem>	2-[(4-fluorophenyl)methanesulfonyl]-2-{6-[1-(2-hydroxy-2-methylpropyl)-2-oxo-1,2-dihydropyridin-4-yl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoylethyl)acetamide	δ 9.11 - 8.53 (m, 1H), 8.20 (d, J=8.5 Hz, 1H), 8.03 - 7.85 (m, 1H), 7.81 - 7.66 (m, 2H), 7.53 - 7.44 (m, 1H), 7.42 - 7.31 (m, 1H), 7.28 - 7.06 (m, 2H), 7.03 - 6.92 (m, 1H), 6.75 - 6.67 (m, 1H), 6.10 (s, 1H), 5.02 - 4.83 (m, 1H), 4.81 - 4.55 (m, 2H), 3.96 (d, J=12.9 Hz, 2H), 3.92 (s, 1H), 3.71 - 3.52 (m,	1.36 O 637.1	11.6	10000.0

				2H), 3.27 - 3.06 (m, 2H), 1.13 (d, J=8.3 Hz, 7H)			
B364		2-[6-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-1,3-benzothiazol-2-yl]-N-(2-sulfamoyl-ethyl)-2-[[4-(trifluoromethyl)phenyl]methanesulfonyl]acetamide	δ d 9.05 and 8.59 (s., 1H), 8.23 - 8.10 (m, 1H), 8.00 - 7.82 (m, 2H), 7.82 - 7.73 (m, 2H), 7.68 - 7.63 (m, 1H), 7.61 - 7.57 (m, 1H), 6.97 (br. s., 2H), 6.83 - 6.76 and 6.63 - 6.55 (m, 1H), 6.72 - 6.66 (m, 1H), 5.10 - 4.53 (m, 2H), 3.82 - 3.58 (m, 2H), 3.54 - 3.43 (m, 3H), 3.26 - 3.15 (m, 2H)	1.5 O 629.1	28.3	10000.0	
B365		2-[6-(2-fluorophenyl)-1,3-benzothiazol-2-yl]-N-(2-sulfamoyl-ethyl)-2-[[4-(trifluoromethoxy)phenyl]methanesulfonyl]acetamide	δ 14.06 and 11.47 (br. s., 1H), 9.04 (br. s., 1H), 8.49 - 8.31 (m, 1H), 8.21 (d, J=8.5 Hz, 1H), 8.07 - 7.72 (m, 4H), 7.69 - 7.60 (m, 1H), 7.58 - 7.23 (m, 16H), 7.05 - 6.88 (m, 4H), 6.14 (s, 1H), 4.97 - 4.77 (m, 2H), 4.76 - 4.59 (m, 2H), 3.63 (d, J=6.1 Hz, 4H), 3.28 - 3.16 (m, 4H)	2.02 O 632.1	17.2	2.1	



B366		2-[6-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1,3-benzothiazol-2-yl]-N-(2-sulfamoyl-2-yl)-N-(2-(trifluoromethyl)phenyl)methanesulfonyl} acetamide	δ 14.31 - 8.88 (m, 1H), 8.47 - 8.26 (m, 1H), 8.19 - 8.07 (m, 1H), 8.00 - 7.93 (m, 1H), 7.89 - 7.49 (m, 6H), 6.97 (br. s., 2H), 6.63 - 6.43 (m, 1H), 6.11 (s, 1H), 5.06 - 4.66 (m, 2H), 3.68 - 3.59 (m, 2H), 3.54 (d, J=16.5 Hz, 3H), 3.21 (t, J=6.9 Hz, 2H)	1.50 O 629.1	4.4	219.1
B367		2-{6-[1-(2-methoxyethyl)-2-oxo-1,2-dihydropyridin-4-yl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl-2-yl)-N-(2-(trifluoromethyl)phenyl)methanesulfonyl} acetamide	δ 14.40 - 11.02 (m, 1H), 9.04 (t, J=5.6 Hz, 1H), 8.59 (d, J=1.7 Hz, 1H), 8.23 - 8.10 (m, 2H), 7.95 - 7.91 (m, 1H), 7.75 (d, J=7.2 Hz, 4H), 7.71 - 7.69 (m, 1H), 7.67 - 7.63 (m, 2H), 7.59 (s, 3H), 7.04 - 6.94 (m, 5H), 6.82 - 6.73 (m, 1H), 6.72 - 6.63 (m, 2H), 6.63 - 6.53 (m, 1H), 6.14 (s, 1H), 5.02 - 4.83 (m, 2H), 4.81 - 4.68 (m, 2H), 4.18 - 4.06 (m, 4H), 3.92 (s, 1H), 3.70 - 3.56 (m, 9H), 3.28 (s, 3H), 3.28 -	1.57 O 673.1	13.5	2208.0




B368		2-[6-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-1,3-benzothiazol-2-yl]-N-(2-sulfamoylethyl)-2-[(4-(trifluoromethoxy)phenyl)methanesulfonyl]acetamide	3.27 (m, 3H), 3.24 - 3.16 (m, 4H) δ 9.23 - 8.57 (m, 1H), 8.29 - 8.12 (m, 1H), 7.99 - 7.91 (m, 1H), 7.90 - 7.83 (m, 1H), 7.81 - 7.68 (m, 1H), 7.59 - 7.52 (m, 1H), 7.49 - 7.45 (m, 1H), 7.43 - 7.37 (m, 1H), 7.32 - 7.23 (m, 1H), 6.99 (s, 2H), 6.86 - 6.52 (m, 2H), 6.14 (s, 1H), 4.99 - 4.42 (m, 2H), 3.70 - 3.56 (m, 2H), 3.47 (d, J=13.8 Hz, 3H), 3.30 - 3.11 (m, 2H)	1.45 Q 645.1	15.8	1597.0			
B369		2-[5-(2-fluoropyridin-4-yl)-1,3-benzothiazol-2-yl]-N-(2-methanesulfonyl)-N-(2-sulfamoylethyl)acetamide	δ 9.00 (t, J=5.8 Hz, 1H), 8.63 (d, J=1.7 Hz, 1H), 8.39 - 8.31 (m, 2H), 8.03 (dd, J=8.5, 1.7 Hz, 1H), 7.90 - 7.84 (m, 1H), 7.72 (s, 1H), 6.96 (s, 2H), 6.09 (s, 1H), 3.66 - 3.58 (m, 2H), 3.27 (s, 3H), 3.24 - 3.16 (m, 2H)	1.29 N 473	1.5	414.5			




B370		2-methanesulfonyl-2-{5-[4-(2-methoxyethoxy)phenyl]-1,3-benzothiazol-2-yl}-N-(2-sulfamoyl-ethyl)acetamide	δ 9.02 (br. s., 1H), 8.38 - 8.13 (m, 2H), 7.87 - 7.64 (m, 3H), 7.15 - 6.89 (m, 4H), 6.04 (br. s., 1H), 4.17 (br. s., 2H), 3.70 (d, J=2.5 Hz, 2H), 3.61 (d, J=5.2 Hz, 2H), 3.34 (br. s., 3H), 3.26 (br. s., 3H), 3.20 (br. s., 2H)	1.47 N 528	1.8	15.5
B371		2-[5-(4-acetamidophenyl)-1,3-benzothiazol-2-yl]-2-methanesulfonyl-N-(2-sulfamoyl-ethyl)acetamide	δ 9.01 (br. s., 1H), 8.33 (br. s., 1H), 8.22 (d, J=8.3 Hz, 1H), 7.87 - 7.66 (m, 6H), 6.98 (br. s., 3H), 6.04 (br. s., 1H), 3.61 (br. s., 2H), 3.25 (br. m., 5H), 2.08 (br. s., 3H)	1.17 N 511	3.0	96.3
B372		2-[5-(6-fluoropyridin-3-yl)-1,3-benzothiazol-2-yl]-2-methanesulfonyl-N-(2-sulfamoyl-ethyl)acetamide	δ 9.00 (t, J=5.8 Hz, 1H), 8.70 (d, J=2.5 Hz, 1H), 8.47 (d, J=1.4 Hz, 1H), 8.44 (td, J=8.2, 2.6 Hz, 1H), 8.30 (d, J=8.3 Hz, 1H), 7.97 (s, 1H), 7.90 (dd, J=8.4, 1.8 Hz, 1H), 7.34 (dd, J=8.7, 2.9 Hz, 1H), 6.96 (s, 2H), 6.07 (s, 1H), 3.62 (q, J=6.9	1.25 N 473	2.5	124.2



				Hz, 2H), 3.26 (s, 3H), 3.23 - 3.18 (m, 2H)			
B373		2-methanesulfonyl-2-[(5-(1,2-oxazol-4-yl)-1,3-benzothiazol-2-yl)]-N-(2-sulfamoyl)ethyl)acetamide	δ 9.60 (s, 1H), 9.33 (s, 1H), 8.98 (t, J=5.6 Hz, 1H), 8.51 (d, J=1.1 Hz, 1H), 8.25 (d, J=8.5 Hz, 1H), 7.88 (dd, J=8.4, 1.5 Hz, 1H), 6.96 (s, 2H), 6.06 (s, 1H), 3.61 (q, J=6.8 Hz, 2H), 3.25 (s, 3H), 3.20 (dd, J=8.8, 6.6 Hz, 2H)	1.09 N 445	3.3	45.7	
B374		2-methanesulfonyl-2-[(5-(pyrimidin-2-yl)-1,3-benzothiazol-2-yl)]-N-(2-sulfamoyl)ethyl)acetamide	δ 9.30 (s, 2H), 9.24 (s, 1H), 9.01 (t, J=5.8 Hz, 1H), 8.59 (d, J=1.7 Hz, 1H), 8.35 (d, J=8.5 Hz, 1H), 7.99 (dd, J=8.5, 1.7 Hz, 1H), 7.21 (s, 1H), 7.11 (s, 1H), 7.01 (s, 1H), 6.96 (s, 2H), 6.08 (s, 1H), 3.62 (q, J=6.8 Hz, 2H), 3.26 (s, 3H), 3.23 - 3.17 (m, 2H)	0.98 N 456	0.8	23.7	



B375		2-[6-(3-fluoro-2-hydroxy pyridin-4-yl)-1,3- benzothiazol-2-yl]-N-(2- sulfamoylethyl)-2-(3,3,3- trifluoropropanesulfonyl) acetamide	δ 12.30 - 12.07 (m, 1H), 8.98 (br. s., 1H), 8.52 - 8.44 (m, 1H), 8.27 - 8.19 (m, 1H), 7.83 - 7.76 (m, 1H), 7.43 - 7.33 (m, 1H), 7.01 (br. s., 1H), 6.97 (s, 2H), 6.31 (s, 1H), 3.85 - 3.53 (m, 4H), 3.23 - 3.17 (m, 2H), 2.90 - 2.83 (m, 2H)	1.10 N 571.0	14.0	786.9
B376		2-[6-(3-fluoro-2-hydroxy pyridin-4-yl)-1,3- benzothiazol-2-yl]-N-(2- sulfamoylethyl)-2-{[4- (trifluoromethoxy)phenyl] methanesulfonyl} acetamide	δ 14.84 - 10.51 (m, 1H), 9.13 - 8.19 (m, 2H), 7.97 (s, 2H), 7.67 - 7.52 (m, 1H), 7.50 - 7.45 (m, 1H), 7.43 - 7.19 (m, 3H), 6.97 (br. s., 2H), 6.44 - 6.27 (m, 1H), 6.15 (s, 1H), 5.05 - 4.62 (m, 2H), 3.63 (d, J=5.8 Hz, 2H), 3.28 - 3.15 (m, 2H)	1.40 O 633.5	7.1	4695.0
B377		2-[5-(5-fluoropyridin-3- yl)-1,3-benzothiazol-2-yl]- 2-methanesulfonyl-N-(2- sulfamoylethyl)acetamide	δ 9.00 (t, J=5.6 Hz, 1H), 8.96 (s, 1H), 8.64 (d, J=1.7 Hz, 1H), 8.56 (s, 1H), 8.33 (d, J=8.5 Hz, 1H), 8.25 (d, J=10.2 Hz, 1H), 7.97 (d, J=8.3 Hz, 1H), 6.96 (s, 2H), 6.08 (s, 1H), 3.62 (q, J=6.8 Hz, 2H),	1.17 N 495	2.9	82.1



B378		2-methanesulfonyl-2- [4-(methoxymethyl) phenyl]-1,3-benzothiazol- 2-yl]-N-(2- sulfamoyl-ethyl)acetamide	3.27 (s, 3H), 3.24 - 3.17 (m, 2H) δ 9.00 (t, J=5.6 Hz, 1H), 8.37 (s, 1H), 8.25 (d, J=8.5 Hz, 1H), 7.86 (d, J=8.5 Hz, 1H), 7.80 (d, J=8.0 Hz, 2H), 7.46 (d, J=8.0 Hz, 2H), 6.96 (s, 2H), 6.06 (s, 1H), 4.49 (s, 2H), 3.62 (q, J=6.6 Hz, 2H), 3.35 (s, 3H), 3.27 (s, 3H), 3.21 (t, J=7.0 Hz, 2H)	1.52 N 498	0.7	6.7			
B379		2-[5-(3-acetamidophenyl)- 1,3-benzothiazol-2-yl]-2- methanesulfonyl-N-(2- sulfamoyl-ethyl)acetamide	δ 10.07 (br. s., 1H), 8.99 (t, J=5.2 Hz, 1H), 8.34 - 8.20 (m, 2H), 8.03 (br. s., 1H), 7.78 (d, J=8.0 Hz, 1H), 7.61 (d, J=7.2 Hz, 1H), 7.51 - 7.37 (m, 2H), 6.96 (s, 2H), 6.07 (s, 1H), 3.62 (d, J=6.1 Hz, 2H), 3.27 (s, 3H), 3.24 - 3.18 (m, 2H), 2.10 (s, 3H)	1.26 N 511	0.5	83.7			

B380		2-[5-(6-fluoropyridin-2-yl)-1,3-benzothiazol-2-yl]-2-methanesulfonyl-N-(2-sulfamoyl)ethyl)acetamide	δ 8.99 (t, J=5.2 Hz, 1H), 8.77 (s, 1H), 8.34 - 8.28 (m, 1H), 8.27 - 8.21 (m, 1H), 8.14 (br. s., 2H), 7.20 (d, J=2.5 Hz, 1H), 6.96 (s, 2H), 6.08 (s, 1H), 3.62 (q, J=6.6 Hz, 2H), 3.27 (s, 3H), 3.21 (t, J=7.0 Hz, 2H)	1.4 O 473	2.0	18.5
B381		2-[5-(3-fluoropyridin-4-yl)-1,3-benzothiazol-2-yl]-2-methanesulfonyl-N-(2-sulfamoyl)ethyl)acetamide	δ 9.01 (t, J=5.0 Hz, 1H), 8.73 (s, 1H), 8.57 (d, J=4.7 Hz, 1H), 8.41 (s, 1H), 8.36 (d, J=8.3 Hz, 1H), 7.97 (s, 1H), 7.85 - 7.76 (m, 2H), 6.96 (s, 2H), 6.09 (s, 1H), 3.66 - 3.59 (m, 2H), 3.27 (s, 3H), 3.21 (t, J=7.0 Hz, 2H)	1.15 N 473	1.1	40.2
B382		tert-butyl 4-(2-{methanesulfonyl}[(2-sulfamoyl)ethyl]carbamoyl)methyl}-1,3-benzothiazol-5-yl)-1,2,3,6-tetrahydropyridine-1-	δ 9.02 (t, J=5.4 Hz, 1H), 8.20 - 8.12 (m, 1H), 7.71 (d, J=8.5 Hz, 1H), 7.00 (s, 2H), 6.07 (s, 1H), 5.38 (t, J=4.8 Hz, 1H), 4.10 (br. s., 1H), 3.70 - 3.60 (m, 4H), 3.29 (s, 3H), 3.24 (t, J=6.9 Hz, 3H), 2.12 -	1.71 N 559	3.1	36.5

		carboxylate	1.93 (m, 3H), 1.50 (s, 9H)			
B383		2-[5-(2-fluoropyridin-3-yl)-1,3-benzothiazol-2-yl]-2-methanesulfonyl-N-(2-sulfamoyl-ethyl)acetamide	δ 9.00 (br. s., 1H), 8.36 - 8.29 (m, 3H), 8.26 (t, J=8.9 Hz, 1H), 7.77 (d, J=8.3 Hz, 1H), 7.54 (t, J=5.8 Hz, 1H), 6.96 (s, 2H), 6.08 (s, 1H), 3.62 (q, J=6.3 Hz, 2H), 3.27 (s, 3H), 3.21 (t, J=7.0 Hz, 2H)	1.25 N 473	0.7	13.0
B384		2-methanesulfonyl-2-[5-(1-methyl-1H-pyrazol-5-yl)-1,3-benzothiazol-2-yl]-N-(2-sulfamoyl-ethyl)acetamide	δ 9.00 (br. s., 1H), 8.30 (d, J=8.0 Hz, 1H), 8.25 (s, 1H), 7.68 (d, J=8.3 Hz, 1H), 7.52 (s, 1H), 6.96 (br. s., 2H), 6.53 (s, 1H), 6.06 (s, 1H), 3.93 (s, 3H), 3.62 (d, J=6.3 Hz, 2H), 3.26 (s, 3H), 3.20 (t, J=6.9 Hz, 2H)	1.02 N 458	8.2	827.6
B385		2-[5-(2,6-difluoropyridin-3-yl)-1,3-benzothiazol-2-yl]-2-methanesulfonyl-N-(2-sulfamoyl-ethyl)acetamide	δ 9.00 (t, J=5.6 Hz, 1H), 8.53 - 8.40 (m, 1H), 8.37 - 8.27 (m, 2H), 7.76 (d, J=8.3 Hz, 1H), 7.37 (dd, J=8.3, 2.5 Hz, 1H), 6.96 (s, 2H), 6.08 (s, 1H), 3.62 (q, J=6.7 Hz, 2H), 3.26 (s, 3H), 3.23 - 3.16 (m, 2H)	1.38 N 491	3.5	20.5


			2H)				
B386		tert-butyl 4-[2-({[(3R)-2-oxopyrrolidin-3-yl]carbamoyl}(phenyl)methanesulfonyl)methyl]-1,3-benzothiazol-6-yl]benzoate	1H NMR (400MHz, DMSO- d ₆) δ	2.25 M 606.1	17.1 14.3		
B388		2-{6-[1-(2-hydroxy-2-methylpropyl)-2-oxo-1,2-dihydropyridin-4-yl]-1,3-benzothiazol-2-yl}-2-methanesulfonyl-N-(2-sulfamoyl)acetamide	δ	1.02 O 541.0	5.3 4444.0		

B389		2-{5-[1-(2-hydroxy-2-methylpropyl)-2-oxo-1,2-dihdropyridin-4-yl]-1,3-benzothiazol-2-yl}-2-methanesulfonyl-N-(2-sulfamoylethyl)acetamide	δ 9.02 (br. s., 1H), 8.46 (br. s., 1H), 8.29 (d, J=8.0 Hz, 1H), 8.02 - 7.69 (m, 2H), 6.98 (br. s., 2H), 6.85 (br. s., 1H), 6.75 (d, J=4.7 Hz, 1H), 6.07 (br. s., 1H), 4.88 (br. s., 1H), 4.00 - 3.89 (m, 3H), 3.61 (br. s., 2H), 3.26 (br. s., 2H), 3.19 (d, J=9.6 Hz, 2H), 1.13 (br. s., 6H)	1.03 O 543.1	2.0	6304.0
B390		2-{5-[1-(2-hydroxy-2-methylpropyl)-6-oxo-1,6-dihdropyridin-3-yl]-1,3-benzothiazol-2-yl}-2-methanesulfonyl-N-(2-sulfamoylethyl)acetamide	δ 9.00 (br. s., 1H), 8.30 - 8.26 (m, 1H), 8.22 (d, J=8.8 Hz, 1H), 8.17 - 8.13 (m, 1H), 8.01 - 7.95 (m, 1H), 7.75 - 7.68 (m, 1H), 6.99 (br. s., 2H), 6.55 (d, J=9.1 Hz, 1H), 6.04 (br. s., 1H), 4.03 (br. s., 2H), 3.60 (br. s., 2H), 3.25 (br. s., 3H), 3.19 (br. s., 2H), 1.13 (br. s., 6H)	1.07 O 543.1	3.5	10000.0

B393		2-[5-(3,3-difluoroazetidine-1-carbonyl)-1,3-benzothiazol-2-yl]-2-methanesulfonyl-N-(2-sulfamoyl-ethyl)acetamide	δ 9.02 (br. s., 1H), 8.38 (s, 1H), 8.29 (d, $J=8.5$ Hz, 1H), 7.97 (br. s., 1H), 7.83 (d, $J=8.3$ Hz, 1H), 6.96 (br. s., 2H), 6.08 (s, 1H), 5.00 - 4.75 (m, 2H), 4.69 - 4.44 (m, 2H), 3.62 (d, $J=5.8$ Hz, 2H), 3.26 (s, 3H), 3.20 (t, $J=6.6$ Hz, 2H)	0.98 N 497	50.3	5747.0
B394		N-[2-(4-fluorophenyl)ethyl]-2-{methanesulfonyl}[(2-sulfamoyl-ethyl)carbamoyl-methyl]-1,3-benzothiazole-5-carboxamide	δ 9.04 (t, $J=5.8$ Hz, 1H), 8.38 (d, $J=1.4$ Hz, 1H), 8.30 (d, $J=8.5$ Hz, 1H), 7.83 (dd, $J=8.4, 1.5$ Hz, 1H), 6.99 (s, 2H), 6.08 (s, 1H), 4.89 (br. s., 2H), 4.55 (br. s., 2H), 3.65 - 3.56 (m, 2H), 3.26 (s, 3H), 3.20 (dd, $J=7.7, 6.1$ Hz, 2H)	1.25 N 543	37.4	1595.0

Reference 1

2-(6-Phenyl-1,3-benzothiazol-2-yl)-N-(2-sulfamoyl-ethyl)-4-pentenamide



Compound R1a. Ethyl 2-(6-bromobenzo[d]thiazol-2-yl)pent-4-enoate

[00274] Compound R1a (2.4 g, 35% yield) was prepared from ethyl 6-bromo-2-chlorobenzo[d]thiazole as described in the general procedure given for Compound

10 B196b. HPLC: RT = 1.15 (LCMS Method M). MS (ES): m/z = 341.7 [M+H]⁺. ¹H NMR (500MHz, CHLOROFORM-d) δ 8.01 (d, J=1.9 Hz, 1H), 7.94 - 7.79 (m, 1H), 7.58 (dd, J=8.5, 1.9 Hz, 1H), 5.80 (ddt, J=17.1, 10.2, 6.9 Hz, 1H), 5.15 (dq, J=17.1, 1.5 Hz, 1H), 5.08 (dd, J=10.2, 1.4 Hz, 1H), 4.34 - 4.18 (m, 3H), 3.03 - 2.90 (m, 1H), 2.90 - 2.73 (m, 1H), 1.35 - 1.22 (m, 3H).

Compound R1b. Ethyl 2-(6-phenylbenzo[d]thiazol-2-yl)pent-4-enoate

[00275] Compound R1b (120 mg, 29%) was prepared from Compound R1a as described in the general procedure given for Compound A1a. HPLC: RT = 0.86 (LCMS

20 Method M). MS (ES): m/z = 419.7 [M+H]⁺. ¹H NMR (500MHz, DMSO-d₆) δ 8.70 - 8.54 (m, 1H), 8.36 (d, J=1.9 Hz, 1H), 7.89 (d, J=8.8 Hz, 1H), 7.68 - 7.59 (m, 1H), 6.89 (s,


2H), 5.82 - 5.66 (m, 1H), 5.08 (dd, $J=17.1, 1.7$ Hz, 1H), 5.04 - 4.94 (m, 1H), 4.18 (dd, $J=8.0, 7.2$ Hz, 1H), 3.55 - 3.37 (m, 2H), 3.16 - 3.04 (m, 2H), 2.76 (d, $J=1.1$ Hz, 1H), 2.66 (d, $J=7.2$ Hz, 1H).

5 Reference 1

[00276] Reference 1 (14 mg, 46%) was prepared from Compound R1b as described in the general procedure given for Compound B2a. HPLC: RT = 0.93 (LCMS Method M). MS (ES): $m/z = 416.0$ $[M+H]^+$. ^1H NMR (500MHz, DMSO- d_6) δ 8.63 (t, $J=5.8$ Hz, 1H), 8.38 (d, $J=1.4$ Hz, 1H), 8.03 (d, $J=8.5$ Hz, 1H), 7.80 (dd, $J=8.4, 1.8$ Hz, 1H), 7.78 - 7.70 (m, 2H), 7.56 - 7.46 (m, 2H), 7.44 - 7.33 (m, 1H), 6.91 (s, 2H), 5.87 - 5.70 (m, 1H), 5.12 (dd, $J=17.2, 1.8$ Hz, 1H), 5.07 - 4.97 (m, 1H), 4.28 - 4.16 (m, 1H), 3.49 (td, $J=13.9, 7.4$ Hz, 2H), 3.18 (d, $J=5.0$ Hz, 1H), 3.13 (t, $J=7.3$ Hz, 2H), 2.87 - 2.76 (m, 1H), 2.77 - 2.65 (m, 1H).

15 Reference 2

N-((3-isopropylisoxazol-5-yl)methyl)-2-methyl-2-(6-phenylbenzo[d]thiazol-2-yl)propanamide




[00277] Reference 2 was prepared as described in the general procedure given for Reference 1. HPLC: RT = 2.16 (LCMS Method B). MS (ES): $m/z = 420.1$ $[M+H]^+$. ^1H NMR (400MHz, CHLOROFORM- d) δ 8.11 - 8.05 (m, 2H), 7.90 (m, 1H), 7.75 (dd, $J=8.5, 1.8$ Hz, 1H), 7.68 - 7.62 (m, 2H), 7.52 - 7.46 (m, 2H), 7.44 - 7.37 (m, 1H), 5.93 (s, 1H), 4.55 (dd, $J=5.9, 0.6$ Hz, 2H), 3.07 - 2.95 (m, 1H), 1.84 (s, 6H), 1.24 (s, 3H), 1.22 (s, 3H).

25

Reference 3


N-((3-isopropylisoxazol-5-yl)methyl)-2-methyl-2-(6-phenylbenzo[d]thiazol-2-yl)propanamide



[00278] Reference 3 was prepared as described in the general procedure given for Reference 1. HPLC: RT = 1.97 (LCMS Method B). MS (ES): $m/z = 393.1$ $[M+H]^+$. ^1H
5 NMR (400MHz, CHLOROFORM- d) δ 8.12 - 8.06 (m, 2H), 7.77 (dd, $J=8.5, 1.8$ Hz, 1H), 7.67 - 7.62 (m, 2H), 7.53 - 7.46 (m, 2H), 7.44 - 7.38 (m, 1H), 4.70 (d, $J=6.0$ Hz, 2H), 2.55 (s, 3H), 1.86 (s, 6H).


WHAT IS CLAIMED IS:

1. A compound of Formula (I):



- 5 or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is independently selected from: halogen, CN, $\text{CO}_2(\text{C}_{1-4} \text{ alkyl})$, $-\text{CO}-\text{R}_j$,



- 10 (a 5- to 6-membered heteroaryl comprising: carbon atoms and 1-4 heteroatoms selected from N, NR^c , O, and $\text{S}(\text{O})_p$; wherein said heteroaryl is substituted with 0-3 R^a);

R^2 is, independently at each occurrence, selected from: halogen, OH, $\text{C}_{1-4} \text{ alkyl}$, $\text{C}_{1-4} \text{ alkoxy}$, $\text{C}_{1-4} \text{ haloalkyl}$, $\text{C}_{1-4} \text{ haloalkoxy}$, CN, NH_2 , NO_2 , $\text{NH}(\text{C}_{1-4} \text{ alkyl})$, $\text{N}(\text{C}_{1-4} \text{ alkyl})_2$, CO_2H , $\text{CO}_2(\text{C}_{1-4} \text{ alkyl})$, and CONH_2 ;


R^3 is independently selected from: $-\text{SO}_2\text{R}^5$ and $-\text{NHCOR}^6$;

- 15 R^4 independently selected from: $\text{---}(\text{CH}_2)_s\text{---R}^7$ and $\text{---}(\text{CH}_2)_t\text{---R}^8$;


- R^5 is independently selected from: $\text{C}_{1-6} \text{ alkyl}$ substituted with 0-1 R^9 , $\text{C}_{2-6} \text{ alkenyl}$, $\text{C}_{1-6} \text{ haloalkyl}$, $\text{C}_{1-6} \text{ alkoxy}$, $-(\text{CH}_2)_m-(\text{O})_n-(\text{C}_{3-6} \text{ carbocycle substituted with 0-3 } R^b)$, and $-(\text{CH}_2)_m-(\text{O})_n-(5\text{- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, } \text{NR}^c, \text{O, and } \text{S}(\text{O})_p; \text{ wherein said heterocycle is substituted with 0-2 } R^b)$;
- 20




R^6 is independently selected from: $\text{C}_{1-6} \text{ alkyl}$, $\text{C}_{2-6} \text{ alkenyl}$, $\text{C}_{1-6} \text{ alkoxy}$, $\text{C}_{1-4} \text{ haloalkyl}$, $-(\text{CH}_2)_m-(\text{C}_{3-6} \text{ carbocycle substituted with 0-3 } R^b)$,




-(CH₂)_m-(pyridyl substituted with 0-2 R^b), -NH(C₁₋₄ alkyl), -NHCH₂CO₂(C₁₋₄ alkyl),



- R⁷ is independently selected from: CONH₂, CONH(C₁₋₄ alkyl),
CON(C₁₋₄ alkyl)₂, SO₂NHSO₂(C₁₋₄ alkyl), SO₂NH(CH₂)₂₋₄CO₂(C₁₋₄ alkyl),
5 NHSO₂NH₂, NHSO₂(C₁₋₄ alkyl), N(C₁₋₄ alkyl)SO₂NH₂,




R⁸ is independently selected from , , ,




heteroaryl comprising: carbon atoms and 1-4 heteroatoms selected from N, NR^c, O, and S(O)_p; wherein said phenyl and heteroaryl are substituted with 0-2 R¹¹;

R⁹ is independently selected from: halogen, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy, NH₂, CO₂H, CO₂(C₁₋₄ alkyl), SO₃H, CONHR^d, NHCONHR^d,

NHCO_2R^d , , and 5- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR^g , O, and $\text{S}(\text{O})_p$;

- R^{10} is independently selected from: OH, C_{1-6} alkyl, C_{2-6} alkenyl, NH_2 , $\text{NH}(\text{C}_{1-6}$ alkyl substituted with 0-1 $\text{CO}_2(\text{C}_{1-4}$ alkyl)), $\text{NH}(\text{C}_{2-6}$ alkyl),
- 5 $\text{NH}(\text{C}_{1-4}$ haloalkyl), NHPh , phenyl substituted with 0-2 halogens, and




R^{11} is, independently at each occurrence, selected from: halogen, C_{1-4} alkyl, C_{1-4} haloalkyl, NH_2 , and phenyl;

- R^a is, independently at each occurrence, selected from: halogen, C_{1-6} alkyl substituted with 0-1 R^f , C_{1-4} alkoxy substituted with 0-1 R^f , C_{1-6} haloalkyl, C_{1-6} haloalkoxy, OH, CN, NO_2 , CO_2H , $\text{CO}_2(\text{C}_{1-4}$ alkyl), NR^gR^h , CONR^gR^h , CONR^gR^j , NHCOR^i , NHCO_2R^i , $\text{SO}_2\text{NR}^g\text{R}^h$, $-(\text{O})_n-(\text{CH}_2)_t-\text{R}^j$, and $-\text{CO}-\text{R}^j$;
- 10

- R^b is, independently at each occurrence, selected from: halogen, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, OH, CN, NH_2 , NO_2 , $\text{NH}(\text{C}_{1-4}$ alkyl),
- 15 $\text{N}(\text{C}_{1-4}$ alkyl) $_2$, CO_2H , $\text{CO}_2(\text{C}_{1-4}$ alkyl), $\text{SO}_2(\text{C}_{1-4}$ alkyl), CONH_2 , and $\text{CONH}(\text{C}_{1-4}$ alkyl);

R^c is, independently at each occurrence, selected from: H, C_{1-6} alkyl substituted with 0-1 R^e , $\text{CO}(\text{C}_{1-4}$ alkyl), $\text{CO}_2(\text{C}_{1-4}$ alkyl), COBn , CO_2Bn , $-(\text{CH}_2)_t$ -piperidinyl, $-(\text{CH}_2)_t$ -morpholinyl, $-(\text{CH}_2)_t$ -piperazinyl, pyrimidinyl,

- 20 $-(\text{CH}_2)_t-(\text{C}_{3-6}$ carbocycle substituted with 0-2 R^e), and 

R^d is, independently at each occurrence, selected from: C_{1-6} alkyl and $-(\text{CH}_2)_t$ -(phenyl substituted with 0-2 R^e);

R^e is, independently at each occurrence, selected from: halogen, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, and C_{1-4} haloalkoxy;

R^f is, independently at each occurrence, selected from: OH, halogen, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, and C_{1-4} haloalkoxy;

5 R^g is, independently at each occurrence, selected from: H and C_{1-4} alkyl;

R^h is, independently at each occurrence, selected from: H, C_{1-6} haloalkyl and C_{1-6} alkyl substituted with 0-1 R^f ;

R^i is, independently at each occurrence, selected from: C_{1-4} haloalkyl and C_{1-4} alkyl substituted with 0-1 R^f ;

10 R^j is, independently at each occurrence: C_{3-6} carbocycle or a 4- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR^g , O, and $S(O)_p$; wherein said carbocycle and heterocycle are substituted with 0-2 R^f ;



m and t are, independently at each occurrence, selected from 0, 1, 2, and 3;

n is, independently at each occurrence, selected from 0 and 1;

15 p is, independently at each occurrence, selected from 0, 1, and 2; and

s is, independently at each occurrence, selected from 1, 2, and 3.

2. A compound according to claim 1, wherein the compound is of Formula (Ia) or (Ib):





or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

m and t are, independently at each occurrence, selected from 0, 1, and 2; and

s is, independently at each occurrence, selected from 1 and 2.

3. A compound according to claim 1 or claim 2, wherein wherein the compound is of Formula (IIa) or (IIb):




or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

R^2 is independently selected from: halogen and C_{1-4} alkyl.

- 10 4. A compound according to any one of claims 1 to 3, wherein:

R^1 is independently selected from: 4-halo-Ph, 6-halo-pyrid-3-yl, and





R^4 is ; and

R^6 is independently selected from: C_{1-4} alkyl, $-CHF_2$, $NHBn$, 4- CF_3 -Ph, and

- 15 pyrid-3-yl.

5. A compound according to claim 1 or claim 2, wherein wherein the compound is of Formula (IIIa) or (IIIb):







or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

R² is independently selected from: halogen, C₁₋₄ alkyl and C₁₋₄ haloalkyl.

- 5 6. A compound according to any one of claims 1, 2 and 5, wherein:





R^1 is independently selected from:




- 10 R^a and selected from: isoxazolyl, pyrazolyl, 1-R^c-pyrazolyl, pyridyl, and pyrimidinyl);

R⁴ is independently selected from: , ,



- 15 $\text{---} \text{CH}_2 \text{---} \text{O} \text{---} \text{C}_{1-4} \text{ alkyl}$;

R⁵ is independently selected from: C₁₋₄ alkyl substituted with 0-1 R⁹, C₂₋₄ alkenyl, -(CH₂)₀₋₁-C₃₋₆ cycloalkyl, -(CH₂)₀₋₁-(phenyl substituted with 0-1 R^b) and



R⁹ is independently selected from: C₁₋₄ alkoxy, C₁₋₄ haloalkyl, NH₂, and

5 NHCO₂Bn;


R^a is, independently at each occurrence, selected from: OH, halogen, CN, C₁₋₄ alkyl substituted with 0-1 OH, C₁₋₄ alkoxy, -O(CH₂)₁₋₂O(C₁₋₄ alkyl),


C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy, NH₂, CO₂H, CO₂(C₁₋₄ alkyl), CONH₂,

CONH(C₁₋₄ alkyl), CONH(CH₂)₂₋₃OH, CONH(CH₂)₁₋₃O(C₁₋₄ alkyl),

10 CON(C₁₋₄ alkyl)(CH₂)₁₋₃O(C₁₋₄ alkyl), CONH(C₁₋₄ haloalkyl), NHCO(C₁₋₄ alkyl),

NHCO(C₁₋₄ haloalkyl), NHCO₂(C₁₋₄ alkyl), SO₂N(C₁₋₄ alkyl)₂, SO₂NH(CH₂)₂₋₃OH,


pyrazolyl, -(CH₂)₀₋₂-morpholinyl, -CO-morpholinyl, piperazinyl, ,



R^b is independently selected from: halogen and C₁₋₄ haloalkyl;

15 R^c is, independently at each occurrence, selected from: H, C₁₋₄ alkyl,

-(CH₂)₂(C₁₋₄ alkoxy), -(CH₂)₀₋₂-(phenyl substituted with 0-1 halo),

-(CH₂)₀₋₂-piperidinyl, -(CH₂)₀₋₂-morpholinyl, and ; and


R^f is, independently at each occurrence, selected from: OH, halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, and C₁₋₄ haloalkoxy.



20



7. A compound according to any one of claims 1, 2, 5 and 6, wherein:


R¹ is independently selected from: Ph, 3-halo-Ph, 4-halo-Ph, 3-C₁₋₄ alkoxy-Ph, 4-CH₂OH-Ph, 3-CN-Ph, 4-CN-Ph, 4-CO₂H-Ph, 4-CO₂(C₁₋₄ alkyl)-Ph,

3-NHCO(C₁₋₄ alkyl)-Ph, 4-NHCO(C₁₋₄ alkyl)-Ph, 4-(pyrazol-1-yl)-Ph,

2-C₁₋₄ alkoxy-pyridyl, pyrimidinyl and  ;

R⁴ is independently selected from: , ,

, , and

5  ;


R⁵ is independently selected from: C₁₋₄ alkyl substituted with 0-1 R⁹, and C₂₋₄ alkenyl, Bn, and 4-halo-Bn; and


R⁹ is independently selected from: C₁₋₄ alkoxy, C₁₋₄ haloalkyl, NH₂, and NHCO₂Bn.

10

8. A compound according to any one of claims 1, 2, 5, 6 and 7, wherein:

R¹ is independently selected from: Ph, 3-halo-Ph, 4-halo-Ph, 3-C₁₋₄ alkoxy-Ph, 4-CH₂OH-Ph, 3-CN-Ph, 4-CN-Ph, 4-CO₂H-Ph, 4-CO₂(C₁₋₄ alkyl)-Ph, 3-NHCO(C₁₋₄ alkyl)-Ph, 4-NHCO(C₁₋₄ alkyl)-Ph, 4-(pyrazol-1-yl)-Ph, pyrimidinyl and

15  ;


R⁴ is  ;


R⁵ is independently selected from: C₁₋₄ alkyl substituted with 0-1 R⁹, and C₂₋₄ alkenyl, Bn, and 4-halo-Bn; and

20 R⁹ is independently selected from: C₁₋₄ alkoxy, C₁₋₄ haloalkyl, NH₂, and NHCO₂Bn.

9. A compound according to any one of claims 1, 2, 5, 6, 7 and 8, wherein:

R¹ is independently selected from: Ph, 3-F-Ph, 4-F-Ph, 3-OMe-Ph, 4-CH₂OH-Ph, 3-CN-Ph, 4-CN-Ph, 4-CO₂H-Ph, 4-CO₂Me-Ph, 3-NHCOMe-Ph, 4-NHCOMe-Ph,


4-(pyrazol-1-yl)-Ph, pyrimidin-5-yl, and ; and


R⁵ is independently selected from: Me, Et, Pr, *i*-Bu, , Bn, 4-F-Bn, 5 -(CH₂)₂OMe, -(CH₂)₂CF₃, -(CH₂)₂NH₂, and -(CH₂)₂NHCO₂Bn.

10. A compound according to any one of claims 1, 2, 5, 6 and 7, wherein:

R¹ is Ph;

R⁴ is independently selected from: SO₂NH(C₂₋₆ alkenyl),



10 SO₂NH(CH₂)₃CO₂(C₁₋₄ alkyl), C₁₋₄ alkoxy, and

C₁₋₄ alkyl;

R⁵ is independently selected from: C₁₋₄ alkyl, C₂₋₄ alkenyl, -(CH₂)₂O(C₁₋₄ alkyl), and -(CH₂)₂NHCO₂Bn.

15 11. A compound according to any one of claims 1, 2, 5, 6, 7 and 10, wherein:

R⁴ is independently selected from: SO₂NH(CH₂)₄CH=CH₂,


SO₂NH(CH₂)₃CO₂(*t*-Bu), OMe, and Me;

R⁵ is independently selected from: Me, , -(CH₂)₂OMe, and -(CH₂)₂NHCO₂Bn.

20


12. A compound according to any one of claims 1, 2, 5 and 6, wherein:

R¹ is independently selected from:




(phenyl substituted with 0-2 R^a), and (a heteroaryl substituted with 0-2 R^a and selected from: isoxazolyl, pyrazolyl, 1-R^c-pyrazolyl, pyridyl, and pyrimidinyl);

R⁴ is independently selected from:



R⁵ is independently selected from: C₁₋₄ alkyl substituted with 0-1 R⁹,

-(CH₂)₀₋₁-C₃₋₆ cycloalkyl, benzyl substituted with 0-1 R^b, and



R⁹ is independently selected from: C₁₋₄ alkoxy, C₁₋₄ haloalkyl, NH₂, and NHCO₂Bn;


R^a is, independently at each occurrence, selected from: OH, halogen, C₁₋₄ alkyl

substituted with 0-1 OH, C₁₋₄ alkoxy, -O(CH₂)₂O(C₁₋₄ alkyl), C₁₋₄ haloalkyl,

C₁₋₄ haloalkoxy, NH₂, CONH₂, CONH(C₁₋₄ alkyl), CONH(CH₂)₂₋₃OH,


CONH(CH₂)₁₋₃O(C₁₋₄ alkyl), CON(C₁₋₄ alkyl)(CH₂)₁₋₃O(C₁₋₄ alkyl),

CONH(C₁₋₄ haloalkyl), NHCO₂(C₁₋₄ alkyl), SO₂N(C₁₋₄ alkyl)₂, SO₂NH(CH₂)₂₋₃OH,



R^b is independently selected from: CN, halogen and C_{1-4} haloalkyl;


R^c is, independently at each occurrence, selected from: H, C_{1-4} alkyl substituted
 5 with 0-1 C_{1-4} alkoxy, $-(\text{CH}_2)_{0-2}\text{-(phenyl substituted with 0-1 halo)}$, $-(\text{CH}_2)_{0-2}\text{-piperidinyl}$,



R^f is, independently at each occurrence, selected from: OH, CN, halogen,
 C_{1-4} alkyl, and C_{1-4} alkoxy.


10 13. A compound according to any one of claims 1, 2, 5, 6 and 12, wherein:




R^1 is independently selected from: 3- $(\text{CH}_2)_2\text{OH-Ph}$, 4- $(\text{CH}_2)_2\text{OH-Ph}$,
 4- $\text{O}(\text{CH}_2)_2\text{O}(\text{C}_{1-4}\text{ alkyl})\text{-Ph}$, 4- C_{1-4} haloalkoxy-Ph, 4- $\text{NH}_2\text{-Ph}$, 4- $\text{CONH}_2\text{-Ph}$,
 4- $\text{CONH}(\text{C}_{1-4}\text{ alkyl})\text{-Ph}$, 4- $\text{CONH}(\text{CH}_2)_2\text{OH-Ph}$, 3- $\text{CONH}(\text{CH}_2)_2\text{O}(\text{C}_{1-4}\text{ alkyl})\text{-Ph}$,
 4- $\text{CONH}(\text{CH}_2)_2\text{O}(\text{C}_{1-4}\text{ alkyl})\text{-Ph}$, 4- $\text{CONH}(\text{C}_{1-4}\text{ haloalkyl})\text{-Ph}$,
 15 3- $\text{CON}(\text{C}_{1-4}\text{ alkyl})(\text{CH}_2)_2\text{O}(\text{C}_{1-4}\text{ alkyl})\text{-Ph}$, 4- $\text{NHCO}_2(\text{C}_{1-4}\text{ alkyl})\text{-Ph}$,
 4- $\text{SO}_2\text{N}(\text{C}_{1-4}\text{ alkyl})_2\text{-Ph}$, 4- $\text{SO}_2\text{NH}(\text{CH}_2)_2\text{OH-Ph}$, 1*H*-3- C_{1-4} haloalkyl-pyrazol-4-yl,
 1- C_{1-4} alkyl-pyrazol-4-yl, 1-Bn-pyrazol-4-yl, 3- C_{1-4} alkyl-pyrid-4-yl, 6-OH-pyrid-2-yl,
 6-OH-pyrid-3-yl, 2-OH-pyrid-4-yl, 6- C_{1-4} alkoxy-pyrid-2-yl, 2- C_{1-4} alkoxy-pyrid-3-yl,
 6- C_{1-4} alkoxy-pyrid-3-yl, 2- C_{1-4} alkoxy-pyrid-4-yl, 6-halo-pyrid-3-yl, 2-halo-pyrid-4-yl,
 20 6- C_{1-4} haloalkyl-pyrid-3-yl, 5- C_{1-4} alkyl-6-halo-pyrid-3-yl,
 3-halo-6- C_{1-4} alkoxy-pyrid-4-yl, pyrimidin-5-yl,



14. A compound according to any one of claims 1, 2, 5, 6, 12 and 13, wherein:

- R^1 is independently selected from: 3-(CH₂)₂OH-Ph, 4-(CH₂)₂OH-Ph,
 4-O(CH₂)₂OMe-Ph, 4-OCF₃-Ph, 4-NH₂-Ph, 4-CONH₂-Ph, 4-CONH(*t*-Bu)-Ph,
 4-CONH(CH₂)₂OH-Ph, 3-CONH(CH₂)₂OMe-Ph, 4-CONH(CH₂)₂OMe-Ph,
 5 4-CON(Me)(CH₂)₂OMe-Ph, 4-CONHCH₂CF₃-Ph, 4-NHCO₂Me-Ph,
 4-NHCO₂(*t*-Bu)-Ph, 4-SO₂N(Me)₂-Ph, 4-SO₂NH(CH₂)₂OH-Ph, 1*H*-3-CF₃-pyrazol-4-yl,
 1-Me-pyrazol-4-yl, 1-(*i*-Bu)-pyrazol-4-yl, 1-Bn-pyrazol-4-yl, 3-Me-pyrid-4-yl,
 6-OH-pyrid-2-yl, 6-OH-pyrid-3-yl, 2-OH-pyrid-4-yl, 6-OMe-pyrid-2-yl,
 2-OMe-pyrid-3-yl, 6-OMe-pyrid-3-yl, 2-OMe-pyrid-4-yl, 6-F-pyrid-3-yl, 2-F-pyrid-4-yl,
 10 2-Cl-pyrid-4-yl, 6-CF₃-pyrid-3-yl, 5-Me-6-F-pyrid-3-yl, 3-F-6-OMe-pyrid-4-yl,





10

15. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of any one of claims 1-14, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2013/050972

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D277/64 C07D417/04 C07D417/10 C07D417/12 C07D417/14
A61K31/428 A61P9/10

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2011/251386 A1 (MASUDA KOJI [JP] ET AL) 13 October 2011 (2011-10-13) cited in the application claims 8, 13, 14 page 1, paragraph [0001] -----	1-15
A	CA 2 784 710 A1 (SHIONOGI & CO [JP]) 23 June 2011 (2011-06-23) claim 2 page 1, paragraph [0001] -----	1-15
A	WO 2004/094394 A1 (LILLY CO ELI [US]; EACHO PATRICK IRVING [US]; FOXWORTHY-MASON PATRICIA) 4 November 2004 (2004-11-04) cited in the application claims 1, 10 -----	1-15



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

4 October 2013

Date of mailing of the international search report

04/11/2013

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Beligny, Samuel

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2013/050972

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2011251386 A1	13-10-2011	EP 2351744 A1	03-08-2011
		TW 201021798 A	16-06-2010
		US 2011251386 A1	13-10-2011
		WO 2010044441 A1	22-04-2010

CA 2784710 A1	23-06-2011	CA 2784710 A1	23-06-2011
		CN 102753545 A	24-10-2012
		EP 2514749 A1	24-10-2012
		KR 20120123325 A	08-11-2012
		TW 201125865 A	01-08-2011
		US 2012253040 A1	04-10-2012
		WO 2011074560 A1	23-06-2011

WO 2004094394 A1	04-11-2004	EP 1615900 A1	18-01-2006
		US 2006276522 A1	07-12-2006
		WO 2004094394 A1	04-11-2004
